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Summary 
Prenatal alcohol exposure (PAE) can lead to fetal alcohol spectrum disorder (FASD). 
FASD refers to a range of lifelong conditions caused by PAE, characterised by a 
distinctive facial phenotype, growth deficiencies and/or neurobehavioural 
impairments. This thesis presents four studies that I conducted to address 
knowledge gaps relevant to the epidemiology of PAE and FASD. 
First, objective measures of PAE are essential for identifying children at risk of 
adverse outcomes. Biomarkers have been advocated for use in universal PAE 
screening programs but their validity had not been comprehensively evaluated. I 
conducted a systematic review and found that biomarker test performance varied 
widely across studies. The quality of published studies was low, resulting in 
insufficient evidence to support the use of objective measures of PAE in practice. 
Second, the prevalence of FASD in the UK was unknown. Active case ascertainment 
studies have not been possible due to funding and ethical issues. To overcome 
these issues, I developed an algorithm to estimate FASD prevalence using existing 
data from a population-based birth cohort in England (ALSPAC). Up to 17% of 
children met criteria for FASD, indicating that it is a significant public health 
concern.  
Third, although PAE is the sole necessary cause of FASD, it is not always sufficient. 
Understanding risk factors for FASD is important for informing prevention 
strategies. However, existing studies have mostly been limited to discussion of 
association, rather than causation. I produced a causal diagram to depict 
hypothesised causal pathways to FASD. I used this diagram to guide analyses in a 
FASD risk factor study, reported below. 
Finally, I investigated FASD risk factors using multivariable logistic regression within 
the ALSPAC cohort. Prenatal stress, smoking and mental health problems increased 
the odds of FASD. Social support and folic acid supplementation were protective. 
These results indicate novel potential targets for FASD intervention. 
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Chapter 1 1 
Chapter 1. Introduction 
 
1 Overview 
This thesis aims to describe the epidemiology of prenatal alcohol exposure (PAE) 
and fetal alcohol spectrum disorder (FASD). In this introductory chapter, I describe 
the existing evidence on PAE and FASD, and the knowledge gaps that I will address 
in this thesis. The main aims and research questions of this thesis are presented at 
the end of this chapter.  
2 Background 
2.1 Alcohol use in pregnancy: existing evidence and knowledge gaps 
2.1.1 Introduction to alcohol in pregnancy 
Alcohol is a teratogen. It is associated with a range of adverse perinatal and long-
term outcomes including spontaneous abortion, preterm delivery, cognitive and 
behavioural impairment.1-6 During pregnancy, alcohol consumed by the mother 
passes freely through the placenta and within one hour the level of alcohol within 
the fetal bloodstream approximates that of the mother.7 The fetus cannot 
effectively process alcohol and the intrauterine environment creates a recycling 
loop for ethanol, whereby the ethanol excreted by the fetus re-enters the fetal 
bloodstream as it swallows the amniotic fluid. The fetus therefore experiences 
prolonged exposure to ethanol and the primary route for elimination of this 
substance is through the metabolic capacity of the mother.8,9 Evidence from animal 
studies suggests that alcohol disrupts fetal development through a variety of 
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mechanisms including cell damage and death, disrupted growth factor signalling, 
altered gene expression and hypoxia.10  
2.1.2 Prevalence of alcohol use in pregnancy 
The UK has the fourth highest prevalence of PAE in the world, according to a 
systematic review and meta-analysis, published in 2017. This review produced a 
pooled prevalence estimate of 41% for any PAE, although there was significant 
heterogeneity between studies.11 Recent prospective studies produce higher 
estimates, suggesting that 75% to 79% of women in the UK drink while 
pregnant.12,13 The prevalence and quantity of prenatal alcohol use is highest in the 
first trimester.12,13 While most women significantly reduce their intake or abstain 
after the first trimester, 34% to 63% continue to drink alcohol in the second 
trimester and 49% in the third trimester.12,13 Up to 33% of women report binge 
drinking at some point during pregnancy, most commonly in the first trimester5,12 
and the prevalence of chronic/heavy PAE (daily drinking or consuming more than 8 
units per week) ranges from 1% to 3% in the second and third trimesters.12-18 
2.1.3 Outcomes associated with alcohol use in pregnancy 
Heavy episodic and chronic prenatal alcohol consumption are the most likely to 
lead to adverse outcomes, including FASD (described below).19 Reviews of the 
effects of low to moderate PAE on developmental outcomes are inconclusive20-22 
and debate is ongoing as to whether it is possible to identify a safe limit for 
drinking in pregnancy.23 A meta-analysis, published in 2017,24 explored the impact 
of drinking up to 32g of alcohol per week during pregnancy (equivalent to the 
upper limit of previous UK antenatal guidelines25), compared to abstinence, on a 
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range of pregnancy and childhood outcomes. The authors found an 8% increase in 
the odds of a child being small for gestational age and some evidence for an 
increased odds of preterm birth following light PAE. However, evidence was sparse 
for most outcomes and confidence intervals for the preterm birth estimate were 
inconclusive.24 Studies of the effects of low to moderate PAE on neurocognitive and 
behavioural outcomes have produced results that range from evidence of 
harm,22,26-28 to null findings,20,29-34 to evidence of benefit.14,35,36 Studies of the 
effects of low to moderate PAE on growth trajectories and birth outcomes have 
also produced mixed results.13,37-42 Discrepancies in findings are likely due to 
measurement error of the exposure and outcome (in some samples children may 
have been too young for comprehensive assessment of neurodevelopmental 
outcomes),43 and residual confounding due to the socioeconomic patterning of 
prenatal alcohol use (discussed further in Chapter 5). 
2.1.4 Guidance on alcohol use in pregnancy 
These inconsistencies in the evidence base are reflected in guidelines for drinking 
in pregnancy. Most countries in America, Asia, Europe and Australasia endorse a 
clear abstinence message.44 Since 1981, the USA Surgeon General’s statement has 
advised pregnant women, or those planning a pregnancy, not to drink alcohol.45 UK 
guidelines for drinking in pregnancy have been unclear. Up until 2016 the 
Department of Health, National Institute for Health and Care Excellence (NICE), 
NHS Choices and Royal College of Obstetricians and Gynaecologists recommended 
that, while it is safest not to drink while pregnant, there is no known risk of harm at 
low levels and suggested that if women choose to drink they should not exceed 
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one to two units once or twice per week.25,46,47 In 2016, the UK Chief Medical 
Officer (CMO) issued new guidance stating that women should avoid alcohol 
throughout pregnancy.48 This guidance has since been adopted by NHS Choices and 
the Royal College of Obstetricians and Gynaecologists.49,50 NICE have issued a 
statement in support of the CMO recommendations, but are yet to update their 
Antenatal Care Guideline (last checked 26.02.2018).25,51 
2.1.5 Public awareness and attitudes towards PAE guidance 
The Infant Feeding Survey 2010 reported that 29% of women did not receive any 
information about PAE from health professionals. Women who did receive advice 
reported being given mixed messages, with some being told to abstain and some to 
limit the amount they drank.52 Given the inconclusive evidence about the risks of 
low to moderate levels of PAE, opinions about PAE guidance are also divided. Some 
groups endorse a ‘no alcohol no risk’ perspective and suggest that guidance that 
takes a precautionary approach by advising abstention is warranted.24,53 Others 
warn against the ‘policing of pregnancy,’ state that giving up alcohol may be a 
‘pointless sacrifice,’ and argue that women should be free to make an educated 
choice about whether they drink while pregnant or trying to conceive.53-55 
In the context of the inconsistencies in UK guidance, mixed advice from healthcare 
professionals and differences in public opinion, 71% of individuals said that they 
found PAE guidance confusing, when asked in a 2015 study.56 In contrast, the 
report from the public consultation on the updated CMO guidance found that 80% 
of respondents thought that the abstinence message was clear and helped to 
resolve some of the confusion around the previous guidelines.48 Clarification of the 
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guidance is only part of the picture. Studies have found that public awareness of 
the PAE guidance is low (in 2015, 40% of individuals reported that they did not 
know what the government guidance was)56 and adherence to guidance on 
prenatal lifestyle factors is also low.57-59 Therefore, the impact of the change in 
guidance on public awareness and alcohol use in pregnancy remains to be seen. 
2.1.6 Conclusions and implications for this thesis 
In summary, existing epidemiological studies suggest that PAE is a significant public 
health concern in the UK. However, there is wide variation in results between 
studies. A major limitation of the existing evidence base is the reliance on self-
report methods for ascertaining PAE. Self-report methods are likely to 
underestimate true PAE for reasons including social desirability bias, fear of 
persecution, and an inability to accurately recall and quantify drinking behaviour.60-
64 The measurement error introduced by self-reported PAE creates uncertainty in 
prevalence estimates and complicates attempts to investigate the adverse 
outcomes associated with PAE, as described in the next section. Objective 
measures are needed to strengthen epidemiological research into PAE. For 
clinicians, objective measures of PAE could support FASD diagnosis and guide 
efforts to prevent alcohol-related harm.65-70 Biomarkers of prenatal alcohol use 
have been proposed as an objective alternative to self-report, but have not been 
comprehensively evaluated. To address this research gap, I present a systematic 
review of the validity of objective measures of prenatal alcohol use in Chapter 2 of 
this thesis.  
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2.2 Fetal alcohol spectrum disorder (FASD): existing evidence and 
knowledge gaps 
FASD is an umbrella term that describes a range of consequences of prenatal 
exposure to alcohol including a distinctive facial phenotype, growth deficiencies 
and neurobehavioural impairments that persist across the lifespan.71 Figure 1 
provides an overview of the main subtypes that are recognised within the FASD 
continuum, according to the core features of FASD. Differences between diagnostic 
frameworks for FASD are described in more detail in Chapter 3. Generally, 
conditions within the FASD spectrum are said to include fetal alcohol syndrome 
(FAS), partial fetal alcohol syndrome (pFAS) and alcohol-related 
neurodevelopmental disorder (ARND). Some frameworks suggest an additional 
category, known as alcohol-related birth defects (ARBD), but this subtype is not 
widely accepted.72 
FAS is the most recognisable form of FASD and is characterised by a triad of facial 
anomalies (short palpebral fissure length, thin upper lip and smooth philtrum), 
growth impairment and central nervous system (CNS) dysfunction. Figure 2 shows 
the facial phenotype of FAS. An estimated one in 10 children with FASD will have 
FAS and therefore it represents a relatively rare subtype within the spectrum.11 
Due to the specificity of the facial phenotype to alcohol exposure, FAS can be 
diagnosed without confirmed PAE.75 In other words, when information about PAE is 
not available, the facial phenotype can be used as a proxy indicator of exposure. 
Partial FAS (pFAS) is used to describe individuals who have two of the features of 
the FAS facial phenotype and CNS dysfunction. ARBDs refer to congenital 
anomalies with confirmed PAE. Finally, ARND is the most common subtype of FASD, 
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but it is the most difficult to diagnose. ARND is the non-dysmorphic subtype of 
FASD and diagnosis requires confirmation of PAE and significant CNS 
impairment.72,73 Often evidence of PAE is missing or inaccurate and CNS 
dysfunction is not apparent until later in childhood.43 Therefore, FASD is thought to 
be significantly underdiagnosed. One study that carried out assessments in a high 
risk sample of fostered and adopted children found that 80% of children with FASD 
had not been previously diagnosed.76 For this reason, FASD has been referred to by 
some as an invisible disability.77  
Figure 1: Summary of FASD subtypes and core features 
 
Fetal alcohol 
syndrome 
Partial fetal 
alcohol 
syndrome 
Alcohol-
related 
neurodevelo
pmental 
disorder 
Alcohol-
related birth 
defects 
 (FAS) (pFAS) (ARND) (ARBD)a 
Prenatal alcohol 
exposure (PAE) 
Confirmed or 
unconfirmed 
Confirmed Confirmed Confirmed 
Central nervous 
system (CNS) 
impairment 
Yes Yes Yes Not required 
Facial anomalies Yes 
(3 features) 
Yes 
(2 features) 
Not required 
Yes 
(2 features) 
Growth deficiency Yes Not required Not required Not required 
Congenital 
structural defects Not required Not required Not required Yes 
a ARBD is included in the Institute of Medicine guidelines but is not recognised as a subtype 
within most FASD frameworks. 
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Figure 2: The three diagnostic facial features of FAS include: 1) short palpebral fissure length, 2) a smooth 
philtrum (Rank 4 or 5 on the Lip-Philtrum Guide), and 3) a thin upper lip (Rank 4 or 5 on the Lip-Philtrum Guide). 
Lip-Philtrum Guides 1 and 2 are used to rank upper lip thinness and philtrum smoothness. The philtrum is the 
vertical groove between the nose and upper lip. The guides reflect the full range of lip and philtrum shapes with 
Rank 3 representing the population mean. Ranks 4 and 5 reflect the thin lip and smooth philtrum that 
characterize the FAS facial phenotype. Guide 1 is used for Caucasians and all other races with lips like 
Caucasians. Guide 2 is used for African Americans and all other races with lips as full as African Americans. 
Examples of the FAS facial phenotype across three races: Native American, Caucasian, and African American. 
Copyright 2015, Susan Astley PhD, University of Washington 
 
2.2.1 Prevalence of FASD 
Notwithstanding difficulties in detection, research suggests that FASD is one of the 
most common causes of preventable developmental disability worldwide.78 Studies 
from the USA, Croatia, France, Poland and Italy suggest that 1% to 10% of children 
in the general population have FASD.79-87 The prevalence of FASD is higher among 
children in care, where the pooled prevalence is 17%.88 Rural communities in South 
Africa, where binge pattern PAE is common, have the highest known prevalence of 
FASD in the world (up to 28%).80,89 FASD is associated with over 400 comorbid 
conditions90 and a significantly increased risk of adverse outcomes in later life 
including mental health conditions, lack of independent living and involvement 
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with the criminal justice system.91,92 Early identification is important for improving 
outcomes among affected individuals and for preventing future alcohol-exposed 
pregnancies, but is complicated by difficulties in case ascertainment.65,69,93  
Despite known high levels of prenatal alcohol use in the UK, there are no reliable 
estimates of the prevalence of FASD.94 In the absence of empirical studies, one 
study, published in 2017, estimated that 3.3% (95% CI 2.0% - 4.9%) of children in 
the general population of the UK may have FASD based on a calculation that 
considered the prevalence of PAE and the assumption that one in 13 children with 
PAE will develop FASD.86  
Existing UK studies have been limited to FAS rather than the full spectrum of FASD 
and have methodological limitations, including the use of surveillance methods. 
Surveillance methods use existing records, such as birth defects registers and 
hospital admissions data, and benefit from being relatively inexpensive and easy to 
implement.95 However, studies that use surveillance methods are likely to 
underestimate FASD because most subtypes are not readily detectable at birth and 
case ascertainment is often performed by individuals who are not FASD 
specialists.10,95 This is borne out in data from the Scottish Paediatric Surveillance 
Unit, which showed that between 2010 and 2015 FAS was reported to affect 0.19 
per 1,000 children.96 In Wales, the Congenital Anomaly Register and Information 
Service (CARIS) reported that FAS occurred in 0.78 per 10,000 live births between 
1998 and 2015.97 Hospital admissions data are also of limited use for ascertaining 
prevalence, since FASD is not often a reason for hospitalisation and under-
recognition of FASD means that it is less likely to be coded as a co-existing 
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condition in routine admissions data.10,98 The Health and Social Care Information 
Centre (HSCIC) in England reported 0.17 per 10,000 admissions in which FAS was 
recorded as a primary or secondary diagnosis in 2012 to 2013.99,100 Morleo and 
colleagues reported that the rate of hospital admissions for FAS was 0.08 per 
10,000 population in England between 2002 and 2008.98 Three other UK studies 
found no cases of FAS, using a range of methodologies including health visitor 
screening and medical record review (total number of participants/records = 
12,741).101-103 Gregory and colleagues identified 72 potential cases of FASD during a 
retrospective audit of children who visited a UK community paediatric clinic 
between 2010 and 2013. However, it was not possible to calculate the prevalence 
due to an uncertain denominator.104 
Other methodological difficulties with ascertaining prevalence include the fact that 
health professionals in the UK report a lack of knowledge and confidence in 
identifying FASD.105 Information on PAE is often missing or inaccurate and this 
further complicates FASD identification. Perceived stigma and the lack of a clearly 
defined care pathway have been cited as additional reasons for not investigating 
potential cases of FASD in the UK.96,105,106 The International Statistical Classification 
of Diseases and Related Health Problems (ICD-10) only includes a code for FAS 
(Q86.0 Fetal alcohol syndrome [dysmorphic]) and not for FASD.107 This is likely to 
further contribute to the lack of routine reporting for the full spectrum of FASD 
cases. A meta-analysis published in 2017 reported a FAS prevalence of 37 per 
10,000 in the European region.11 Therefore, the FAS prevalence estimates 
described above are significantly lower than what would be expected, given the 
high levels of PAE in the UK and based on comparisons with international studies.  
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In summary, several factors point to the likelihood that the prevalence of FAS and 
FASD is significantly underestimated in the UK. Active case ascertainment studies 
(where researchers recruit and actively assess participants in the general 
population, most commonly in the form of in-school prevalence studies) have 
produced higher prevalence estimates than surveillance methods and have been 
advocated as the preferred approach for FASD prevalence studies.95 In 2015/16, 
the All Party Parliamentary Group (APPG) on FASD and British Medical Association 
expressed an urgent need for a population-based prevalence study in the UK to 
guide prevention efforts and policy for alcohol use in pregnancy.10,108 However, to 
date, proposals for active case ascertainment studies of FASD in the UK have not 
been successful.108 To address this research gap, I developed and validated FASD 
case ascertainment algorithms (Chapter 3) to enable investigation of the 
epidemiology of FASD using existing data from a population-based birth cohort in 
England (the Avon Longitudinal Study of Parents and Children; ALSPAC). In Chapter 
4, I describe a study in which I applied these case ascertainment algorithms to 
estimate the prevalence of FASD in the ALSPAC cohort. 
2.2.2 Risk factors for FASD 
Alcohol is the sole necessary cause of FASD, however it is not always sufficient. 
Following any PAE an estimated one in 13 children will develop FASD and one in 67 
will develop FAS.11,86 Differences in maternal alcohol metabolism, maternal physical 
characteristics such as weight, and co-occurring exposures are thought to influence 
the risk of FASD.109-111 However, much of the FASD literature has centred around 
discussion of association, rather than causation.109,111 While information about 
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association is important for describing who is at risk of FASD, understanding the 
causal factors that influence the teratogenicity of PAE is essential for identifying 
potential opportunities for intervention and prevention. In Chapter 5, I present a 
causal diagram of risk factors for FASD, based on a systematic literature search and 
narrative synthesis. In Chapter 6, I use this causal diagram to inform multivariable 
analyses of risk factors for FASD using data from the ALSPAC cohort. 
3 Thesis aims and research questions 
3.1 Aims 
i. To assess the validity of the biological tests that are available to obtain an 
objective measure of prenatal alcohol exposure (PAE).  
ii. To describe the epidemiology of fetal alcohol spectrum disorder (FASD) 
within a population-based birth cohort in England (ALSPAC). 
3.2 Research questions 
i. What is the diagnostic accuracy of objective measures of prenatal alcohol 
use? 
ii. What is the prevalence of FASD within the ALSPAC cohort? 
iii. What are the risk factors for FASD within the ALSPAC cohort?  
4 Thesis synopsis 
This introductory chapter has described the context and research questions for this 
thesis. 
Chapter 2 presents a systematic review of the validity of objective measures of 
prenatal alcohol use. 
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Chapter 3 describes the development and validation of case ascertainment 
algorithms for FASD. 
Chapter 4 applies the FASD case ascertainment algorithms that I developed in 
Chapter 3 to produce prevalence estimates for FASD using data from a population 
based birth cohort in England (ALSPAC). 
Chapter 5 presents a narrative literature review and causal diagram (directed 
acyclic graph; DAG) of risk factors for FASD. 
Chapter 6 applies the FASD case ascertainment algorithms from Chapter 3 and uses 
the causal diagram from Chapter 5 to inform a multivariable analysis of potentially 
modifiable causal risk factors for FASD using ALSPAC data. 
Chapter 7 provides a summary of the main results, strengths and limitations, 
implications and conclusions of this thesis.
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Chapter 2. Validity of objective measurement of alcohol use in 
pregnancy: a systematic review  
 
The results from this chapter were published in Pediatrics (McQuire C, Paranjothy 
S, Hurt L, Mann M, Farewell D, Kemp A. Objective measures of prenatal alcohol 
exposure: a systematic review. Pediatrics. 2016;138(3): doi: 10.1542/peds.2016-
0517). 
1 Overview 
This chapter describes a systematic review of the validity of biomarkers of prenatal 
alcohol exposure (PAE). First, I describe existing approaches to PAE screening and 
introduce biomarkers of PAE. I then present the systematic review methods, 
results, discussion and conclusions. Finally, I describe the implications of this review 
for the remaining chapters in this thesis. 
2 Background 
2.1 Current practice in screening for prenatal alcohol use 
Routine antenatal screening is available for all pregnant women in the UK. 
Screening aims to identify a range of conditions including haematological disorders, 
infections, fetal anomalies, gestational diabetes, Down Syndrome and genetic 
disorders.25,112,113 Screening is also available for lifestyle-related behaviours such as 
cigarette smoking. The harms associated with tobacco use in pregnancy are well 
known and midwives can use self-report measures in conjunction with carbon 
monoxide testing to refer women to National Health Service (NHS) smoking 
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cessation services.114 While antenatal screening for physical health conditions and 
tobacco use is well established in the UK, there is no standardised process to assess 
prenatal alcohol use, despite the known risks to the fetus. The Welsh Government 
recommends that midwives discuss alcohol use with pregnant women at the first 
antenatal appointment and NICE state that women should be advised about the 
risks associated with prenatal alcohol consumption.25,115 However, there is a lack of 
guidance on how to assess prenatal alcohol use and a recent UK survey reported 
that 40% of midwives do not routinely ask about PAE.116 Poor screening for alcohol 
use in antenatal care has been identified as a significant barrier to support.64  
Self-report measures are the most common method for assessing maternal alcohol 
use.117 A range of brief screening questionnaires have been used to assess 
hazardous drinking among pregnant women including: TWEAKa, T-ACEb, CAGEc, 
NETd, the Alcohol Use Disorder Identification Test (AUDIT), AUDIT-consumption 
(AUDIT-C) and the Short Michigan Alcohol Screening Test (SMAST).118-120 These 
measures may be useful for identifying particularly high risk pregnancies. However, 
most prenatal alcohol use is occasional and low level12,13,52 and therefore, 
measures of hazardous drinking may not be applicable for the majority of 
individuals in the general antenatal population. The timeline follow-back procedure 
(TLFB), another self-report method, captures the daily frequency and quantity of 
alcohol consumption for particular drinks within a specified time period and thus 
documents the full spectrum of alcohol use.121 The TLFB and an abbreviated 
                                                        
a TWEAK has five items: tolerance, worried, eye-opener, amnesia and cut-down 
b T-ACE has four items: tolerance, annoyed, cut-down, eye-opener 
c CAGE has four items: cut down, annoyed, guilt, eye-opener 
d NET has three items: normal drinker, eye-opener, tolerance 
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version, known as the retrospective diary,63 have been shown to elicit higher 
estimates of maternal drinking than those reported using other measures.63,122,123 
Some consider TLFB based measures to be the gold standard in maternal alcohol 
assessment.117 However, no studies have been conducted to evaluate the 
diagnostic accuracy of the TLFB with a sample of pregnant women.  
Although self-report measures are widely used to estimate prenatal alcohol use, 
they are likely to underestimate true consumption and, therefore, represent an 
imperfect reference standard. A systematic review and meta-analysis found that 
the estimated prevalence of PAE was four times higher in studies that tested for 
biomarkers of ethanol metabolism, compared to those that used self-report.124 The 
underreporting of PAE in self-report measures could be due to factors including a 
fear of persecution, social stigma, difficulties in accurately quantifying alcohol use 
and the fact that mothers may simply not remember their drinking habits during 
the antenatal period.60,125-127 
2.2 Biomarkers: objective measures of prenatal alcohol use 
Due to the limitations of self-report methods, biomarkers have received increasing 
attention as an objective way to establish gestational alcohol use.117,126,128-133 
Biomarkers are “indicators or signalling events in biological systems.”134(p. 488) 
Objective measurement has been defined as a procedure that prevents individuals 
from misrepresenting themselves in terms of the characteristics that are being 
measured by the test.135 
Biomarkers of alcohol metabolism can be classified into two categories: direct and 
indirect. Direct markers of alcohol use include the measurement of ethanol itself in 
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breath and urine. However, ethanol can only be detected for a very short period 
with these methods (typically less than one day), and therefore these direct tests 
are difficult to implement in research and practice.117,130 Other direct markers, such 
as ethanol metabolites, can be detected for longer periods of time and therefore 
may have better clinical utility. Examples of such biomarkers include fatty acid ethyl 
esters (FAEEs). FAEEs do not freely cross the placenta and, therefore, FAEEs in 
meconium (the first stool of the neonate) can be considered to be direct 
biomarkers of fetal alcohol exposure.134 Other direct markers of recent alcohol 
consumption include ethyl glucuronide (EtG) and ethyl sulphate (EtS). EtG can be 
measured in urine for around five days after use and EtS for around one and a half 
days.136,137 Finally, phosphatidylethanol (PEth) is a direct ethanol metabolite that 
can be detected in blood for approximately three weeks following alcohol 
intake.117,138 
Indirect markers are those that signal alcohol-induced pathology following 
prolonged exposure. Examples include the liver enzyme gamma-
glutamyltransferase (GGT); mean corpuscular volume (MCV), a measure of red 
blood cell volume; and carbohydrate-deficient transferrin (CDT), a form of iron-
transporting transferrin. All are elevated following sustained heavy alcohol use and 
have been used most commonly to evaluate alcohol use among those with alcohol 
misuse disorders.117,130,139 Table 1 provides a summary of objective measures of 
PAE. 
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Table 1 (continued overleaf): Overview of objective measures of prenatal alcohol use 
 Biomarker Matrix Detection windowa Lowest 
detectable level 
of alcohol use  
Direct 
biomarkers 
Ethanol Blood, breath, urine < 1 day Lowb 
Ethyl sulphate (EtS) Urine  30 hours Low/moderate 
Blood < 1 day 
Placenta Unknown  
Fetal tissue Unknown 
Meconium  Reflects 2nd and 3rd trimester exposure 
Ethyl glucuronide (EtG)  Urine < 5 days Low/moderate 
Hair Maternal hair: months to years depending on hair 
lengthc  
Neonatal hair: captures third trimester exposure and 
typically sheds 3 months after birth 
Moderate 
Blood < 1 day 
Meconium  Reflects 2nd and 3rd trimester exposure. 
Placenta Unknown 
Fetal tissue Unknown 
Fatty acid ethyl esters 
(FAEEs) 
Meconium 
 
Reflects 2nd and 3rd trimester exposure. Moderate 
Hair Maternal hair: months to years depending on hair 
length  
Neonatal hair: captures third trimester exposure and 
typically sheds 3 months after birth  
Blood 1 day 
Haemoglobin 
acetaldehyde adducts 
(Hb-Ach) 
Blood ≤ 4 weeks Moderate 
Phosphatidylethanol 
(PEth)  
Blood ≤ 3 weeksd  Moderate 
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 Biomarker Matrix Detection windowa Lowest detectable 
level of alcohol use  
Indirect 
biomarkers 
Alanine aminotransferase (ALT) Blood ≤ 3 weeks High 
Acetaldehyde-protein adducts 
(APAs) 
Blood < 4 weeks High 
Aspartate aminotransferase 
(AST) 
Blood < 3 weeks High 
Carbohydrate deficient 
transferrin (CDT) 
Blood < 4 weeks High 
Gamma glutamyltransferase 
(GGT) 
Blood ≤ 3 - 4 weeks High 
Mean corpuscular volume 
(MCV) 
Blood ≤ 17 weeks High 
Ratio of 5-hydroxytryptophol/5-
hydroxyindolylacetic acid  
(5-HTOL/5-HIAA) 
Urine < 1 day Moderate/high 
Notes: Biomarkers in this table were identified from Joya et al. (2012)130 and from the search for the current review. 
a Detection window refers to the period in which the biomarker can be detected following alcohol consumption. 
b Definitions vary between studies. This review classifies light drinking as equivalent to < 3 drinks per week, moderate drinking 3 to 7 drinks per week, and 
heavy drinking > 7 drinks per week or a binge pattern of ≥ 4 drinks per occasion. 
c Hair grows at approximately 1 cm per month. The section closest to the root represents the most recent period of exposure. 
d In maternal blood; duration in neonatal blood unknown. 
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3 Study rationale and aim 
Recently, some groups have advocated the introduction of universal biomarker 
screening programmes for PAE.127,140 For example, meconium testing is 
recommended within the Canadian FASD National Screening Tool Kit.141 However, 
the evidence for the diagnostic accuracy of biomarker testing has not been 
comprehensively evaluated. In this context, the aim of this chapter was to present 
a systematic review of the diagnostic accuracy of objective measures of PAE. 
4 Method 
I followed the Cochrane Collaboration guidelines for systematic reviews of 
diagnostic test accuracy,142 the Standards for the Reporting of Diagnostic Accuracy 
Studies (STARD),143 and the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement.144 The study protocol was published in the 
PROSPERO international prospective register of systematic reviews 
(www.crd.york.ac.uk; record number CRD42014015420). 
4.1 Search strategy 
I searched 13 electronic databases, including sources of grey literature, from 
January 1990 to August 2015 for original articles using combinations of terms 
related to objective measures and diagnostic accuracy and prenatal alcohol 
exposure. Searches were limited to publications from January 1990 onwards to 
increase precision. A scoping exercise of existing non-systematic reviews revealed 
no relevant articles prior to 1990.126,130,134,137,145 Databases are listed in Figure 4 and 
the full search strategy for Medline is available in Appendix 1. The Medline search 
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string was translated for use in all other databases. I searched supplementary 
sources for articles published between November 2012 and October 2015 and 
contacted authors to request further information about missing or conflicting data. 
4.2 Inclusion and exclusion criteria 
Eligible studies were those that investigated the diagnostic accuracy of any 
objective measure of PAE in comparison to any reference standard, among 
pregnant and/or postpartum women and/or neonates. The Cochrane Collaboration 
defines a gold standard reference test as the method, procedure, or measurement 
that is widely accepted as being the best available and against which new 
developments should be compared.146 Due to the inherent limitations of self-report 
and because there is no consistently applied method for measuring alcohol use in 
pregnancy, no one reference test could be considered the gold standard for the 
purposes of this review.147 
Eligible study designs included randomised screening studies and diagnostic 
‘cohort-type’, and ‘case-control type’ studies. Diagnostic accuracy studies are 
typically cross-sectional in design. Participants either have the target condition or 
not (i.e. prenatal alcohol consumption) at the point of inclusion and they receive 
the reference test to verify their status, which is compared to the result of the 
index test(s). However, these studies can be further classified as diagnostic ‘cohort 
type’, ‘case-control type’ or ‘nested case-control type’. Cohort type studies recruit 
participants based on a single set of inclusion criteria that are not based on 
whether the target condition is present or absent (e.g. all women attending a 
healthcare centre in the first trimester of their pregnancy), whereas case-control 
Chapter 2 22 
type studies use different selection criteria based on whether the target condition 
is present or absent (e.g. the study selects one group of women who are known to 
have consumed alcohol while pregnant and one group of abstainers). Diagnostic 
nested case-control studies are those in which cases and controls are drawn from a 
well-defined cohort and then a subset of cases and controls are selected for 
analysis.148-150 
I excluded conference abstracts, studies with missing outcome data, and studies of 
non-human animals. Non-English language publications were excluded due to a 
lack of funding for translation costs.  
4.3 Study selection 
After removing duplicates, I screened the search records against the pre-
determined inclusion criteria and excluded ineligible studies based on the title or 
abstract. I obtained full text versions to determine the inclusion of potentially 
relevant studies. A random selection of 10% of these studies were independently 
assessed for eligibility by two members of the supervisory team (LH and SP). The 
level of agreement for inclusion decisions was 100%.  
4.4 Data extraction 
I extracted all data into a standardised electronic form, which I designed based on 
the Guidelines International Network (GIN) template for diagnostic studies and the 
Standards for Reporting of Diagnostic Accuracy (STARD).143,151 SP or LH 
independently repeated data extraction to ensure accuracy. The extracted 
information included details of the study design, participants, index and reference 
test characteristics and diagnostic accuracy outcomes. Alcohol data were classified 
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according to the United States National Institute on Alcohol Abuse and Alcoholism 
criteria for the general population in which one standard drink is equivalent to 0.6 
oz or 14 g of ethanol and light drinking is equivalent to < 3 drinks per week, 
moderate drinking 3 to 7 drinks per week, and heavy drinking > 7 drinks per week 
or a binge pattern of ≥ 4 drinks per occasion.152  
4.5 Quality assessment  
I used a modified version of the Quality Assessment of Diagnostic Accuracy Studies 
tool (QUADAS-2) to assess the methodological quality of included diagnostic 
accuracy studies.150 QUADAS-2 was tailored to address specific areas of relevance 
for the review, following guidance from the Cochrane Collaboration.153,154 The 
methodological quality evaluation assessed risk of bias in nine domains: participant 
selection, reference standard, detection window, partial verification, differential 
verification, incorporation bias, uninterpretable results, withdrawals and selective 
outcome reporting (see Appendix 2 for full quality coding criteria).  
4.6 Analysis and data synthesis 
The Rutter and Gatsonis hierarchical summary receiver operating characteristic 
(HSROC) model is recommended for meta-analyses of diagnostic accuracy data. 
However, a minimum of four studies per test is required for this method.155,156 
Moses-Littenberg SROC curves can be generated in Review Manager (RevMan)157 
software with fewer than four studies, but are not recommended for use, except 
for in exploratory analyses, such as investigations of heterogeneity.156 Due to the 
diverse nature of the data, which included a variety of measures and assay 
methods across multiple matrices, none of the index test categories had a sufficient 
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number of studies to facilitate meta-analysis. Therefore, I conducted a narrative 
synthesis of the data.  
The key diagnostic accuracy outcomes were sensitivity, specificity, predictive 
values, and likelihood ratios. Figure 3 presents a schematic summary of the key 
diagnostic accuracy outcomes. Sensitivity and specificity are used widely and 
capture the intrinsic accuracy of a test, as they are not influenced by the 
prevalence of the target condition.158 Sensitivity and specificity are conditional on 
the ‘disease status’ of the individual (i.e. whether the target condition, in this case 
PAE, is present or absent). Sensitivity is the proportion of true positives that are 
correctly identified by the test and specificity is the proportion of true negatives 
that are correctly identified by the test. In absolute terms, a test with a sensitivity 
of 80% will detect 80 out of every 100 individuals with the target condition but will 
miss 20. A test with a specificity of 90% will correctly identify 90 out of every 100 
individuals without the target condition but 10 will be wrongly identified as having 
the condition.156,159 
NICE have previously recommended that sensitivity and specificity values of 80% 
(with a lower 95% confidence interval limit of greater than 70%) indicate 
acceptable diagnostic test accuracy.160 However, it is important to note that the 
relative importance of sensitivity and specificity values are likely to vary according 
to the condition being assessed. There is no research to suggest what level of 
diagnostic accuracy is acceptable for assessing PAE, or the relative importance of 
false positive and false negative errors. 
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Figure 3: Schematic overview of key diagnostic accuracy statistics 
  
While sensitivity and specificity have been considered fundamental metrics within 
diagnostic test accuracy research, some argue that positive and negative predictive 
values provide greater clinical utility.158,161 Positive and negative predictive values 
are conditional on the test outcome and capture the probability that a test will 
provide the correct result. In clinical practice, it is often the case that only the index 
test result, rather than the true presence of the target condition, is known. 
Therefore, it is important to evaluate how many individuals with positive test 
results actually have the condition of interest.161,162 Positive predictive value (PPV) 
refers to the proportion of individuals with a positive test result who are correctly 
identified as having the target condition. Negative predictive value (NPV) refers to 
the proportion of individuals with a negative test result who are correctly identified 
as not having the target condition. In absolute terms, for a test with a positive 
predictive value of 80%, 80 out of every 100 individuals with a positive test result 
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will have the target condition, but 20 will not. For a test with a negative predictive 
value of 90%, 90 out of every 100 individuals with a negative test result will not 
have the target condition, but 10 will. Unlike sensitivity and specificity, positive and 
negative predictive values are dependent on prevalence and therefore, it may not 
be possible to generalise findings across settings, where prevalence differs.158,159,162 
Finally, likelihood ratios express how many times more or less likely a participant 
with the target condition is to have a particular test result than those without the 
target condition.163 The particular advantage of likelihood ratios is that, like 
predictive values, they give the probability of the target condition given certain test 
results. Furthermore, they are not dependent on a fixed prevalence of the target 
condition and can be adapted to accommodate differences in baseline prevalence 
across settings. Thus, they have greater potential for generalisability and clinical 
application than predictive values.163  
I used RevMan to collate the diagnostic accuracy data.157Where necessary, the 
RevMan calculator was used to derive diagnostic summary statistics from true 
positive, true negative, false positive and false negative values and vice-versa. If 
there were insufficient data to enable the use of the RevMan calculator, R 
software164 was used to conduct an exhaustive search of all possible 2 x 2 tables 
that were consistent with the data supplied in the primary study. I generated 
confidence intervals using the exact binomial method165 in RevMan for sensitivity 
and specificity values and with the MedCalc online calculator166 for predictive 
values. Confidence intervals for likelihood ratios were generated using the method 
described by Koopman.167 
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Many studies reported a range of diagnostic accuracy values according to 
characteristics such as positivity cut-off and period of measurement. To aid clarity 
of findings, I report only the highest values of both sensitivity and specificity per 
study within the summary of results.  
5 Results 
5.1 Search results 
From 4,278 search records, 12 studies with 1,614 unique participants, were eligible 
for inclusion. Figure 4 presents a flow diagram of the search and study selection 
process, and Table 2 presents the characteristics of the included studies. 
5.2 Characteristics of included studies 
Eligible studies included data on participants from the USA (5),168-172 Korea (2),173,174 
Spain (1),175 South Africa (1),176 and Finland (1)177, and combined data from the USA 
and Jordan (1),178 and Canada and Israel (1).179 Diagnostic accuracy data were 
available for eight types of biomarker: carbohydrate deficient transferrin 
(CDT),168,172,177 ethyl sulphate (EtS),168,172 ethyl glucuronide (EtG),168,172,175 fatty acid 
ethyl esters (FAEEs),168-171,173,176,178,179 gamma glutamyltransferase (GGT),168,172,177 
haemoglobin acetaldehyde adducts (Hb-Ach),177 mean corpuscular volume 
(MCV)177 and phosphatidylethanol (PEth),168,172,174 within six matrices: 
meconium,168-170,173,176,178,179 placenta,171 maternal urine,168,172 maternal 
blood,168,172,174,177 maternal hair172,175 and infant blood.168 Eight studies investigated 
tests of moderate to heavy prenatal alcohol consumption168,171,172,174,176-179 and 
nine recruited women from high-risk settings, such as substance misuse clinics.168-
172,176-179 Eight of the eligible studies recruited pregnant women who reported 
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abstinence from alcohol as a comparison group.168-170,172-174,178,179 Two of these 
studies included an additional control group of pregnant women from cultures that 
promote abstinence from alcohol.178,179 Three of the studies explored test 
performance for distinguishing between heavy drinkers and women with lower 
levels of prenatal alcohol consumption171,176,177 and one study did not report 
characteristics of the control group.175 
Figure 4: Flow diagram of the search and study selection process 
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Table 2 (continued overleaf): Characteristics of included studies of objective measures of prenatal alcohol exposure (PAE).  
Study Country Casesa Controlsa High risk 
setting 
PAE level Study 
prevalence 
of PAE 
Matrix Analyte(s) Period of 
sample 
collection 
Reference 
standard 
Bakhireva 
2014168 
USA 28 32 Substance 
misuse clinic 
Moderate-
heavy 
47% Meconium FAEE Postnatal TLFB and AUDIT 
Infant blood PEthb Postnatal 
Maternal blood CDT, GGT, 
PEthb 
Prenatal 
Maternal urine EtG, EtSb Prenatal 
Bearer 
1999169 
USA 56 88 Substance 
misuse clinic 
Any 39% Meconium FAEE Postnatal Maternal postnatal 
interview 
Bearer 
2003176 
South 
Africa 
19 6 Dop system 
region 
Heavy 76% Meconium FAEE Postnatal TLFB 
Bearer 
2005178 
Jordan 
& USA 
13c 211c Substance 
misuse clinic 
Heavy 6%c Meconium FAEE Postnatal Maternal postnatal 
interview 
Chan 
2003179 
Canada 
& Israel 
6 73 Women with 
alcoholism 
Heavy 8% Meconium FAEE Postnatal Controls: 
unspecified self-
report 
Cases: confirmed 
by the referring 
agency or 
physician 
Gauthier 
2015171 
USA 11 69 Premature 
newborns 
Heavy 14% Placenta FAEE Postnatal Self-report based 
on AUDIT 
Gutierrez 
2015172 
USA 42d 43d Substance 
misuse clinic 
Moderate-
heavy 
49% Maternal blood CDT, GGT, 
PEth 
Prenatal TLFB and AUDIT 
Maternal urine EtG, EtS 
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Study Country Casesa Controlsa High risk 
setting 
PAE level Study 
prevalence 
of PAE 
Matrix Analyte(s) Period of 
sample 
collection 
Reference 
standard 
Maternal hair EtG 
Joya 2016175 Spain 30 50 NR Any 38% Maternal hair EtG Postnatal Meconium EtG 
Kwak 
2014a173 
Korea 54 182 NR Low-
moderate 
23% Meconium FAEE Postnatal Unspecified self-
report 
Kwak 
2014b174 
Korea 117 
30 
8 
188 
275 
297 
NR Low 
Moderate 
 Heavy 
38% 
10% 
3% 
Maternal blood PEth Prenatal Unspecified self-
report 
Ostrea 
2006170 
USA 93 31 Substance 
misuse clinic 
Any 75% Meconium FAEE Postnatal Unspecified self-
report, MAST, 
CAGE and TACE 
Sarkola 
2000177 
Finland 13e 31e Substance 
misuse clinic 
Heavy 30% Maternal blood CDT, GGT, 
Hb-Ach, 
MCV 
Prenatal Unspecified self-
report 
Abbreviations: AUDIT, Alcohol Use Disorder Identification Test; CAGE, cut down, annoyed, guilt, eye-opener; CDT, carbohydrate deficient transferrin; EtG, 
ethyl glucuronide; EtS, ethyl sulphate; FAEE, fatty acid ethyl esters GGT, gamma glutamyltransferase; Hb-Ach, haemoglobin acetaldehyde adducts; PEth, 
phosphatidylethanol; MAST, Michigan Alcohol Screening Test; NA not applicable; NR, not reported; TACE, tolerance, annoyed, cut-down, eye-opener; TLFB, 
timeline follow-back procedure. 
a Number of participants included in analysis. Cases are participants with the defined level of PAE within the study and controls are those without PAE as 
defined by the study. 
b I excluded data from this study that compared the results of postnatal maternal EtG, EtS, GGT, CDT and PEth in dried infant blood spots with prenatal self-
report due to the short detection window of these biomarkers. 
c The number of cases and controls were not reported in this study. Therefore, the figures presented in the table are those that provided the closest match to 
the study outcome data based on a simulation of all possible values in R software. 
d Cases and controls for analysis of hair EtG. Due to missing data, there were 41 cases and 42 controls in the analysis of urine EtG and EtS, 40 cases and 43 
controls in the analysis of PEth, and 40 cases and 42 controls in the analysis of GGT and CDT. 
e Due to missing data, there were 13 cases and 28 controls for GGT analyses due to exclusion of three participants with hepatitis C and elevated alanine 
aminotransferase. 
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5.3 Methodological quality of included studies 
Results of the QUADAS-2 quality assessment are presented in Figure 5 and Figure 6.  
Figure 5: Methodological quality summary for each included study. Ratings indicate risk of bias for each 
domain. Green symbol = low risk; yellow symbol = unclear risk; red symbol = high risk. 
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Figure 6: Methodological quality ratings for each domain represented as a percentage across all included 
studies. 
 
All but one of the included studies had a high risk of bias for the reference standard 
domain due to the use of a self-report reference standard.168-174,176-179 Self-report is 
known to be an imperfect reference standard for reasons previously described. The 
remaining study175 used meconium EtG as the reference standard. This study was 
considered to have an unclear risk of bias as the validity of meconium EtG has not 
been established and there is a lack of agreement about the optimal positivity 
threshold for this biomarker.180-182 Seven studies had a high risk of bias in the 
participant selection domain due to the use of diagnostic case-control 
designs,168,169,172,173,176,178,179 which may inflate diagnostic accuracy 
estimates.149,183,184 Nine studies had a low risk of bias for uninterpretable 
results,168,170,173-179 withdrawals,168,172-179 differential verification,168,169,171-177 and 
partial verification.168,171-177,179 One study had a high risk of incorporation bias, as 
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EtG was used to indicate alcohol exposure in both the reference standard and 
index test.175 
Seven studies had a low risk of bias for the detection window 
domain.168,169,173,175,177-179 Of these studies, two reported data for multiple index 
tests both with and without an appropriate window of detection.168,178 To reduce 
the risk of bias, I excluded data from one study that looked at the agreement 
between self-reported alcohol use in the first trimester and meconium testing,178 
as meconium does not begin to accumulate until the second and third 
trimesters.134 I also excluded data from another study that compared self-reported 
PAE during the second trimester with postnatal tests of maternal EtG, EtS, GGT, 
CDT and PEth in dried infant blood spots due to the short detection window of 
these biomarkers.168 Of the remaining studies, two had an unclear risk of bias and 
three had a high risk of bias. Two of these studies170,176 were deemed to have a 
high risk of bias as the accuracy of meconium testing was verified against alcohol 
use across the whole of pregnancy, including the first trimester before meconium is 
generated. It was not possible to exclude first trimester data from my analysis due 
to the way results were reported. One study,172 which collected maternal hair 
during pregnancy for EtG testing, was also considered to have a high risk of bias as 
the specimen may have captured alcohol use prior to pregnancy due to the broad 
detection window of EtG within this matrix.  
Finally, selective outcome reporting introduced a high risk of bias in four 
studies.169,176,178,179 Of these studies, three measured multiple FAEEs in meconium 
but only reported the diagnostic accuracy outcomes for a subset of these 
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FAEEs.169,176,178 Two studies171,178 did not provide sufficient data to enable the 
calculation of missing true positive, true negative, false positive and false negative 
values. For these studies, I used a R simulation to produce data that replicated the 
sensitivity, sensitivity and predictive values reported in one of the studies,171 and to 
generate values that approximated the published data in another study.178 For the 
remaining study of meconium FAEEs,179 the positive predictive value reported in 
the study did not match the value suggested by the raw data (see Table 3 for 
further details). The study authors were unable to provide data to further explore 
this discrepancy. Finally, I was not able to replicate the published sensitivity and 
specificity values based on the true positive, true negative, false positive, and false 
negative values presented in one study of maternal hair testing.175 Following 
correspondence with the authors the correct sensitivity and specificity values were 
derived based on the raw values presented in the paper (see Table 6).  
5.4 Diagnostic test accuracy results 
Tables 3 to 8 present diagnostic accuracy outcomes with 95% confidence intervals.  
5.4.1 Meconium testing 
Meconium testing for FAEEs was the most commonly investigated index test, 
featuring in seven studies.168-170,173,176,178,179 The diagnostic accuracy of FAEEs varied 
widely across studies (see Table 3). A measure of the total concentration of four 
FAEEs showed the highest levels of diagnostic accuracy overall, but there were a 
high number of false positives in one study168 and specificity was inconsistent.168,179  
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5.4.2 Placenta testing 
One study measured FAEEs in the placenta tissue of a sample of premature 
deliveries.171 Sensitivity and specificity values were high, although 30% to 56% of 
positive test results were false positives (see Table 4).  
5.4.3 Blood testing 
Four studies investigated CDT, GGT, Hb-Ach, MCV and PEth168,172,174,177 within 
prenatal samples of maternal blood. Blood biomarkers generally demonstrated 
high specificity but low sensitivity (see Table 5). Likelihood ratios suggested that 
the accuracy of PEth testing improved as PAE increased from low to moderate to 
heavy. However, findings of high levels of sensitivity (100%) and specificity (96%) in 
one study of heavy PAE174 were not replicated in two other studies in which 
sensitivity ranged from 18% to 22%.168,172  
5.4.4 Hair testing 
Maternal hair was tested for EtG in two studies,172,175 with contrasting results (see 
Table 6). Neither of the studies demonstrated high levels of both sensitivity and 
specificity.  
5.4.5 Urine testing 
Two studies of maternal urine testing found that measures of EtS and EtG had low 
sensitivity but high specificity168,172 (see Table 7).  
5.4.6 Test batteries 
Three studies investigated the diagnostic accuracy of test batteries, which included 
combinations of different biomarkers across several matrices.168,172,177 Sensitivity 
was poor, while specificity was generally good (see Table 8). 
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Table 3 (continued overleaf): Diagnostic accuracy outcomes for studies of meconium testing for prenatal alcohol exposure (PAE). 
Index test 
analyte(s) 
Study Trimester 
of PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Ethyl 
arachidonate 
Bearer 
2005178(a,b) 
3rd GC/FID 306 ng/g 88 (55-98) 63 (56-70) 9 (6-21) 99 (95-100) 2.3 (1.7-3.1) 0.2 (0.1-0.9) 
Ostrea 
2006170 
Any GC/MS 902 ng/g 18 (11-28) 97 (83-100) 94 (73-100) 28 (20-38) 5.7 (0.8-40.9) 0.8 (0.8-1.0) 
Ethyl 
docosahexanoate 
Ostrea 
2006170 
Any GC/MS 1000 ng/g 4 (1-11) 100 (89-100) 100 (40-
100) 
26 (18-35) ∞ (0.1-∞) 1.0 (0.9-1.0) 
Ethyl laurate Ostrea 
2006170 
Any GC/MS 50 ng/g 19 (12-29) 81 (63-93) 75 (53-90) 25 (17-35) 1.0 (0.4-2.3) 1.0 (0.8-1.2) 
Ethyl linoleate Bearer 
2005178(a,b) 
2nd GC/FID 383 ng/g 89 (64-100) 58 (51-65) 9 (6-20) 99 (95-100) 2.2 (1.8-2.7) 0.1 (0.0-0.9) 
Bearer 
1999169(b) 
3rd GC/FID 1 pmol/g 68 (54-80) 51 (40-62) 47 (36-58) 71 (60-82) 1.4 (1.1-1.8) 0.6 (0.4-1.0) 
Ostrea 
2006170 
Any GC/MS 250 ng/g 27 (18-37) 97 (83-100) 96 (80-100) 31 (22-41) 8.3 (1.2-59.0) 0.8 (0.7-0.9) 
Ethyl linolenate Ostrea 
2006170 
Any GC/MS 100 ng/g 3 (1-9) 100 (89-100) 100 (29-
100) 
26 (18-34) ∞ (0.1-∞) 1.0 (0.9-1.0) 
Ethyl myristate Ostrea 
2006170 
 
 
Any GC/MS 50 ng/g 68 (57-77) 29 (14-48) 74 (63-83) 23 (11-39) 1.0 (0.7-1.2) 1.1 (0.6-2.1) 
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Index test 
analyte(s) 
Study Trimester 
of PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Ethyl oleate Bearer 
2005178(a,b) 
3rd GC/FID 445 ng/g 80 (46-95) 58 (51-65) 5 (5-18) 99 (93-100) 1.8 (1.3-2.6) 0.4 (0.2-1.1) 
Bearer 
2003176 
Any GC/MS/MS 32 ng/g 84 (60-97) 83 (36-100) 94 (71-100) 63 (24-91) 5.1 (0.8-30.6) 0.2 (0.1-0.6) 
Bakhireva 
2014168 
Any GC/MS 50 ng/g 86 (67-96) 25 (11-43) 50 (35-65) 67 (35-90) 1.1 (0.9-1.5) 0.6 (0.2-1.7) 
 Ostrea 
2006170 
Any GC/MS 50 ng/g 49 (39-60) 58 (39-75) 78 (65-87) 28(17-40) 1.2 (0.7-1.9) 0.9 (0.6-1.2) 
Ethyl palmitate Ostrea 
2006170 
Any GC/MS 50 ng/g 58 (47-68) 42 (25-61) 75 (63-84) 25 (14-39) 1.0 (0.7-1.4) 1.0 (0.6-1.6) 
Ethyl stearate Ostrea 
2006170 
Any GC/MS 100 ng/g 19 (12-29) 87 (70-96) 82 (60-95) 26 (18-36) 1.5 (0.5-4.1) 0.9 (0.8-1.1) 
Total 
concentration of 
4 FAEEsc 
Bakhireva 
2014168 
Any GC/MS 600 ng/g 100 (88-100) 13 (4-29) 50 (36-64) 100 (40-100) 1.1 (1.0-1.3) 0.0 (0.0-2.5) 
 Chan 
2003179(d) 
Any GC/FID 600 ng/g 100 (54-100) 98 (93-100) 63 (24-91) 100 (95-100) 73.0 (10.4-
511.3) 
0.0 (0.0-1.1) 
Total 
concentration of 
6 FAEEse 
Bakhireva 
2014168 
Any GC/MS 10,000 
ng/g 
86 (67-96) 13 (4-29) 46 (32-61) 50 (16-84) 1.0 (0.8-1.2) 1.1 (0.3-4.2) 
Bakhireva 
2014168 
Any GC/MS 100,000 
ng/g 
29 (13-49) 81 (64-93) 57 (29-82) 57 (41-71) 1.5 (0.6-3.9) 0.9 (0.7-1.2) 
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Index test 
analyte(s) 
Study Trimester 
of PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Total 
concentration of 
9 FAEEsf 
Kwak 
2014a173 
2nd or 3rd LC/MS/MS 20 nmol/g 4 (0-13) 98 (95-100) 41 (5-85) 78 (72-83) 2.2 (0.4-13.1) 1.0 (0.9-1.0) 
Abbreviations: CI, confidence interval; FAEEs, fatty acid ethyl esters; GC/FID, gas chromatography with flame ionization detection; GC/MS, gas chromatography 
mass spectrometry; GC/MS/MS, gas chromatography tandem mass spectrometry; LR+, positive likelihood ratio; LR-, negative likelihood ratio; NPV, negative 
predictive value; PPV, positive predictive value; sens, sensitivity; spec, specificity. 
a Confidence intervals are an approximation, due to missing data, based on a simulation of all possible 2 x 2 table in R software assuming N = 224 and 13 individuals 
with the target condition (cases). The summary statistics reported in this table are those from the original study. The corresponding values suggested by the R 
simulation were sensitivity 85%, specificity 63%, PPV 12% and NPV 99% for ethyl arachidonate; sensitivity 92%, specificity 58%, PPV 12% and NPV 99% for ethyl 
linoleate; sensitivity 77%, specificity 58%, PPV 10% and NPV 98% for ethyl oleate. 
b Bearer 1999 and Bearer 2005 include the same participants. 
c Ethyl palmitate, ethyl stearate, ethyl oleate, ethyl linoleate. 
d The PPV presented in this table (63%) for Chan 2003 is the value reported in the primary study. However, my calculations produce a PPV of 87% based on the 
reported number of participants included in the sensitivity and specificity analyses (79 total, including 6 cases) and reported values of 100% specificity and 98% 
sensitivity. The authors were unable to provide the original data to further explore this discrepancy. 
e Ethyl palmitate, ethyl palmitoleate, ethyl stearate, ethyl oleate, ethyl linoleate, ethyl arachidonate. 
f Ethyl palmitate, ethyl palmitoleate, ethyl stearate, ethyl oleate, ethyl linoleate, ethyl linolenate, ethyl arachidonate, ethyl laurate, ethyl myristate. 
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Table 4: Diagnostic accuracy outcomes for one study of placenta testing for prenatal alcohol exposure (PAE) 
Index test 
analyte(s) 
Study Trimest
er of 
PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Ethyl stearate Gauthier 
2015171 
Any GC/MS NR 82 (48-98) 87 (77-94) 50 (26-74) 97 (88-100) 6.3 (3.2-12.3) 0.2 (0.1-0.7) 
Ethyl linoleate Gauthier 
2015171 
Any GC/MS NR 82 (48-98) 83 (72-91) 44 (22-66) 97 (88-100) 4.7 (2.6-8.4) 0.2 (0.1-0.8) 
Total 
concentration 
of 3 FAEEsa 
Gauthier 
2015171 
Any GC/MS NR 82 (48-98) 94 (86-98) 70 (39-91) 97 (90-100) 14.1 (5.2-38.0) 0.2 (0.1-0.7) 
Total 
concentration 
of 4 FAEEsb 
Gauthier 
2015171 
Any GC/MS NR 82 (48-98) 93 (84-98) 64 (35-87) 97 (89-100) 11.3 (4.6-27.5) 0.2 (0.1-0.7) 
Abbreviations: CI, confidence interval; FAEEs, fatty acid ethyl esters; GC/MS, gas chromatography mass spectrometry; LR+, positive likelihood ratio; LR-, negative 
likelihood ratio; NPV, negative predictive value; NR, not reported; PPV, positive predictive value; sens, sensitivity; spec, specificity. 
a Ethyl oleate, ethyl linoleate and ethyl linolenate. 
b Ethyl oleate, ethyl linoleate, ethyl linolenate and ethyl stearate. 
 
  
Chapter 2 40 
Table 5 (continued overleaf): Diagnostic accuracy outcomes for studies of blood testing for prenatal alcohol exposure (PAE). 
Index 
test 
analyte 
Study Trimester 
of PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
%CDTa Bakhireva 
2014168 
Any HPLC 2% 4 (0-18) 100 (89-100) 100 (3-100) 54 (41-67) ∞ (0.1-∞) 1.0 (0.9-1.0) 
Gutierrez 
2015172 
Any HPLC 2% 5 (1- 17) 100 (92-100) 100 (16-100) 53 (41-64) ∞ (0.2-∞) 1.0 (0.9-1.0) 
Sarkola 
2000177 
Any Immuno-
assay 
NR 15 (2-45) 87 (70-96) 30 (4-78) 71 (54-85) 1.2 (0.2-5.7) 1.0 (0.7-1.3) 
Total 
CDT  
Sarkola 
2000177 
Any Immuno-
assay 
NR 8 (0-36) 94 (79-99) 33 (1-91) 71 (54-84) 1.2 (0.1-12.0) 1.0 (0.8-1.2) 
GGT Bakhireva 
2014168 
Any Enzymatic 
rate 
method 
40 U/L 15 (4-33) 100 (89-100) 100 (40-100) 57 (43-70) ∞ (0.5-∞) 0.9 (0.7-1.0) 
Gutierrez 
2015172 
Any Enzymatic 
rate 
method 
40 U/L 20 (9-36) 98 (87-100) 89 (52-100) 56 (44-68) 8.4 (1.1-64.2) 0.8 (0.7-1.0) 
Sarkola 
2000177 
Any Immuno-
assay 
NR 31 (9-61) 79 (59-92) 40 (12-74) 71 (52-86) 1.4 (0.5-4.2) 0.9 (0.6-1.3) 
Hb-Ach Sarkola 
2000177 
Any Immuno-
enzymatic 
method 
NR 0 (0-25) 97 (83-100) 0 (0-98) 70 (54-83) 0.0 (0.0-33.4) 1.0 (1.0-1.1) 
MCV Sarkola 
2000177 
Any Coulter C7 
cell 
counter 
NR 15 (2-45) 100 (89-100) 100 (16-100) 74 (58-86) ∞ (0.5-∞) 0.8 (0.7-1.1) 
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Index 
test 
analyte 
Study Trimester 
of PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
PEth Bakhireva 
2014168 
Any LC/MS/MS 8 ng/mL 22 (8-41) 100 (89-100) 100 (54-100) 60 (45-72) ∞ (0.8-∞) 0.8 (0.6-1.0) 
Gutierrez 
2015172 
Any LC/MS/MS 8 ng/mL 18 (7-33) 100 (92-100) 100 (59-100) 57 (45-68) ∞ (0.9-∞) 0.8 (0.7-1.0) 
Kwak 
2014b173 
1st LC/MS/MS 4.2 nmol/Lb 100 (63-100) 96 (93-98) 43 (20-67) 100 (99-100) 27.0 (15.1-48.2) 0.0 (0.0-0.9) 
Kwak 
2014b173 
1st LC/MS/MS 3.8 nmol/Lb 67 (47-83) 96 (93-98) 67 (47-83) 96 (93-98) 18.3 (9.5-35.4) 0.3 (0.2-0.6) 
Kwak 
2014b173 
1st LC/MS/MS 1.2 nmol/Lb 41 (32-50) 95 (91-98) 85 (72-93) 72 (66-78) 8.6 (4.4-16.8) 0.6 (0.5-0.7) 
Abbreviations: CDT, carbohydrate deficient transferrin; CI, confidence interval; GGT, gamma glutamyltransferase; Hb-Ach, haemoglobin acetaldehyde adducts; 
HPLC, high performance liquid chromatography; LC/MS/MS, liquid chromatography tandem mass spectrometry; LR+, positive likelihood ratio; LR-, negative 
likelihood ratio; MCV, mean corpuscular volume; NPV, negative predictive value; NR, not reported; PEth, phosphatidylethanol; PPV, positive predictive value; 
sens, sensitivity; spec, specificity. 
a Percentage of CDT in total transferrin. 
b A threshold of 4.2 nmol/L was specified for the detection of heavy PAE, 3.8 nmol/L for moderate PAE and 1.2 nmol/L for low PAE. 
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Table 6: Diagnostic accuracy outcomes for studies of hair testing for prenatal alcohol exposure (PAE) 
Index 
test 
analyte 
Study Trimester 
of PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
EtG Gutierrez 
2015172 
Any LC/MS/MS 8 pg/mg 19 (9-34) 86 (72-95) 57 (29-82) 52 (40-64) 1.4 (0.5-3.6) 0.9 (0.8-1.1) 
Joya 
2016175(a) 
2nd or 3rd UPLC 11 pg/mg 87 (69-96) 56 (41-70) 54 (39-69) 88 (71-96) 2.0 (1.4-2.8) 0.2 (0.1-0.6) 
Abbreviations: CI, confidence interval; EtG, ethyl glucuronide; LC/MS/MS, liquid chromatography tandem mass spectrometry; LR+, positive likelihood 
ratio; LR-, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; UPLC, ultra-high performance liquid chromatography-
tandem mass spectrometry; sens, sensitivity; spec, specificity. 
a The diagnostic accuracy outcomes presented in the table are for 2nd and 3rd trimester alcohol exposure and were derived from the raw values presented 
in the original paper, rather than the published sensitivity and specificity values. I am grateful to the authors for clarifying the data. Corresponding values 
for 3rd trimester alcohol exposure were sensitivity 77% and specificity 72%. 
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Table 7: Diagnostic accuracy outcomes for studies of maternal urine testing for prenatal alcohol exposure (PAE) 
Index test 
analyte(s) 
Study Trimester 
of PAE 
Assay Positivity 
threshold 
Sens % 
(95% CI) 
Spec % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
EtG Bakhireva 
2014168 
Any LC/MS/MS 25 ng/mL 15 (4-33) 97 (84-100) 81 (28-99) 57 (42-70) 4.6 (0.5-38.5) 0.9 (0.8-1.0) 
Gutierrez 
2015172 
Any LC/MS/MS 39 ng/mL 5 (1-17) 98 (87-100) 67 (9-99) 51 (40-63) 2.0 (0.2-21.7) 1.0 (0.9-1.1) 
EtS Bakhireva 
2014168 
Any LC/MS/MS 7 ng/mL 15 (4-33) 100 (89-100) 100 (40-100) 57 (43-70) ∞ (0.5-∞) 0.9 (0.7-1.0) 
Gutierrez 
2015172 
Any LC/MS/MS 7 ng/mL 7 (2-20) 98 (87-100) 75 (19-99) 52 (40-63) 3.1 (0.3-28.3) 0.9 (0.9-1.0) 
Abbreviations: CI, confidence interval; EtG, ethyl glucuronide; EtS, ethyl sulphate; LC/MS/MS liquid chromatography tandem mass spectrometry; LR+, positive 
likelihood ratio; LR-, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; sens, sensitivity; spec, specificity. 
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Table 8 (continued overleaf): Diagnostic accuracy outcomes for studies of objective test batteries of maternal biomarkers for prenatal alcohol exposure (PAE). 
Index test 
analyte(s) 
Study Trimeste
r of PAE 
Assay Positivity 
thresholda 
Sens % 
(95% CI) 
Spec% 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Blood GGT, 
%CDT and 
PEth, urine 
EtG and EtS  
Bakhireva 
2014168 
Any Enzymatic rate 
method, HPLC, 
LC/MS/MS 
GGT 40 U/L 
CDT 2% 
PEth 8 ng/mL 
EtG 25ng/mL  
EtS 7 ng/mL 
32 (16-52) 97 (84-100) 90 (56-100) 62 (47-75) 10.3 (1.4-76.2) 0.7 (0.5-0.9) 
Hair EtG and 
urine EtG 
Gutierrez 
2015172 
Any LC/MS/MS EtG 8 pg/mg 
EtG 38.7 ng/mL 
22 (11-38) 83 (69-93) 56 (30-80) 52 (40-65) 1.3 (0.5-3.2) 0.9 (0.8-1.2) 
Hair EtG and 
urine EtS 
Gutierrez 
2015172 
Any LC/MS/MS EtG 8 pg/mg 
EtS 7.2 ng/mL 
24 (12-40) 83 (69-93) 59 (33-82) 53 (40-65) 1.5 (0.6-3.5) 0.9 (0.7-1.1) 
Hair EtG and 
blood GGT 
Gutierrez 
2015172 
Any LC/MS/MS, 
enzymatic rate 
method 
EtG 8 pg/mg 
GGT 40 U/L 
33 (19-49) 83 (69-93) 65 (41-85) 56 (43-69) 2.0 (0.9-4.4) 0.8 (0.6-1.0) 
Hair EtG and 
blood 2% 
CDT 
Gutierrez 
2015172 
Any LC/MS/MS, 
HPLC 
EtG 8 pg/mg 
CDT 2% 
23 (11-38) 86 (71-95) 60(32-84) 54 (41-66) 1.6 (0.6-4.0) 0.9 (0.7-1.1) 
Hair EtG and 
blood PEth 
Gutierrez 
2015172 
Any LC/MS/MS EtG 8 pg/mg 
PEth 8 ng/mL 
28 (15-44) 86 (72-95) 65 (38-86) 56 (43-68) 2.0 (0.8-4.8) 0.8 (0.7-1.1) 
Hair EtG and 
blood CDT 
and GGT 
Gutierrez 
2015172 
Any LC/MS/MS, 
HPLC, 
enzymatic rate 
method 
EtG 8 pg/mg 
CDT 1.7% 
GGT 40 U/L 
50 (34-66) 56 (41-72) 53 (36-69) 54 (39-70) 1.2 (0.7-1.9) 0.9 (0.6-1.3) 
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Index test 
analyte(s) 
Study Trimeste
r of PAE 
Assay Positivity 
thresholda 
Sens % 
(95% CI) 
Spec% 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Hair EtG and 
blood GGT 
and PEth 
Gutierrez 
2015172 
Any LC/MS/MS, 
enzymatic rate 
method 
EtG 8 pg/mg 
GGT 40 U/L 
PEth 8 ng/mL 
38 (23-54) 83 (69-93) 68 (45-86) 58 (45-71) 2.3 (1.0-4.9) 0.8 (0.6-1.0) 
Hair EtG and 
blood PEth 
and % CDT 
Gutierrez 
2015172 
Any LC/MS/MS, 
HPLC 
EtG 8 pg/mg 
PEth 8 ng/Ml 
CDT 1.7% 
43 (27-59) 60 (43-74) 50 (32-68) 52 (37-67) 1.1 (0.6-1.8) 1.0 (0.7-1.4) 
Blood MCV 
and GGT 
Sarkola 
2000177 
Any Coulter C7 cell 
counter and 
immunoassay 
NR 38 (14-68) 79 (59-92) 45 (17-77) 73 (54-88) 1.8 (0.7-4.8) 0.8 (0.5-1.3) 
Abbreviations: CDT, carbohydrate deficient transferrin; CI, confidence interval; EtG, ethyl glucuronide; EtS, ethyl sulphate; GGT, gamma glutamyltransferase; HPLC, 
high performance liquid chromatography; LC/MS/MS, liquid chromatography tandem mass spectrometry; LR+, positive likelihood ratio; LR-, negative likelihood ratio; 
MCV, mean corpuscular volume; NPV, negative predictive value; PEth, phosphatidylethanol; PPV, positive predictive value; sens, sensitivity; spec, specificity. 
a A test battery was considered positive if at least one of the results for an individual biomarker exceeded the designated positivity threshold. 
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6 Discussion 
This systematic review demonstrated that the reported accuracy of biomarkers of 
PAE varied widely across studies. Overall, tests of the total concentration of four 
FAEEs (ethyl palmitate, ethyl stearate, ethyl oleate and ethyl linoleate) showed the 
highest levels of sensitivity. Sensitivity was 100% in two studies of meconium 
testing,168,179 and 82% in one study of placenta testing.171 However, specificity was 
inconsistent (13% to 98%). Positive likelihood ratios ranged from 1, suggesting little 
test utility, to 73. As a guide, positive likelihood ratios greater than 10 may indicate 
that a test is informative.159 Confidence intervals were wide due to a small number 
of cases in these studies, which led to imprecise estimates of diagnostic accuracy. 
Placenta testing for FAEEs was conducted with a sample of premature newborns.171 
It is important to note that because alcohol is a risk factor for prematurity,185 the 
prevalence of PAE is likely to be higher within this sample than in the general 
population. Accordingly, positive predictive values from this study are likely to be 
higher than what would be expected within routine antenatal care.162  
There is no consensus on what level of diagnostic accuracy is acceptable for 
objective measurement of PAE. Many screening initiatives prioritise sensitivity over 
specificity and thus permit a high number of false positive results to maximise early 
detection of asymptomatic conditions.186 As early diagnosis and intervention are 
associated with improved outcomes for children with FASD65 it could be argued 
that a test with high sensitivity could be favoured over specificity, as it may support 
appropriate monitoring and follow-up among children with suspected PAE. 
However, there are ethical considerations. Prenatal alcohol use is an emotive issue 
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and false positive errors may lead to stigmatisation, unnecessary burden on 
healthcare resources, and may even be used in legal proceedings against 
mothers.113,127,140,186,187 Conversely, false negative errors represent a missed 
opportunity to provide support to those affected by PAE.127 Many screening 
programmes are conducted in a tiered fashion with high sensitivity favoured over 
specificity in the initial phase. Some authors have suggested that second-tier 
screening, using methods such as comprehensive maternal interviews and clinical 
assessment of children with suspected PAE, may be used as a strategy to reduce 
false positive results.127 However, these methods also have limitations. Information 
from maternal interview may be inaccurate, and the cognitive-behavioural profile 
associated with PAE is diverse and may not be detectable until later in childhood, 
thus precluding the opportunity for early intervention. Given the implications of 
both types of test error, various authors have suggested that both high sensitivity 
and specificity are a prerequisite for the introduction of PAE screening.127,186,187  
6.1 Limitations of the evidence 
The methodological quality of studies included in this review was generally poor. 
There was a high risk of bias due to the use of imperfect self-report reference 
standards, case-control diagnostic designs, and selective outcome reporting. 
Therefore, it is unclear whether the low diagnostic accuracy values of the objective 
measures in this review were due to a true lack of test validity, or were simply an 
artefact of comparison with an imperfect reference standard. As self-report 
reference standards are known to underestimate true PAE it is possible that the 
biomarker index tests explored in this review did correctly detect true PAE, while 
the self-report reference standards did not. This lack of agreement in classification 
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would lead to false positive results and reduced specificity. However, it is also 
possible that the observed false positives were genuine. Incidental exposure to 
ethanol can occur through an individual’s diet, medications, mouthwash and hand 
sanitizer, although the extent to which incidental exposure influences biomarker 
tests for PAE has not been fully established.188-192 It is unlikely that false negative 
results are due to the use of an imperfect reference standard as mothers are 
unlikely to report that they drank alcohol while pregnant when they had not.123 
Therefore, the low sensitivity values demonstrated by many studies in this review 
may be considered the most persuasive evidence against the validity of current 
objective measures of PAE. Some authors have proposed that apparent false 
negative errors may occur because self-report measures are better able to detect 
low levels of alcohol use than many of the objective measures, which typically 
detect moderate to heavy consumption. This raises the possibility that pregnant 
women who report drinking modest amounts of alcohol could be detected by the 
self-report reference standard but not the index test.124 This explanation is not 
likely to account for findings in the present review, however, as the majority of 
included studies investigated moderate to heavy self-reported PAE.  
Case-control diagnostic designs may produce overestimates of diagnostic 
accuracy.149,184 However, this form of bias is not likely to influence the conclusions 
of this review as most studies did not show high levels of accuracy despite the use 
of case-control diagnostic designs. It is, however, important to note that PAE 
prevalence is fixed by design in many of the studies included in this review due to 
the use of case-control methods and it is not possible to generalise predictive 
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values from individual studies to settings with a different prevalence of 
PAE.158,159,162 
6.2 Limitations of the review 
This study is the first systematic review of its kind and provides a rigorous 
evaluation of the evidence relating to the diagnostic accuracy of a range of 
objective measures of PAE. The results are broadly consistent with findings from 
existing non-systematic reviews, which suggest the need for improved objective 
measures of PAE.117,130,134 However, due to the diverse nature of the data and a 
limited number of studies per index test it was not possible to address some of the 
objectives listed in the original protocol. For example, I was not able to conduct the 
intended meta-analyses to answer questions about the relative impact of study 
characteristics on test accuracy. The search strategy was comprehensive and 
covered a range of published and unpublished sources. It is possible that some 
studies were missed as a result of excluding non-English language publications. 
However, this is unlikely to have had a significant impact on the results, since the 
supplementary search that I conducted included other reviews that did consider 
publications in any language and these did not reveal any further relevant 
studies.124 
As previously noted, participants were mainly recruited from high risk settings, 
such as substance misuse clinics. Therefore, findings have limited applicability to 
general population samples. Population-based studies of biomarkers of PAE are 
needed to inform universal screening strategies and to clarify the epidemiology of 
PAE and its developmental consequences in the short- and long-term. 
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6.3 Implications for research and practice 
Prenatal alcohol use is a challenging and emotive issue. Consequently, tests to 
detect PAE must be accurate, feasible, and acceptable to the population. These 
criteria are emphasised in the World Health Organisation and UK National 
Screening Committee guidelines for screening procedures.193,194 This review 
demonstrates that the evidence base for the accuracy of current objective 
measures of PAE is not yet robust enough to support their use in routine care. 
Studies of meconium screening for PAE in Scotland195 and Canada196 suggest high 
consent rates under conditions of anonymity (95% to 99%). However, participation 
rates are significantly lower when screening is not anonymised (78%).196 More 
research is required to establish which method is most feasible and acceptable to 
stakeholders including clinicians, policy makers and families.140,186,196,197  
Assay methods for the biomarkers included in this review were highly variable. This 
is likely to account for some of the observed heterogeneity in findings. Future work 
that aims to standardise procedures may provide a clearer picture of the 
performance of different biomarkers for PAE. Furthermore, positivity thresholds 
must be validated with general population samples. The 600 ng/g (2 nmol/g) cut-
off for total concentration of four FAEEs was derived from a study that compared 
abstainers to women with alcoholism and, therefore, may not be suitable for 
determining PAE in the general population.179 
With the exception of hair testing, objective measures of PAE have a limited 
detection period, which does not span the whole of pregnancy (see Table 1). For 
many women, patterns of alcohol consumption change throughout pregnancy. 
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Women are most likely to drink in the first trimester and then reduce their intake 
or abstain in later trimesters.12 Risk of harm to the developing fetus is highest if a 
mother drinks heavily throughout pregnancy,19 however first trimester exposure 
poses a particular risk of physical abnormalities including dysmorphic facial 
features.198 Meconium testing only captures PAE late in the second and third 
trimesters of pregnancy and, therefore, may fail to identify a large proportion of 
babies at risk of alcohol-related harm.134 In addition, currently available biomarkers 
have insufficient sensitivity to detect low levels of PAE, which is the most prevalent 
pattern of consumption among pregnant women.12 An objective test which 
measures alcohol itself in breath, urine, or blood could detect low level use. 
However, because alcohol is only present in these matrices for a matter of hours, 
this form of test is difficult to implement in research or in practice.117,130 Due to the 
limitations of current biomarkers, authors have emphasised the need for novel 
biomarkers that can detect even low levels of alcohol use across the duration of 
pregnancy.117 
Given the absence of a gold standard test, research attempting to validate 
objective measures of PAE may benefit from abandoning the classic diagnostic 
accuracy paradigm, in which validity is determined by agreement between the 
index test and reference standard. Instead, future research may benefit from using 
a clinical validation approach,199 in which a convergent body of evidence is used to 
increase confidence in the validity of a measure. Some studies have adopted this 
method to demonstrate the predictive validity of meconium testing. Prospective 
studies have reported a significant inverse relationship between levels of FAEEs in 
meconium and cognitive outcomes up to age 15.200,201 Such evidence lends support 
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to the validity of FAEEs as markers of PAE, but require replication. Animal models 
may also be useful for the development of novel testing procedures for 
PAE.117,202,203 However, translation from animal studies to human populations is 
complicated by differences in alcohol exposure methods, gestation and alcohol 
metabolism. In summary, validation will rely on an ongoing body of research that 
produces convergent evidence to suggest that objective measures are meaningfully 
associated with PAE.199  
7 Conclusions 
Tests of the total concentration of FAEEs in meconium and placenta tissue offer 
some promise as objective measures of PAE but findings are inconsistent, studies 
are small-scale and require replication. Therefore, I conclude that current evidence 
is insufficient to support the use of objective measures of PAE in clinical practice. 
The poor performance of many of the measures evaluated in this review could be 
due to a true lack of diagnostic validity or a result of bias introduced by sub-optimal 
study design, most notably the absence of a gold standard for PAE. Further 
research that investigates test validity, acceptability, and feasibility within large 
population-based samples is required to inform strategies for population-based 
screening and epidemiological research.  
8 Implications for this thesis 
One of the reasons for completing this review was to determine whether there 
were suitable objective measures that I could use to investigate the epidemiology 
of PAE for this thesis. Since the evidence base does not support the validity of 
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current objective measures of PAE, I decided not to pursue this avenue further. 
Instead, I decided to investigate the epidemiology of one of the consequences of 
PAE; fetal alcohol spectrum disorder (FASD). The remaining chapters in this thesis 
will describe the development of novel case ascertainment algorithms for FASD 
(Chapter 3), a study of the prevalence of FASD in a population-based sample in 
England (Chapter 4), and studies that seek to elucidate causal risk factors for FASD 
(Chapters 5 and 6).
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Chapter 3. Development and validation of case ascertainment 
algorithms for FASD 
 
1 Overview 
In this chapter, I describe how I developed and validated a series of novel case 
ascertainment algorithms for FASD. First, I provide a summary of current diagnostic 
frameworks for FASD and describe the chapter aims and objectives (Sections 2 and 
3). In Section 4, I describe the development of the case ascertainment algorithms. 
In Section 5, I describe the algorithm validation stage. I conclude with a general 
discussion of the strengths and limitations of my approach and the implications of 
this work for the remaining research in this thesis.  
2 Background 
2.1 Rationale for development of a FASD case ascertainment algorithm 
As described in Chapter 1, efforts to investigate the epidemiology of FASD in the UK 
have been compromised by suspected underreporting, due to reliance on 
surveillance methods. Funding and ethical issues have meant that active case 
ascertainment studies of FASD in the general population have not been possible.108 
To overcome these challenges, I explored a novel approach, using data from an 
existing population-based birth cohort. I sought to determine if it was possible to 
develop and apply an algorithm, based on an existing diagnostic framework for 
FASD, to the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort data 
to ascertain FASD cases. If feasible, this would offer an opportunity to investigate 
FASD epidemiology at the population level. Furthermore, this design minimises the 
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cost and ethical concerns surrounding an active-case ascertainment study of FASD, 
as participants have already provided consent, and the anonymised data have been 
used in a range of research studies, including studies of neurodevelopmental 
outcomes.204  
2.2 Diagnostic frameworks for FASD 
There is no universally accepted diagnostic framework for assessing fetal alcohol 
spectrum disorder (FASD). Although there is broad consensus on FASD subtypes 
and the core features (summarised in Chapter 1), diagnostic frameworks differ in 
the specific criteria and thresholds used to define FASD. Differences also exist in 
the nomenclature used to describe subcategories within the FASD continuum. 
Differing criteria lead to variations in case ascertainment and subsequent 
prevalence estimates.78,205-207 A brief description of the main frameworks that are 
currently in use is given below. Appendix 3 provides a full summary and 
comparison of the different criteria and diagnostic categories for the main FASD 
classification systems. 
The first formal guidelines for FASD diagnosis were introduced by the Institute of 
Medicine (IOM) in 1996, following a mandate from the U.S. Congress.208 The IOM 
criteria formed the basis of all subsequent FASD frameworks, but have been 
criticised for not providing clear thresholds for what constitutes abnormality in 
each domain. For example, they did not specify the degree of growth deficiency or 
cognitive impairment required to meet criteria. Consequently, the original IOM 
guidelines are not generally used in present-day assessment of FASD.73  
56 
Chapter 3 
Hoyme and colleagues produced the first revision of IOM guidelines in 2005 in 
response to criticism about the lack of clinical utility of the original IOM guidelines. 
The IOM 2005 criteria retained the original IOM diagnostic categories, but added 
standardised cut-offs for central nervous system (CNS), growth and facial criteria. 
The IOM 2005 criteria have been used widely within studies of FASD epidemiology 
and were revised again in 2016, based on expert consensus.74,82,83,209  
The FASD 4-Digit Diagnostic Code was developed by Astley and colleagues based on 
empirical studies at the University of Washington. Versions of the 4-Digit Code 
were published in 1997, 1999 and 2004. It is used in specialised FASD clinics as part 
of the Centers for Disease Control and Prevention’s (CDC’s) funded Washington 
Diagnostic and Prevention Network, which has been running for over 20 years.67,75  
The FASD Canadian guidelines for diagnosis were first published in 2005 with the 
intention of providing a unified approach to FASD identification. Within the 
Canadian guidelines, a slight adaptation of the 4-Digit Code criteria was mapped on 
to FASD diagnostic categories, using the IOM nomenclature (with the exception of 
ARBD, which was removed).72 The Canadian guidelines were revised in 2016. 
Notable changes included the introduction of a threshold for the PAE criterion and 
new terminology for the FASD subtypes (described further in Appendix 3).210,211  
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
criteria for Neurodevelopmental Disorder-Prenatal Alcohol Exposure (ND-PAE)212 is 
the newest addition to the range of FASD frameworks that are available. ND-PAE 
was proposed to describe the full range of developmental disabilities associated 
with PAE. ND-PAE was placed within the ‘conditions for further study’ section of 
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the DSM-5. This means that there was insufficient evidence to include it as a formal 
mental disorder diagnosis in DSM-5 and it is not intended for use in clinical 
practice. Nevertheless, the inclusion of ND-PAE in the influential DSM-5 has been 
heralded as a major step forward in raising the profile of FASD in mainstream 
diagnosis.213,214 Furthermore, as DSM is an internationally recognised medical 
taxonomy, the inclusion of ND-PAE has been viewed by some as progress towards a 
universal classification of FASD.215 
Other guidelines include the International Classification of Diseases (ICD-10) and 
the CDC guidelines (both of which proposed criteria for diagnosing FAS but not for 
the entire spectrum of FASD, thereby underestimating the true burden of the 
consequences of PAE).11,78,107 The criteria of the FASD Study Group of the Research 
Society on Alcoholism,216 guidelines by Sokol and Clarren,217 the FAS Checklist,218 
Smith’s Recognizable Patterns of Human Malformations,219 the Emory Fetal Alcohol 
Centre Clinical Criteria,207 and the Two Eyed Seeing Wheel220 are examples of other 
guidelines. None of these are widely accepted.88,221  
2.2.1 Justification of the use of the FASD Canadian (2005) guidelines for this study 
As described above, there are several diagnostic guidelines available for FASD. The 
field has undergone much development and, currently, there is no consensus on 
the optimal framework to use to identify FASD. In the absence of universal criteria 
for FASD, I had to decide which of the available frameworks was the most 
appropriate to use to develop an algorithm for FASD case ascertainment, to be 
applied to data that have already been collected.  
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I chose to use the FASD Canadian guidelines (2005) as the basis for the FASD case 
ascertainment algorithms for the following reasons. First, these guidelines are 
currently the most unified approach to FASD identification (combining the criteria 
from the FASD 4-Digit Diagnostic Code and IOM revised criteria).  
Second, the Canadian 2005 guidelines have been widely adopted across FASD 
services in Canada,222 are endorsed by the British Medical Association,10 the UK 
FASD Trust,106 expert consensus guidelines for the identification of attention deficit 
hyperactivity disorder and associated FASD,223 and the UK National Clinic for Fetal 
Alcohol Spectrum Disorder,224 as the model of best-practice. Evidence suggests that 
the Canadian guidelines have led to increased consistency and multidisciplinary 
collaboration within FASD clinics.222  
Third, the Canadian guidelines have also been used in a research context, having 
been adopted for a global prevalence study of FASD, supported by the World 
Health Organisation and National Institute on Alcohol Abuse and Alcoholism.225 
Fourth, compared to the Canadian guidelines, some suggest that the threshold for 
FASD is too liberal in other guidelines. Although there is no gold standard to 
determine which of the available FASD frameworks is better for identifying those 
affected by PAE,207 studies that have applied the different diagnostic frameworks to 
the same sample of individuals give an indication of how the choice of framework 
can influence case ascertainment. These studies found that more individuals were 
classified as having FASD under the IOM 2005 criteria than the other 
frameworks.206,207 For example, 60% of individuals in a study of 1,581 referrals to a 
FASD clinic in the USA received a FASD diagnosis based on the IOM 2005 criteria, 
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compared to 38% with the 4-Digit Code, and 25% with the Canadian 2005 
guidelines, predominantly due to differences in the facial phenotype and CNS 
criteria.207 Compared to other frameworks, the IOM criteria have the most liberal 
thresholds for head circumference and facial phenotype measures, and they retain 
ARBD as a diagnostic category. The authors of the IOM guidelines advocate this 
inclusive approach to FASD diagnosis on the basis that more liberal criteria may 
lead to opportunities for early detection and intervention for individuals within the 
broad continuum of FASD.74 However, critics argue that the relaxed criteria may 
threaten the validity of the diagnosis.206 Fifth, the Canadian guidelines (2005) do 
not specify a threshold for PAE when determining FASD. This approach is the most 
consistent with current antenatal guidelines, which recommend abstinence from 
alcohol as the safest option during pregnancy, and with evidence that suggests that 
there is no known safe level of PAE.48,226 In contrast, the IOM 2005 criteria offered 
a qualitative description of the threshold for maternal alcohol exposure, describing 
it as “a pattern of excessive intake characterized by substantial regular intake or 
heavy episodic drinking.”(p. 18)73 This description does not specify what quantity of 
alcohol is considered excessive or heavy and has been called confusing by authors 
of the Canadian guidelines.72 In contrast to the Canadian 2005 guidelines, the DSM-
5, revised IOM 2016 and Canadian 2016 guidelines all provide a threshold for the 
alcohol exposure criterion (described further in Appendix 3). However, even the 
authors of the 2016 revision to the Canadian guidelines, who specify a threshold 
for their FASD diagnosis, add a note of caution advising that drinking below this 
limit has not been studied in enough detail to be considered safe; that various 
factors influence susceptibility to alcohol-related harm; and that the public health 
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advice should be to avoid alcohol in pregnancy.211 Therefore, the most appropriate 
criteria for alcohol exposure domain remains uncertain until there is clearer 
evidence on the dose-response relationship between PAE and FASD. 
The updated Canadian (2016) guidelines have yet to be evaluated.227 Therefore, I 
chose to use the Canadian 2005 guidelines for FASD diagnosis as the criteria upon 
which to develop the FASD case ascertainment algorithms for this study. Figure 7 
summarises the diagnostic categories from the Canadian 2005 guidelines, based on 
the core criteria for FASD. Specific criteria are described in Table 9. 
Figure 7: Summary of core domains and corresponding subtypes of FASD within the Canadian 2005 guidelines 
for diagnosis 
 Fetal alcohol 
syndrome 
(FAS) 
Partial fetal alcohol 
syndrome (pFAS) 
Alcohol-related 
neurodevelopment
al disorder (ARND) 
Prenatal alcohol 
exposure (PAE) 
Confirmed or 
unconfirmed Confirmed Confirmed 
Central nervous 
system (CNS) 
impairment  
Yes Yes Yes 
Facial anomalies 
Yes 
(3 features) 
Yes 
(2 features) 
Not required 
Growth deficiency Yes Not required Not required 
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3 Aim and objectives 
3.1 Aim 
i. To develop case ascertainment algorithms for FASD and evaluate their 
validity. 
3.2 Objectives 
i. To use the FASD Canadian guidelines for diagnosis (2005) as a basis for 
developing algorithms that can be applied to the ALSPAC cohort data for 
FASD case ascertainment. 
ii. To specify a decision-making framework and use this to identify appropriate 
ALSPAC measures and thresholds for FASD symptomology. 
iii. To develop a series of algorithms that systematically vary CNS and PAE 
criteria to address ambiguity in the FASD Canadian guidelines for diagnosis 
(2005). 
iv. To validate the algorithms by calculating diagnostic accuracy statistics that 
compare the performance of each algorithm to the FASD classifications 
assigned by an expert case conference panel. 
4 Development of case ascertainment algorithms for FASD 
4.1 Method 
4.1.1 Data source 
ALSPAC is a prospective longitudinal birth cohort study, which recruited 14,541 
pregnant women from the Bristol area between 1990 and 1992. Follow-up of 
participants is ongoing and children from the original cohort are now 
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approximately 25 years old.228,229 The ALSPAC dataset includes extensive repeated 
measures of prenatal exposures, child behavioural and psychological outcomes, 
growth, facial features and sociodemographic factors, collected through a range of 
questionnaires, in-clinic assessments and data linkage (including the National Pupil 
Database and the Pupil Level Annual School Census). 
ALSPAC sample characteristics, study phases, methodology and representativeness 
have been described in previous publications,228,229 and in detail on the study 
website (http://www.alspac.bris.ac.uk/welcome/index.shtml). Compared to the 
general population of mothers with children under the age of one in Britain at the 
time of recruitment, and those in the Avon area who were not enrolled in the 
ALSPAC study, participants in the ALSPAC sample were of higher socioeconomic 
status and were less likely to be of non-White ethnicity.228,229 Children in the 
ALSPAC sample were comparable to the UK general population on growth 
measures, but had higher levels of educational attainment on average.228,230 These 
differences present some limitations when attempting to generalise prevalence 
estimates from the ALSPAC cohort to the general population of the UK (Chapter 4). 
Representativeness is less of a concern for the validity of the risk factor regression 
analyses that I present in this thesis (Chapter 6). As Rothman notes, it is not 
representativeness, but the ‘laws of nature’ and understanding of causal 
mechanisms that allows for the generalisation of proposed cause-effect 
relationships.231 In Chapter 5, I present hypothesised causal mechanisms for the 
relationships between a range of exposures and FASD. In Chapter 6, I use 
multivariable analyses to quantify these relationships. 
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4.1.2 Study approval 
Ethical approval for this study was obtained from the ALSPAC Ethics and Law 
Committee (IRB00003312) and the Local Research Ethics Committees.232 Project 
approval was granted by the ALSPAC Executive Committee on the 2nd March 2016 
(Project B2620). 
4.1.3 Participants 
I included data from all singleton pregnancies in the core ALSPAC sample (i.e. those 
recruited during pregnancy between 1991 and 1992). I excluded participants who 
were not alive at one year of age, participants with genetic conditions and those 
who did not speak English as a primary language. This produced an eligible sample 
of 13,495 participants.  
4.1.4 Procedure 
I developed a series of FASD case ascertainment algorithms based on the Canadian 
guidelines for diagnosis (2005).72 Given the wealth of information available in the 
ALSPAC dataset, I aimed to develop a case-definition that best reflected real-life 
practice in FASD diagnosis. Thus, I specified a decision making framework to select 
variables and thresholds for FASD-relevant outcomes, as described below.  
4.1.4.1 Variable selection 
First, I identified potentially relevant variables from the ALSPAC dataset by 
searching the ALSPAC data dictionary233 for terms and measures relevant to the 
pre-specified Canadian FASD criteria. For example, I searched PDF and Excel 
spreadsheet documentation for key words relating to FASD criteria, such as 
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“communication,” and for known measures such as “Strengths and Difficulties 
Questionnaire” or “SDQ.” This search revealed that there were sufficient data 
within ALSPAC to derive a FASD classification based on the FASD Canadian 
guidelines for diagnosis (2005),72 including repeated prospective measurement of 
prenatal exposures and child phenotype. Data were obtained for all relevant 
variables at each available time point from birth up to the age of 15.  
I discussed the suitability of the variables that I identified from this search with an 
expert group that included a consultant psychiatrist from the UK National Clinic for 
Fetal Alcohol Spectrum Disorder (RM), a community paediatrician (AK) and an 
educational psychologist (AH). Table 9 provides a summary of the relevant ALSPAC 
measures that correspond to the FASD Canadian guidelines (2005). In Appendix 4, I 
provide a more detailed description of the measures, including the age of 
participants at data collection, procedures, and thresholds. Important factors for 
differential diagnosis were identified from FASD diagnostic guidelines and were 
considered in the exclusion criteria and FASD classifications, as described in 
Appendix 5. Children who were known to have a genetic condition were excluded 
from the sample.  
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Table 9: FASD Canadian guidelines for diagnosis (2005) and corresponding ALSPAC measures. Full details of 
ALSPAC measures are provided in Appendix 4. 
FASD Canadian guidelines (2005) criterion ALSPAC measures 
Prenatal alcohol exposure 
Confirmation of maternal alcohol use during 
the index pregnancy based on reliable clinical 
observation, self-report, reports by a reliable 
source, medical records documenting positive 
blood alcohol, alcohol treatment or 
social/legal/medical problems. No threshold 
specified. 
Maternal self-reported prenatal alcohol 
consumption 
 
Central nervous system 
Impairment in ≥ 3 subdomains including: 
a. Hard and soft neurologic signs 
b. Brain structure 
c. Cognition 
d. Communication 
e. Academic achievement 
f. Memory 
g. Executive functioning and abstract reasoning 
h. Attention deficit/hyperactivity 
i. Adaptive behaviour, social skills, social 
communication 
 
A domain is considered “impaired” when on a 
standardized measure: scores are ³ 2 SD below 
the mean or there is a discrepancy of ≥ 1 SD 
between subdomains. When standardized 
measurements are not available, a clinical 
judgment of “significant dysfunction” is made. 
a. Hard and soft neurologic signs 
ALSPAC coordination test, cerebral palsy, seizures 
b. Brain structure 
Occipital frontal circumference 
c. Cognition 
Wechsler Intelligence Scale for Children (WISC-III) 
d. Communication 
Wechsler Objective Language Dimensions, special 
educational needs for communication, speech/language 
problems 
e. Academic achievement 
Special educational needs, exam scores at Key Stages 1 
and 2 
f. Memory 
WISC-III forward digit span task, non-word repetition 
task 
g. Executive functioning and abstract reasoning 
Opposite Worlds task, Counting Span task, Stop Signal 
task, Backwards Digit Span task 
h. Attention deficit/hyperactivity 
ADHD, Strengths and Difficulties Questionnaire (SDQ) 
hyperactivity, Sky Search task 
i. Adaptive behaviour, social skills, social communication 
Diagnostic Analysis of Nonverbal Accuracy scale faces 
subtest, Social Communication Disorders Checklist 
score, SDQ conduct or peer problems, oppositional 
defiant disorder, conduct disorder, disruptive behaviour 
disorder, school emotional/behavioural difficulties, SEN 
for behavioural/emotional needs, autism. 
Growth 
≤ 10thpercentile for pre- and/or postnatal 
height or weight or weight-to-height ratio 
Clinical assessment  
Face 
Short palpebral fissure length (≤ 3rd percentile), 
Smooth philtrum 
Thin upper lip 
Three-dimensional (3D) facial scan data 
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4.1.4.2 Thresholds for impairment 
4.1.4.2.1 Prenatal alcohol exposure 
The FASD Canadian guidelines (2005) do not specify a threshold for the PAE 
criterion. However, they do state that the amount and frequency of alcohol use 
should be documented if this information is available.72 In practice, clinicians 
consider the PAE profile of individuals who are referred for FASD assessment.224 I 
collated data on prenatal alcohol consumption across a range of maternal self-
report measures in ALSPAC. These included: dose/frequency measures (number of 
glassese of alcohol per week or per day in the first trimester, around the time the 
mother first felt the baby move, and in the third trimester; measured at 18 weeks 
gestation, 32 weeks gestation and 8 weeks postpartum, respectively); total weekly 
alcohol consumption (number of drinks per week; measured at 8 and 32 weeks 
gestation); binge drinkingf (measured at 18 and 32 weeks gestation); and finally, a 
measure that captured the amount that a mother drank in the period before 
pregnancy (dose/frequency) and whether she subsequently changed her drinking 
behaviour during pregnancy.  
4.1.4.2.2 Central nervous system 
Appendix 4 provides an overview of the relevant CNS tests that were available in 
ALSPAC and the thresholds that were chosen to indicate impairment. According to 
the Canadian FASD guidelines,72 the CNS criterion is met when there is evidence of 
                                                        
e  The ALSPAC questionnaire defined a glass of alcohol as equivalent to a pub measure of spirits, ½ 
pint lager/beer, wine glass of wine etc. 
f ‘Binge drinking’ was defined as the consumption of the equivalent of two pints of beer, four glasses 
of wine or four pub measures of spirits on a single occasion. 
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impairment in three or more CNS subdomains. In the first instance, I used available 
norms for standardised tests to determine thresholds for impairment that were 
established and reliable. For example, I used standard thresholds for the Strengths 
and Difficulties Questionnaire (SDQ; full information and scoring criteria are 
provided at http://www.sdqinfo.com). This measure has established reliability and 
validity based on a general population sample of 10,438 five to 15-year-olds in 
Britain.234  
If commonly accepted test norms were not available I used thresholds from the 
research literature, if they appeared justified. For example, several studies have 
defined poor motor performance as an ALSPAC coordination test score <5th centile, 
so I selected this threshold for the case ascertainment algorithms.235 
If existing norms were not readily available, I established thresholds based on the 
distribution of participant data within ALSPAC. Thresholds for significant 
dysfunction were set at ≥ 2 standard deviations below the mean for data that were 
normally distributed, or ≤ 3rd percentile for data with a skewed distribution. If the 
test value at the 3rd percentile was not unique (e.g. if it spanned from 3rd - 5th 
percentile), I selected the next lowest unique value (e.g. 2nd percentile). I assigned 
different thresholds according to participant sex and age categories, when there 
was evidence of differential performance. Final decisions about appropriate 
thresholds for impairment were made in consultation with the expert group (RM, 
AH, AK). 
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4.1.4.2.3 Facial phenotype 
Facial phenotype data were available from 3D scans, which were carried out when 
ALSPAC participants were approximately 15 years old. I obtained data from ALSPAC 
that classified upper lip thinness and philtrum smoothness based on a system 
developed by Wilson-Nagrani and colleagues.236 This morphological trait scale 
ranks philtrum shape on a progressive six-point scale that ranges from 0 (smooth 
philtrum) to 6 (deep groove extending through vermilion border), and upper lip 
fullness on a three-point scale (0 thin; 1 medium; 2 thick). The University of 
Washington lip-philtrum guide is the recommended method for assessing the FAS 
facial phenotype. Following discussion with Dr Wilson-Nagrani, I reclassified the 
ALSPAC philtrum data to approximate the recommended classifications from the 
University of Washington lip scale, such that philtrum scores of 0 - 1 and an upper 
lip vermilion score of 0 on the Wilson-Nagrani et al. scale were deemed 
comparable to the recommended University of Washington rank 4/5 lip-philtrum 
classifications.  
I used the University of Washington palpebral fissure length z-score calculator237 to 
identify age and sex-specific cut-offs for short palpebral fissure length, defined as a 
z-score of ≤ 1.96, based on the recommended Scandinavian charts.238 
4.1.4.2.4 Growth data 
I used the LMS Growth add-in for Microsoft Excel,239 which is based on reference 
data from a nationally representative sample,240 to categorise children using the 
appropriate centiles for their sex and age (from birth to age 9). The LMS Growth 
add-in did not have reference values for the length of babies born before 35 weeks. 
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Therefore, I calculated birth length centiles for babies with a gestational age of less 
than 35 weeks using the Fenton 2013 weight calculator.241 This measure uses 
reference data from several large population-based surveys of preterm births (N = 
34,639), including a sample from Scotland.242 Although the FASD Canadian 
guidelines specify a 10th percentile cut-off for growth deficiency, I chose to use a 9th 
percentile cut-off to be consistent with paediatric practice in the UK.106 
4.2 Algorithm specifications 
As I was developing the case ascertainment algorithms for FASD, it became 
apparent that there was an element of ambiguity in some of the criteria. For 
example, the FASD Canadian guidelines (2005) state that the pattern of PAE should 
be documented but do not specify a threshold, noting that “the evaluation of 
‘significant alcohol exposure’ is often confusing.” 72(p.S11) Other guidelines suggest 
thresholds for PAE73,74,212,227 (described in Appendix 3), but note that there is 
insufficient evidence to determine whether any amount of PAE can be considered 
safe.227  
The Canadian guidelines also recommend that a diagnosis should only be made 
when “there is evidence of pervasive brain dysfunction…defined by severe 
impairment in three or more…neurodevelopmental domains.”227(p.193) However, 
they do not offer clear direction about what to do when there are inconsistencies 
between measures that assess the same domain of functioning over time, or when 
using different tests. For example, should the adaptive functioning domain be 
classed as impaired only when there is consistent evidence of impairment across all 
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measures and/or informants, or is evidence of impairment on one, or some of 
these measures sufficient to indicate impairment?  
To address these uncertainties, I created a series of algorithms that systematically 
explored a range of CNS and PAE criteria combinations. These algorithms 
corresponded to different levels of convergent evidence and symptom or exposure 
severity. Following the case conference validation process (described in Section 5), 
I also added a Revised CNS category to reflect further recommendations made by 
the expert panel (summarised in Appendix 8). Figure 8 provides a schematic 
representation of the different combinations of the CNS and PAE criteria, and the 
resulting algorithm names. Algorithm specifications are provided in Table 10. Full 
details of the measures included in the FASD algorithms are provided in Appendix 
4. Consistent with the FASD Canadian guidelines (2005), the algorithms defined FAS 
as the presence of the full facial phenotype, growth deficiency, and CNS 
impairment, with or without confirmed PAE (all domains in Table 10). pFAS was 
defined as the partial facial phenotype, CNS impairment and confirmed PAE (all 
domains in Table 10, except domain 2). ARND was defined as CNS impairment with 
confirmed PAE (domains 1 and 4 in Table 10).  
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Figure 8: Schematic representation of the case ascertainment algorithms for FASD that were generated by varying combinations of the central nervous system and prenatal alcohol 
exposure (PAE) criteria. Full definitions for the Liberal, Mid, Strict and Revised CNS criteria, and the terminology for all PAE categories are provided in Table 10. 
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Table 10 (continued overleaf): ALSPAC FASD case ascertainment algorithm specifications 
Domain Subdomain Case-definition specification 
Liberal CNS Mid CNS Strict CNS Revised CNS 
1. Central 
Nervous 
System 
       (CNS)a 
 
Impairment 
in ≥ 3 
subdomains 
a) Hard and soft 
neurologic signs 
≤5th percentile 
in ALSPAC coordination 
test OR ≥ 2 seizures not 
due to postnatal insult OR 
cerebral palsy 
≤5th percentile in ALSPAC 
coordination test OR 
cerebral palsy 
As for Mid ≤5th percentile 
in ALSPAC coordination test OR 
≥ 2 seizures not due to 
postnatal insult) OR cerebral 
palsy 
b) Brain structure Head circumference ≤ 2nd 
percentile at birth 
Head circumference ≤ 2nd 
percentile at birth AND 
age 7 
As for Mid Head circumference ≤ 2nd 
percentile at birth OR age 7 
c) Cognition  Score ≤ 70 on total, verbal 
or performance IQ OR 
discrepancy of ≥ 1 SD 
between subdomains 
As for Liberal As for Liberal Score ≤ 70 on total, verbal or 
performance IQ OR discrepancy 
of ≥ 1 SD between subdomains. 
Not impaired if discrepancy 
between subdomains but IQ ≥ 
120 
d) Communication: 
receptive and 
expressive 
Score ≤ 2 SD from the 
mean for WOLD listening 
comprehension OR WOLD 
expressive language OR 
teacher-reported 
communication 
impairment at any time 
point 
Impaired on any two of 
the measures in this 
domain 
Score ≤ 2 SD from the 
mean for WOLD listening 
comprehension AND 
WOLD expressive 
language AND teacher-
reported impairment at 
any time point 
Impaired on any two of the 
measures in this domain 
(including consideration of SEN 
communication needs) 
e) Academic 
achievement 
Failing to meet the 
expected level at school at 
any time point (Key Stage 
1 Level 1 or W; Key Stage 
2 < Level 4) OR SEN at any 
time point 
Failing to meet the 
expected level at school at 
all time points (Key Stage 1 
Level 1 or W; Key Stage 2 < 
Level 4) OR SEN at any 
time point 
SEN at any time point Failing to meet the expected 
level at school at all time points 
OR SEN at any time point. Do 
not mark as impaired if IQ ≤ 79. 
Do not mark as impaired if 
normal educational attainment 
and a reason other than 
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Domain Subdomain Case-definition specification 
Liberal CNS Mid CNS Strict CNS Revised CNS 
cognitive and learning needs for 
SEN. 
f) Memory Score ≤3rd percentile on 
Forward Digit Span OR 
Non-Word Repetition Task 
As for Liberal ≤3rd percentile on 
Forward Digit Span 
Score ≤3rd percentile on 
Forward Digit Span OR Non-
Word Repetition Task 
 
 
g) Executive 
functioning and 
abstract reasoning  
 
 
Score ≤3rd percentile for 
any of the available 
measures: Opposite 
Worlds task, Counting 
Span task, Stop Signal 
task, Backwards Digit Span 
task 
 
 
Score ≤3rd percentile for 
two of the available 
measures 
 
 
Counting Span AND 
Backwards Digit Span 
score ≤3rd percentile 
OR Stop-Signal AND 
Opposite Worlds score 
≤3rd percentile 
 
 
Score ≤3rd percentile for two of 
the available measures 
h) Attention 
deficit/hyperactivity 
Score ≤3rd percentile for 
Sky Search OR ADHD OR 
high SDQ hyperactivity 
ADHD OR high SDQ 
hyperactivity 
ADHD Convergent evidence across 2 
measures or impairment 
reported by both informants for 
SDQ (teacher and parent) OR 
ADHD 
i) Adaptive 
behaviour, social 
skills, social 
communication 
High SDQ peer OR 
conduct problems OR 
ODD/CD OR ≥ 7 DANVA 
errors OR score ≥ 9 on 
SCDC OR autism OR 
teacher-reported 
emotional or behavioural 
difficulties 
High SDQ peer OR conduct 
problems OR ODD/CD OR 
autism OR two of the 
following: ≥ 7 DANVA 
errors OR score ≥ 9 on 
SCDC OR teacher-reported 
emotional or behavioural 
difficulties 
ODD/CD OR autism Impaired on any two of the 
measures in this domain or 
impairment reported by both 
informants for SDQ (teacher 
and parent) including 
consideration of SEN 
behavioural, emotional and 
social development needs OR 
autism 
2. Growth  £ 9th percentile for: birth weight AND/OR birth length and postnatal height AND/OR birth and postnatal BMI 
3. Face  Full facial phenotype (for FAS): short palpebral fissure length (≤ 2.5th percentile) AND smooth philtrum AND thin upper 
lip (equivalent to ranks 4-5 on the lip-philtrum guide) 
Partial facial phenotype (for pFAS): any two features from the full facial phenotype 
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Domain Subdomain Case-definition specification 
Liberal CNS Mid CNS Strict CNS Revised CNS 
4. Prenatal 
alcohol 
exposure 
(PAE) 
 Any PAE: Any level of prenatal alcohol exposure at any time in pregnancy; Mid PAE: Two trimesters of prenatal alcohol 
exposure and/or binge drinking; Strict PAE: Three trimesters of prenatal alcohol exposure and/or binge drinking; 
Canadian PAE: Seven or more standard Canadian drinks per week (11.9 UK units) or any binge drinkingb; ND-PAE: > 13 
drinks per month, with > 2 drinks per occasion; NICE PAE: ≥ 1-2 drinks once or twice per week or ≥ 4 units of alcohold 
Abbreviations: CNS, central nervous system; DANVA, Diagnostic Analysis of Non-Verbal Accuracy; IQ, intelligence quotient; ND-PAE, Neurodevelopmental 
Disorder-Prenatal Alcohol Exposure; NICE, National Institute for Health and Care Excellence; ODD/CD, oppositional/conduct disorder; PAE, prenatal alcohol 
exposure; SD, standard deviation; SCDC, Social Communication Disorders Checklist; SDQ, Strengths and Difficulties Questionnaire; SEN, special educational 
needs; WOLD, Weschler Objective Language Dimensions. 
a CNS criterion met if there is evidence of impairment in ≥ 3 subdomains (a - i). The Revised CNS case-definition requires that this includes impairment in the 
subdomains that measure adaptive functioning (e and i). 
b The FASD Canadian 2016 guidelines suggest that more than one binge drinking episode is required to meet the PAE criteria; however, the ALSPAC data 
categorise binge drinking as: none, 1-2 days, 3-4 days, 5-10 days, > 10 days, or every day per month. Therefore, it was not possible to separate participants with 
one binge drinking episode from those with two or more.  
c DSM-5 ND-PAE criterion of ‘more than minimal exposure’. Exposed to alcohol at any time during gestation, including prior to pregnancy recognition, and the 
exposure level was more than minimal (i.e. more than 13 drinks in any one month, with more than two drinks on any drinking occasion. 
d Drinking in excess of NICE 2008 antenatal guideline limits ≥1-2 drinks once or twice per week; equivalent to ~ 32g / 4 units of alcohol. 
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5 Validation of the FASD case ascertainment algorithms 
5.1 Method 
The data source and study approval process were described in Section 4.1. 
5.1.1 Participants and sampling strategy 
In the validation stage of this study, I selected a stratified random sample of 31 
participant profiles from the eligible ALSPAC sample to be considered by an expert 
case conference panel. The sample was stratified to ensure that at least two 
participant profiles were considered for each of the 24 algorithm specifications and 
that at least three participants did not meet criteria for FASD under any of the case 
ascertainment algorithms. By definition, participants who met criteria for the more 
stringent FASD classifications (i.e. higher levels/duration of PAE or more 
convergent evidence or severe symptoms for the CNS criteria) also met criteria for 
the less stringent classifications. Figure 9 presents the number of participants in the 
validation sample who met criteria for each of the case ascertainment algorithms.  
5.1.2 Case conference procedure 
The case conference panel was hosted at Cardiff University on 17th January 2017 
and consisted of a one-day meeting involving a consultant psychiatrist and national 
FASD specialist (RM), community paediatrician (AK) and educational psychologist 
(AH). The meeting was audio recorded and administrative support was provided by 
a member of staff from the professional and support services team at Cardiff 
University (JH). Appendices 4, 5 and 6, show the documents that were given to the 
panel members for the case conference. During the case conference, the expert 
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panel were given 31 participant profiles and asked to decide for each profile 
whether, on the balance of probability, a diagnosis of FASD would be made in 
clinic, based on the information provided. Panel members were given a score 
sheet, based on the FASD Canadian guidelines (2005), and a description of the 
relevant ALSPAC measures. Panel members were blind to the FASD classification 
status that was assigned to each participant based on the application of the case 
ascertainment algorithms. Panel decisions on FASD status were reached by 
consensus during the meeting.  
Figure 9: Sample for the FASD case ascertainment algorithm validation process. The number in each cell 
corresponds to the number of participants who met criteria for FASD under the corresponding algorithm 
specification. Total N = 31. 
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5.1.3 Analysis 
I calculated diagnostic accuracy statistics to compare the performance of each of 
the FASD case ascertainment algorithms (index tests), with the FASD classifications 
assigned by the expert case conference panel (reference standard). Algorithm 
performance was quantified using sensitivity and specificity statistics and the 0,1 
method, which identifies the shortest distance to the top left hand corner of a 
Receiver Operating Characteristic (ROC) plot, defined as d = √ ([1-Sensitivity]2 + [1-
Specificity] 2).243 The rationale behind this method is that an algorithm that had 
perfect agreement with the case conference panel would pass through the top left 
hand corner of the ROC plot. Therefore, shorter distances indicate greater 
agreement between the case ascertainment algorithm and the expert consensus 
panel. This method places equal importance on sensitivity and specificity. Further 
considerations about the relative importance of sensitivity and specificity are 
described later in this chapter, with reference to the qualitative results from the 
case conference panel. Confidence intervals for sensitivity and specificity estimates 
were generated using the Wilson method, which is recommended for sample sizes 
≤ 40.244 In addition to the quantitative analyses, I produced a qualitative summary 
of the panel discussion that took place for each participant profile and the 
corresponding FASD outcome decision. I also recorded the recommendations that 
members of the case conference panel made for refinement of the FASD case 
ascertainment algorithms. 
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5.2 Quantitative results 
Diagnostic accuracy statistics for each of the FASD case ascertainment algorithms 
are presented in Table 11 and a ROC plot is provided in Figure 10. The Mid CNS/Any 
PAE case ascertainment algorithm had the highest level of agreement with the 
FASD classifications that were assigned by the expert consensus panel. Ninety-one 
percent of individuals who were classified as having FASD by the case conference 
panel were assigned a FASD classification by this algorithm (95% CI 62% - 98%). 
Specificity for the Mid CNS/Any PAE case ascertainment algorithm was 55% (95% CI 
34% - 74%), indicating that nine out of 20 individuals who met criteria for FASD 
under this definition were not classified as having FASD by the panel. Overall, this 
algorithm had the shortest distance to the top left hand corner of the ROC plot (0,1 
value = 0.46). The Mid CNS/Mid PAE and Revised CNS/Any PAE case ascertainment 
algorithms had the next highest level of diagnostic accuracy, relative to the case 
conference panel decision, with both algorithms having the same values for 
sensitivity, specificity and the 0,1 statistic (64% [95% CI, 35% - 85%]; 70% [95% CI, 
48% - 85%]; and 0.47, respectively). However, confidence intervals were wide for 
all estimates, due to the small sample size. In summary, the three top-performing 
ALSPAC FASD case-definitions, based on the diagnostic accuracy statistics, were the 
Mid CNS/Any PAE, Mid CNS/Mid PAE and Revised CNS/Any PAE algorithms.  
5.3 Qualitative results 
A full qualitative summary of discussions from the case conference panel about 
FASD classification decisions is presented in Appendix 7. The case conference panel 
reached consensus for all participant FASD classifications. However, in many cases, 
they reported a lack of confidence in their classifications due to missing 
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information or discrepancies between test results in key domains. The panel noted 
that in real-life clinical settings they would have sought further testing and 
information, including an in-depth discussion with the child’s caregivers, before 
reaching a FASD outcome decision for many of the cases.  
During the case conference, panel members discussed the factors that most 
influenced their decisions about participants’ FASD classification. The panel made 
several recommendations for refinements to the FASD case ascertainment 
algorithm, which are summarised in Appendix 8. These were incorporated into the 
Revised CNS case ascertainment algorithms. 
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Table 11: Test accuracy statistics for ALSPAC FASD case ascertainment algorithms (index test), compared to 
case conference panel FASD classification (reference standard). Measures with shortest 0,1 distance highlighted 
in bold. 
FASD case-definition 
TP FP FN TN Na Sens % 
(95% CI) 
Spec % 
(95% CI) 
0,1b 
Lib CNS; Any PAE 11 17 0 3 31 100 (74 - 100) 15 (5 - 36) 0.85 
Lib CNS; Mid PAE 8 11 3 9 31 73 (43 - 90) 45 (26 - 66) 0.61 
Lib CNS; Strict PAE 4 6 6 14 30 40 (17 - 69) 70 (48 - 85) 0.67 
Lib CNS; Canadian PAE 2 4 9 16 31 18 (5 - 48) 80 (56 - 94) 0.84 
Lib CNS; ND-PAE 4 4 7 16 31 36 (15 - 65) 80 (56 - 94) 0.67 
Lib CNS; NICE PAE 5 5 6 15 31 45 (21 - 72) 75 (51 - 91) 0.60 
Mid CNS; Any PAE 10 9 1 11 31 91 (62 - 98) 55 (34 - 74) 0.46 
Mid CNS; Mid PAE 7 6 4 14 31 64 (35 - 85) 70 (48 - 85) 0.47 
Mid CNS; Strict PAE 4 3 6 17 30 40 (17 - 69) 85 (64 - 95) 0.62 
Mid CNS; Canadian PAE 2 2 9 18 31 18 (5 - 48) 90 (68 - 99) 0.82 
Mid CNS; ND-PAE 3 2 8 18 31 27 (9 - 57) 90 (68 - 99) 0.73 
Mid CNS; NICE PAE 4 3 7 17 31 36 (15 - 65) 85 (64 - 95) 0.65 
Strict CNS; Any PAE 6 3 5 13 27 55 (28 - 79) 81 (57 - 93) 0.49 
Strict CNS; Mid PAE 5 1 6 15 27 45 (21 - 72) 94 (72 - 99) 0.55 
Strict CNS; Strict PAE 3 0 7 16 26 30 (11 - 60) 100 (81 - 100) 0.70 
Strict CNS; Canadian PAE 2 0 9 16 27 18 (5 - 48) 100 (81 - 100) 0.82 
Strict CNS; ND-PAE 3 0 8 16 27 27 (10 - 57) 100 (81 -100) 0.73 
Strict CNS; NICE PAE 3 0 8 16 27 27 (10 - 57) 100 (81 - 100) 0.73 
Rev CNS; Any PAE 7 6 4 14 31 64 (35 - 85) 70 (48 - 85) 0.47 
Rev CNS; Mid PAE 6 3 5 17 31 55 (28 - 79) 85 (64 - 95) 0.48 
Rev CNS; Strict PAE 3 2 7 18 30 30 (11 - 60) 90 (70 - 97) 0.71 
Rev CNS; Canadian PAE 1 1 10 19 31 9 (2 - 38) 95 (76 - 99) 0.91 
Rev CNS; ND-PAE 1 1 10 19 31 9 (2 - 38) 95 (76 - 99) 0.91 
Rev CNS; NICE PAE 2 2 9 18 31 18 (5 - 48) 90 (70 - 97) 0.82 
Abbreviations: CI, confidence interval; CNS, central nervous system; FN, false negative; FP, false 
positive; Lib; liberal; PAE, prenatal alcohol exposure; Rev, revised; Sens, sensitivity; Spec, specificity; 
TN, true negative; TP, true positive. 
a N refers to number of participants out of the total case conference sample (N = 31) with sufficient 
information available to determine FASD classification for each case-ascertainment algorithm. For 
example, some participants had missing data on PAE for one or more trimester and, therefore, had 
insufficient data available to meet Strict PAE case ascertainment algorithms.  
b 0,1 statistic indicates distance from the top left hand corner of a Receiver Operating Characteristic 
(ROC) plot with lower values indicating better test performance. 
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Figure 10: Receiver operating characteristic (ROC) plot depicting diagnostic accuracy of the FASD case 
ascertainment algorithms, relative to the FASD classifications assigned by the expert case conference panel. 
Dashed arrows represent distance from the top left hand corner of the ROC plot (which would indicate perfect 
agreement with the case conference panel) and text boxes indicate the 0,1 statistic for the three FASD case 
ascertainment algorithms with the highest level of agreement with the case conference panel. Note: the Mid 
CNS/Mid PAE and Revised CNS/Any PAE data points overlap, as they appear in the same position in the plot. 
  
0.47 
0.46 
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6 Discussion 
6.1 Main results 
In this chapter, I demonstrated that it was possible to develop FASD case 
ascertainment algorithms based on the FASD Canadian guidelines (2005)72 and 
consultation with clinical experts, for application to a population-based birth 
cohort (ALSPAC). The Mid CNS/Any PAE algorithmg had the highest levels of 
agreement with the expert case conference panel (sensitivity 91%; specificity 55%; 
0,1 value 0.46), offering support for its validity.  
The algorithms with the next highest levels of agreement were the Mid CNS/Mid 
PAE and Revised CNS/Any PAE algorithms (for both: sensitivity 64%, specificity 70%; 
0,1 value 0.46). To my knowledge, this is the first study to develop and validate 
FASD case ascertainment algorithms for use in an epidemiological study. The FASD 
classification algorithms are transparent and can potentially be applied to other 
international cohorts to enable valid comparison of prevalence across settings, 
subject to equivalence of measures and data availability. 
6.2 Strengths and limitations 
6.2.1 Data considerations 
A key strength of the ALSPAC dataset was that it included extensive information 
that enabled each of the domains within the FASD Canadian guidelines for 
diagnosis (2005) to be assessed. Measures included an array of multidisciplinary, 
multi-rater assessments, which were conducted with a large population-based 
                                                        
g The Mid CNS/Any PAE classification corresponds to an intermediate level of FASD symptom 
severity, convergent evidence across a range of central nervous system measures, and evidence of 
any level of confirmed prenatal alcohol exposure. 
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sample. Tests were carried out by qualified personnel, including psychologists and 
speech and language therapists, and a range of informants, including parents and 
teachers. In addition, the involvement of a FASD specialist, paediatrician and 
educational psychologist in the algorithm development and validation steps, 
enabled a multidisciplinary approach to FASD case identification and validation of 
the algorithms, in a manner that approximated recommended FASD case 
conference procedures.72 
However, it is important to note that the tests that were used to derive FASD 
classifications were not administered with this specific purpose in mind and, 
therefore, may not be optimal for FASD identification. The FASD Canadian 
guidelines for diagnosis include an appendix that lists the tests that are most 
commonly used by FASD assessment teams.72 The ALSPAC dataset and resulting 
algorithms did include some of these measures, such as the WISC-III and the 
Movement Assessment Battery for Children, although these were administered in 
an abbreviated form.235,245,246 Other tests that were listed in the Canadian appendix 
were not available in the ALSPAC dataset. For example, the Wilson-Nagrani et al. 
scale for lips236 was used to assess the FAS facial phenotype, rather than the 
recommended University of Washington lip-philtrum guide.247 The choice of tests 
used to ascertain FASD status will inevitably influence classification outcomes and, 
therefore, prevalence estimates. Nevertheless, it is reasonable to assume that 
measures that purport to measure the same domain of functioning should have 
convergent validity. Furthermore, I identified alternatives to the measures listed in 
the Canadian appendix in consultation with the expert group to ensure that the 
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measures selected from those available in ALSPAC were the most suitable for FASD 
assessment.  
Measures of prenatal alcohol consumption were based on maternal self-report and 
are likely to be subject to measurement error. Although self-report measures of 
PAE have their limitations, the fact that most of the data were collected 
prospectively and anonymously should reduce the risk of recall bias and mitigate 
some of the issues that contribute to inaccuracies in self-reported PAE, such as fear 
of persecution and social desirability bias. Furthermore, the PAE questionnaires 
benefitted from the use of standard indicators for drink sizes and 
dose/frequency/type response formats for specific time points in pregnancy. These 
aspects have been shown to improve the validity of self-report measures of alcohol 
use.62  
6.2.2 Algorithm validation 
Qualitative data suggested that the expert panel lacked confidence in some of their 
classification decisions, often due to missing data in participant profiles and the 
lack of face-to-face contact with children and their caregivers to support clinical 
decision-making. Therefore, while the case conference panel provides some 
indication of the performance of the FASD algorithms, relative to expert consensus, 
the panel cannot be considered a gold standard reference test, as it did not 
replicate a thorough in-clinic assessment process.  
It is also important to note that the expert panel were involved in both the 
algorithm development and validation stages. This may have increased the 
diagnostic accuracy performance of the algorithms. Finally, confidence intervals 
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were wide for diagnostic accuracy statistics due to the small sample size. Whilst a 
larger sample may have been preferable to increase precision in diagnostic 
accuracy estimates, panel members had a limited amount of time available to 
contribute to this process and, therefore, the sample size was restricted to ensure 
that it was feasible to conduct the validation step in a one-day face-to-face meeting 
format. 
Follow-up studies that evaluate the performance of the FASD algorithms with 
alternative reference standards are warranted, but were beyond the scope of this 
thesis due to time and resource constraints. For example, it would be useful to 
evaluate algorithm performance relative to FASD classifications made by an 
independent expert panel, general population active case ascertainment screening 
methods (such as in-school screening),95 FASD clinic-based assessments, and GP-
linked datasets.248 
6.2.3 Sensitivity and specificity of the algorithms 
Specificity estimates indicated that the Mid CNS/Any PAE case ascertainment 
algorithm may have produced a high proportion of false positive results (i.e. the 
algorithm classified some participants as FASD when the case conference panel did 
not). This suggests that the algorithm may overestimate FASD. It is possible that 
the alcohol exposure criterion, which allowed for any PAE to be sufficient for 
consideration of a FASD classification, may have been too liberal. As described 
previously, evidence of the risk of harm at low levels of PAE is inconclusive.24 
However, Astley and Grant point out that one in seven of the children diagnosed 
with FAS in their Washington clinic have exposure in the low to moderate range (1 - 
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8 drinks per week),43 and the absence of a threshold for exposure is the most 
consistent interpretation of the Canadian 2005 guidelines for diagnosis. 
Alternatively, it may be that the apparently low specificity values could be due to 
an imperfect reference standard. The qualitative results showed that many of the 
participant profiles that were classified as ‘not FASD’ by the panel were considered 
possible cases, subject to further investigation. The panel appeared to only classify 
participants as having FASD when they were fairly certain that they met criteria, 
and tended to classify participants as not having FASD when they were uncertain. 
Therefore, it seemed reasonable to favour high sensitivity, rather than high 
specificity, when choosing which of the case ascertainment algorithms with the 
highest overall accuracy (0,1 value) to select for the analyses that follow in this 
thesis. 
6.2.4 Differential diagnosis 
Many of the features of FASD are not specific to PAE and, therefore, guidelines 
characterise FASD as a ‘diagnosis of exclusion.’ To address this issue, I excluded 
participants who were known to have a genetic condition from the sample. 
However, it was not possible to rule out other exposures that may have 
contributed to developmental outcomes on a case-by-case basis (the impact of 
differential diagnosis on FASD prevalence estimates is discussed further in Chapter 
4). Nevertheless, the implications of co-occurring exposures for FASD classifications 
were discussed with the expert group during the validation step. The group 
acknowledged that while prenatal exposure to other substances (such as cigarette 
smoking and illicit drug use) and perinatal insults (such as hypoxia) complicate 
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efforts to determine whether alcohol was the key contributor to a child’s 
developmental profile, exposure to multiple adverse factors is the norm among 
children with FASD and does not rule out the potential contribution of alcohol as an 
important causal factor. 
7 Conclusion and implications for this thesis 
It was feasible to develop FASD case ascertainment algorithms to enable 
investigation of the epidemiology of FASD in the ALSPAC cohort. Since the Mid 
CNS/Any PAE FASD case ascertainment algorithm had the highest levels of 
agreement with the expert case conference panel, this algorithm will be used to 
identify individuals who meet criteria for FASD in the prevalence and risk factor 
analyses that follow in Chapters 4 and 6. The Mid CNS/Mid PAE and Revised 
CNS/Any PAE case-definition algorithms had the next highest levels of agreement 
with the validation panel and will be used in the sensitivity analyses for prevalence 
estimates in Chapter 4. 
It is important to note that the FASD classifications that are derived from 
application of the algorithms in this thesis are not intended to provide formal 
‘diagnoses’ of FASD. As described above, FASD diagnosis requires input from a 
multidisciplinary team in a clinic setting, with an opportunity to interact with 
caregivers, to allow a thorough analysis of a child’s developmental profile and to 
support differential diagnoses. For the purposes of this research, ‘cases’ and 
reference to ‘participants with FASD’ refers to individuals who meet the case 
ascertainment algorithm criteria for FASD, rather than individuals who have 
received a formal FASD diagnosis.  
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Chapter 4. Prevalence and characteristics of fetal alcohol spectrum 
disorder in England: a population-based birth cohort study 
 
1 Overview 
In this chapter, I present prevalence estimates for fetal alcohol spectrum disorder 
(FASD), using data from a population-based birth cohort in England (ALSPAC). First, 
I describe why there is a need for a study of FASD prevalence in the UK and present 
the chapter aims and objectives. As with many epidemiological studies, missing 
data are an issue in the ALSPAC cohort. Therefore, next, I describe the strategies 
that I used to address missing data and discuss their relative validity. I then present 
FASD prevalence estimates and describe the sociodemographic and clinical 
characteristics associated with FASD. In the final section, I present a discussion of 
the strengths and limitations of my approach, compare these results with the 
existing literature, and discuss the implications of this work. 
2 Background 
FASD is thought to be a major cause of developmental disability, affecting up to 
10% of children in the general population in Europe and North America.79-87 
Prenatal alcohol use is common in the UK,11-13 but the prevalence of FASD is 
unknown.94 The International Charter on Prevention of FASD, published in 2014, 
describes the lack of public and professional awareness of FASD and calls for 
prevalence research as an important step in informing prevention efforts.249 The All 
Party Parliamentary Group (APPG) on FASD noted that a lack of UK-based research 
on the epidemiology of FASD has led to inadequate service provision.108 Gregory 
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and colleagues echoed the sentiments of the APPG, stating that “The most obvious 
difficulty in trying to persuade health commissioners of the need to fund services 
for assessments and management of cases of FAS/FASD is the lack of clarity 
regarding the number of children affected. It has wrongly been assumed that this is 
a rare disorder and that no additional support is needed to manage them.”104(p.233)   
Active case ascertainment methods, such as in-school screening methods, are the 
preferred approach for FASD prevalence studies; however, they are costly and 
resource intensive.95 To date, active case ascertainment studies of FASD have not 
been possible in the UK due to a lack of funding and ethical issues.108 Given these 
challenges, I applied the FASD case ascertainment algorithms that I developed in 
Chapter 3 to existing data from a population-based birth cohort in England to 
estimate the prevalence of FASD. 
3 Aims and objectives 
3.1 Aims 
i. To estimate the prevalence of FASD in the ALSPAC cohort. 
ii. To describe the sociodemographic and clinical characteristics associated 
with FASD. 
3.2 Objectives 
i. To consider the validity of using complete case, single imputation and 
multiple imputation methods to address missing data in the ALSPAC cohort. 
ii. To estimate the prevalence of FASD within the ALSPAC cohort, using 
complete case, single imputation and multiple imputation methods. 
iii. To use descriptive statistics to summarise the sociodemographic and clinical 
characteristics associated with FASD. 
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4 Method 
4.1 Data source 
The Avon Longitudinal Study of Parents and Children (ALSPAC; described in Chapter 
3 section 4.1.1).  
4.2 Study approval 
Ethical approval for this study was obtained from the ALSPAC Ethics and Law 
Committee (IRB00003312) and the Local Research Ethics Committees.232 Project 
approval was granted by the ALSPAC Executive Committee on the 2nd March 2016 
(Project B2620).   
4.3 Participants 
This study included singleton pregnancies within the core ALSPAC sample. 
Participants with genetic conditions, participants who were not alive at one year of 
age, and participants who did not speak English as a primary language were 
excluded. Participants who were in the armed forces social class category were 
excluded due to sparse data, which caused computational problems in imputation 
and risk factor models (N = 28). 
4.4 Outcome 
The primary outcome was total FASD prevalence, defined as the proportion of 
participants who met criteria for any condition within the FASD continuum, based 
on the Mid CNS/Any PAE case ascertainment algorithm (described in Chapter 3; 
Table 10). Secondary outcomes were the prevalence of FASD subtypes, including 
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fetal alcohol syndrome (FAS), partial fetal alcohol syndrome (pFAS) and alcohol-
related neurodevelopmental disorder (ARND). 
4.5 Statistical analysis: the analytical challenge posed by missing data 
Missing data are common in longitudinal datasets, including ALSPAC. In this 
section, I describe missing data types and methods, in the context of FASD 
prevalence research.  
4.5.1 Types of missing data 
Little and Rubin provide a terminology to describe the different relationships 
between missing and observed data.250 Data are missing completely at random 
(MCAR) if missingness is not related to the data values; for example, if data are 
missing due to a power cut during a computer task. However, unless built into the 
study designh MCAR is rarely assumed to hold.251 
Data are missing at random (MAR) if any systematic differences between the 
missing and observed values can be fully explained by differences in the observed 
data. For example, if missing blood pressure measurements are lower than the 
observed measures but only because younger people are less likely to have their 
blood pressure monitored then data are said to be MAR given age.252 
Data are missing not at random (MNAR) if there are still systematic differences 
between the missing and observed data, even after the observed data are taken 
into account.252 It is not possible to determine whether data are MAR or MNAR 
based on the observed data, since knowledge of this relationship relies on knowing 
                                                        
h For example, in ‘planned missing’ data designs, participants may be randomly allocated to respond 
to a subset of measures. 
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the values of the unobserved data. As missing data are often beyond the control of 
the researcher, and the researcher is unlikely to be aware of, or have access to, all 
of the data that predict missingness, most data are expected to be at least partly 
MNAR.253 I will describe the implications of the MAR and MNAR assumptions for 
the analyses in this chapter in the discussion section.  
Data that are MCAR will not produce biased prevalence estimates but will lead to 
decreased precision due to reduced sample size. When outcome data are more 
likely to be missing given certain values of the exposure, or depend on the 
unobserved values of the outcome, then prevalence estimates will be biased.252,254 
For example, FASD prevalence will be underestimated if children with incomplete 
data have higher levels of a given causal risk factor (such as binge PAE) than those 
with complete data. Prevalence will also be underestimated if children with 
incomplete data have poorer performance than those with complete data on 
measures relevant to FASD, such as lower IQ.  
4.5.2 Analysis methods for missing data 
Missing data complicate attempts to determine FASD prevalence. In this section, I 
describe the different missing data strategies that have been used in existing FASD 
research. I also describe the missing data strategies that I used to estimate the 
prevalence of FASD in the ALSPAC sample, and how I evaluated the relative validity 
of each of these strategies. 
4.5.2.1 Complete case methods 
Complete case methods are ubiquitous in epidemiology. Under a complete case 
approach, analyses are restricted to include only participants with observed data 
 Chapter 4 93 
for all relevant variables. This approach is justified on the grounds of simplicity 
when the loss of information is minimal and the missing data represent a random 
sample of all participants (MCAR).250 Complete case analysis is not usually 
appropriate as data are rarely MCAR.252 Therefore, using this method can lead to 
biased results and a loss of precision. Nevertheless, since complete case methods 
have been used in FASD prevalence studies,84,85 I decided to investigate the validity 
of applying this missing data strategy and its impact on prevalence estimates. For 
the complete case prevalence analyses, I excluded all children who had missing 
data on any of the measures that were included in the Mid CNS/Any PAE FASD case 
ascertainment algorithm. To determine whether the MCAR assumption was 
plausible, I investigated missing data patterns using the misstable command in 
Stata 14.2155 and compared the distribution of key sociodemographic factors, risk 
factors and clinical characteristics among participants with complete versus 
incomplete data on the measures required to ascertain FASD status. 
4.5.2.2 Single imputation methods 
Single imputation is another approach for handling missing data and involves 
replacing missing data with one fixed value.250 Examples include mean substitution 
(missing data are replaced with the average of the observed values) and last 
observation carried forward methods (missing data are replaced with the last 
observed value in longitudinal studies).251 Single imputation methods benefit from 
being straightforward to implement. However, they do not account for uncertainty 
in the imputed values and lead to unrealistically small estimates of variability.252  
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In FASD prevalence studies, single imputation strategies have also been used and 
often involve replacing missing exposure and symptom data with zero (i.e. they 
interpret missing data as indicating no PAE and/or no impairment). For example, in 
their study of FASD prevalence, Okulicz-Kozaryn and colleagues used the following 
single imputation method: “All uncertainties and missing test results (unless it was 
clearly reported that a child was not able to do the test) were interpreted in the 
child’s favour…It was also assumed that all missing data on prenatal alcohol 
exposure would be interpreted as no exposure.” 81(p.64) Accordingly, for the single 
imputation analyses in this chapter, I assumed that missing PAE data indicated no 
exposure and that missing CNS, growth and facial data indicated no impairment. 
This is a strong assumption and I explore the validity of this single imputation 
strategy later in this chapter, when I describe the missing data patterns within this 
sample.  
4.5.2.3 Multiple imputation methods 
Multiple imputation can be used to address missing data problems in 
epidemiological analyses, under the assumption that data are MCAR or MAR.255 
Multiple imputation is a statistical technique that generates multiple sets of 
possible values for missing data, based on the distribution of the observed data.  
Multiple imputation comprises three stages. In the first stage, the imputation 
procedure creates multiple versions of the dataset, in which missing values are 
imputed by sampling from the distribution of possible unobserved values 
conditional on the observed values. This step incorporates uncertainty in the 
imputed values by adding variability into the values across the imputation sets. The 
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second stage of multiple imputation uses conventional statistical procedures to fit 
the models that are of interest in the substantive analysis to each of the imputation 
sets. The effect estimates from each of the imputation sets will differ due to the 
inherent variability in the imputation process. In the final stage, estimates from 
across the imputation sets are combined using Rubin’s combination rules.252,256 
Rubin’s rules attribute the appropriate amount of variability into pooled estimates 
from imputed data by accounting for both within- and between-imputation 
variability and the number of imputation sets, therefore taking into account the 
uncertainty of the imputed values. Using Rubin’s rules, pooled prevalence 
estimates are calculated as the average proportion across the number of 
imputation sets, denoted as m, as follows: (proportion1 + proportion2 ... + 
proportion20)/m. Estimated total variance is calculated as: ([estimated average 
within-imputation variance] + [1 + m-1] x [estimated between-imputation 
variance]).  
I used multiple imputation methods to address missing data in the ALSPAC cohort 
under the assumption that data were MAR. It is important to note that MAR is an 
assumption, rather than a property of the data. To increase the plausibility of the 
MAR assumption, I used an inclusive strategy for the imputation model, which 
included hypothesised risk factors for FASD, sociodemographic variables, clinical 
characteristics and auxiliary variables.252,253 Auxiliary variables are not included in 
the main analyses of interest (i.e. are not key exposures, confounders or 
outcomes), but are included in the imputation model “solely to improve the 
performance of the missing data procedure.” 253(p.331) Types of auxiliary variables 
include variables that predict whether a value is missing and variables that predict 
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the values of missing data (e.g. the inclusion of binge drinking at 8 weeks 
postpartum to predict PAE).253 I selected auxiliary variables based on whether they 
had been identified as potentially relevant to the causal context of FASD (described 
in Chapter 5). 
To generate the imputation sets, I used multiple imputation by chained equations 
(MICE) in Stata 14.2.155,257 MICE is appropriate for use with the mixed pattern of 
missing data in this sample.258 The MICE procedure is as follows: given a dataset in 
which variables x1, ….., xk have missing values, all missing values are initially 
imputed at random. Then, the first variable to have one or more missing values (x1) 
is regressed on all of the other variables in the imputation model (x2, ….., xk). This 
estimation step is limited to participants with observed x1. Missing values in x1 are 
then imputed by random draws from the posterior predictive distribution of x1. This 
process is repeated for all other variables with missing values x2, …., xk, which are 
regressed on all of the other variables, including the imputed values of the 
preceding variables in this sequence. One iteration of this sequence is called a 
cycle. I used 10 cycles to produce each imputed data set and generated 20 
imputation sets, following guidance from Sterne and colleagues.252 Imputation 
models were specified as binary, ordered categorical, non-ordered categorical and 
continuous for each variable as appropriate.255,257  
FASD status is a complex variable. It is a composite binary outcome (FASD/not 
FASD) that is derived from multiple subcomponent variables including PAE data, 
psychological test scores, clinical assessments and questionnaire data that are 
measured at multiple time points, using a range of informants. Models that impute 
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subcomponents of composite outcomes have been shown to lead to increased 
precision and reduced bias, relative to methods that impute the composite 
outcomes directly.259,260 Therefore, rather than imputing FASD status as a 
composite outcome, I imputed the missing values of FASD subcomponents. 
Following imputation, I combined these subcomponent values using the mi passive 
command in Stata258 and applied the FASD case ascertainment algorithm to 
construct the final FASD composite outcome. Appendix 9 provides the full 
specification for the multiple imputation model. 
To assess the performance of the multiple imputation model, I used the 
midiagplots509 command in Stata to compare observed, imputed and completed 
data values.  
4.5.3 Prevalence estimation  
I generated prevalence estimates for total FASD and FASD subtypes (FAS, pFAS and 
ARND) for each of the missing data strategies (complete case, single imputation, 
multiple imputation), by applying the Mid CNS/Any PAE FASD case ascertainment 
algorithm to the relevant sample. For analyses based on the complete case and 
single imputation strategies, prevalence was defined as the number of participants 
in the sample who met criteria for FASD, divided by the total relevant sample. For 
estimates based on multiply imputed data, I applied the FASD case ascertainment 
algorithm to each imputation set and generated pooled prevalence estimates, 
following Rubin’s rules.256  
I calculated 95% confidence intervals using the Wilson method for the complete 
case and singly imputed data.261 The Wilson method is preferable to the standard 
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normal approximation method when sample sizes are small or proportions are 
close to 0 (for example, when exploring outcomes that are relatively rare, such as 
FAS).244 For estimates based on multiply imputed data, I generated 95% confidence 
intervals using Rubin’s rules.256 
4.5.4 Sample characteristics by FASD status 
As well as estimating the potential burden of FASD (prevalence), it is useful to know 
who is most likely to be affected by FASD and to describe their clinical presentation 
to inform efforts for targeted prevention and assessment. Therefore, I calculated 
descriptive statistics to summarise participant sociodemographic and clinical 
characteristics, according to FASD status, using the multiply imputed data. All 
statistics were calculated using Rubin’s combination rules.256 
I note that there will be an element of circularity in the description of some of the 
clinical characteristics that I present. For example, by definition, all children with 
FASD will have at least three subdomains of CNS impairment and confirmed PAE.i 
However, other characteristics such as patterns of PAE, the relative profile of 
specific subdomains of CNS impairment, growth and facial features are free to vary 
and may give some indication of the most common profiles of impairment among 
children with FASD. 
                                                        
i Except for FAS, which can be diagnosed without confirmation of PAE (expected to be a minority of 
cases). 
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5 Results  
5.1 Participants 
Figure 11 provides a summary of the number of participants included in each of the 
prevalence analyses, by the type of imputation strategy. There were 15,730 
consented children in the ALSPAC dataset. After applying the eligibility criteria, 
13,495 children remained in the sample. This sample size was preserved using the 
single and multiple imputation strategies to replace missing data. However, missing 
data led to substantial attrition in the complete case sample. 13,272 children had 
missing data for one or more of the measures in the FASD case ascertainment 
algorithm, producing a final complete case sample of 223. 
5.1.1 Missing data patterns 
Appendix 9 describes the proportion of missing data in the eligible sample for each 
of the variables included the imputation model. The proportion of missing data 
ranged from 0% for maternal age, gestational age at delivery, and child sex 
variables to 70% for teacher-reported communication problems at school. Forty-
nine percent of participants had incomplete PAE data. Missing data patterns 
included a combination of monotone missing (where participants dropped out at 
one time point and did not complete any further measures in ALSPAC), unit missing 
(where participants had missing information for an entire questionnaire or clinic 
session) and item missing (where participants had missing data for some items of a 
measure, but not others).250 Appendix 10 presents the characteristics of 
participants with complete data, compared to those who had missing data for one 
or more of the measures required to ascertain FASD status. 
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Figure 11: Flow diagram depicting eligible and final sample for the FASD prevalence estimates, by missing data strategy 
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Participants with complete data differed from those with incomplete data on a 
range of demographic characteristics, prenatal exposures and clinical 
characteristics, indicating that data were not MCAR. For example, compared to 
those with complete data, mothers of children with incomplete data were younger 
at delivery (aged 30 years or over: incomplete 37%; complete 53%), were more 
likely to report that pregnancy was unplanned (incomplete 31%; complete 16%), 
and were of lower socioeconomic status according to a range of indicators (e.g. 
home owner: incomplete 73%; complete 92%). During pregnancy, mothers of 
children with incomplete data were less likely to report drinking alcohol overall 
(incomplete 69%; complete 73%), but more likely to report binge drinking 
(incomplete 22%; complete 19%). They were also more likely to have smoked 
(incomplete 28%; complete 14%), less likely to have taken vitamin supplements 
(incomplete 54%; complete 57%), and were more likely to have significant 
depression (incomplete 21%; complete 13%) and anxiety (incomplete 24%; 
complete 18%) symptoms. Children with incomplete data had poorer outcomes on 
a range of measures including lower IQ, lower academic attainment, special 
educational needs, conduct problems, emotional and behavioural problems at 
school, and growth deficiency. However, outcomes were in the opposite direction 
for some measures; for example, a higher proportion of children with complete 
data had a smooth philtrum and thin upper lip (full details in Appendix 10).  
5.1.2 Validity of missing data strategies for estimating FASD prevalence 
The preceding analyses indicated that the missing data in this sample imposed 
several limitations that compromised the validity of the complete case and single 
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imputation strategies for estimating FASD prevalence. First, missing data led to 
significant attrition in the complete case sample. Only 2% of eligible participants 
had sufficient data to remain in the complete case sample. Second, comparison of 
the characteristics of participants with complete versus incomplete data revealed 
that missingness was associated with risk factors for FASD,j including lower 
socioeconomic status, adverse prenatal exposures and poorer outcomes on the 
clinical characteristics that contribute to FASD status. This suggests that both the 
complete case strategy and the single imputation strategy (which assumed that 
missing data were indicative of no PAE/no impairment), were likely to be invalid 
and lead to underestimates of FASD prevalence. Since these strategies have been 
widely used in existing FASD studies, in the next section, I present prevalence 
estimates based on the complete case, single imputation and multiple imputation 
strategies to demonstrate their impact on FASD prevalence estimates. However, 
given the limitations described above, I consider the prevalence estimate based on 
multiply imputed data to be the most valid. 
5.2 FASD prevalence  
5.2.1 Complete case prevalence estimates 
Based on the complete case sample, 16 children (7.2%; 95% CI 4.5% - 11.3%) met 
criteria for any FASD. Fifteen children (6.7%; 95% CI 4.1% - 10.8%) met criteria for 
ARND and one child (0.4%; 95% CI 0.08% - 2.5%) met criteria for pFAS. None of the 
children met criteria for FAS. 
                                                        
j FASD risk factors are discussed further in Chapters 5 and 6. 
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5.2.2 Single imputation prevalence estimates 
In the analyses that used the single imputation method to address missing data, 
6.0% (95% CI 5.7% - 6.5%) of children met criteria for FASD. ARND was the most 
common subtype of FASD, accounting for 5.8% (95% CI 5.5% - 6.2%) of FASD cases. 
None of the children met criteria for FAS, and 0.2% (95% CI 0.1% - 0.3%) met 
criteria for pFAS.  
5.2.3 Multiple imputation prevalence estimates 
In analyses with multiply imputed data, 17.0% (95% CI 16.1% - 17.8%) of children 
met criteria for any FASD. ARND was the most common subtype of FASD, affecting 
15.4% (95% 14.4% - 16.4%) of children. For the remaining FASD subtypes, 1.6% 
(95% CI 1.1% - 2.1%) of children met criteria for pFAS, 0.02% (95% CI 0.00% - 0.04%) 
met criteria for FAS with confirmed PAE, and 0.01% (95% CI 0.00% - 0.02%) met 
criteria for FAS without confirmed PAE.  
5.2.3.1 Sensitivity analyses with multiply imputed data 
I conducted sensitivity analyses to explore the impact of using different case 
ascertainment algorithms to estimate total FASD prevalence. The primary 
algorithm was the Mid CNS/Any PAE case ascertainment algorithm (results 
described above). I also applied the Mid CNS/Mid PAE and the Revised CNS/Any 
PAE algorithms. These algorithms have been described in full in Chapter 3 (see 
Table 10 for algorithm criteria and Table 11 for test accuracy statistics). Briefly, 
compared to the Mid CNS/Any PAE algorithm, the Mid CNS/Mid PAE algorithm had 
a more stringent PAE criterion (which required evidence of two trimesters of PAE 
and/or binge drinking). The Revised CNS/Any PAE algorithm had the same PAE, 
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facial and growth criteria as the Mid CNS/Any PAE algorithm but incorporated the 
changes to the CNS criteria that were recommended by the expert consensus panel 
(panel recommendations described in Appendix 8). The Mid CNS/Mid PAE and 
Revised CNS/Any PAE algorithms had lower sensitivity and higher specificity values 
than the Mid CNS/Any PAE case ascertainment algorithm (sensitivity 64% and 
specificity 70% for both; compared to 91% sensitivity and 55% specificity for the 
Mid CNS/Any PAE algorithm), but similar performance on the overall accuracy 
metric (0,1 statistic 0.47 for both; compared to 0.46 for the Mid CNS/Any PAE 
algorithm).  
Based on the Mid CNS/Mid PAE case ascertainment algorithm, 12.7% (95% CI 
11.9% - 13.4%) of children met criteria for any FASD. Using the Revised CNS/Any 
PAE case ascertainment algorithm, 12.8% (95% CI 12.0% - 13.5%) of children met 
criteria for any FASD. This indicates that the FASD prevalence estimates remained 
relatively high, even when algorithms with lower sensitivity, higher specificity, and 
more stringent PAE and CNS criteria were used. 
5.3 Participant characteristics by FASD status 
In this section, I present participant sociodemographic and clinical characteristics, 
according to FASD status, using the multiply imputed data. 
5.3.1 Sociodemographic and pregnancy characteristics 
Appendix 11 presents full details of the sociodemographic and pregnancy 
characteristics of participants, according to FASD status. Overall, FASD was more 
common among children whose mothers were of lower socioeconomic status. For 
example, 22% of mothers of children who met criteria for FASD had a partly skilled 
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or unskilled occupation compared to 14% of mothers whose children did not have 
FASD, and mothers of children with FASD were less likely to be homeowners (57%) 
than mothers of children who did not have FASD (76%). Patterns were similar for all 
other indicators of socioeconomic status, including maternal and paternal 
education and paternal social class. Mothers of children with FASD were younger 
than those without FASD. Sixty-nine percent of mothers of children with FASD were 
under 30 years old at the time of delivery, compared to 62% of mothers of children 
without FASD. Children with FASD were more likely to be male (66%). Thirty-nine 
percent of mothers of children with FASD reported that their pregnancy was 
unplanned, compared to 30% of mothers of children without FASD. 
5.3.2 Prenatal alcohol exposure and clinical characteristics 
Appendix 12 provides a full overview of the PAE patterns and clinical characteristics 
of participants, by FASD status. These results are summarised below. 
5.3.2.1 Prenatal alcohol exposure (PAE) 
PAE was common in this sample. Overall, 79% of mothers drank some amount of 
alcohol while pregnant and 25% reported binge drinking during pregnancy. 
According to weekly dose/frequency measures, levels of PAE were generally low. 
Most women reported that they drank less than one glass of alcohol per week 
during pregnancy (42%). Twenty-two percent of participants reported drinking up 
to six glasses of alcohol per week and 3% reported drinking seven or more glasses 
of alcohol per week. 
Figure 12 presents a summary of reported maternal alcohol use by FASD outcome. 
Across all measures, children who met criteria for FASD had higher levels of PAE 
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than children without FASD, although differences were relatively modest. Children 
with FASD were more likely to have been exposed to binge-level PAE at any point in 
pregnancy and to have been exposed to alcohol on a weekly basis.  
Figure 12: Patterns of prenatal alcohol exposure by FASD status based on multiply imputed data 
 
 
5.3.2.2 Clinical characteristics 
Figure 13 presents the proportion of participants who met criteria for each of the 
core FASD criteria (growth, facial phenotype, CNS and PAE), by FASD status. 
Consistent with the low prevalence of the dysmorphic subtypes of FASD (FAS and 
pFAS), there was a low prevalence of growth deficiency (FASD 12%; not FASD 8%) 
and the FAS facial phenotype (FASD 0.7%; not FASD 0.5%). By definition, all 
individuals with FASD had a CNS impairment in three or more subdomains, 
compared to 6% of individuals without FASD. 
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Figure 13: Proportion of participants who met criteria for each of the primary FASD domains by FASD status 
based on multiply imputed data 
 
Figure 14 describes the proportion of individuals with impairment in each of the 
CNS subdomains by FASD status. The most commonly impaired subdomains were 
cognition (FASD 77% impaired; not FASD 52% impaired), attention 
deficit/hyperactivity (FASD 60% impaired; not FASD 10% impaired) and adaptive 
behaviour (FASD 85% impaired; not FASD 29% impaired). In the sample as a whole, 
56% of children met criteria for cognitive impairment, predominantly due to having 
a difference of at least one standard deviation between IQ subscale scores (55%). 
5.3.3 Comparison of participant characteristics by missing data strategy 
To investigate which factors were most influential in accounting for the higher 
prevalence of FASD in the analysis with multiple imputed data, I compared the 
patterns of PAE and clinical characteristics across each of the missing data 
strategies. The relative pattern of sociodemographic, PAE and clinical 
characteristics of individuals with and without FASD was broadly consistent across 
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analyses. Compared to the complete case and single imputation methods, the 
multiply imputed data contained a higher proportion of individuals with PAE (up to 
10% increase), growth deficiency (up to 4% increase) and CNS impairment in at 
least three subdomains (up to 13% increase) (see Figure 15). 
Figure 14: Proportion of participants who met criteria for impairment in each CNS subdomain by FASD status 
based on multiply imputed data 
 
Figure 15: Proportion of participants who met criteria for each of the main FASD domains in analyses with 
complete case, single imputation, and multiple imputation methods 
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Figure 16 presents a comparison of the proportion of participants with impairment 
in each CNS subdomain, by missing data strategy. For all CNS subdomains, the 
multiply imputed data had the highest proportion of participants with impairment. 
The largest increases, relative to the complete case and singly imputed data, were 
in the cognitive (up to 10% increase) and adaptive functioning (up to 12% increase) 
subdomains. Overall, the increased prevalence of impairment across CNS 
subdomains, combined with the increased prevalence of PAE accounted for the 
higher prevalence of FASD in the analyses with multiply imputed data, compared to 
the complete case and single imputation methods.  
Figure 16: Proportion of participants who met criteria for impairment in each CNS subdomain in analyses with 
complete case, single imputation and multiple imputation methods 
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11.3%) in complete case analyses and 17.0% (95% CI 16.1% - 17.8%) in analyses 
with multiply imputed data. The estimates for total FASD that I have presented, 
based on the complete case and single imputation strategies, are broadly 
consistent with the upper limit of studies in other European countries. To date, the 
only countries in Europe with estimates of FASD prevalence based on active-case 
ascertainment methods in the general population are Poland,81 France (Reunion 
Island)262 and Italy.82,83 These studies, and recent meta-analyses, published in 2016 
and 2017, have produced prevalence estimates of 1% to 6% for FASD in Europe.80,86 
Although the prevalence estimates that I have presented based on the complete 
case and single imputation methods are similar to other European studies and, 
therefore, have some face validity, exploration of missing data patterns indicated 
that these estimates were likely to be biased. Participants with incomplete data 
experienced more adverse prenatal exposures, including prenatal binge drinking, 
and had poorer performance on the cognitive and behavioural measures that were 
relevant to FASD. Therefore, analyses based on the complete case data and the 
single imputation strategy (which assumed that missing PAE and phenotype data 
indicated no exposure and no impairment) were likely to underestimate FASD 
prevalence.  
The FASD prevalence estimate of 17%, based on multiply imputed data, is the most 
plausible prevalence estimate in this study, due to the ability of this method to 
reduce the bias introduced by missing data.252,255 This prevalence estimate is 
significantly higher than existing estimates from other countries in Europe and the 
USA, which report a maximum prevalence of 10%,79-87 but lower than estimates 
from South Africa, where prenatal binge drinking is more common and FASD 
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prevalence is up to 28%.89 The FASD prevalence estimates based on multiply 
imputed data remained relatively high (13%) in sensitivity analyses that applied 
two FASD case ascertainment algorithms with lower sensitivity and higher 
specificity to the multiply imputed data, demonstrating that the high prevalence 
estimate in the primary analysis was not fully explained by the higher sensitivity 
and lower specificity of the Mid CNS/Any PAE case ascertainment algorithm.  
6.1.2 PAE prevalence 
Given that the UK has one of the highest rates of PAE in the world, FASD 
prevalence would also be expected to be relatively high. A recent meta-analysis 
produced a pooled prevalence estimate for PAE of 41% in the UK, representing the 
fourth highest prevalence of PAE in the world (behind Denmark [45.8%]; Belarus 
[46.6%] and Ireland [60.4%]).11 Recently published studies that have prospectively 
assessed PAE, suggest that 75% to 79% of women in the UK drink some amount of 
alcohol while pregnant, and that up to 33% binge drink.2,13 Consistent with these 
estimates, the data from the ALSPAC cohort indicate that up to 79% of women 
drank some amount of alcohol during pregnancy and 25% drank at binge levels. 
Compared to the levels of PAE reported in this UK sample, European studies of 
FASD in the general population suggest lower levels of alcohol consumption. Thirty-
six percent of women in Poland, and up to 69% of women in Italy reportedly 
consume alcohol while pregnant.81-83 According to the World Health Organisation, 
the prevalence of heavy episodic drinking among women aged 15 years or more in 
Italy is 0.7%, compared to 20.9% in the UK.263,264 Binge pattern alcohol 
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consumption is particularly harmful to fetal development and therefore would be 
expected to increase FASD prevalence, as described further in Chapter 5. 
The reported level of PAE based on dose/frequency measures, however, was 
generally low. Fifty-one percent of participants who met criteria for FASD had 
mothers who reported a maximum intake of less than one glass of alcohol per 
week during pregnancy. Interpretation of the effect of the reported quantity of PAE 
on FASD risk is complicated, as maternal self-report is likely to underestimate true 
levels of exposure.124 The fact that a quarter of women reported binge drinking 
points to underreporting on dose/frequency measures. Furthermore, multiple co-
occurring risk factors and maternal characteristics influence blood alcohol 
concentrations, the duration of fetal alcohol exposure and, therefore, alcohol 
teratogenicity.8 This has led some to question whether it will ever be possible to 
determine a ‘safe’ threshold for PAE.265 In summary, evidence of FASD among 
individuals with low level PAE could represent a true harmful effect of low levels of 
exposure or underreporting of higher levels of exposure, and of course will have 
been influenced by the chosen FASD case ascertainment algorithm, which 
considered evidence of any PAE as sufficient to meet the alcohol criterion for FASD.  
6.1.3 FASD symptomology 
Results indicated that the most common symptoms among individuals who met 
criteria for FASD were not specific to PAE. Symptoms were similar to those shown 
by children with a range of emotional, behavioural and developmental disorders. 
For example, the most common areas of impairment among individuals with FASD 
were cognition (77% impaired), adaptive functioning (85% impaired), education 
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(74% impaired) and attention deficit/hyperactivity (60% impaired). Such results are 
consistent with a recent meta-analysis that indicated that 51% of individuals with 
FASD had attention deficit/hyperactivity disorder, 69% had a cognitive disorder and 
91% had conduct and/or behavioural problems.90 Cognitive impairment, 
particularly a discrepancy in performance and verbal IQ, was common in the 
ALSPAC sample (56% had impaired cognition, mainly due to a significant 
discrepancy between verbal and performance IQ subdomains). This, coupled with a 
high prevalence of educational problems (25% of whole sample) and adaptive 
behaviour problems (39% of whole sample), in conjunction with high levels of PAE 
(79% of whole sample), contribute to the relatively high prevalence of FASD that I 
reported in this study.  
FASD was more common among children of lower socioeconomic status and 
among children whose mother reported having an unplanned pregnancy. These 
results are consistent with previous studies111 and the proposed causal basis for 
these associations are investigated further in Chapter 5. The finding that FASD 
occurred in twice as many boys as girls in this sample was unexpected, as most 
general population studies of FASD have found no clear sex difference.79,81,83,266,267 
A study of referrals for FASD assessment in Washington State found that boys were 
more likely to be diagnosed with FASD than girls.268 Conversely, studies in ALSPAC 
and the UK Millennium Cohort Study have found that boys are less likely than girls 
to have cognitive, mental health and/or behavioural problems following 
PAE.5,14,35,269,270  
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6.1.4 FASD subtypes 
ARND was the most common subtype of FASD, accounting for 5.8% of FASD cases 
in the analyses that used single imputation and 15.4% of FASD cases in analyses 
with multiply imputed data. The dysmorphic subtypes of FASD (FAS and pFAS) were 
less common. Across the analyses, a maximum of 0.03% of participants were 
classified as FAS and 1.6% as pFAS.  
The prevalence of ARND in this sample is higher than estimates from existing 
European studies, while the prevalence of FAS is lower. Active case ascertainment 
studies from Poland,81 Croatia,84,85 and Italy82,83 have produced estimates of 0.05% 
to 0.8% for ARND, 0.4% to 1.7% for FAS,81-85 and 0.8% to 5.0% for pFAS.81-85 As 
described in Chapter 1, existing UK studies of FAS have relied on surveillance 
methods, which are thought to significantly underestimate prevalence. Previously, 
the highest reported prevalence of FAS in the UK was 0.19 per 1,000 (~0.02%) 
based on data from a FAS surveillance study in Scotland between 2010 and 2015.96 
Using a simulation method that incorporated PAE data to estimate likely FAS 
prevalence, a recent study estimated that 0.6% of children in the UK may have 
FAS.11 Therefore, the FAS prevalence estimate of 0.03% in the ALSPAC sample may 
represent an underestimate. It is important to note that the facial scan data were 
collected at age 15 and there is evidence to suggest that the facial features 
associated with PAE may become less prominent over time.271,272 This may have led 
to reduced detection of children with FAS in this sample, but will not have 
influenced prevalence estimates for total FASD. 
 Chapter 4 115 
The higher prevalence of ARND that I report in this chapter, relative to the existing 
literature, may be explained in part by key differences in study design. Existing 
active case ascertainment studies of FASD in Europe81-83 and many others within 
the USA79,273 and South Africa,89,274-278 follow a tiered screening protocol based 
primarily on child dysmorphology (growth, facial features and head circumference), 
with some brief neurobehavioural measures. Since studies that follow this design 
prioritise FASD assessment based on the visible features of FASD, ARND is likely to 
be “severely undercounted.” 82(p.2346) Furthermore, most of these studies have used 
the IOM-revised guidelines for FASD.73 These guidelines provide more liberal facial 
phenotype criteria than the Canadian guidelines,72 which may also contribute to 
higher FAS prevalence estimates than those reported in this chapter. Finally, the 
evaluation of child physical and neurobehavioural outcomes in the ALSPAC dataset 
are much more extensive than the assessments that have been possible in the 
active case ascertainment studies, which are subject to more resource and time 
restrictions. This too is likely to have contributed to higher prevalence estimates for 
FASD, relative to existing studies.  
6.2 Strengths and limitations 
To the best of my knowledge, this study is the first to produce an estimate of FASD 
prevalence and associated characteristics in a general population sample from 
England. It provides a novel approach to FASD case ascertainment, including the 
use of multiple imputation to reduce bias due to missing data. To date, FASD 
prevalence studies have included three main approaches: i. Surveillance and record 
review methods; ii. Clinic-based studies; iii. Active case ascertainment (e.g. in-
school screening).95 The study presented in this chapter introduces a fourth 
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potential approach, based on a form of retrospective active case ascertainment. 
The design of this study has the following advantages. It is likely to increase capture 
of the full spectrum of FASD, since it does not rely on dysmorphology screening as 
a gateway to assessment; it facilitates a large population-based investigation of 
FASD using a comprehensive range of measures to assess child phenotype in a 
manner that is significantly less costly, resource intensive and time consuming than 
traditional active case ascertainment methods; and, as it uses existing data, it can 
be conducted without additional requirements for consent from participants, 
which maximises participation rates. Low participation rates are an issue in FASD 
prevalence studies. For example, 49% to 83% of eligible children did not participate 
in recent FAS and FASD active case ascertainment studies in Italy, Croatia and 
Poland, leading to imprecise prevalence estimates, small sample sizes, and raising 
questions about the generalisability of the sample to the general population.81,83,84 
Therefore, given that it has not yet been possible to conduct an active case 
ascertainment study of FASD in the UK, the method described in this chapter 
arguably provides the best currently available means of exploring the epidemiology 
of FASD at a population level.  
However, there are several important limitations of this study. First, the validity of 
the prevalence estimates necessarily depend on the validity of the case 
ascertainment algorithm. Sensitivity analyses showed that the prevalence of total 
FASD varied between 13% to 17% based on application of the three best-
performing case ascertainment algorithms to the multiply imputed data. The 
validation process, and strengths and limitations of the FASD case ascertainment 
algorithms have been described in Chapter 3. Furthermore, an ideal clinical 
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assessment for FASD would include an in-person evaluation, including genetic 
microarray testing to support differential diagnosis.279 This was not possible in the 
present study due to resource constraints (only a limited number of participant 
profiles could be reviewed due to time limitations in the expert case conference 
panel), and the use of secondary data that did not include microarray testing. In a 
study of 80 children with suspected FASD who were referred for genetic testing in 
the UK, Douzgou and colleagues found that 9% received an alternative diagnosis, 
due to the presence of a chromosome disorder.280 Therefore, it must be 
emphasised that the prevalence estimates provided in this chapter represent the 
number of children who met the criteria for FASD based on the Mid CNS/Any PAE 
case ascertainment algorithm. This is not equivalent to a formal diagnosis. It may 
be that given the opportunity for a gold standard clinical and genetic assessment, 
some of the children would not be considered to have FASD based on differential 
diagnosis (i.e. that other pre- or postnatal factors might be considered to offer a 
more plausible explanation for the aetiology behind their clinical profile). 
Nevertheless, results still indicated that there were a significant proportion of 
children who had symptoms that suggest compromised development and who 
could potentially benefit from early intervention and additional support.  
Other limitations stem from the concept of FASD as a whole. As described 
previously, many of the diagnostic criteria are non-specific to FASD. Therefore, as 
emphasised by the authors of the 4-Digit Diagnostic Code, in a child with prenatal 
alcohol (and other) exposure(s), and with the exception of those with the FAS facial 
phenotype, alcohol exposure may be fully, partially or not accountable for an 
observed pattern of impairment. Therefore, in the simplest terms, the prevalence 
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estimates reported in this chapter indicate that up to 17% of children in the ALSPAC 
sample were exposed to alcohol prenatally and have evidence of impairment in 
three or more CNS domains, based on the pre-specified criteria. It is not possible to 
prove conclusively that PAE was the key causal factor in determining the outcomes 
of these children. Equally, it is not possible to rule out alcohol as an important 
causal factor.  
As described in Chapter 3, some of the tests in ALSPAC, such as the Weschler 
Intelligence Scale for Children (WISC-III), were administered in an adapted form. 
This may have influenced participant FASD status classifications. Most notably, 55% 
of participants in this study had a discrepancy of 15 points or more in verbal IQ 
versus performance IQ scores. While the authors of the WISC note that such 
discrepancies are not infrequent, their norms, based on a standardisation sample 
from the USA, indicate that such discrepancies tend to occur in a smaller 
proportion (24%) of the general population.281 Furthermore, much of the data on 
prenatal exposures and child behaviour were measured using self-report. These 
data are likely to be subject to measurement error.61,62 
Data on prenatal alcohol use in the ALSPAC cohort were collected between 1991 
and 1992, at which time there were no formal guidelines for drinking in 
pregnancy.282 Therefore, there is a question around the generalisability of these 
results to the present day. Despite the changes in guidance, the prevalence of PAE 
in the ALSPAC sample was similar to recently published estimates of PAE in terms 
of both the prevalence of any alcohol consumption and binge level alcohol use.12,13 
This suggests that results from this chapter may reflect present day patterns of PAE 
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and, therefore, FASD. However, it is important to note that because FASD is 
determined by a complex interplay of multiple risk factors that co-occur with 
maternal alcohol use, FASD prevalence could be subject to change based on the 
relative prevalence of co-occurring risk and protective factors (see Chapters 5 and 
6). Mothers in the ALSPAC sample were slightly more affluent and children had 
higher levels of educational achievement than the general population, which poses 
further limitations on the ability to generalise findings from this sample to the 
general population of the UK.228,229 Specifically, the estimates of FASD prevalence in 
this sample may be lower than estimates derived from samples with lower 
socioeconomic status and those that include children with poorer educational 
outcomes on average.  
It is important to note that the effective use of multiple imputation methods to 
reduce bias due to missing data rests on the assumption that data are missing at 
random (MAR); in other words, that any systematic differences between the 
observed and missing values can be fully explained by the observed data. If data 
are missing not at random (MNAR) then analyses based on multiple imputation 
may not be valid. Sterne and colleagues252 and Graham283 note that some data will 
inevitably be MNAR. For example, missing data on prenatal alcohol use are likely to 
be determined by the true unobserved data for prenatal alcohol use, since women 
with high levels of consumption may be less likely to respond. Nevertheless, the 
inclusion of multiple measures of maternal alcohol use in the imputation model 
and correlates of PAE, such as socioeconomic status and prenatal smoking, 
increases the likelihood that data are at least partly MAR. Overall, the important 
point to consider is not whether data are ‘purely’ MAR or MNAR, but rather what 
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impact the MNAR data are likely to have on the results.252,283 Of key importance to 
the prevalence analyses in this chapter is the extent to which the imputed 
prevalence estimate, based on the final composite FASD status outcome (FASD/not 
FASD), is likely to reflect the true prevalence of FASD in this sample. The inclusive 
component-based multiple imputation strategy that I used is likely to increase the 
plausibility of the MAR assumption, and therefore increase confidence in analyses 
with multiply imputed data for the following reasons. First, the imputation model 
included a comprehensive range of hypothesised risk factors for FASD that would 
be expected to convey information about likely FASD outcome. Second, the 
availability of the FASD status outcome is more likely to be determined by specific 
aspects of the child’s phenotype (MAR), rather than their (unobserved) FASD status 
classification (MNAR). For example, a child’s level of hyperactivity, conduct 
problems and cognitive ability are likely to influence whether they attend the in-
clinic assessments, and/or whether their caregiver has completed the study 
questionnaires, and consequently whether a child has an observed FASD status 
outcome. Therefore, inclusion of the specific phenotype variables in the imputation 
model increases confidence in the MAR assumption. Furthermore, data in the 
ALSPAC cohort were collected without a specific research question in mind. Since 
participants were blind to the purpose of this study, missingness is less likely to 
depend on FASD status. 
Finally, the imputation model included a range of auxiliary variables, which have 
been shown to reduce the bias introduced by MNAR missingness.253 In summary, 
even with the expectation that some data were not MNAR, the analyses with 
multiply imputed data benefit from a substantially increased sample size and are 
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likely to be less biased than the estimates that used complete case and single 
imputation methods to address missing data.  
6.3 Implications for research and practice 
The results from this chapter indicate that FASD may be a significant public health 
concern in England. FASD is more common among children born to parents of 
lower socioeconomic status and children from unplanned pregnancies, suggesting 
that these subgroups may be particularly useful to target for prevention, 
assessment and intervention strategies.  
Further studies are required to corroborate results. In particular, active case 
ascertainment studies of FASD in the UK may be particularly informative in terms of 
shedding further light on the epidemiology of FASD in the general population. As 
the British Medical Association note, UK-based epidemiological data on the 
prevalence of FASD are essential for supporting the case for improved diagnostic 
and management services in order to improve outcomes among individuals with 
FASD and their families.10 Prevalence data are also important for informing policy 
on PAE and supporting the development of health economics models for FASD in 
the UK.284 
7 Conclusion 
FASD may be a common cause of developmental disability in England, affecting up 
to 17% of children in the general population. Results require corroboration and 
should be considered a starting point for further investigation of the potential 
burden of FASD in the UK.  
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8 Implications for this thesis 
Results from this chapter indicate that a significant proportion of children in the 
ALSPAC sample met criteria for FASD. Therefore, it is possible and necessary to 
investigate risk factors for FASD among this group. In Chapter 5, I will present a 
narrative synthesis of the literature on FASD risk factors, using causal diagram 
methodology. This will be followed by a multivariable analysis of causal risk factors 
for FASD in Chapter 6.
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Chapter 5. The causal web of FASD: a causal diagram approach 
 
1 Overview 
In this chapter, I present a causal diagram (directed acyclic graph; DAG) that I 
constructed to describe the aetiological context of FASD. First, I describe causal 
inference theory and introduce causal diagrams. Next, I present the aims and 
objectives of the chapter and describe the literature review methodology. I then 
present the results of the literature synthesis and the corresponding DAG. I 
conclude the chapter with a discussion of the strengths and limitations of my 
approach and the implications of this work for the remaining research in this thesis. 
2 Background 
Prenatal alcohol exposure (PAE) is the sole necessary cause of FASD, but it is not 
always sufficient.285 Among women who drink any amount of alcohol in pregnancy, 
an estimated one in 13 will have a child with FASD and one in 67 will have a child 
with FAS.11,86 Fetal alcohol exposure interacts with multiple factors in a complex 
process to determine offspring outcome. Accordingly, rather than a simple causal 
chain, the image of a spider’s web has been considered most appropriate for 
describing the causal context of FASD.286,287  
Much of the existing FASD literature simply lists risk factors and reports 
associations with little consideration of the underlying causal structure.109,111 The 
term ‘risk factor’ obscures the distinction between a predictor variable and a 
cause.288 It is important to try to distinguish between causal and non-causal 
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associations and, specifically, to consider the combinations of causal structures, 
available data, and analysis strategies that may give rise to non-causal associations. 
While knowledge of predictor variables is important for identifying who is most at 
risk of FASD and for targeting interventions, causal knowledge is important for 
identifying effective mechanisms for prevention and intervention programmes.289 
In this chapter, I present a causal diagram (DAG) to describe my assumptions about 
the causal structure of the variables that are involved in the pathways to FASD. 
DAGs are emerging as a gold standard method for supporting causal inference and 
reducing bias in epidemiological studies.290-294 They offer a novel approach to the 
synthesis of the risk factor literature for FASD. Results from this chapter will guide 
the analyses and interpretation of results in my study of FASD risk factors, which I 
present in Chapter 6. 
2.1 Causal inference 
Causal inference, defined as the science of inferring the presence and magnitude of 
cause-effect relationships from data, is a central aim of epidemiology.290,295 The 
counterfactual theory of causation has been used as a framework to support causal 
inference within epidemiology.296 Under a counterfactual definition, causality 
refers to the notion “had the exposure differed, the outcome would have 
differed.”297(p. 1) Measures of association such as risk differences, risk ratios and 
odds ratios can be given a causal interpretation, subject only to strong 
assumptions, the central of which is exchangeability. Exchangeability refers to the 
idea that the risk of the outcome in Group 1 would have been the same as the risk 
in Group 2, had the participants in Group 2 received the exposure given to Group 1, 
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and vice-versa. Given exchangeability, the observed risk is equal to the 
counterfactual risk. In randomised controlled trials, the participants in different 
exposure groups are exchangeable, since treatment allocation is independent of 
participants’ characteristics. Therefore, the measure of association equals the 
causal effect, provided there is no additional bias for reasons such as differential 
loss to follow up or failure of the randomisation process.298 However, for many 
public health issues, including PAE, randomisation of exposure is unethical and/or 
unfeasible and, therefore, it is necessary to rely on observational data. Measures of 
(conditional)k association from observational designs can be used to estimate 
causal effects if conditional exchangeability is created by appropriate control of 
bias, such as adjustment for confounders.288 
The presence of a valid statistical association is the starting point for causal 
inference. However, associations do not provide information about underlying 
causal structure. A statistical measure that conveys the strength of the relationship 
between variables X and Y will be identical regardless of whether X causes Y or Y 
causes X. In fact, four possible causal structures may account for an association 
between variables X and Y. Exposure X may lead to outcome Y, and thus X has a 
causal effect on Y. Alternatively, Y may cause X. This is an example of reverse 
causation. Another possibility is that there is a common cause (Z) of both X and Y. 
In this case, Z is a confounding variable. Finally, conditioning onl a common effect 
                                                        
k Conditional associations refer to adjusted effect estimates. Marginal associations are unadjusted 
(crude) effect estimates. This language is used to aid comparison with the wider causal diagram 
literature. 
l Or equivalently: stratifying on, adjusting for, selecting on the basis of.  
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can create an association between X and Y. Figure 17 presents a schematic 
representation of possible causal structures. 
Figure 17: Four causal structures that can produce statistical association. Adapted from Daniel, R. (2015). An 
Introduction to Causal Inference. Advanced Course in Epidemiological Analysis. London School of Hygeine and 
Tropical Medicine. X, exposure; Y, outcome; Z, covariate. 
 
2.2 Approaches for strengthening causal inference in epidemiology 
Several methods have been proposed to support causal inferences in observational 
epidemiology, including criterion-based methods such as the Bradford-Hill 
viewpoints.299 However, there are no steadfast rules that can prove that an 
observed association is due to a causal effect and each rule is subject to limitations 
and/or exceptions.300 Triangulation offers an approach for supporting causal 
inferences, using evidence synthesis. During triangulation, results are collated from 
studies that used different methodologies, each of which is assumed to have 
different sources of bias. The rationale is that if the results across a range of 
approaches indicate the same conclusion, then this increases confidence in 
aetiological inferences.301,302  
Contemporary study designs, which include negative control studies and Mendelian 
randomisation studies, have also been used to support causal inferences. For 
Association	within	the	population	(marginal	association):
a)	X	 Y X	causes	Y	(direct	cause)
b)	X Y Y	causes	X	(reverse	causality)
Z
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Association	within	the	subpopulation	(conditional	association):
d)		X Y X	and	Y	have	a	common	effect	that	we	have	conditioned	on	 (collider/selection	bias)
Z
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example, in studies of prenatal exposures, negative control studies have compared 
the strength of maternal versus paternal associations to distinguish between 
effects that are due to in-utero exposure and those that are due to confounding. 
The rationale is that if maternal and paternal associations are similar, effects may 
be due to confounding (e.g. due to shared environmental factors). Conversely, if 
maternal exposures are more strongly associated with child outcomes than 
paternal exposures, there is support for intrauterine causal processes.303 For 
example, one study found that children born to mothers who smoked while 
pregnant had lower birthweight, while no association was observed for paternal 
smoking during that period,289 thus lending support to an intrauterine causal 
mechanism.  
Mendelian randomisation studies are based on the fact that genes are randomly 
assigned at conception and are, therefore, free from confounding. Some studies 
have used variations in alcohol-metabolising genes as instrumental variables for 
PAE to demonstrate that alcohol exposure has a causal influence on developmental 
outcomes (described later in this chapter).303 
Causal diagrams, known as DAGs, have also been used to strengthen causal 
inferences in epidemiology. Judea Pearl devised the unifying framework that 
provided this graphical method and formal language for causal inference. Pearl 
reasoned that the combination of observed data plus causal knowledge allows 
individuals to move beyond the realm of statistical association to that of 
causality.304 DAGs provide a tool for explicitly characterising assumptions about the 
causal relationships between exposures, covariates, and outcomes (these variables 
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are known as nodes in DAG terminology).305 The graphical rules that underlie DAGs 
are supported by mathematical theory.304 They provide a mechanism for 
identifying which variables should be controlled for, and which should not, to 
minimise bias in effect estimates on the basis of the assumptions encoded in the 
DAG.304 In scenarios where DAGs contain a large number of variables they become 
less clear as visual overviews of the causal context, but maintain their utility as a 
theory driven approach to statistical modelling strategies. In contrast to data-
driven approaches, it is the hypothesised causal relationships depicted by the DAG, 
rather than measures of statistical significance that guide variable selection.294 A 
detailed description of DAG language and theory is provided in Appendix 13.  
Since DAGs have utility both as visual representations of hypothesised causal 
processes and as tools to support statistical modelling strategies, I chose to develop 
a DAG to describe the causal context of FASD (this Chapter), and to use this DAG to 
inform the statistical modelling strategy for the FASD risk factor analyses (Chapter 
6). 
3 Aim and objectives 
3.1 Aim 
i. To describe what is known about the aetiology of FASD.  
3.2 Objectives 
i. To conduct a systematic literature search to identify FASD risk factors and 
their potential mechanism(s) of action. 
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ii. To consider each risk factor identified in the literature search and its role 
within the DAG, using a combination of narrative synthesis plus a priori 
knowledge and hypotheses. 
iii. To consider other factors which may not be risk factors but may play an 
important role in the DAG, using a combination of narrative synthesis plus a 
priori knowledge and hypotheses. 
iv. To use causal diagram theory and the results from objectives i - iii to create 
and interpret a DAG of the causal context of FASD. 
4 Method 
4.1 Literature search  
I searched Medline from inception to 2nd March 2016 for existing systematic 
reviews of FASD risk factors using the search terms “(fasd or fetal) adj1 alcohol” 
AND “Risk Factors/” AND “systematic review.mp.” This search produced two 
references, one of which, by Esper and colleagues (2014),111 was relevant to the 
aims of this chapter.  
Esper et al.’s review provided an overview of the demographic, psychological and 
social factors that are associated with FASD. However, it had little discussion of 
causality. To obtain more detailed information about possible causal structures, I 
searched for evidence in the full text articles of the included studies from this 
review. I also conducted separate searches for each risk factor in Medline to 
identify further information and to find studies that were published after Esper et 
al.’s review. In each search, I combined search terms for FASD and the relevant risk 
factor. For example, the search for prenatal stress was: (fasd or fetal) adj1 alcohol 
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AND stress* AND pregnan*. When available, review articles of specific risk factors 
were used as an efficient way to gain a summary of evidence and to identify key 
references.  
I carried out supplementary searches of the electronic table of contents (eTOC) 
pages for relevant journals including: Pediatrics; Alcoholism: Clinical and 
Experimental Research; the Canadian Medical Association Journal; and the Journal 
of Developmental & Behavioral Pediatrics. I also searched for relevant UK-based 
evidence from the Infant Feeding Survey;17,52,306 the Millennium Cohort Study;307 
and ALSPAC.229 Other supplementary sources included the National Organization 
on Fetal Alcohol Syndrome (NOFAS) and EUFASD electronic newsletters, a manual 
search of the reference lists of relevant studies, ResearchGate and FASD 
conference abstracts.308-310 Supplementary searches were concluded on the 22nd 
December 2017. 
4.2  Evidence synthesis 
DAGs convey assumptions about how the world works for a particular causal 
question. They are constructed based on subject-matter knowledge and 
hypotheses. To determine the most plausible structure for the aetiology of FASD, I 
used informal triangulation methods to evaluate the evidence from the literature 
search. Unlike systematic reviews, which seek to compare results from studies that 
are relatively homogenous, triangulation seeks to compare evidence from studies 
from a diverse range of approaches. The advantage of triangulation is that any 
biases are assumed to differ across the diverse study types. This increases 
confidence in causal inferences if similar effect estimates are obtained.311 In this 
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narrative synthesis, I sought to compare results from studies that used at least two 
different approaches to address the same causal question. For example, I 
considered evidence from studies that used Mendelian randomisation, negative 
controls, multivariable regression with observational data, qualitative data, twin 
studies, cross-setting comparisons, randomised controlled trials, and animal 
studies. 
To provide a framework for categorising the FASD risk factors, I used Abel and 
colleagues’ distinction between provocative and permissive factors.285 The risk 
factors described in the DAG fall into the category of permissive factors. Permissive 
factors are “predisposing behavioural, social, or environmental characteristics (e.g. 
alcohol consumption patterns, socioeconomic status, culture) that can produce 
certain biological conditions. These conditions…increase fetal vulnerability to 
alcohol’s teratogenic effects.”285(p. 446) Provocative causes, by contrast, are “the 
biological conditions (e.g. high blood alcohol levels, decreased antioxidant status) 
resulting from these permissive factors, which create the internal milieu 
responsible for the increased fetal vulnerability to alcohol at the cellular level.”285(p. 
446) Provocative factors have typically been explored in animal studies. In humans, 
the precise biological mechanisms that account for alcohol teratogenicity and 
result in FASD remain poorly understood.10 Where available, I will discuss evidence 
about provocative factors with the aim of supporting inferences about the causal 
nature of permissive factors. 
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4.3 Consideration of factors other than risk factors that are relevant to the 
causal structures in the DAG 
Based on the principles of DAG theory, and my subject matter knowledge of the 
challenges associated with FASD identification and the measurement of prenatal 
exposures, I specified a series of nodes to represent my assumptions about the 
most relevant sources of measurement error and residual bias. These are described 
in more detail in Section 5.1.3.  
4.4 DAG construction 
I used DAGitty (www.dagitty.net/)312 to draw a DAG, based on the information that I 
collated in objectives i - iii. DAGitty is a platform for creating and analysing causal 
diagrams. It operationalises the graphical rules (described in Appendix 13) to 
identify which set of covariates should be adjusted for, and which should not, to 
minimise bias in multivariable causal effect estimates.312 DAGitty code is provided 
in Appendix 14. 
Although DAGitty is a useful tool for analysing complex DAGs, the space in the 
browser window is finite and the DAG becomes of limited use as a visual 
representation when the causal structure is particularly complex. Therefore, I used 
DAGitty as an analytical tool to identify biasing pathways, but created a Figure of 
the DAG using Microsoft PowerPoint313 to provide a clearer visual representation of 
the hypothesised causal pathways to FASD.  
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5 Results 
In this section, I present the literature review and corresponding DAG that I created 
to describe the causal context of FASD. In Chapter 6, I describe how I used the DAG 
to inform the statistical modelling strategy for FASD risk factors. 
The DAG (Figure 18) provides a visual description of the hypothesised aetiological 
context of FASD, based on a synthesis of current evidence. To enable comparison 
of the literature review with the causal relationships depicted in the DAG, I first 
describe the groupings of variables that were implied following the evidence 
synthesis. I then present the supporting evidence from the literature synthesis for 
each variable (node). 
5.1 Categories of relationships implied by the literature review and DAG 
5.1.1 Causal risk factors 
Given that alcohol is the single necessary cause for FASD, other causal risk factors 
were hypothesised to influence the risk of FASD in two ways: by changing the risk 
of alcohol exposure during pregnancy and/or by changing the effect of alcohol on 
the fetus. These causal risk factors are described below. The supporting evidence 
follows in Section 5.2. 
5.1.1.1 Primary causal risk factor 
Prenatal alcohol use is the sole necessary cause of FASD. The effect of maternal 
alcohol use is mediated by proximal unmeasured causal processes, or provocative 
factors, that include fetal alcohol exposure, hypoxia, free radical damage, 
epigenetic changes and disrupted neurotransmitter functioning.10  
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Figure 18: Directed acyclic graph (DAG) depicting the hypothesised causal pathways to FASD 
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5.1.1.2 Effect modifiers  
Although PAE is the sole necessary cause of FASD, it is also useful to study 
exposures that modify the effect of PAE on FASD to identify opportunities for harm 
reduction. Identified effect modifiers include maternal age, genotype, prenatal 
stress, prenatal mental health, prenatal nutrition, BMI, prenatal smoking, and 
prenatal illicit drug use.110,111,314 Within this group of effect modifiers, some are 
potentially amenable to intervention (prenatal mental health, prenatal stress, 
prenatal nutrition, BMI, prenatal smoking, and prenatal illicit drug use) and some 
are not (maternal age, genotype). Modelling strategies that estimate the effect of 
proposed causal effect modifiers on FASD can suggest useful potential targets for 
intervention. Therefore, I will focus on a subset of these potentially modifiable risk 
factors in the analyses that I present in Chapter 6. 
5.1.1.3 Distal causal risk factors FASD 
Most of the risk factors that have been identified for FASD feature at a more distal 
stage in the causal pathway. These factors become independent from FASD once 
the proximal causal factors (patterns of PAE) and effect modifiers have been 
accounted for. Distal factors include: substance use of friends and family, social 
support, socioeconomic status, marital status, maternal FASD symptomology, 
alcohol use before pregnancy, religion, abuse and unplanned pregnancy.  
Although these factors feature at a more distal stage of the causal pathway to 
FASD, some may be useful targets for intervention. For example, if low social 
support increases the risk of FASD by increasing prenatal stress, which in turn 
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increases the risk of PAE, then social support initiatives may be a useful focus for 
intervention. I will investigate the effect of social support on FASD in Chapter 6. 
5.1.2 Non-causal factors (risk markers) 
Having another child with FASD and postnatal alcohol use are depicted as risk 
markers for FASD. These factors do not lie on the causal pathway between 
substance use in the current pregnancy and FASD, since they occur outside of the 
index pregnancy. Nevertheless, they may be useful indicators of adverse prenatal 
exposures and, therefore, may be informative for identifying children who require 
follow-up and assessment. 
5.1.3 Other categories  
In the preceding sections, I described categories of FASD risk factors and risk 
markers. Here, I specify other nodes that were included in the DAG to represent 
potential sources of bias and measurement error. 
5.1.3.1 Confounding: clustering of adverse exposures/events 
Adverse exposures and events such as substance use, unhealthy diet, life stressors 
and adverse pre- and postnatal environments, tend to co-occur.315-319 Rather than 
one of these factors simply causing the others, it is likely that their co-occurrence 
reflects some latent common cause. This common cause has been labelled ‘risky 
behaviour’ in some DAGs that link alcohol use and smoking, and in studies that 
explore binge drinking and unplanned pregnancy.320,321 Therefore, for the DAG that 
I present in this chapter, I have included an overarching node labelled “risky 
behaviour/unspecified common causes of maternal alcohol use and other adverse 
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exposures” to represent the latent factors that cause adverse exposures to co-
occur. The clustering of adverse exposures may be due to a variety of unknown and 
unmeasured factors. Therefore, this common cause node was added to the DAG to 
represent this potential source of residual confounding. In the analysis of FASD risk 
factors that follows in Chapter 6, I describe a factor in the ALSPAC dataset that I 
used to partially control for this source of confounding. 
5.1.3.2 Measurement error 
In many epidemiological studies, it is not possible to directly measure the true 
exposure and true outcome. Therefore, it is necessary to rely on surrogate 
measures that approximate but do not perfectly match the values of the true 
exposure and outcome.322 The degree of bias depends on the extent to which the 
measured values deviate from the true values.323 Measurement error of PAE and of 
FASD is a particular concern. Therefore, for reasons of transparency, I represented 
these sources of error as extra nodes in the DAG. It is important to note that 
measurement error is implicitly acknowledged for all reported exposures in the 
DAG (e.g. prenatal smoking, prenatal stressful life events), however I chose not to 
depict these factors as extra nodes for reasons of visual clarity. 
5.1.3.2.1 Measurement error of the exposure: PAE 
Ascertainment of PAE often relies on maternal self-report or incomplete medical 
records, which are thought to underestimate true maternal alcohol use.61,62 As 
described in Chapter 2, established biomarkers for PAE are not currently available.  
True PAE is influenced not only by patterns of maternal alcohol use, but also by 
maternal and fetal metabolism, and a range of other factors that modify the 
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teratogenic effects of alcohol.26 In the absence of measures of fetal blood alcohol 
concentration, there will be measurement error of true PAE. Therefore, in the DAG, 
I depicted self-reported maternal alcohol use as a source of measurement error. It 
is a factor that is associated with, but distinct from, true maternal alcohol use. 
Measurement error of the primary exposure (true maternal alcohol use) will also 
contribute to measurement error of the outcome (FASD diagnosis), since alcohol 
use is a diagnostic criterion for FASD. 
5.1.3.2.2 Measurement error of the outcome: FASD diagnosis 
FASD diagnosis is a surrogate for true FASD status. FASD diagnosis is influenced by 
a range of factors. These factors are represented as separate nodes within the DAG 
and include: the choice of diagnostic framework (described further in Appendix 3), 
adequacy of FASD detection (e.g. the availability of diagnostic services for FASD), 
and consideration of factors for differential diagnosis (described further in 
Appendix 5).76 The FASD Canadian guidelines for diagnosis (2005), describe the 
issue of differential diagnosis as follows: “The face of FAS is the result of a specific 
effect of ethanol teratogenesis altering growth of the midface and brain. Those 
exposed to other embryotoxic agents may display a similar, but not identical, 
phenotypic facial development, impaired growth, a higher frequency of anomalies 
and developmental and behavioural abnormalities... Knowledge of exposure 
history will decrease the possibility of misdiagnosing FASD.”72(p S7) As FASD shares 
many overlapping features with other disorders and exposures, it has been 
described as a diagnosis of exclusion.324 
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5.1.3.3 Biological mechanisms (provocative factors) 
The specific biological mechanisms that cause FASD are still under investigation.10 
Therefore, within the DAG, I depicted these provocative factors as a broad category 
of unmeasured factors that mediate the relationship between PAE and FASD 
(denoted as a large connecting arrow between true prenatal alcohol use and true 
FASD). 
5.2 Supporting evidence by variable type 
In this section, I present the narrative synthesis of evidence that supports the 
inclusion of factors in the DAG, and their position, under the subheadings: lifestyle 
factors, sociodemographic factors, pregnancy factors, stress and social support, 
maternal characteristics and family factors.  
5.2.1 Lifestyle factors 
5.2.1.1 Patterns of prenatal alcohol exposure (PAE) 
The impact of PAE is thought to vary according to the dose, frequency and timing of 
exposure. However, residual confounding, measurement error and individual 
variability across a vast range of covariates complicate efforts to determine what 
pattern of maternal alcohol use will lead to FASD in an individual case. 
Nevertheless, on average, binge and heavy chronic patterns of maternal alcohol 
use are most likely to result in FASD.19,79,276,325-327 While these results provide 
insight into the effects of heavy episodic drinking, evidence about the impact of 
lower-level PAE on FASD is less clear. As described in Chapter 1, evidence on the 
effects of low to moderate PAE on developmental outcomes is limited and 
inconsistent, ranging from evidence of harm to evidence of slight 
 Chapter 5 140 
benefit.20,21,26,27,328 For example, in an observational study that used data from the 
Millennium Cohort Study, Kelly and colleagues found that 3-year old boys who 
were born to mothers who reported drinking no more than one to two units of 
alcohol per week or per occasion during pregnancy had a lower risk of hyperactivity 
and conduct problems than those born to abstainers.14 Negative control studies 
that compare the strength of association for maternal and paternal exposures have 
also been used to investigate the causal effects of low to moderate PAE, but did 
not find evidence to support intrauterine effects on child IQ or head 
circumference.329,330 In contrast, Mendelian randomisation studies have offered 
evidence that low to moderate PAE can cause persistent conduct problems and 
adversely affect cognitive and academic outcomes.26,27,331 Despite inconsistencies 
in the evidence, Mendelian randomisation studies provide stronger causal evidence 
than observational studies that low to moderate alcohol use can cause adverse 
developmental outcomes. They suggest that the apparent null or protective effects 
of low to moderate PAE, are likely to be due to residual confounding, owing to the 
socioeconomic patterning of prenatal alcohol use.21,24,26Overall, Clarren and 
colleagues argue that “based on the variabilities between mothers and fetuses, 
metabolism, genetics, interactions of environmental factors, it is very unlikely that 
‘absolute risk’ for the harmful effects of alcohol consumption during pregnancy will 
be established and the question of ‘how much is too much’ will remain 
unanswered. Thus, the best advice is no exposure equals no risk.”265 
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5.2.1.2 Alcohol use before pregnancy 
Alcohol use before pregnancy predicts FASD.111,266 Mothers of children with FASD 
are more likely to drink at high levels before pregnancy, to have had longer 
‘drinking careers’ (i.e. more years of drinking alcohol), to have a history of alcohol 
abuse and to have been referred to alcohol treatment, relative to 
controls.276,325,327,332 Chronic alcohol consumption impairs the functioning of 
alcohol metabolising enzymes and can lead to malnutrition due to reduced intake 
and absorption of key nutrients, thus increasing the risk of FASD.285,333-336 
Therefore, alcohol use prior to pregnancy can influence FASD risk by influencing 
alcohol metabolism and creating a nutritional state that can compromise fetal 
development.  
In the UK, up to 91% of women aged 16 to 45 report drinking some level of alcohol 
and excessive alcohol consumption is common.337,338 Up to 47% of women aged 16 
to 44 drink above national guideline recommendations (> 3 units per day) and 
approximately 30% binge drink (> 6 units per day).337 Few women follow guidance 
for prenatal alcohol use when planning a pregnancy58 and alcohol use increases the 
risk of unplanned pregnancy.321,339-341 If pregnancy is unplanned, women are less 
likely to modify their alcohol intake, due to delayed pregnancy recognition.321,339-341 
Therefore, alcohol use prior to pregnancy is a significant risk factor for PAE and 
FASD.  
5.2.1.3 Postnatal alcohol use 
Postnatal levels of alcohol consumption are higher among mothers of children with 
FASD.82,83,266,274,276,278,342-345 Of course, heavy postnatal alcohol use cannot cause 
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FASD among children who have already been born. It can, however, indicate a 
continuing pattern of heavy alcohol use and serve as a risk marker for previous and 
future alcohol-exposed pregnancies. Heavy postnatal alcohol consumption may be 
a useful proxy for PAE, as women may be more likely to disclose heavy current 
drinking than prenatal drinking. Studies from the USA and Italy found that self-
reported prenatal alcohol use was not consistently different between mothers of 
children with FASD and controls, but current consumption was significantly 
higher.79,82,345 In contrast, studies in the Western Cape of South Africa (where 
maternal self-report is believed to be more reliable, due to normative binge 
drinking patterns and higher levels of PAE) show consistently higher levels of self-
reported PAE and current consumption among mothers of children with 
FASD.266,274,276,278,342,344 In summary, postnatal drinking patterns may be particularly 
useful as a risk marker for PAE and for future FASD risk in populations that are 
particularly susceptible to underreporting of PAE.  
5.2.1.4 Smoking during pregnancy 
Prenatal cigarette smoking is more common among mothers of children with FASD 
than those without.111,266 Smoking and PAE may interact synergistically to increase 
the risk of FASD-related outcomes including low birth weight.346 Proposed biologic 
mechanisms for the interaction between tobacco and alcohol include common 
effects on nutrient availability, oxidative stress and vasoconstriction of the placenta 
and umbilical cord, which can lead to hypoxia and prolonged uterine exposure to 
ethanol.8,285,346  
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In addition to its interactive effect with PAE, prenatal smoking is independently 
associated with reduced fetal growth, low birthweight and cognitive and 
behavioural impairment.315,347-353 Evidence suggests that the impact of smoking on 
decreased birth weight is 1.5 to 3 times greater than that of PAE.315,354 Therefore, 
prenatal tobacco exposure is also an important factor for differential diagnosis in 
FASD.  
Prenatal smoking is associated with several other factors in the DAG. It is more 
common among mothers with an unplanned pregnancy, mothers with other forms 
of substance use, mothers who report prenatal stress, younger mothers, and 
mothers of lower socioeconomic status.52,316,347,351  
5.2.1.5 Illicit drug use during pregnancy 
Prenatal illicit drug use is more prevalent among mothers of children with 
FASD273,325 and it can lead to physical, cognitive and behavioural impairments that 
are relevant to FASD diagnosis.317,355 Since prenatal drug exposure can lead to 
FASD-relevant symptomology, it is an important consideration for differential 
diagnosis. Cocaine, opiates and amphetamines have been found to increase the 
risk of intrauterine growth restriction, low birth weight, small head circumference 
and congenital anomalies.317,350,355,356 However, the effect of illicit substance 
exposure on birthweight and fetal growth is thought to be less severe and 
persistent than that of PAE and prenatal smoking.315,349 Evidence suggests that 
children with prenatal illicit substance exposure may show catch-up growth after 
infancy357 and that effects are significantly attenuated following adjustment for co-
occurring adverse social factors.318 Evidence on the effect of marijuana exposure on 
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growth outcomes has been inconsistent.315,349,358 However, there is some evidence 
that prenatal marijuana use may lead to subtle impairments in executive 
functioning, motor skills, attention and memory in childhood and adolescence.359-
361 In a mouse model study, synthetic cannabinoids were found to interact 
synergistically with ethanol to increase the prevalence of ocular defects. 
Investigations indicated that the defects may have been caused by suppression of 
the Shh signalling pathway, which is involved in brain and facial development.362  
Evidence about the long-term effects of cocaine, opiates and amphetamines on 
neurodevelopmental outcomes in humans is inconclusive. Prenatal cocaine 
exposure may impair attention, speech and language development.363-365 Opiate 
exposure can lead to neonatal abstinence syndrome, which is characterised by 
abnormal arousal and irritability.355,356 Prenatal amphetamine exposure has been 
linked to smaller subcortical volume, externalising behaviour, and deficits in 
attention and memory.366-368  
It is unclear whether illicit drugs modify the effects of PAE. Schempf and colleagues 
failed to find an interaction between PAE and maternal illicit drug use on birth 
outcomes.318 However, evidence suggests that prenatal illicit drug exposure and 
PAE share common biological mechanisms of harm including restricted blood flow 
to the fetus and altered neuroendocrine regulation.317,369 
In relation to other variables in the DAG, prenatal illicit drug use is associated with 
a range of social and psychological factors including low socioeconomic status, 
stress, mental health problems, abuse and low social support.317,318,370 Although 
maternal drug use may contribute to subsequent adverse social and psychological 
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outcomes, such factors are primarily perceived as preceding factors that increase 
the likelihood of drug use as a strategy for self-medication.318 Illicit drug use 
increases the risk of inadequate prenatal care, pregnancy complications, poor 
nutrition and is more common among older women and those with an unplanned 
pregnancy.64,317,318,369  
5.2.1.6 Prenatal nutrition 
Optimal nutrition is important for fetal development.314 NICE guidelines 
recommend that pregnant women should eat a varied and healthy diet, take folic 
acid supplements before pregnancy and throughout the first trimester, and take 
vitamin D supplements during pregnancy and while breastfeeding.371 Folic acid and 
vitamins C and D are available to eligible low-income women in the UK via the 
Healthy Start Programme.372 The Royal College of Obstetricians and Gynaecologists 
advises pregnant women against taking some vitamin supplements, particularly 
vitamin A, which may be teratogenic in high doses.373 Nutrient deficiency during 
pregnancy increases the risk of a range of adverse outcomes including neural tube 
defects, restricted fetal growth, low birth weight and skeletal deformity.374-376 
Therefore, prenatal nutrition is an important consideration for differential 
diagnosis when assessing FASD. 
Prenatal nutrition also features at several other points in the causal context of 
FASD. Nutrition modifies the impact of PAE on FASD, influences maternal BMI, and 
is influenced by maternal substance use, maternal mental health, stress, antenatal 
care, whether pregnancy was planned or not, and socioeconomic 
status.109,285,314,377,378 Recent evidence from the ALSPAC cohort found that greater 
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consumption of processed foods in pregnancy was associated with heavier alcohol 
intake and that a healthier diet was associated with light-to-moderate alcohol 
intake.379 These associations may be due to latent factors such as tendencies 
towards healthy or unhealthy lifestyle behaviours (depicted as the “risky 
behaviour” node in the DAG). 
Among children with PAE, lower calorific intake has been found to increase the risk 
of FASD, while evidence from animal studies suggest that specific nutrients 
(including: vitamin A, docosahexaenoic acid, folate, zinc, choline, vitamin E, 
selenium, riboflavin, calcium, docosapentaenoic acid, zinc, b-vitamins, iron and 
protein) may reduce the risk of FASD-relevant outcomes including physical 
malformations, growth deficiency, behavioural regulation and memory.109,314,380-383 
During pregnancy, mothers of children with FASD report a lower intake of key 
nutrients and report being hungry more often than controls.274,384 Deficient 
nutrient intake does not, however, fully explain increased risk for FASD. Even when 
dietary intake is equivalent, alcohol-exposed rats weigh less and produce offspring 
with poorer outcomes than unexposed rats.381,385 Alcohol competes with nutrients 
that are essential for fetal development due to shared metabolic pathways.386,387 
Alcohol consumption can also lead to impaired placental blood flow and nutrient 
transportation.314,336,388,389 Nutritional supplementation has been found to 
attenuate FASD symptomology in some animal models.314 Optimal nutrition may 
protect offspring from alcohol-related harm by reducing the oxidative stress caused 
by alcohol metabolism.390,391 
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Several biological mechanisms have been proposed to account for ethanol-
nutrition interactions. Nutrition influences the rate of ethanol metabolism and 
blood alcohol concentrations.392 For example, alcohol-exposed rats given a low-
calorie diet have slower rates of ethanol metabolism and greater levels of fetal 
toxicity (reduced litter size and more fetal deaths) than adequately nourished 
rats.381 Low-calorie and low-protein diets have been found to reduce the activity of 
alcohol-metabolising enzymes, leading to sustained blood alcohol 
concentrations.336,393 Finally, inadequate nutrition may interact with PAE to 
influence gene expression. Shankar and colleagues demonstrated that alcohol-
exposed, undernourished rats showed altered expression of several genes, 
including those associated with growth, stress regulation, cell proliferation and 
apoptosis.393  
Trials of pre- and postnatal nutritional interventions with alcohol-exposed children 
have found complex and inconsistent results.394-396 The Collaborative Initiative on 
Fetal Alcohol Spectrum Disorders (CIFASD) is carrying out a prospective cohort 
study in Ukraine that explores the effect of prenatal multivitamin and choline 
supplementation on children with and without PAE. Follow-up at six to twelve 
months failed to find an interaction between gestational alcohol use and 
nutritional supplementation on developmental outcomes (Bayley Scales of Infant 
Development)394 or information processing (habituation paradigm).395 However, 
there was a significant interaction between periconceptual alcohol use, nutritional 
supplementation and child sex. Bayley Mental Development Index scores were 
lowest in males who had been exposed to alcohol in the periconceptual period and 
who did not receive multivitamin supplementation.394 A small (N = 55) randomised 
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controlled trial of postnatal choline supplementation among school-aged children 
with FASD found no improvement in neurobehavioural symptoms.397 However, the 
consequences of PAE may be subtle and are often difficult to detect until later in 
childhood.43. Therefore, the effects of pre- and postnatal nutritional 
supplementation on FASD symptoms in children are not yet established.  
5.2.2 Sociodemographic factors 
5.2.2.1 Socioeconomic status 
Indicators of socioeconomic status (SES) including low maternal education, low 
income and unemployment have been identified as risk factors for FASD.111,266 
Perhaps counterintuitively in light of these results, the UK Infant Feeding Survey 
has consistently found that women within higher social classes are more likely to 
drink during pregnancy than those from lower social classes.16,18,52,306 UK-based 
cohort studies have echoed these results, showing that women who drink in 
pregnancy are more highly educated, less likely to live in deprived areas, and more 
likely to be employed than abstainers.13,26,398 Although high SES is associated with 
an increased risk of prenatal alcohol use, mothers of low SES who do drink during 
pregnancy are more likely to do so in a binge pattern.26 As well as differences in the 
social patterning of alcohol use, children born to high SES mothers may be 
relatively protected against the harms of PAE due to factors associated with social 
advantage.328 Based on the available evidence, it is hypothesised that SES is 
associated with FASD via the causal pathways proposed by Abel and colleagues,285 
in which low SES contributes to FASD through its influence on drinking patterns, 
stress, mental health, substance use and nutrition. 
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5.2.2.2 Maternal age 
Several studies have found that older maternal age is associated with an increased 
risk of FASD.111,266 Older mothers are more likely to drink during pregnancy than 
younger mothers.13,16,18,52,306 Blood alcohol concentration (BAC) per unit dose 
increases with age, leading to higher levels of exposure per unit consumed among 
the offspring of older mothers.399-402 Higher BACs may be partly explained by age-
related changes in body composition including an increased body-fat-to-water ratio 
among older individuals.399,401-403 Some studies have also found differences in rates 
of ethanol metabolism among older participants, although results are mixed.400-
402,404-409 Chronic alcohol exposure, which is associated with maternal age, can 
impair the function of enzymes responsible for transporting nutrients that are 
important for fetal development.389,410 Thus, older maternal age is proposed to 
increase the risk of FASD due to increased PAE and reduced nutrient availability. 
5.2.2.3 Marital status  
Mothers of children with FASD are less likely to be married and more likely to be 
cohabiting with a partner than controls.111,274,276,325,343,344,411,412 Existing studies do 
not offer an explanation as to the causal basis of this relationship, however it is 
possible that marriage may protect against FASD by offering a form of social 
support. It may also indicate fewer relationship problems, which have been cited as 
a source of prenatal stress and predictor of PAE among mothers of children with 
FASD (see Section 5.2.4.1). In addition, marriage is associated with higher 
socioeconomic status, which in turn predicts a lower risk of FASD. Unplanned 
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pregnancy, a further risk factor for PAE, is lower among married women and this 
too may reduce the risk of FASD (see Section 5.2.3.4). 
5.2.2.4 Religion 
In their review of FASD risk factors, Esper and colleagues concluded that ‘less 
religious’ women had an increased risk of having a child with FASD.111 However, the 
evidence base is mixed. Three studies in South Africa found that mothers of 
children with FASD reported a lower frequency of church attendance and prayer 
than controls.274,276,344 However, in Italy, women categorised as more religious 
were more likely have a child with FASD than those classed as less religious.82,83 
Other studies have found no significant differences in the religious practices of 
mothers of children with FASD and those without.413 These studies do not provide 
any insight into possible causal relationships between religion and FASD. However, 
the extent to which religion may protect against, or be a risk factor for, FASD is 
likely to depend on its association with more proximal risk factors for FASD, such as 
alcohol use, unplanned pregnancy and social support. For example, religions differ 
in their stance towards alcohol consumption. The Islamic faith promotes 
abstinence from alcohol and abstinence is high among Muslims.414 The prevalence 
of FASD is 50 times lower than the global average in the World Health Organisation 
(WHO) Eastern Mediterranean Region, where the population is predominantly 
Muslim.11 In contrast, wine is part of Communion in the Catholic faith and 
abstinence is much less common among Catholics.414 Astley and colleagues found 
that mothers of children with FAS were more likely to become abstinent in the 
future if they reported a religious affiliation and more satisfactory support 
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networks.70 Finer and colleagues found that religion was associated with a reduced 
risk of unplanned pregnancy.415 Therefore, it is possible that religion may protect 
against FASD if the faith promotes abstinence from alcohol, or drinking in 
moderation, reduces the risk of unplanned pregnancy, and offers a satisfactory 
form of social support for mothers. 
5.2.3 Pregnancy factors 
5.2.3.1 Parity 
Parity is higher among mothers of children with FASD, relative to controls.111,266 
Some authors have suggested that higher parity could increase susceptibility to 
alcohol teratogenicity due to greater levels of uterine collagen and elastin, which 
reduce blood flow and contribute to fetal hypoxia.285 However, experimental 
studies suggest that it is maternal age, rather than parity that modifies the effect of 
PAE on offspring outcomes.403,416 When rats of the same age, but different parity, 
are exposed to equivalent levels of alcohol the number of birth defects are 
comparable across groups. In contrast, older rats are more likely to produce 
offspring with birth defects following PAE than younger rats, when parity is 
equivalent.416,417 Based on this evidence, in the DAG, I depicted parity as an effect 
of maternal age in the DAG, rather than a direct causal factor for FASD. 
5.2.3.2 Pregnancy complications 
Mothers of children with FASD report more complications including preterm 
delivery, fetal distress, miscarriage, stillbirth, placental abruption and admission to 
special care baby units.276,326,411,412 Pre- and perinatal complications are an effect of 
PAE and therefore may serve as a marker for FASD risk. 
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Complications during pregnancy and delivery have also been linked to other 
exposures including prenatal smoking, prenatal illicit drug use, poor nutrition and 
high levels of prenatal stress.276,326,369,374,411,412,418-420 The risk of pregnancy 
complications may be mitigated by access and adherence to antenatal care 
recommendations and monitoring.25,64  
5.2.3.3 Antenatal care 
Compared to controls, mothers of children with FASD are less likely to have 
received antenatal care, more likely to have accessed care late in pregnancy and 
more likely to have attended fewer antenatal appointments.273,325,326,411,412 
Substance misuse may act as a barrier to antenatal care. The NICE Pregnancy and 
Complex Social Factors guideline suggests that women who misuse substances are 
less likely to access prenatal care due to negative staff attitudes, fear about the 
involvement of children’s services, and feelings of guilt.64  
As well as influencing uptake of antenatal care, prenatal substance use may be 
influenced by antenatal care. For example, mothers accessing antenatal care via 
the NHS are provided with information about the risks of prenatal substance use 
and are given details of organisations including Alcohol Concern, the Drug and 
Alcohol Helpline and smoking cessation services.421 In the USA, pregnant women 
who have health insurance are approximately 50% less likely to have consumed 
alcohol in the last month, further suggesting that antenatal care can influence PAE 
(although this relationship may also be due to the association between PAE and 
socioeconomic status).422 Therefore, there is a time-dependent causal relationship 
between prenatal substance use and antenatal care. As it is not possible to have 
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feedback loops within DAGs, the full sequence can be conceptualised as a series of 
time-dependent factors: substance use before pregnancy → prenatal substance use 
at time 1 → attendance at antenatal care → prenatal substance use at time 2. For 
clarity of presentation, in the DAG I depicted antenatal care as a consequence of 
prenatal substance use (time 1 relationship).  
5.2.3.4 Unplanned pregnancy 
Worldwide, 40% of pregnancies are unplanned,423 ranging from 16% in the UK,341 
35% in Africa, and 51% in North America.423 Unplanned pregnancy is a risk factor 
for FASD. Among a sample of mothers of children with FAS in the USA, 73% of live 
births were unplanned.70 The median time to pregnancy recognition among women 
with an unplanned pregnancy is five weeks.321 Unplanned pregnancy is more 
common among women who drink regularly and/or binge drink,321,339-341 and binge 
drinking is associated with inadequate methods of contraception.424 Therefore, the 
risk of unintended PAE during the periconceptual period is high. 
Studies from England, Ireland and the USA indicate that women who have an 
unplanned pregnancy are less likely than those with a planned pregnancy to follow 
advice for prenatal lifestyle behaviours including alcohol use, smoking and 
diet.57,58,425 A qualitative study of pregnant women who attended alcohol 
establishments in South Africa suggested that some women with unplanned 
pregnancies continued to drink because they did not feel a connection or 
responsibility for their unborn baby, and some women reported drinking in an 
attempt to abort the fetus.426  
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Other factors associated with an increased risk of unplanned pregnancy include low 
socioeconomic status, single marital status, exposure to intimate partner violence, 
smoking, illicit drug use and younger maternal age; while religion is associated with 
a decreased risk.70,321,339,341,415,427 Some of these factors may be causal and others 
may be risk markers for unplanned pregnancy due to their association with other 
causal factors. For example, low socioeconomic status may have a causal 
relationship with unplanned pregnancy, as in some countries, women may be less 
likely to commit limited financial resources to contraceptives. Studies conducted in 
the USA show that unplanned pregnancy is more common among poorer 
women,415 and in one study 43% of women who gave birth to a child with FAS 
reported that they could not afford contraception.70 Conversely, socioeconomic 
status was not found to be associated with unplanned pregnancy in a UK study, 
where contraception is available for free.341 Intimate partner violence may be 
causally associated with unplanned pregnancy due to an increased risk of sexual 
coercion, and sabotage of contraception.427,428 Substance use before pregnancy 
may be causally associated with unplanned pregnancy, as it increases the likelihood 
of not using contraception.424,429 Further consequences of unplanned pregnancy 
include late prenatal care and complications during pregnancy.321,339,340,415,430  
5.2.4 Stress and social support 
5.2.4.1 Prenatal stress 
Prenatal stress may increase vulnerability to FASD.285 Mothers of children with 
FASD are more likely to report that pregnancy was a particularly stressful time and 
to have experienced stressful life events, including abuse and interpersonal 
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violence.111,287 Qualitative evidence suggests that some mothers may use alcohol to 
alleviate stress during pregnancy.70,344,426 Prenatal stress has been found to predict 
co-occurrence of PAE and prenatal smoking, illicit drug use, and poor prenatal 
nutrition.316,318 It is important to acknowledge that substance use may also cause 
prenatal stress.276 However, in the literature, stress is typically thought to precede 
substance use. This implies the following causal structure: prenatal stress at time 1 
→ PAE → prenatal stress at time 2. To aid clarity of presentation and prevent 
feedback loops, I presented the time 1 relationship from stress → PAE in the DAG.  
As well as influencing drinking behaviour, prenatal stress may exacerbate the 
teratogenic effects of alcohol.431 In a Ukrainian study, prenatal depression and PAE 
jointly influenced neurodevelopmental outcomes in infants. This effect may be 
partially mediated through prenatal stress.294 Reviews of animal studies have 
concluded that PAE and stress operate synergistically to impair developmental 
outcomes.286 For example, one primate study explored the impact of prenatal 
exposure to alcohol and a noise stressor on attention and neuromotor outcomes in 
offspring.432 Concurrent exposure to PAE and stress produced deficits in 
coordination, response speed, and birthweight, while exposure to PAE alone did 
not significantly affect these outcomes. Another primate study found a significant 
interaction between prenatal stress and PAE on behavioural outcomes. Animals 
that had been exposed to both prenatal stress and PAE showed increased levels of 
hyperactivity and stereotypies postpartum compared to animals exposed only to 
one of these factors, and non-exposed controls.433 However, evidence is 
inconsistent and not all studies have found an interaction between PAE and stress 
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in producing outcomes relevant to FASD symptomology, possibly as a result of 
small sample size.434-436  
Several biological mechanisms have been proposed to account for observed 
interactions between PAE and stress in FASD. One hypothesis is that PAE and 
prenatal stress produce lasting changes in the functioning of the fetal 
hypothalamic-pituitary-adrenal (HPA) axis, which is involved in the stress response. 
This effect is heightened in the presence of both PAE and stress, relative to their 
individual contribution.437,438 Adrenocorticotrophic hormone responses to a 
postnatal stressor have been found to be higher in primates exposed to both 
prenatal stress and PAE than those exposed to PAE alone.301,437 Endocrine 
dysregulation may contribute to the risk of FASD by influencing behavioural, 
cognitive and emotional functioning.432,438 Another suggestion is that dual exposure 
contributes to fetal hypoxia by restricting uterine blood flow and suppressing fetal 
breathing. Hypoxia promotes cell damage, which may lead to midfacial 
abnormalities431 and can be particularly damaging in areas such as the 
hippocampus and cerebellum which are involved in attention, motor function and 
learning.285,432 Prenatal stress has been independently linked to adverse child 
outcomes and congenital anomalies and is also a consideration for differential 
diagnosis.431,439-441 
5.2.4.2 Maternal mental health 
Mental health disorders are common among mothers of children with 
FASD.70,111,327 Among a clinic-based sample of 80 mothers of children with FAS in 
the USA, 96% had one or more mental health disorders.70 The mechanisms that link 
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prenatal mental health to child outcomes are poorly understood; however, effects 
are thought to be facilitated primarily via increased stress hormone circulation and 
altered HPA functioning, as described in the previous section.442-444  
Bandoli and colleagues found that unmedicated maternal depression and PAE 
interacted to predict poorer outcomes on the Bayley Scales of Infant Development 
(BSID) at ages six and twelve months; while maternal depression, alone, was not 
independently associated with neurodevelopmental outcomes.294 Santucci and 
colleagues also failed to find an association between prenatal depression and BSID 
scores.445 Other studies have found an independent association between prenatal 
depression symptoms and poorer emotional-behavioural and cognitive outcomes 
in children up to age eight.377,378 These effects were thought to be partially 
mediated through an unhealthy prenatal diet. Overall, results are inconsistent with 
regards to the independent influence of prenatal mental health on FASD-related 
symptomology. Following a review of the evidence, Waters and colleagues 
concluded that, with the exception of conduct problems, prenatal depression does 
not appear to independently influence child neurodevelopmental outcomes.443 
Therefore, associations between prenatal mental health and FASD are thought to 
be largely mediated by the prenatal stress response, rather than mental health 
itself.  
In addition to its interaction with PAE, maternal mental health may influence 
drinking behaviour due to the use of alcohol for self-medication.426,446 A 
prospective study that investigated the comorbidity of alcohol use disorder and 
major depression found that depression often preceded alcohol use disorder.447 
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Furthermore, mothers who have a child with FAS and subsequently receive mental 
health treatment are more likely to report abstinence, suggesting a promising 
target for FASD prevention.70 Maternal mental health issues may also affect fetal 
development by increasing the risk of other adverse exposures including illicit 
substance use, smoking and poor prenatal nutrition.318,377,378,448  
5.2.4.3 Social support in pregnancy 
Social support has been defined as “the degree to which a person’s basic needs are 
gratified through interaction with others.”449(p. 54) Social support is typically 
provided by family and friends and can include general support (when the recipient 
feels liked, loved or respected) and instrumental support (when the recipient has 
opportunities for practical assistance including financial support and child care).449 
Social support during pregnancy is associated with reduced alcohol intake in 
European and American samples.449,450 Mothers who have given birth to a child 
with FASD are more likely to achieve abstinence in the future if they report having 
a large, satisfactory support network.70 However, the beneficial effects of social 
support on alcohol use may be less apparent among women in poverty, and within 
subcultures that normalise drinking in pregnancy.426,451 In summary, social support 
may protect against PAE by attenuating the impact of stressors and reducing the 
likelihood that alcohol will be used as a coping strategy. 
5.2.4.4 Abuse 
FASD is more common among children born to women who have experienced 
childhood physical or sexual abuse and/or intimate partner violence.70,111,276,327 
Substances including alcohol may be used as a self-medication strategy to alleviate 
 Chapter 5 159 
stress and mental health symptoms among those who have experienced abuse.452 
Abuse influences whether mothers reduce their alcohol intake following pregnancy 
recognition. Seventy-two percent of mothers of children with FAS reported that 
they did not want to reduce their alcohol use because they were in an abusive 
relationship.70 Abuse may also influence risk of FASD by acting as a barrier to 
adequate antenatal care. Women experiencing domestic abuse may be prevented 
from accessing antenatal care by the perpetrator or may be reluctant to access 
antenatal care due to concerns that disclosure of abuse would make the situation 
worse, or would lead to involvement of child protection services.64  
5.2.5 Other maternal psychological and physical characteristics 
5.2.5.1 Maternal physical characteristics 
In a review of the evidence, May and colleagues concluded that maternal “body 
mass significantly and obviously moderates risk for FASD.” 109(p. 21) Lower maternal 
height, weight and BMI have been found to consistently predict FASD in studies in 
South Africa.266,274,276,342,343,413 Studies conducted in Italy and the USA have been 
less consistent with regards to BMI, but found that mothers of children with FASD 
tended to be shorter or weighed less than those without FASD.79,109,273,345  
Several mechanisms have been proposed to account for the effect of maternal BMI 
on FASD risk. Maternal physical characteristics influence the distribution of alcohol 
after it is consumed. As alcohol is distributed in body water, blood alcohol 
concentrations (BACs), and therefore PAE, tends to be higher in smaller 
women.110,453 As well as influencing BACs, higher maternal weight and BMI may 
indicate adequate nutrition. Although higher BMI may protect against FASD, it is 
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important to note that maternal obesity is associated with a range of adverse 
outcomes including gestational diabetes mellitus, induction of labour and preterm 
delivery.454 
5.2.5.2 Maternal FASD symptomology 
Mothers of children with FASD are more likely to have symptoms of FASD 
themselves, including cognitive impairment and small head circumference.266,274,327 
Maternal FASD symptomology leads to an increased risk of mental disorders. Up to 
94% of individuals with FASD have comorbid mental health disorders,93 including 
conduct disorder (91%), ADHD (51%), and depression (35%).90 In turn, impaired 
mental health increases the risk of PAE (as described in Section 5.2.4.2). Fifty-five 
percent of individuals with FASD experience drug or alcohol dependence later in 
life,90 thus increasing the risk of FASD in subsequent generations.  
5.2.5.3 Knowledge and attitudes towards PAE and FASD 
Public awareness of the risks of PAE is low. Inconsistencies in UK guidance and 
mixed advice from health professionals are likely to contribute this lack of 
awareness.94 A UK study, published in 2015, sought to determine what the general 
public knew about PAE and FASD.56 This study found that 40% of participants did 
not know the current government guidance on PAE. Most participants (71%) also 
said that government guidance on PAE was unclear, and some said that this lack of 
clarity was likely to lead to messages being disregarded.56 Health professionals in 
the UK have been found to give mixed advice to women about PAE. The Infant 
Feeding Survey 2010 reported that 30% of expectant mothers were not given any 
information about alcohol use in pregnancy. Among women who received advice, 
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36% were given information on reducing their intake and 29% on stopping 
drinking.52  
In the absence of clear evidence about a ‘safe’ threshold for PAE, opinions can be 
polarised. Some groups endorse a ‘no alcohol no risk’ message, while others warn 
against the ‘policing of pregnancy’ and suggest that women should be free to make 
an educated choice about whether they drink when trying to conceive and during 
pregnancy.53,54 
FASD is not well understood by the public and health professionals in the UK and 
internationally.10 A UK study of 674 individuals found that while 87% had heard of 
FASD, knowledge of the condition was limited.56 A 2011 survey of over 600 
midwives in East Anglia found that only 10% were able to identify the core features 
of FASD, and less than 2% reported that they were ‘very prepared’ to deal with the 
condition.116 Among professionals who are aware of FASD, some are reluctant to 
consider a diagnosis over concerns that it is stigmatising and because of a lack of 
FASD services.106 
For the purposes of DAG construction, public health guidance on alcohol use was 
hypothesised to influence public and professional knowledge on the risks of PAE, 
which in turn was proposed to influence PAE.  
5.2.6 Family factors 
5.2.6.1 Alcohol use of friends and family 
Mothers of children with FASD report higher levels of alcohol consumption by their 
partner, family and friends.79,111 Ceccanti and colleagues found that alcohol 
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problems in the family increased the likelihood of having a child with FASD by nine 
times.345 Alcohol use by friends and family may impact on PAE in various ways. 
First, the drinking behaviour of those in close social networks may represent the 
norms within that context. For example, a binge pattern of drinking may not be 
viewed as problematic in some communities in South Africa where heavy episodic 
alcohol use is commonplace.413 Second, some women may feel coerced into 
drinking before and during pregnancy as a result of the behaviour of friends and 
family. In a study of mothers of children with FAS, Astley and colleagues reported 
that 36% of women said that they did not want to reduce their alcohol intake 
because their partner did not want them to, and 20% because their family and 
friends did not want them to.455  
Strong correlations between maternal substance use and the substance use of 
friends and family could also be due to processes of self-selection. Self-selection 
theories posit that individuals pick companions who are similar to themselves and 
who are supportive of their behaviour. Evidence supports self-selection as a 
mechanism that accounts for similarities in substance misuse behaviour within 
social networks.456 In the DAG, I represented this mechanism via the unspecified 
“risky behaviour” node that influences both maternal substance use and also the 
drinking behaviour of those who have been selected as part of the mother’s social 
network.  
Finally, as described above, mothers of children with FASD are more likely to have 
symptoms of FASD themselves, and to report that the maternal grandmother has a 
history of alcohol problems.274,327 This raises the possibility of intergenerational 
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transmission of FASD – a phenomenon that has received support via controlled 
animal studies.457 Heavy alcohol use by the maternal grandmother could indicate 
the presence of a risk genotype for heavy alcohol use,458 could result in epigenetic 
changes that increase the risk of heavy alcohol use in later generations457 and could 
provide a model of problematic alcohol use that is adopted by offspring via social 
learning.459  
Emerging evidence from animal studies suggests that paternal alcohol consumption 
could influence the epigenetics of sperm DNA by influencing methylation patterns 
in sites that are important to developmental outcomes.460 Paternal alcohol use has 
been associated with FASD symptomology including low birth weight, reduced 
brain size, microcephaly, impaired learning and hyperresponsiveness,330,461 
although results have been inconsistent.462 In a 2016 review, Day and colleagues 
stated that “the alcohol consumption of the father during his lifetime can lead to 
FASD in his offspring.”461(p.16) However, the authors note that the interaction 
between maternal and paternal alcohol use requires further investigation, and that 
studies have not been able to demonstrate that epigenetic inheritance, solely due 
to paternal drinking, can cause a specific phenotype.461 Furthermore, with the 
exception of FAS, all diagnoses within the FASD continuum require evidence of 
maternal alcohol consumption. By definition, therefore, paternal alcohol use 
cannot currently be considered a sole cause of FASD. Further research is required 
to elucidate the precise mechanisms through which familial alcohol consumption 
influences the risk of FASD in future generations.462 
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5.2.6.2 Having another child with FASD 
Population-based data from the USA indicate that between nine and 29% of 
mothers identified within the FAS Surveillance Network had another child with 
FASD.325 An early study, published in 1979, found that 70% of children with FAS had 
a sibling with confirmed or suspected FAS.463 Therefore, having a sibling with FASD 
is a strong risk marker for FASD. 
Having another child with FASD is also a strong predictor of subsequent alcohol-
exposed pregnancies.69,325,326,463 In a cross-sectional study of mothers of children 
with FAS, 80% subsequently had an unplanned pregnancy, of which 75% were 
alcohol-exposed.70 In the absence of intervention, women who are at risk of having 
another child with FASD exist within the same causal context as that which 
surrounded their first affected pregnancy. Thus, identifying mothers who have had 
a child with FASD is an important focus for targeted prevention.69  
5.2.6.3 Genetics 
Genetic factors influence vulnerability to FASD. Twin studies show that dizygotic 
twins have differential susceptibility to FASD, while monozygotic twins have high 
levels of concordance.326,464-467 Animal models of FASD demonstrate that different 
strains of mice have diverse outcomes according to their genotype.468,469 Finally, 
observational studies have found that particular genetic variants are more common 
among alcohol-exposed children who develop FASD, compared to those who do 
not.470,471 
Existing reviews have demonstrated that genetic factors modify susceptibility to 
alcohol-related harm.458,472-474 A range of genes have been investigated in animal 
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models of FASD, including aldehyde dehydrogenase (ALDH), Fancd2, Cdon, Gli2, 
Shh, Nos1, PDGFRA, hinfp, foxi1, mars, plk1 and vangl2; however, these genes are 
yet to be explored in human studies.474 In humans, polymorphisms of alcohol 
dehydrogenase (ADH) genes, have been the primary focus of investigation.472-474 
ADH enzymes oxidise ethanol to acetaldehyde and account for up to 95% of alcohol 
metabolism. ALDH and CYPE2E1 also influence ethanol metabolism in humans, 
however their role in FASD susceptibility is yet to be established.470,473 
Polymorphisms at the ADH1B locus produce enzymes that affect the rate of 
ethanol clearance. In populations of European ancestry, the slow-metabolising 
allele, ADH1B*1, is the typical variant and occurs in approximately 95% of 
individuals. The rare ADH1B*2 and ADH1B*3 alleles convert ethanol to 
acetaldehyde 75-88 times faster than ADH1B*1.475 Maternal and infant ADH1B 
genotype has been found to influence risk of FASD as, with the exception of one 
study,476 fast-metabolising alleles have been associated with a reduced risk of FASD 
symptomology following PAE.470,477-480  
Using data from the ALSPAC cohort, Lewis and colleagues27 explored the impact of 
ADH polymorphisms on children’s IQ following PAE. Rare variants of four child 
single nucleotide polymorphisms (SNPs; ADH7 rs284779, ADH1B rs4147536, ADH1A 
rs975833 and ADH1A rs2866151; herein referred to as the SNP set) were negatively 
associated with IQ at age eight for children with low to moderate alcohol exposure 
in-utero (1 to 6 units per week). These rare variants were hypothesised to be 
associated with slower metabolism, leading to relatively increased alcohol 
exposure and teratogenicity.27,481 However, a study of in-vivo alcohol metabolism 
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failed to show that these SNPs influenced blood or breath alcohol 
concentrations.482 Within Lewis and colleagues’ study another SNP, ADH4 
rs4148884, had divergent effects. The rare allele was associated with decreased 
offspring IQ when present in the maternal genotype, but increased IQ when 
present in the child’s genotype. These SNPs were not associated with IQ among 
children of non-drinking mothers, suggesting that genotype acted as an effect 
modifier following maternal alcohol intake. In a separate study, the SNP set 
identified by Lewis et al. was found to modify the relationship between alcohol use 
and cognitive decline in older age, providing further evidence that these factors are 
meaningful indicators of genetic vulnerability to alcohol-related harm.481  
As well as influencing alcohol metabolism, genotype may influence drinking 
behaviour, hence the interest in ADH variants as instrumental variables in 
Mendelian randomisation studies.289 Patterns of alcohol consumption tend to run 
in families and several genes have been found to contribute to risk of 
alcoholism.458,462 ADH1B has been widely studied and research shows that 
individuals with the rare allele consume less alcohol than those with the typical 
allele, and have a reduced risk of alcoholism.483-486 In pregnancy, mothers with the 
rare ADH1B allele have been found to consume significantly less alcohol before 
pregnancy and to be 50% less likely to binge drink during pregnancy.487 In 
summary, genotype may influence the risk of FASD through its influence on both 
alcohol metabolism and drinking behaviour.26  
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6 Discussion 
The aetiology of FASD is multifaceted and complex. Following prenatal exposure to 
alcohol, FASD risk is determined by a range of lifestyle, sociodemographic, 
maternal, social, gestational, and genetic factors that mutually influence children’s 
outcomes. The DAG that I have presented provides a summary of the distal and 
proximal factors that causally influence FASD risk, as well as the factors that are 
proxies for causal factors or (non-causal) risk markers for FASD. The principles of 
causal diagram theory can be applied to this DAG to inform statistical modelling 
strategies for epidemiological studies of FASD. 
6.1 Strengths and limitations 
6.1.1 Literature review and DAG methodology 
The literature review and DAG build upon evidence from existing reviews of risk 
factors for FASD109,111,488 to provide an updated synthesis using the latest evidence 
from observational human studies and animal experiments. The use of DAG 
methodology represents a novel approach to the study of FASD and adds clarity to 
causal inferences in an area that has mostly been confined to discussions of 
association. As a visual representation, the DAG presents a unified summary of the 
current evidence on the aetiology of FASD. 
Since the DAG has been constructed based on current subject-matter knowledge 
and my interpretation of plausible causal structures, it may be subject to change as 
new evidence emerges. This is not a limitation of the DAG approach, but rather 
reflects the realities of making causal inferences within a developing evidence base. 
In its current form, the DAG that I have presented may be a useful working 
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template for researchers of FASD, who can use this tool to guide their analyses and 
update the causal structure of this diagram, as necessary. 
It is important to note that the causal inferences derived from the DAG rest on the 
assumption that the diagram is valid. The DAG is based on my interpretation of the 
evidence and therefore, it is possible that given the same evidence another 
researcher may depict the relationships differently. Furthermore, the limitations 
inherent in the evidence base will necessarily apply to the results from this review 
and the DAG. Many proposed risk factors for FASD, such as prenatal substance 
exposure and maternal stress, cannot be manipulated for ethical and practical 
reasons.489 The evidence that I have used to construct the DAG was, therefore, 
based on experimental studies with animals and observational studies with 
humans. Animal studies have allowed the causal status of ethanol as a teratogen to 
be established490 and have enabled causal conclusions about the influence of 
covariates such as stress and genetics on outcomes relevant to FASD.434,469,491 
Furthermore, in contrast to human studies, in which adverse exposures and health 
behaviours tend to co-occur, animal studies can isolate and evaluate the effects of 
specific exposures. However, animal models are imperfect substitutes for human 
studies for reasons including differences in alcohol metabolism, gestational 
processes, and their inability to replicate higher-level behavioural outcomes.286 No 
single animal model has replicated all of the attributes of FASD.490 Observational 
studies of humans pose fewer concerns than animal studies in terms of exploring 
associations between a variety of co-occurring social and lifestyle factors and the 
full spectrum of FASD. However, this advantage is countered by the potential for 
bias due to lack of experimental control. For example, Esper and colleagues111 used 
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the Newcastle-Ottawa Scale (NOS)492 to assess quality evidence for the studies of 
maternal risk factors for FASD that were included in their review. They noted that 
quality was generally high for the selection criteria (maximum quality score for 
eight out of 13 eligible studies; indicating appropriate FASD case definition, 
selection and definition of controls, and representativeness) but low for the 
comparability criteria (10 out of 13 eligible studies had a score of one out of a 
maximum of two; indicating limitations in the case-control matching procedures 
and/or a lack of adjustment for key confounders), and low for the exposure 
criterion (one to two stars out of four for all studies; indicating that ascertainment 
of exposure was not based on appropriate records, that interviewers were not 
blind to case/control status, that there were different methods of ascertainment 
for cases and controls and/or that there was a differential response rate for cases 
and controls). In general, observational studies are at risk of bias due to residual 
confounding, misclassification of the exposure and/or outcome, and differential 
loss to follow-up. In the evidence synthesis for the DAG, as well as studies with 
traditional observational designs, I included negative control and Mendelian 
randomisation studies. Although these studies are also subject to potential 
limitations (the contribution of paternal epigenetic factors to prenatal 
development in studies with negative controls remains to be established; and 
effect estimates may be biased towards the null in Mendelian randomisation 
studies if genetic instruments are weakly correlated with the exposure of 
interest),303,330,486,487 the sources of bias differ for each approach and therefore, 
under a triangulation method, the fact that the evidence from these different study 
designs points to a similar causal conclusion for many of the nodes of interest 
 Chapter 5 170 
increases confidence in the causal hypotheses presented in the DAG.302,303 
However, it may never be possible to determine whether the pathways suggested 
by the observational and animal studies represent the true causal pathways to 
FASD. Although this is a limitation of causal inference in general, compared to 
conventional modelling strategies, DAG methodology benefits from providing 
transparency about causal assumptions and likely remaining sources of bias. 
6.1.2 The utility of DAGs in casual inference 
Recently, there have been some criticisms about the gain in popularity of DAGs as 
tools to support causal inference. Kreiger and Davey Smith argue that DAGs have 
become synonymous with ‘casual inference’ and that this unnecessarily narrows 
the scope of causal inquiry in epidemiology.302  They assert that “robust causal 
inference…comprises a complex narrative, created by scientists appraising, from 
diverse perspectives, different strands of evidence produced by myriad methods. 
DAGs can of course be useful, but should not alone wag the causal tale.” 302(p.1789) I 
agree, and this is why I have drawn upon a broad body of evidence to support the 
causal pathways depicted in the DAG. Daniel and colleagues attribute Kreiger and 
Davey Smith’s criticism to a misinterpretation of the role of DAGs in causal 
inference. As they point out, DAGs do not purport to provide a substitute for 
careful consideration of the evidence base. Instead they are a result of this.493 
Under this view, I would contend that the narrative synthesis that I have conducted 
is the causal inference approach, while the DAG is the tool that summarises key 
causal assumptions and enables application of graphical rules to guide appropriate 
analyses and interpretation within a causal framework. 
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Finally, DAGs are nonparametric and debate is ongoing as to whether it is possible 
to represent effect modification and, if so, how it should be represented. This is 
particularly problematic when trying to describe the aetiological context of FASD. In 
this context, while there is a sole necessary cause (alcohol), several effect modifiers 
may be present that influence whether PAE results in FASD. In the DAG (Figure 18), 
I have followed Weinberg494 and Thompson’s495 suggestion by representing effect 
modification with an arrow that intersects the intermediate causal pathway from 
PAE to FASD,494 although other representations have been suggested.496,497 
VanderWeele and Robins indicate effect modification as separate arrows from 
exposures that each lead to the outcome variable.496 However, when considering 
FASD, this conceptualisation does not acknowledge the fact that in the absence of 
PAE, another exposure cannot independently influence true FASD. Other 
conceptualisations of effect modification suggest that interacting variables can be 
represented as separate nodes that lead to a single composite node that contains 
both exposures. However, for the purposes of this chapter this representation 
would become too visually complex and would interfere with the ability the 
interpret the DAG.497 It is important to reiterate that, since DAGs are non-
parametric, they are entirely agnostic as to whether or not there is effect 
modification. My representation of effect modification as an intersecting arrow in 
the direct pathway between PAE and FASD is purely for visual illustration. To 
enable analysis of the DAG in the DAGitty platform (i.e. to identify covariate 
adjustment sets for the risk factor analysis in Chapter 6), I directly connected the 
arrows from the proposed effect modifiers to the FASD outcome to allow 
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application of the graphical rule algorithms (DAGitty code is available in Appendix 
14).498 
7 Implications for this thesis 
The DAG presented in this chapter formalises and unifies current knowledge about 
the causal context of FASD. I believe that this DAG provides a useful synthesis of 
evidence for those interested in the epidemiology of FASD, and will strengthen my 
analysis plan and interpretation in subsequent chapters of my thesis.  
In the next chapter (Chapter 6), I will describe how I used the information from the 
DAG to design and execute the statistical analysis strategy in my analysis of FASD 
risk factors using data from the ALSPAC cohort.
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Chapter 6. Risk factors for fetal alcohol spectrum disorder: a 
population-based birth cohort study 
 
1 Overview 
In this chapter, I investigate risk factors for FASD using data from a population-
based birth cohort in England (ALSPAC). First, I present the aims and objectives of 
this chapter, followed by the methods, which include a description of how I used 
the causal diagram that I developed in Chapter 5 to inform the statistical modelling 
strategy. I then present the results from univariable and multivariable logistic 
regression analyses. I conclude the chapter with a summary of the main results and 
a discussion of the strengths and limitations of this work. 
2 Background 
There is significant variability in the outcomes of children who have been exposed 
to alcohol prenatally. Chapter 4 showed that although 79% of children in the 
ALSPAC cohort had PAE, only 17% met criteria for FASD. Furthermore, there were 
only modest differences in patterns of PAE between children with and without 
FASD. Therefore, it is important to identify which factors influence susceptibility to 
FASD to inform strategies for prevention and intervention. 
In Chapter 5, I reviewed the published literature on FASD risk factors and produced 
a causal diagram (DAG) to synthesise this evidence. This review indicated that the 
aetiology of FASD is complex. Following PAE, a child’s risk of developing FASD is 
influenced by lifestyle factors, sociodemographic characteristics, pregnancy factors, 
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stress, social structures and maternal psychological and physical characteristics. 
Based on the DAG, I identified a subset of potentially modifiable causal risk factors 
for FASD, which will be explored in the multivariable analyses that I present in this 
chapter. These factors are: patterns of prenatal alcohol use, smoking, illicit drug 
use, nutrition, mental health, stress and social support. 
3 Aim and objectives 
3.1 Aim 
To quantify the effect of potentially modifiable risk factors for FASD among children 
who have been exposed to alcohol prenatally in the ALSPAC cohort. 
3.2 Objectives 
i. To use the causal diagram (DAG) that I developed in Chapter 5 to develop 
statistical models to evaluate the association between potentially 
modifiable risk factors and FASD. 
ii. To quantify the association between different patterns of prenatal alcohol 
use, smoking, illicit drug use, nutrition, mental health, stress and social 
support and FASD among children who have been exposed to alcohol 
prenatally. 
4 Method 
4.1 Data source 
The ALSPAC cohort (described in Chapter 3, Section 4.1.1).  
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4.2 Study approval  
Ethical approval for this study was obtained from the ALSPAC Ethics and Law 
Committee (IRB00003312) and the Local Research Ethics Committees.232 Project 
approval was granted by the ALSPAC Executive Committee on the 2nd March 2016 
(Project B2620). 
4.3 Participants 
This study included participants from the core ALSPAC sample with confirmed PAE, 
based on maternal self-report. I excluded twins and triplets, participants who were 
known to have a genetic condition, participants who were not alive at one year of 
age and participants who did not speak English as a primary language. Participants 
who were in the armed forces social class category were excluded due sparse data, 
which caused problems with convergence in imputation and risk factor models (N = 
28).  
4.4 Variables 
4.4.1 Outcome 
The outcome was any FASD based on the Mid CNS/Any PAE case ascertainment 
algorithm (described in Chapter 3), which was coded as a binary (FASD/not FASD) 
variable. 
4.4.2 Exposures 
The exposures of interest were the potentially modifiable causal risk factors for 
FASD that I identified using a causal diagram (DAG; described in Chapter 5). These 
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variables are described further below. Full details of the original data collection 
methods and variables are available in the ALSPAC data dictionary.233 
4.4.2.1 Prenatal substance use 
4.4.2.1.1 Patterns of prenatal alcohol exposure 
Dose/frequency (categorical): Mothers completed self-report questionnaires that 
described the number of glassesm of alcohol that they consumed per week or per 
day in the first trimester (data collected at 18 weeks gestation), around the time 
they first felt the baby move (data collected at 32 weeks gestation) and in the third 
trimester (data collected at 8 weeks postpartum). To overcome issues with 
convergence in multiple imputation models and to reduce sparse data categories, I 
generated a summary variable that described the maximum amount of PAE 
consumed at any time during pregnancy as follows: less than 1 glass per week,n 1 
to 6 glasses per week, 7 or more glasses per week. 
Weekly alcohol consumption (categorical): Using the categorical dose/frequency 
measure described above, I generated a binary (yes/no) variable to indicate alcohol 
consumption on a weekly basis during pregnancy.  
Measures of alcohol (continuous): Mothers reported the number of measures of 
alcohol that they consumed per weekday and weekend day for each of the 
                                                        
m The ALSPAC questionnaire defined a glass of alcohol as equivalent to a pub measure of spirits, ½ 
pint lager/beer, wine glass of wine etc. 
n This category also included participants who reported ‘never’ drinking on this measure. These 
participants were identified as having drank some amount of alcohol while pregnant based on other 
drinking measures (including binge drinking, continuous measures of alcohol per week, and/or a 
lack of reduction in consumption compared to alcohol use before pregnancy). Therefore, these 
participants were considered to drink occasionally in pregnancy.  
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following types of alcohol: beer/lager (half-pints), wine (glasses), spirits (pub 
measures), and other (asked to describe), at 8 and 32 weeks gestation. Responses 
were summed to provide a continuous measure of weekly consumption. 
Binge drinking (categorical): Information on binge drinking, defined as drinking the 
equivalent of two pints of beer, four glasses of wine or four pub measures of spirits 
on a single occasion, was collected using a self-report questionnaire at 18 and 32 
weeks gestation. From this information, I created a binary (yes/no) variable to 
indicate binge drinking at any time during pregnancy. 
4.4.2.1.2 Prenatal smoking 
Mothers completed questionnaires that asked them whether they smoked 
cigarettes during each trimester and to report the quantity that they smoked. Data 
were collected at 8, 18 and 32 weeks gestation and 8 weeks postpartum. I created 
a binary (yes/no) variable to indicate smoking at any time during pregnancy. 
4.4.2.1.3 Prenatal illicit drug use 
Mothers reported whether they had used amphetamines, barbiturates, cannabis, 
crack cocaine, cocaine, heroin, methadone, ecstasy, ‘hard drugs’ and ‘other drugs’ 
at any point during pregnancy, and the frequency with which each drug had been 
taken. Information about first and second trimester use was collected at 18 weeks 
gestation and information about third trimester use was collected at 8 weeks 
postpartum. I created a binary (yes/no) variable to indicate any drug use at any 
time in pregnancy. 
 Chapter 6 
 
178 
4.4.2.1.4 Prenatal nutrition 
Vitamin supplements: At 18 and 32 weeks gestation, mothers completed a self-
report questionnaire that asked whether they had taken any of the following 
vitamin supplements during pregnancy: iron, zinc, calcium, folic acid and 
multivitamins. I generated binary (yes/no) variables to indicate whether the 
mother had taken each of the supplements at any time during pregnancy. 
Daily nutrient intake: Mothers completed a food frequency questionnaire at 32 
weeks gestation, which asked them about their consumption of 43 different foods. 
Information from the food frequency questionnaire was used to calculate 
approximate daily nutrient intakes, as reported previously.499 I used dietary 
reference values from the British Nutrition Foundation,500 recommendations from 
the European Food Safety Authority,501 Weichelbaum and colleagues,502 the Drug 
and Therapeutics Bulletin,374 and the National Institutes of Health503 to create 
binary variables that indicated whether participants had met the recommended 
daily intake for each nutrient (met/not met).o  
4.4.2.2 Prenatal mental health 
Maternal prenatal mental health symptoms were assessed using self-report 
measures at 18 and 32 weeks gestation. Maternal anxiety symptoms were 
measured using the Crown-Crisp Experiential Index (CCEI)504 and maternal 
depression symptoms were measured using the Edinburgh Postnatal Depression 
                                                        
o Within the ALSPAC study, scores have recently been derived from factor analyses to represent a 
variety of composite dietary patterns including: ‘healthy’, ‘processed’, ‘confectionary’, ‘vegetarian’ 
and ‘traditional’. These were not available at the time that I conducted the analyses for this chapter, 
but may be of interest for future study.  
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Scale (EPDS), which has been found to be a valid indicator of prenatal depression 
symptoms.505 I used a threshold of 9 or more to indicate prenatal anxiety and a 
threshold of 13 or more to indicate prenatal depression (the highest 15% of 
scores), following previous work by O’Connor and colleagues.506 I created a binary 
variable to indicate whether mothers exceeded the threshold for anxiety or 
depression at any time during pregnancy (yes/no). 
4.4.2.3 Prenatal stress 
Mothers completed a 42-item life-events inventory at 18 weeks gestation and 8 
weeks postpartum, which asked about stressful life events that occurred in early to 
mid pregnancy. I created binary variables to indicate whether mothers had 
experienced each of the following life events during pregnancy: bereavement, 
relationship difficulties, major financial problems, moving house, and accident or 
illness during pregnancy. I also generated variables to indicate whether mothers 
reported having been ‘very affected’ by each of these life events (yes/no).  
In addition, I derived continuous variables that indicated the total number of life 
events that mothers experienced across pregnancy, and the total number of life 
events weighted by how affected the mother reported being by each event (‘very 
affected’ = 4; ‘moderately affected’ = 3; mildly affected = 2; ‘not affected’ = 1; ‘did 
not happen’ = 0), following the procedure reported in the ALSPAC 
documentation.507 
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4.4.2.4 Social support during pregnancy 
At 12 weeks gestation, mothers completed a 10-item questionnaire that asked 
them about their perceived social, emotional and financial support during 
pregnancy. Items were scored from 0 to 3 with higher scores indicating more 
support, yielding a maximum total score of 30.  
4.4.3 Confounding variables 
I used the DAGitty platform312 to analyse the DAG that I developed in Chapter 5 to 
identify which potential confounders to adjust for in each of the multivariable risk 
factor models. DAGitty is a tool for drawing and analysing causal diagrams. It 
applies the graphical rules (described in Appendix 13) to identify which covariates 
should be adjusted for, and which should not, in multivariable statistical models to 
minimise bias in causal effect estimates. Since DAGs are non-parametric, DAGitty 
was used to identify the appropriate covariate set and subsequent multivariable 
statistical analyses were carried out in Stata 14.2.155 
Due to differences in the hypothesised causal and biasing pathways that connected 
each of the exposures of interest with the FASD outcome, adjustment sets differed 
across most of the multivariable models. Table 12 describes the variables that were 
identified as confounders, based on application of the graphical rules in DAGitty, 
for each of the multivariable risk factor models.  
All causal diagrams are presented in Appendix 15. Figure 19 provides an example of 
one of the causal diagrams, using the smoking risk factor model. There were six 
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hypothesised causal pathways that accounted for the total causal effect of prenatal 
smoking on FASD classification among children with PAE. These were:  
i. Prenatal smoking -> ‘true’ FASD (unobserved) -> FASD classification 
ii. Prenatal smoking -> prenatal nutrition -> ‘true’ FASD (unobserved) -> 
FASD classification 
iii. Prenatal smoking -> prenatal nutrition -> BMI -> ‘true’ FASD 
(unobserved) -> FASD classification 
iv. Prenatal smoking -> differential diagnosis (unobserved) -> FASD 
classification 
v. Prenatal smoking -> prenatal nutrition -> differential diagnosis 
(unobserved) -> FASD classification 
vi. Prenatal smoking -> prenatal nutrition ->BMI -> differential diagnosis 
(unobserved) -> FASD classification 
Pathways i. to iii. describe participants who have a pattern of symptoms that met 
the criteria for FASD and whose symptoms were caused by PAE. These are the 
participants with ‘true FASD.’ In contrast, pathways iv. to vi. describe participants 
who met the criteria for FASD but whose presentation may have been better 
explained by factors other than alcohol, if the opportunity was available for 
comprehensive differential diagnosis. All of these pathways contribute to the total 
prevalence of FASD that is observed in this research. Based on the graphical rules 
described in Chapter 5, the least biased estimate of the total causal effect of 
prenatal smoking on FASD could be obtained by including the following variables as 
covariates in the logistic regression model: maternal age at pregnancy, prenatal 
depression, prenatal anxiety, maternal ‘risky behaviour’ personality trait, indicators 
of socioeconomic status, prenatal stress and unplanned pregnancy.   
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Table 12 (continued overleaf): Description of variables that were identified as potential confounders in one or 
more of the multivariable analyses of risk factors for FASD. 
DAG node 
(confounder) 
ALSPAC 
variable(s) 
Categories Time point of 
measurement 
Risk factor 
model(s) 
that 
included 
this variable 
as a 
confounder 
Abuse Physical, sexual 
or domestic 
abuse towards 
the mother in 
childhood or 
during 
pregnancy 
Yes, no 18 & 32 weeks 
gestation,  
2 years 
postpartum 
Mental 
health 
Nutrition 
PAE 
Stress 
Age Maternal age at 
pregnancy 
 <20, 20-29, 30+ 
years 
Pregnancy 
baseline sample 
data 
Smoking 
Drug use Prenatal illicit 
drug usea 
Yes, no 8 weeks 
gestation & 8 
weeks 
postpartum 
Nutrition 
Genotype 
(maternal) 
Maternal 
rs1229984 
genotype  
(≥ 1 rare allele) 
Yes, no Not applicable PAE 
Marital status Marital status Not married, 
married 
8 weeks 
gestation 
Social 
support 
Maternal 
FASD 
Maternal 
grandmother 
had alcoholismb 
Yes, no 12 weeks 
gestation 
Mental 
health 
Mental 
health 
Prenatal anxietya  Score ≥9 on CCEI, 
score <9 on CCEI 
18 & 32 weeks 
gestation 
Nutrition 
PAE 
Smoking 
Stress  Prenatal 
depressiona 
Score ≥13 on EPDS, 
Score <13 on EPDS 
18 & 32 weeks 
gestation 
Patterns of 
maternal 
prenatal 
alcohol 
consumption 
Alcohol 
dose/frequency 
during 
pregnancya 
 
Binge drinking 
during 
pregnancya 
<1 glass per week, 
1-6 glasses per 
week, 
7+ glasses per 
week 
 
Yes/no 
18 & 32 weeks 
gestation,  
8 weeks 
postpartum 
Nutrition 
Pre-
pregnancy 
alcohol use 
Pre-pregnancy 
alcohol use 
≤ 1 - 2 glasses per 
day, 3+ glasses per 
day 
18 weeks 
gestation 
Nutrition 
PAE 
Religion Maternal religion None, Christian, 
other 
12 weeks 
gestation 
Social 
support 
 Chapter 6 
 
183 
DAG node 
(confounder) 
ALSPAC 
variable(s) 
Categories Time point of 
measurement 
Risk factor 
model(s) 
that 
included 
this variable 
as a 
confounder 
Risky 
behaviour 
Mother 
considers herself 
to be impulsivec  
Doesn’t apply, 
applies a bit, 
moderately/certai
nly applies. 
9 years 
postpartum 
Nutrition 
PAE 
Smoking 
Stress 
Smoking Prenatal 
smokinga  
Yes, no 32 weeks 
gestation & 8 
weeks 
postpartum 
Nutrition 
 
Socioeconom
ic status (SES) 
Maternal 
education 
 
Paternal 
education 
CSE, vocational, O 
Level, A Level, 
degree. 
32 weeks 
gestation 
All 
 Maternal social 
class 
 
Paternal social 
class 
Professional, 
managerial/technic
al, skilled non-
manual, skilled 
manual, partly 
skilled, unskilled. 
32 weeks 
gestation 
 
 Home ownership 
status 
Mortgaged/owned
, council/housing 
association, rented 
[private], other. 
8 weeks 
gestation 
 
Stress Prenatal stressa Continuous 
(weighted life 
events score)  
18 weeks 
gestation & 8 
weeks 
postpartum 
Nutrition 
PAE 
Smoking 
Support Prenatal social 
support scorea 
Continuous 12 weeks 
gestation 
Mental 
health 
Stress 
Unplanned Unplanned 
pregnancy 
Yes, no 18 weeks 
gestation 
Nutrition 
PAE 
Smoking 
Abbreviations: CCEI, Crown-Crisp Experiential Index; CSE, Certificate of Secondary 
Education; EPDS, Edinburgh Postnatal Depression Scale. 
a Variable is also an exposure of interest in other multivariable models. 
b Proxy for maternal FASD. 
c Proxy for ‘risky behaviour’. 
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Figure 19: DAGitty output depicting which confounding variables should be included in the multivariable statistical model to minimise bias in the estimate of the total casual effect 
of prenatal smoking on FASD classification (i.e. the minimal sufficient adjustment set). Hypothesised causal pathways are depicted in green. 
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4.5 Statistical analyses 
All statistical analyses were conducted in Stata 14.2.155 
4.5.1 Missing data 
As described in Chapter 4, missing data can lead to bias and imprecision in 
epidemiological analyses. To evaluate the impact of missing data for the risk factor 
analyses in this chapter, I used the misstable command in Stata 14.2155 and created 
a flow chart to describe the frequency of missing data. To investigate whether data 
were missing completely at random (MCAR), I compared the distributions of 
sociodemographic, exposure and outcome data among participants who had 
complete versus incomplete data for multivariable risk factor analyses.  
4.5.2 Participant characteristics 
I calculated descriptive statistics to summarise participant characteristics, based on 
multiply imputed data. I described categorical variables using percentages with 
95% confidence intervals and normally distributed continuous variables using 
means and standard deviations. Confidence intervals and pooled estimates were 
calculated using Rubin’s combination rules.256 
4.5.3 Regression analyses 
I used logistic regression models to derive odds ratios to quantify the strength of 
the association between hypothesised causal risk factors and FASD. Westreich and 
colleagues coined the term the ‘table 2 fallacy’ to describe the issues that arise 
from interpreting multiple exposure effect estimates from the output of a single 
statistical model.508 These include the inappropriate control of variables that lie on 
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mediating pathways, which can lead to biased estimates of the total causal effect 
for one or more of the variables of interest. To overcome these issues, I fitted 
separate regression models for each exposure. 
4.5.4 Population attributable fractions 
While odds ratios are useful for indicating the strength of the relationship between 
a candidate risk factor and FASD, they are less informative for predicting the impact 
of public health interventions.510 To investigate the impact of potential 
interventions on the proportion of children affected by FASD, I calculated 
population attributable fractions (PAFs) using the punaf package for Stata,511 
adapted for use with multiply imputed data.512  
PAFs are calculated as: 
Prevalence(*+,-) − Prevalence(*+,-	|	23	45637894)Prevalence(*+,-)  
In this context, PAFs indicate the proportion of FASD that might be prevented in a 
counterfactual scenario where the exposure has been altered. They provide an 
estimate of the public health impact of intervening upon an exposure, based on the 
assumption that the association between this exposure and FASD is causal. For 
example, for a hypothesised binary risk factor, such as prenatal smoking, the PAF 
indicates the proportion of FASD that would be prevented if no mothers smoked 
during pregnancy and all other factors remained as they were. Since PAFs depend 
on the prevalence of the exposure, as well as the strength of the association 
between the exposure and the outcome, exposures that have the largest 
association with FASD (odds ratio) will not necessarily have the largest PAF. 
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5 Results 
5.1 Missing data 
Appendix 16 presents a flow diagram that shows the number of participants at 
each stage of this study. There were 15,730 consented children in the ALSPAC 
sample. After applying the pre-specified inclusion criteria, 9,135 children were 
eligible for the risk factor analyses. Missing data led to significant attrition in the 
complete case sample. 9,026 eligible participants were excluded from one or more 
of the risk factor analysis models due to missing data on exposure, confounding 
and/or outcome variables. Appendix 9 provides a full summary of the proportion of 
missing data for key variables. 
Children with incomplete data differed from those with complete data on a range 
of characteristics, suggesting that data were not MCAR (full details provided in 
Appendix 17). Compared to children with complete data, children with incomplete 
data were more likely to have been exposed to prenatal binge drinking (47% versus 
34%), smoking (28% versus 13%) and illicit substance use (4% versus 2%). Mothers 
of children with incomplete data were more likely to have prenatal depression 
(21% versus 14%), prenatal anxiety (24% versus 18%), and were less likely to have 
taken prenatal vitamin supplements (45% versus 49% for iron; 20% versus 22% for 
folic acid). Children with incomplete data were more likely to meet criteria for FASD 
than those with complete data (13% versus 9%). Compared to mothers of children 
with complete data, mothers of children with incomplete data were younger (41% 
versus 51% were aged 30 years or over at delivery), were more likely to live in 
council housing (14% versus 3%) and were less likely to have a professional 
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occupation (12% versus 21%). This pattern was consistent across all indicators of 
socioeconomic status.  
To address the issues introduced by missing data (substantial reduction in sample 
size and potential bias due to differential loss to follow-up for exposures and 
outcome), I used multiple imputation to account for missing values for exposure, 
confounder and outcome variables, resulting in a restored sample size of 9,135 for 
all risk factor analyses. The multiple imputation method has been described 
previously in Chapter 4 and the imputation model specification is presented in 
Appendix 9.  
5.2 Sample characteristics 
Table 13 describes the sociodemographic characteristics of participants included in 
the main risk factor analyses, based on multiply imputed data. In this sample of 
children, who had all been exposed to alcohol prenatally, 20.3% met criteria for 
FASD. Compared to children without FASD, children with FASD were more likely to 
be male (FASD 66%; not FASD 48%), born to mothers of younger age (mothers aged 
30 years or over at delivery: FASD 33%; not FASD 43%), and to be of lower 
socioeconomic status. For example, children with FASD were more likely than those 
without FASD to live in council housing (FASD 26%; not FASD 11%), and to have 
mothers with a less skilled occupation (partly skilled/unskilled occupation: FASD 
21%; not FASD 11%).
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Table 13: Participant sociodemographic characteristics, based on multiply imputed data. 
 Total sample 
N = 9,135 
% (95% CI) 
Not FASDa 
 
% (95% CI) 
FASDa 
 
% (95% CI) 
FASD status - 79.7 (78.7 - 80.8) 20.3 (19.2 - 21.3) 
Child gender    
Female 48.5 (47.5 - 49.6) 52.2 (51.0 - 53.4) 34.0 (31.4 - 36.6) 
Male 51.5 (50.4 - 52.5) 47.8 (46.6 - 49.0) 66.0 (63.4 - 68.6) 
Maternal ethnicity    
White 98.0 (97.7 - 98.4) 98.2 (97.9 - 98.5) 97.4 (96.4 - 98.3) 
Non-White 2.0 (1.6 - 2.3) 1.8 (1.5 - 2.1) 2.6 (1.7 - 3.6) 
Maternal age at pregnancy (years) 
<20 3.7 (3.3 - 4.1) 3.1 (2.6 - 3.5) 6.1 (4.7 - 7.5) 
20-29 55.3 (54.3 - 56.4) 53.9 (52.8 - 55.1) 60.9 (58.5 - 63.3) 
30+ 41.0 (40.0 - 42.0) 43.0 (41.8 - 44.1) 33.0 (30.7 - 35.3) 
Home ownership    
Mortgaged/owned 75.2 (74.3 - 76.1) 79.1 (78.0 - 80.1) 59.8 (57.0 - 62.6) 
Council/housing association 14.0 (13.3 - 14.8) 10.9 (10.1 - 11.7) 26.4 (23.8 - 28.9) 
Rented (private) 7.3 (6.8 - 7.9) 6.8 (6.1 - 7.4) 9.7 (8.0 - 11.4) 
Other 3.5 (3.1 - 3.8) 3.3 (2.8 - 3.7) 4.1 (3.0 - 5.3) 
Maternal highest educational qualification 
CSE 18.5 (17.6 - 19.3) 15.2 (14.3 - 16.1) 31.2 (28.8 - 33.7) 
Vocational 9.5 (8.8 - 10.1) 8.9 (8.2 - 9.6) 11.7 (9.9 - 13.5) 
O level 34.2 (33.1 - 35.2) 34.8 (33.7 - 36.0) 31.5 (28.8 - 34.2) 
A level 23.8 (22.9 - 24.7) 25.2 (24.2 - 26.3) 18.1 (16.0 - 20.2) 
Degree 14.1 (13.4 - 14.8) 15.8 (14.9 - 16.6) 7.5 (6.0 - 9.0) 
Maternal social class    
Professional 5.7 (5.2 - 6.2) 6.6 (6.0 - 7.2) 2.3 (1.4 - 3.1) 
Managerial/technical 30.9 (29.8 - 31.9) 32.8 (31.6 - 33.9) 23.4 (21.1 - 25.7) 
Skilled non-manual 42.1 (40.9 - 43.2) 42.0 (40.7 - 43.2) 42.5 (39.5 - 45.4) 
Skilled manual 8.0 (7.3 - 8.7) 7.4 (6.6 - 8.1) 10.5 (8.7 - 12.3) 
Partly skilled/unskilled 13.4 (12.6 - 14.2) 11.3 (10.5 - 12.2) 21.3 (18.9 - 23.8) 
Marital status    
Not married 25.3 (24.4 - 26.2) 22.6 (21.6 - 23.7) 35.7 (33.2 - 38.2) 
Married 74.7 (73.8 - 75.6) 77.4 (76.3 - 78.4) 64.3 (61.8 - 66.8) 
a Total sample size for multiply imputed data = 9,135. The number of participants with and 
without FASD varies for each imputation set. 
Abbreviations: CI, confidence interval; CSE, Certificate of Secondary Education; FASD, fetal 
alcohol spectrum disorder; N, sample size. 
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5.3 Regression results  
Investigation of the output from multiple imputation diagnostics indicated that 
imputed values were plausible, based on the comparison of observed, imputed and 
completed data distributions. For reasons of increased precision and bias 
reduction, the following sections will present the results for analyses with multiply 
imputed data only. 
5.3.1 Prenatal substance use 
Table 14 presents unadjusted and adjusted odds ratios for FASD for the prenatal 
substance exposure variables.  
5.3.1.1 Patterns of prenatal alcohol exposure (PAE) 
There was no clear evidence of a dose-response relationship between the level of 
alcohol consumed among women who drank while pregnant and FASD. Point 
estimates, based on categorical data, provided weak evidence of a potential J-
shaped relationship between the number of drinks per week and FASD (see Figure 
20 and Table 14). Confidence intervals were wide and all odds ratios included the 
null value. Tests of the linear and non-linear (quadratic)513 relationship between 
continuous measures of PAE and FASD showed no evidence of an association 
(adjusted odds ratio [aOR] for linear relationship per 1 unit increase in measures of 
alcohol at 8 weeks gestation 1.00 95% CI 1.00 - 1.02; and 32 weeks gestation aOR 
1.01 95% CI 0.99 - 1.02; aOR for quadratic relationship at 8 and 32 weeks gestation 
both 1.00 95% CI 0.99 - 1.00). Graphs of the unadjusted association between 
continuous measures of PAE and FASD are presented in Appendix 18. 
 Chapter 6 
 
191 
Among women who drank while pregnant, there was some evidence that binge 
drinking increased the odds of FASD. Unadjusted models showed an increase in the 
odds of FASD following binge drinking, compared to not binge drinking (OR 1.52 
95% CI 1.33 - 1.74), however this effect was significantly attenuated in adjusted 
models (aOR 1.10 95% CI 0.95 - 1.28).  
Figure 20: FASD prevalence with 95% confidence intervals by glasses of alcohol per week during pregnancy. 
Alcohol use categories indicate maximum consumption at any point during pregnancy. 
 
5.3.1.2 Prenatal smoking 
Mothers of children with FASD were more likely to have smoked while pregnant. 
Among children with PAE, prenatal smoking increased the odds of FASD by 19% 
(aOR 1.19 95% CI 1.03 - 1.36).  
5.3.1.3 Prenatal illicit drug use 
Mothers of children with FASD were more likely to report illicit substance use than 
those without, however effects were significantly attenuated after controlling for 
confounders and confidence intervals were wide due to the low prevalence of 
prenatal drug use (aOR 1.05 95% CI 0.73 - 1.49). 
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Table 14: Descriptive statistics and odds ratios for FASD among children with PAE as a function of different patterns of prenatal substance use using multiply imputed data. 
 Total sample 
% (95% CI)  
N = 9,135 
Not FASD 
% (95% CI) 
FASD 
% (95% CI) 
Unadjusted odds ratio 
(95% CI) 
Adjusted odds ratio 
(95% CI) 
Prenatal alcohol exposure (maximum weekly consumption during pregnancy; categorical variable)a 
< 1 glass/week 63.5 (62.5 - 64.5) 63.2 (62.0 - 64.4) 64.6 (62.1 - 67.1) Reference Reference 
1-6 glasses/week 31.8 (30.8 - 32.7) 32.3 (31.2 - 33.5) 29.6 (27.1 - 32.1) 0.89 (0.78 - 1.03) 0.96 (0.83 - 1.11) 
7+ glasses/week 4.8 (4.3 - 5.2) 4.5 (4.0 - 5.0) 5.8 (4.6 - 7.0) 1.27 (0.98 - 1.64) 1.20 (0.90 - 1.61) 
Weekly prenatal alcohol exposurea 
No 63.5 (62.4 - 64.5) 63.1 (62.0 - 64.4) 64.6 (62.1 - 67.1) Reference Reference 
Yes 36.5 (35.5 - 37.5) 36.8 (35.6 - 38.0) 35.4 (32.9 - 37.9) 0.94 (0.83 - 1.07) 0.99 (0.86 - 1.13) 
Prenatal binge drinkinga 
No 64.3 (63.2 - 65.5) 66.3 (65.0 - 67.6) 56.5 (53.7 - 59.3) Reference Reference 
Yes 35.7 (34.5 - 36.8) 33.7 (32.4 - 35.0) 43.5 (40.7 - 46.3) 1.52 (1.33 - 1.74) 1.10 (0.95 - 1.28) 
Prenatal smokingb 
No 71.8 (70.9 - 72.7) 74.9 (73.8 - 75.9) 59.9 (57.4 - 62.3) Reference Reference 
Yes 28.2 (27.3 - 29.1) 25.2 (24.1 - 26.2) 40.1 (37.7 - 42.6) 1.99 (1.77 - 2.25) 1.19 (1.03 - 1.36) 
Prenatal illicit drug useb 
No 96.2 (95.8 - 96.6) 96.6 (96.1 - 97.1) 94.6 (93.3 - 95.8) Reference Reference 
Yes 3.8 (3.4 - 4.2) 3.4 (2.9 - 3.9) 5.5 (4.2 - 6.7) 1.63 (1.20 - 2.22) 1.05 (0.73 - 1.49) 
a Adjusted for physical, sexual or domestic abuse towards the mother, maternal age during pregnancy, maternal ADH genotype (rs1229984), prenatal mental health 
(anxiety and depression), pre-pregnancy alcohol consumption (categorical glasses per day), maternal impulsivity, maternal social class, paternal social class, 
maternal education (highest qualification), paternal education (highest qualification), home ownership status, prenatal stress (weighted life events), unplanned 
pregnancy. 
b Adjusted for maternal age during pregnancy, prenatal mental health (anxiety and depression), maternal impulsivity, maternal social class, paternal social class, 
maternal education (highest qualification), paternal education (highest qualification), home ownership status, prenatal stress (weighted life events), unplanned 
pregnancy. 
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5.3.2 Prenatal nutrition 
Results for the effect of prenatal nutrition on FASD are presented in Table 15, 
showing first the results for associations with prenatal vitamin supplements and 
then with daily nutrient intake. Among children with PAE, the odds of FASD were 
lower for those who took folic acid supplements (aOR 0.82 95% CI 0.69 - 0.97). 
There was also weak evidence of a protective effect of iron supplementation (aOR 
0.90 95% CI 0.80 - 1.02). Most point estimates indicated a protective effect of 
meeting the recommended daily intake for each nutrient during pregnancy. 
However, following adjustment for potential confounders, all confidence intervals 
included the null value. 
5.3.3 Prenatal mental health 
Table 16 presents odds ratios for the effect of prenatal mental health symptoms on 
FASD. Twenty-one percent of mothers who drank alcohol during pregnancy 
reported high levels of prenatal depression symptoms and 24% reported high levels 
of prenatal anxiety. Prenatal anxiety and depression increased the odds of FASD by 
30% (aOR 1.30 95% CI 1.13 - 1.50) and 32% (aOR 1.32 95% CI 1.12 - 1.55), 
respectively.  
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Table 15 (continued overleaf): Descriptive statistics and odds ratios for FASD among children with prenatal alcohol exposure as a function of prenatal nutrition using multiply 
imputed data. 
 Total sample 
% (95% CI) 
N = 9,135 
Not FASD 
% (95% CI) 
FASD 
% (95% CI) 
Unadjusted odds 
ratio 
(95% CI) 
Adjusted odds ratioa 
(95% CI) 
Prenatal vitamin supplement useb  
Multivitamin supplements 20.7 (19.8 - 21.5) 21.0 (20.0 - 21.9) 19.5 (17.5 - 21.6) 0.92 (0.79 - 1.06) 0.97 (0.83 - 1.14) 
Calcium supplements 5.8 (5.3 - 6.2) 5.6 (5.0 - 6.1) 6.5 (5.2 - 7.7) 1.17 (0.92 - 1.50) 1.20 (0.92 - 1.58) 
Folic acid supplements 19.4 (18.6 - 20.2) 20.5 (19.5 - 21.5) 15.2 (13.4 - 17.0) 0.70 (0.59 - 0.81) 0.82 (0.69 - 0.97) 
Iron supplements 44.5 (43.5 - 45.5) 44.8 (43.6 - 46.0) 43.3 (40.8 - 45.9) 0.94 (0.84 - 1.06) 0.90 (0.80 - 1.02) 
Zinc supplements 2.1 (1.8 - 2.4) 2.2 (1.8 - 2.5) 1.7 (1.0 - 2.5) 0.79 (0.49 - 1.29) 0.87 (0.52 - 1.45) 
Daily recommended nutrient intake met (RNI)c  
Calories (2303 - 2375 kcal)d 10.0 (9.4 - 10.7) 9.7 (8.9 - 10.5) 11.3 (9.5 - 13.2) 1.19 (0.96 - 1.48) 1.04 (0.83 - 1.32) 
Calcium (700 mg) 81.3 (80.4 - 82.2) 81.8 (80.8 - 82.8) 79.2 (76.9 - 81.6) 0.85 (0.72 - 1.00) 0.97 (0.82 - 1.16) 
Folate (300 µg) 21.1 (20.3 - 22.0) 21.6 (20.6 - 22.6) 19.4 (17.2 - 21.6) 0.88 (0.75 - 1.03) 1.02 (0.86 - 1.20) 
Iodine (140 µg) 56.2 (55.1 - 57.3) 56.8 (55.5 - 58.1) 53.7 (51.2 - 56.3) 0.88 (0.78 - 1.00) 0.98 (0.86 - 1.11) 
Iron (14.8 mg) 9.2 (8.6 - 9.9) 9.4 (8.7 - 10.2) 8.5 (6.9 - 10.1) 0.89 (0.71 - 1.12) 0.96 (0.75 - 1.22) 
Magnesium (270 mg) 36.9 (35.9 - 38.0) 38.2 (36.9 - 39.4) 32.0 (29.3 - 34.8) 0.76 (0.66 - 0.88) 0.97 (0.83 - 1.13) 
Niacin (13 mg) 72.3 (71.3 - 73.2) 73.9 (72.9 - 75.0) 65.8 (63.4 - 68.2) 0.68 (0.60 - 0.77) 0.96 (0.84 - 1.10) 
Omega-3 (250 mg)e 18.9 (18.1 - 19.8) 19.9 (18.9 - 20.9) 15.2 (13.2 - 17.2) 0.72 (0.61 - 0.86) 0.93 (0.77 - 1.12) 
Phosphorous (550 mg) 98.5 (98.2 - 98.8) 98.8 (98.4 - 99.1) 97.6 (96.7 - 98.5) 0.52 (0.31 - 0.85) 0.86 (0.50 - 1.49) 
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 Total sample 
% (95% CI) 
N = 9,135 
Not FASD 
% (95% CI) 
FASD 
% (95% CI) 
Unadjusted odds 
ratio 
(95% CI) 
Adjusted odds ratioa 
(95% CI) 
Potassium (3500 mg) 20.0 (19.1 - 20.8) 19.6 (18.6 - 20.6) 21.4 (19.1 - 23.6) 1.11 (0.95 - 1.30) 1.04 (0.89 - 1.22) 
Riboflavin (1.4 mg) 71.4 (70.4 - 72.4) 72.4 (71.3 - 73.5) 67.4 (65.1 - 69.8) 0.79 (0.70 - 0.89) 0.91 (0.80 - 1.04) 
Selenium (60 µg) 63.4 (62.3 - 64.4) 64.6 (63.3 - 65.8) 58.7 (55.7 - 61.6) 0.78 (0.68 - 0.90) 1.01 (0.86 - 1.17) 
Vitamin B12 (1.5 µg) 97.7 (97.4 - 98.0) 97.9 (97.5 - 98.2) 97.1 (96.0 - 98.1) 0.73 (0.47 - 1.12) 1.06 (0.66 - 1.69) 
Vitamin B6 (1.2 mg) 91.5 (90.9 - 92.1) 92.5 (91.8 - 93.1) 87.7 (85.9 - 89.5) 0.58 (0.47 - 0.70) 0.81 (0.65 - 1.01) 
Vitamin C (50 mg) 79.5 (78.6 - 80.4) 81.5 (80.5 - 82.6) 71.6 (69.3 - 73.9) 0.57 (0.50 - 0.66) 0.86 (0.74 - 1.01) 
Vitamin E (15 mg) 9.0 (8.3 - 9.6) 9.3 (8.6 - 10.0) 7.7 (6.3 - 9.1) 0.81 (0.66 - 1.01) 0.95 (0.77 - 1.18) 
Zinc (7 mg) 69.5 (68.5 - 70.5) 70.8 (69.7 - 72.0) 64.3 (61.7 - 66.9) 0.74 (0.65 - 0.84) 0.97 (0.84 - 1.11) 
a Adjusted for physical, sexual or domestic abuse towards the mother, prenatal illicit drug use, prenatal mental health (anxiety and depression), prenatal 
alcohol consumption (categorical glasses per week and binge), pre-pregnancy alcohol consumption (categorical glasses per day), maternal impulsivity, 
maternal social class, paternal social class, maternal education (highest qualification), paternal education (highest qualification), home ownership status, 
prenatal smoking, prenatal stress (life events), unplanned pregnancy. 
b Reference category is not taking the specified prenatal vitamin supplement. 
c Reference category is not meeting the recommended daily level for the nutrient of interest. 
d RNI 2375 kcal for pregnant women ≤ age 35 and 2303 kcal for pregnant women > age 35 years. 
e RDA from Weichselbaum502 and European Food Safety Authority501 250 mg/day of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) plus 100 to 
200 mg preformed DHA for women during pregnancy or lactation. ALSPAC reports nutrients from fish intake only, so threshold set as 250mg/day for this 
analysis. 
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5.3.4 Prenatal stress and social support 
Results for the effect of specific prenatal stressful life events and social support on FASD are 
presented in Table 17. Unadjusted odds ratios suggested a 4% increase in the odds of FASD 
for each additional prenatal life event among mothers who drank while pregnant (OR 1.04 
95% CI 1.03 - 1.05); however, this effect was attenuated in adjusted estimates (aOR 1.01 
95% CI 1.00 - 1.03). Mothers who reported having major financial problems in pregnancy 
had a 24% increase in the odds of having a child with FASD following prenatal alcohol use 
(aOR 1.24 95% CI 1.05 - 1.46), increasing to 39% among those who reported that they had 
been very affected by these financial problems (aOR 1.39 95% CI 1.11 - 1.75). In general, 
across most of the categories, mothers who reported having been very affected by a 
prenatal life event were more likely to have a child with FASD, compared to those who did 
not report being very affected. However, with the exception of financial problems, effect 
estimates were inconclusive following adjustment for potential confounders.  
Social support had a protective effect on the odds of FASD among children with PAE (aOR 
per 5-point increase in prenatal social support score 0.84 (95% CI 0.79 - 0.89).
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Table 16: Descriptive statistics and odds ratios for FASD among children with prenatal alcohol exposure as a function of prenatal mental health using multiply imputed data. 
 Total sample 
% (95% CI) 
N = 9,135 
Not FASD 
% (95% CI) 
FASD 
% (95% CI) 
Unadjusted odds 
ratio 
(95% CI) 
Adjusted odds 
ratioa 
(95% CI) 
Prenatal anxiety      
No 76.0 (75.1 -76.9) 78.1 (77.1 - 79.1) 67.7 (65.2 - 70.1) Reference Reference 
Yes 24.0 (23.1 - 24.9) 21.9 (20.9 - 22.9) 32.3 (29.9 - 34.8) 1.70 (1.49 - 1.94) 1.30 (1.13 - 1.50) 
Prenatal depression      
No 79.2 (78.4 - 80.1) 81.5 (80.5 - 82.4) 70.5 (68.0 - 73.0) Reference Reference 
Yes 20.8 (19.9 - 21.6) 18.5 (17.6 - 19.5) 29.5 (27.0 - 32.0) 1.84 (1.59 - 2.12) 1.32 (1.12 - 1.55) 
a Adjusted for physical, sexual or domestic abuse towards the mother, maternal grandmother history of alcoholism (as a proxy for maternal FASD), maternal 
social class, paternal social class, maternal education (highest qualification), paternal education (highest qualification), home ownership status, social support 
score.  
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Table 17: Descriptive statistics and odds ratios for FASD among children with prenatal alcohol exposure as a function of prenatal stressful life events and social support using 
multiply imputed data. 
 Total sample 
% (95% CI) 
N = 9,135 
Not FASD 
% (95% CI) 
 
FASD 
% (95% CI) 
 
Unadjusted odds 
ratio 
(95% CI) 
Adjusted odds 
ratio 
(95% CI) 
Stressful life events during pregnancya  
Relationship difficulties (any) 66.5 (65.5 - 67.5) 65.7 (64.6 - 66.9) 69.4 (67.1 - 71.6) 1.18 (1.05 - 1.33) 0.90 (0.78 - 1.03) 
Relationship difficulties (very affected) 13.2 (12.5 - 13.9) 11.8 (11.0 - 12.6) 18.4 (16.2 - 20.5) 1.67 (1.40 - 2.00) 1.10 (0.89 - 1.35) 
Bereavement (any) 22.2 (21.3 - 23.1) 22.4 (21.4 - 23.4) 21.6 (19.5 - 23.6) 0.95 (0.83 - 1.09) 0.98 (0.84 - 1.13) 
Bereavement (very affected) 5.4 (4.9 - 5.8) 5.3 (4.8 - 5.8) 5.6 (4.5 - 6.8) 1.06 (0.83 - 1.36) 0.99 (0.76 - 1.29) 
Major financial problems (any) 19.9 (19.1 - 20.7) 18.1 (17.1 - 19.0) 27.1 (24.7 - 29.6) 1.69 (1.45 - 1.96) 1.24 (1.05 - 1.46) 
Major financial problems (very affected) 7.2 (6.7 - 7.8) 6.2 (5.6 - 6.8) 11.3 (9.6 - 13.0) 1.92 (1.55 - 2.37) 1.39 (1.11 - 1.75) 
Moved house 19.4 (18.6 - 20.2) 18.7 (17.7 - 19.7) 22.2 (19.8 -24.6) 1.24 (1.05 - 1.46) 0.99 (0.82 - 1.18) 
Moved house (very affected) 4.9 (4.4 - 5.3) 4.8 (4.2 - 5.3) 5.4 (4.2 - 6.7) 1.15 (0.86 - 1.53) 0.95 (0.69 - 1.31) 
Accident or illness (any) 16.9 (16.2 - 17.7) 16.6 (15.7 - 17.5) 18.4 (16.4 - 20.4) 1.13 (0.97 - 1.32) 1.07 (0.91 - 1.26) 
Accident or illness (very affected) 4.6 (4.2 - 5.0) 4.4 (3.9 - 4.9) 5.4 (4.3 - 6.5) 1.25 (0.97 - 1.61) 1.17 (0.89 - 1.54) 
Social support during pregnancyb Mean (95% CI) Mean (95% CI) Mean (95% CI)   
Per 5-point increase in support score  19.4 (19.3 - 19.5) 19.7 (19.6 - 19.9) 18.1 (17.8 - 18.4) 0.73 (0.68 - 0.77) 0.84 (0.79 - 0.89) 
a Adjusted for physical, sexual or domestic abuse towards the mother, prenatal mental health (anxiety and depression), maternal impulsivity, maternal social 
class, paternal social class, maternal education (highest qualification), paternal education (highest qualification), home ownership status, social support score. 
Reference category for categorical variables is not having experienced the specified life event. 
b Adjusted for marital status, religion, maternal social class, paternal social class, maternal education (highest qualification), paternal education (highest 
qualification), home ownership status. 
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5.4 Population attributable fractions 
I calculated PAFs for risk factors that were statistically significant in the 
multivariable logistic regression models for FASD. Results are summarised in Table 
18.  
Table 18: Population attributable fractions for prenatal exposures and FASD among children with PAE  
Prenatal factor Population attributable fraction % (95% CI)a 
Smoking 17 (14 - 20) 
Folic acid supplements 22 (13 - 30) 
Anxiety 11 (8 - 14) 
Depression 11 (8 - 14) 
Financial problems (any) 9 (6 - 12) 
Financial problems (very affected) 4 (3 - 6) 
Social support (maximum score of 30) 45 (38 - 52) 
Social support (score of 25) 28 (22 - 33) 
a Counterfactual scenarios are as follows: PAF for smoking represents the proportion of FASD 
cases that would be prevented if no mothers smoked during pregnancy; PAF for vitamin 
supplements represents the proportion of FASD cases that would be prevented if all mothers 
took the supplement; PAFs for prenatal depression and anxiety represent the proportion of FASD 
cases that would be prevented if no mothers exceeded the threshold for significant prenatal 
anxiety or depression symptoms; PAF for financial problems (any) represents the proportion of 
FASD cases that would be prevented if none of the mothers had experienced major financial 
problems during pregnancy; PAF for financial problems (very affected) represents the proportion 
of FASD cases that would be prevented if no mother was ‘very affected’ by major financial 
problems during pregnancy; PAF for social support represents the proportion of FASD cases that 
would be prevented if all mothers had maximum social support (equivalent to a score of 30 on 
the prenatal social support questionnaire). This method follows the approach of the World Health 
Organisation who assign PAFs based on the maximum (or minimum) theoretical possibility for 
continuous exposures.514 I have also presented a more conservative scenario where the mean 
social support score is 25. The distribution of all factors, other than the exposure of interest, 
remains constant when estimating PAFs. 
 
Assuming that the relationships between the hypothesised risk factors in this study 
were causal, and given the exposure distributions in this sample, population 
attributable fractions indicated that: interventions for smoking cessation could 
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reduce the proportion of FASD among children with PAE by approximately 17% 
(95% CI 14% - 20%), folic acid supplementation by 22% (95% CI 13% - 30%) and 
interventions that alleviate prenatal anxiety and depression by 11% (95% CI 8% - 
14%). Social support interventions showed the greatest potential for FASD 
prevention. PAFs indicated that 45% of FASD cases may be prevented if prenatal 
social support was maximal (equivalent to a total score of 30 on the social support 
questionnaire). Based on a more conservative scenario, where social support is 
increased to a score of 25 (approximately 5 points above the sample mean), an 
estimated 28% of FASD cases could be prevented. 
6 Discussion 
6.1 Main results 
This study sought to investigate risk and protective factors for FASD among children 
from a general population sample who were exposed to alcohol prenatally. 
Analyses of the effects of different drinking patterns were inconclusive, as all 
confidence intervals included the null value. However, results suggested that 
several factors increased the odds of FASD following PAE. In order of the 
magnitude of association, these were: being very affected by major financial 
problems during pregnancy (aOR 1.39; 95% CI 1.11 - 1.75), prenatal depression 
(aOR 1.32 95% CI 1.12 - 1.55), prenatal anxiety (aOR 1.30 95% CI 1.13 - 1.50) and 
prenatal smoking (aOR 1.19 95% CI 1.03 - 1.36). Protective factors were: increased 
prenatal social support (aOR per 5-point increase in prenatal social support score 
0.84 95% CI 0.79 - 0.89) and folic acid supplementation (aOR 0.82 95% CI 0.69 - 
0.97).  
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Population attributable fractions (PAFs), based on the exposure distributions in this 
sample, indicated that social support interventions had the greatest potential to 
reduce FASD prevalence among children with PAE, with an estimated 45% 
reduction (95% CI 38% - 52%) for an increase to the maximum social support score 
and 28% reduction (95% CI 22% - 33% for a 5-point increase in social support 
score). Prenatal folic acid supplements had the next largest expected impact on 
FASD prevention (estimated reduction 22%; 95% CI 13% - 30%), followed by 
smoking cessation (estimated reduction 17%; 95% CI 14% - 20%), mental health 
interventions (estimated reduction 11%; 95% CI 8% - 14%), and interventions 
aimed at reducing prenatal financial problems (estimated reduction 4%; 95% CI 3% 
- 6% for those ‘very affected’ by financial problems to 9% reduction; 95% CI 6% - 
12% for those who experience any major financial problem). 
6.2 Comparison with the existing literature 
I provided a detailed summary of the existing literature on FASD risk factors in 
Chapter 5. In this section, I highlight how some of the key results in this chapter 
compare to the existing research and indicate which are the most novel findings 
from this study.  
6.2.1 Patterns of prenatal alcohol exposure (PAE) 
First, as described previously, the existing literature has provided inconsistent 
evidence on the relationship between PAE and developmental outcomes, 
particularly when exposure is in the low to moderate range.20-22 My analysis does 
not provide clear evidence on the effects of different levels of PAE on the risk of 
FASD. There was no evidence of a linear or non-linear association between 
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continuous measures of prenatal alcohol use and FASD status. Categorical 
measures of prenatal alcohol use (glasses of alcohol per week) produced weak 
evidence of a J-shaped relationship between PAE and FASD. Similar relationships 
have been found in other studies of PAE and child outcomes, including the 
Millennium Cohort Study.307 Kelly and colleagues found a J-shaped relationship 
between prenatal alcohol use and behavioural and cognitive outcomes at age 3.14 
Consistent with findings from my analysis, effects in Kelly et al.’s study were 
attenuated following adjustment for confounders, however some effects remained 
statistically significant. Boys with light PAEp were less likely to have conduct and 
hyperactivity problems, and had higher scores on the Bracken School Readiness 
Assessment than those born to abstainers. Studies from the wider alcohol 
literature have also found evidence of a protective effect of low to moderate levels 
of alcohol use and an array of outcomes including: all cause mortality, asthma, 
colorectal cancer, the common cold, coronary heart disease, type 2 diabetes, 
hearing loss and liver cirrhosis.515,516 However, these associations have been 
deemed spurious by some on the grounds that many of these relationships lack a 
plausible biological basis. Furthermore, as described in Chapter 5, patterns of 
alcohol use are highly socially patterned, with light or moderate drinkers typically 
having more favourable circumstances than heavy drinkers and abstainers. 
Consistent with proposals that many of the apparent protective effects of alcohol 
use may be accounted for by methodological shortcomings, the protective effect of 
low-level alcohol use on mortality has been found to disappear after controlling for 
                                                        
p Light drinking was defined as ≤ 1-2 units of alcohol per week or per occasion during pregnancy. 
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abstainer bias (caused by the inclusion of former-drinkers in the abstainer group) 
and study characteristics (including greater confounder adjustment and assessment 
measure quality).515,517 
With regards to prenatal alcohol use, the biological basis for a potential protective 
effect of low to moderate PAE is not well supported. Animal studies have provided 
convincing evidence of alcohol’s status as a teratogen and indicate deleterious 
effects on the developing brain, even at low levels of exposure.23 In their recent 
review of light drinking in pregnancy, Mamluk and colleagues summarised the 
limitations of human studies of PAE.24 They note that the main limitation of 
investigations into the effects of PAE is the risk of bias due to residual confounding. 
Drinking behaviour during pregnancy is strongly associated with socioeconomic 
status, and socioeconomic status is strongly associated with developmental 
outcomes. Although studies typically adjust for a range of indicators of 
socioeconomic status, the potential for uncontrolled confounding remains.24 
Evidence from Mendelian randomisation studies have indicated a detrimental 
effect of PAE on child IQ and educational attainment, even at low levels, and 
support the theory that apparent protective effects are due to residual 
confounding.26,27 
The point estimates that suggested that that heavy and binge-pattern drinking 
increase the odds of FASD are in agreement with the vast majority of research 
findings. Studies in North America and South Africa have consistently found that 
mothers of children with FASD are less likely to reduce their alcohol intake 
following pregnancy recognition and report more binge drinking and more drinks 
 Chapter 6 
 
204 
per week, compared to mothers of children without FASD.89,266,273,274,276-278,325,342 
Studies in Europe have been less consistent. In Italian samples, postnatal drinking 
patterns have been found to be more predictive of FASD than reported prenatal 
drinking.83,345 The authors of these studies note that compared to mothers in the 
South African samples, it was more difficult to engage mothers from Europe in 
“frank and accurate discussion of drinking during the prenatal period.”83(p. 1572) This 
indicates that mothers may underreport their alcohol consumption in the prenatal 
period.  
6.2.2 Prenatal smoking 
Consistent with previous studies,111,266 my analysis showed that FASD was more 
common among children born to mothers who smoked while pregnant. The 
existing literature indicates a synergistic relationship between PAE and smoking on 
perinatal outcomes including preterm labour and birthweight.346 There is a 
plausible biological basis for the combined adverse effects of PAE and prenatal 
smoking on FASD-relevant outcomes. Both are known to disrupt folate metabolism 
and to lead to vasoconstriction of the umbilical cord and placenta, thereby 
contributing to disrupted DNA synthesis, increased hypoxia and prolonged uterine 
exposure to ethanol.8,285,346 
6.2.3 Prenatal stress, mental health and social support 
Results suggesting that prenatal stressful life events, anxiety and depression 
increase the risk of FASD are consistent with wider evidence from human and 
animal studies, which show that offspring exposed to these factors in combination 
with PAE have poorer outcomes than those exposed to either in isolation.286,432,433 
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Stressful life events have been linked to a range of congenital anomalies including 
cleft palate,431 gastroschisis518 and neural tube defects.441 To the best of my 
knowledge this is the first study to demonstrate the impact of stressful life events 
on FASD risk, and further, to indicate that it is the perceived impact, rather than 
simply the occurrence of the event that has the strongest association with FASD. 
Such findings may support the role of a biological stress response in shaping FASD 
risk. Financial problems were associated with a significant increase in the odds of 
FASD. This may indicate that financial problems are particularly stressful for 
mothers, and/or may be an additional marker of social disadvantage, which has 
been strongly associated with FASD.111,266  
Evidence for a protective effect of social support is consistent with previous 
studies, which indicate that social support promotes decreased alcohol 
consumption.449,450 Other studies have found low social support to be associated 
with poorer prenatal mental health and FASD-relevant outcomes including 
decreased birthweight and length,519 thus implicating it as an important target for 
intervention. 
6.2.4 Prenatal nutrition 
As described in Chapter 5, animal studies suggest that nutritional supplementation 
may protect against the risk of FASD-relevant outcomes, such as facial 
abnormalities, adverse behavioural outcomes and growth deficiency.314 Human 
studies of the effects of pre- and postnatal nutritional supplementation among 
children with PAE and FASD have been limited to choline and multivitamin 
supplements and have not provided consistent evidence of benefit.394-396 The 
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results of this analysis suggest that folic acid and iron supplements may warrant 
further investigation as potential candidates for FASD prevention. In rat models, 
iron deficiency has been found to interact with PAE to produce FASD-relevant 
outcomes including neurological anomalies and impaired associative learning.520 
The effect of iron supplementation on FASD has not been investigated in human 
studies. 
Folic acid is crucial for fetal development. It contributes to DNA synthesis and 
protects against neural tube defects.314,521 Animal studies have shown that folic 
acid may be particularly important in alcohol-exposed pregnancies. Ethanol 
disrupts folic acid absorption and folic acid supplementation decreases the risk of 
congenital anomalies and growth restriction following PAE.314  
Unlike the results from the vitamin supplementation analyses, dietary intake 
measures did not indicate protective effects of meeting the recommended daily 
intake for folate. This may be explained by the fact that folic acid does not occur 
naturally in food. It is a synthetic form of a range of molecules that are collectively 
known as folate.376  
6.3 Strengths and limitations 
To the best of my knowledge, this study is the largest to date to investigate risk 
factors for FASD within a population-based birth cohort. The rich dataset provided 
by the ALSPAC study enabled investigation of a comprehensive range of candidate 
risk factors. This study further benefitted from having a transparent and systematic 
framework for confounder selection, based on established principles for causal 
inference.304,522 
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It is important to note that although the application of causal diagrams can 
strengthen causal inference by informing analysis strategies, this approach rests on 
the assumptions of no unmeasured confounding and no measurement bias.302,523 
Furthermore, the causal interpretation of the odds ratios and PAFs that I have 
presented rests on the assumption that the causal pathways that I have proposed 
are correct.  
As described previously, a fundamental limitation of observational studies of 
prenatal exposures is the risk of measurement bias due to the use of self-report 
methods. The ALSPAC sample benefits from repeated prospective measurement of 
many prenatal exposures, however data are still likely to be subject to 
measurement error, particularly for exposures such as smoking, drug and alcohol 
use, which are likely to be underreported due to stigma and social desirability 
bias.60-64 Furthermore, adverse exposures are known to cluster together. Mothers 
who use substances in the prenatal period are more likely to experience a less 
favourable prenatal environment, including greater stress, greater social 
disadvantage and poorer nutrition.524 A key strength of this study was the use of 
the literature synthesis, causal diagram and complimentary multivariable models to 
identify and control for potential confounders. Nevertheless, there is the potential 
for residual confounding due to the multitude of influences on child development 
and imperfect measurement of identified confounders. In particular, I used proxy 
indicators for some of the potential confounders. For example, I used reports that 
the maternal grandmother had alcoholism as a proxy for maternal FASD. This is an 
imperfect proxy, since it is not clear when the reported alcoholism occurred and 
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PAE does not necessarily imply FASD. Furthermore, I used reported maternal 
impulsivity as a partial proxy indicator of a latent variable that I called “risky 
maternal behaviour,” which in turn was proposed to account for the co-occurrence 
of adverse prenatal exposures. This too is an imperfect proxy and the factors that 
influence multiple risk behaviours remain poorly understood and measured. 
Potential misreporting of PAE has the most significant implications for the studies 
in this thesis, as results may be impacted in multiple ways by its misclassification. 
Inaccurate measurement of PAE may have compromised efforts to determine the 
effects of different levels of PAE on the risk of FASD, may have led to 
misclassification of FASD status, and may have resulted in participants with true 
(unreported) PAE having been wrongfully excluded from the eligible sample in this 
study. As described in Chapter 3, FASD status was ascertained using an algorithm, 
which is not equivalent to a gold standard formal diagnosis. Nevertheless, the use 
of a range of prospective measures of PAE at multiple time points is a strength of 
the ALSPAC study and is likely to improve the classification of exposure status and 
developmental functioning, relative to retrospective reporting.  
Multiple imputation methods were used to maximise sample size and to minimise 
the bias caused by missing data. However, some exposures such as prenatal drug 
use, were relatively uncommon in this sample. This led to sparse data in some 
analyses and wide confidence intervals. Confidence intervals included the null 
value for the many of the effect estimates. Due to the large number of factors 
investigated, it is also possible that some of the significant results are a chance 
finding. 
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Finally, the effects of prenatal alcohol use and other exposures are thought to 
differ according to the timing and duration of exposure.13,19 In my analyses it was 
not possible to test for interactions with time due to sparse data in complete case 
analyses and convergence issues in multiple imputation models, due to model 
complexity. Therefore, the risk factor analyses that I presented in this chapter 
represent average effects across the whole of pregnancy. If trimester-specific 
interactions were present, the total causal effect estimates that I have presented in 
the preceding analyses may represent a simplification of the true relationship 
between patterns of PAE and co-occurring exposures. 
6.4 Implications for research and practice 
Since alcohol use in pregnancy is the sole necessary cause of FASD, prevention 
efforts must focus on reducing PAE. Exposure may occur prior to pregnancy 
recognition, and knowledge of the risks of PAE and related guidance is generally 
low.56 The recent revisions to the UK guidance on PAE, which promote abstinence, 
are a welcome contribution to efforts to reduce the burden of FASD, to resolve the 
confusion around guidance, and to bring the public health messaging for PAE in line 
with the majority of international recommendations.48 However, as it is recognised 
that many women may choose to drink some amount of alcohol in pregnancy, and 
others may have alcohol use disorders, including dependence, it is important to 
consider other factors that contribute to FASD risk. Research that increases 
understanding of the factors that influence susceptibility to FASD among children 
with PAE is also important from an aetiological perspective, to improve knowledge 
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of mechanisms of harm, and to support efforts for prevention in populations with 
high levels of PAE, such as the UK.11  
The PAFs that I have presented indicate potential targets for interventions to 
reduce FASD prevalence. However, it is important to highlight that these estimates 
are based on the exposure distributions in this sample, and are not generalisable to 
populations with a different prevalence of exposure.525 Furthermore, when 
considering these potential interventions, is it important to note that these 
statistics simply indicate the expected reduction of FASD under the counterfactual 
scenario in which the exposure has been removed. However, in this context, the 
intervention and corresponding causal effect is poorly defined.526 PAFs do not 
indicate what format of intervention may be effective, or any unanticipated 
adverse effects. For example, although the PAFs suggest that interventions that 
reduce prenatal depression and anxiety could reduce FASD, management of mental 
health conditions in pregnancy requires consultation with experienced clinicians, 
particularly when considering the benefits and risks of pharmacological 
treatment.527  
Intensive peer-support interventions have been shown to be feasible and 
acceptable to women in the UK,528 and may promote pregnancy-related health 
behaviours, such as breastfeeding maintenance.529 Therefore, such interventions 
may also be of interest for FASD prevention. For other exposures, such as prenatal 
smoking, cessation initiatives are already routine in the UK,114 and results from my 
analyses suggest that these initiatives may have particular benefits for alcohol-
exposed pregnancies. Conclusions about whether nutritional supplementation may 
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be protective, and whether stressful life events increase FASD risk are tentative, 
however. Confidence intervals indicated uncertainty in the direction of effect for 
most estimates.  
Nevertheless, since adequate nutrition is vital for optimal fetal development and 
stress is known to adversely affect child outcomes, potential interventions are 
likely to have benefits for the mother and child that extend beyond FASD 
prevention. Nutritional supplementation has been of interest at both the prenatal 
stage, where the focus is to prevent FASD among alcohol-exposed individuals, and 
postnatally, where the focus is to ameliorate the adverse behavioural and cognitive 
effects of PAE. As described in Chapter 5, while animal studies have supported 
nutritional supplementation for FASD, human studies have been inconclusive and 
limited to a small number of supplements (multivitamins and choline). More 
research is required to confirm whether nutritional interventions for FASD are 
effective and, if so, to determine the optimal levels and timing for 
supplementation, and to investigate the combined effect of multiple 
supplements.530  
Studies that evaluate the effect of folic acid supplementation may be an important 
priority for FASD research, given that folic acid is established as an important 
protective factor against neural tube defects,376 and that it is associated with a 
decreased risk of FASD in this study and in controlled animal experiments.314 Since 
observational studies of nutrition in humans may be particularly prone to residual 
confounding by socioeconomic and lifestyle factors, where feasible, randomised 
controlled trials of nutritional supplementation are recommended.531 A large 
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randomised controlled trial, published in 1991, demonstrated that taking 4mg of 
folic acid daily before pregnancy and in the first trimester led to a 72% reduction in 
the risk of neural tube defects. Consequently, over 80 countries have now 
introduced mandatory fortification of flour with folic acid.376 Population-level folic 
acid fortification has not been introduced in the UK, but interventions have been 
implemented at the individual level. NICE guidelines recommend that women 
should take folic acid supplements if planning a pregnancy and in the first 
trimester,371 and folic acid supplements are available to women with low income in 
the UK via the Healthy Start Programme.372 A review, published in 2018,376 
concluded that there are no risks associated with high levels of folic acid intake. 
Given that mandatory fortification has led to a reduced incidence of neural tube 
defects, and that there is no evidence of an upper threshold for folic acid intake, 
the authors argued that mandatory folic acid fortification should be introduced 
universally.376 Therefore, if feasible, it may also be informative to conduct a natural 
experiment to investigate the incidence of FASD in countries that have introduced 
mandatory folic acid fortification at the population level.  
Unlike the nutritional supplements, there was no evidence of a protective effect of 
meeting the recommended daily intake for a range of micronutrients in this 
chapter. Within ALSPAC, scores have recently been derived from factor analyses to 
represent a variety of composite dietary patterns including: ‘healthy’, ‘processed’, 
‘confectionary’, ‘vegetarian’ and ‘traditional’.379,499 Further research that 
investigates the association between FASD risk and these more holistic 
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representations of prenatal diet may offer further insights into the role of nutrition 
in FASD. 
7 Conclusions 
Several factors influence susceptibility to FASD among children with PAE. Prenatal 
smoking, mental health problems and stress may increase the risk of FASD, while 
social support and nutritional supplementation may be protective. Findings from 
this chapter suggests several candidate risk factors that warrant further 
investigation and suggest that in addition to efforts to reduce PAE, public health 
interventions that promote smoking cessation and folic acid supplementation may 
also benefit FASD prevention efforts. Social support interventions may also present 
promising opportunities for FASD prevention. 
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Chapter 7. Summary of main results and conclusions 
 
1 Overview 
The main aims of this thesis were:  
i. To assess the validity of the biological tests that are available to obtain 
an objective measure of prenatal alcohol exposure (PAE).  
ii. To describe the epidemiology of fetal alcohol spectrum disorder (FASD) 
within a population-based birth cohort in England (ALSPAC). 
 
In this concluding chapter, I summarise the key results from this thesis for each of 
the research questions that I specified, consider the main strengths and limitations 
of my analyses, propose avenues for future research, and present the overarching 
implications and conclusions of this work. A detailed discussion, including 
comparison with the extant literature, has been provided in each of the results 
chapters within this thesis. 
2 Main results 
This thesis presented several novel methodological and empirical contributions to 
further the understanding of the epidemiology of PAE and FASD. In this section, I 
describe how the results from my research address the research questions that I 
proposed in the introductory section of this thesis. 
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2.1 Research Question 1: What is the diagnostic accuracy of objective 
measures of prenatal alcohol use? 
I conducted the first systematic review of the validity of objective measures of PAE 
(Chapter 2) and found that:  
• The evidence does not offer strong support for the use of current 
biomarkers of PAE in practice.  
• Tests of the total concentration of four fatty acid ethyl esters (FAEEs; ethyl 
palmitate, ethyl stearate, ethyl oleate and ethyl linoleate) in meconium and 
placenta tissue showed the highest levels of sensitivity (82% to 100%), but 
specificity was variable (13% to 98%).  
• Evidence was sparse for most biomarkers and the methodological quality of 
included studies was low for reasons including the lack of a gold standard 
reference test. 
2.2 Research Question 2: What is the prevalence of FASD within the ALSPAC 
cohort? 
I developed and validated a series of novel FASD case ascertainment algorithms 
that could be applied to identify individuals who met criteria for FASD within the 
ALSPAC cohort (Chapter 3). I applied these algorithms to provide what is, to the 
best of my knowledge, the first population-based prevalence estimate of FASD in 
the UK (Chapter 4). Overall. I found that: 
• It was feasible to use case ascertainment algorithms to estimate the 
prevalence of FASD in an existing population-based dataset (ALSPAC). 
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• The complete case and single imputationq methods that are commonly used 
in FASD prevalence studies are likely to underestimate FASD prevalence. 
Analyses with multiply imputed data provide more plausible estimates of 
FASD prevalence. 
• The estimated prevalence of FASD in the UK could be as high as 17%, 
indicating that FASD may be a significant public health concern. 
• Alcohol-related neurodevelopmental disorder (ARND) - the non-dysmorphic 
subtype of FASD - was the most prevalent subcategory, and classified 15.4% 
of children in analyses with multiply imputed data. Partial fetal alcohol 
syndrome (pFAS) and fetal alcohol syndrome (FAS) - the dysmorphic 
subtypes of FASD - were less common. Across the analyses, a maximum of 
1.6% of participants met criteria for pFAS and 0.03% for FAS. 
• FASD was more common among children of lower socioeconomic status 
and those born to mothers who reported that their pregnancy was not 
planned. 
2.3 Research Question 3: What are the risk factors for FASD within the 
ALSPAC cohort? 
I presented a novel synthesis of the evidence of FASD risk factors, using causal 
diagram (DAG) methodology (Chapter 5) and used this to inform statistical models 
that quantified the effect of hypothesised causal risk factors on FASD among 
children with PAE (Chapter 6). I found that: 
                                                        
q These single imputation methods equate missing PAE data with no exposure, and missing CNS data 
with no impairment. 
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• There was no clear dose-response relationship between the amount of 
alcohol consumed during pregnancy and FASD. 
• Among children with PAE, the following factors increased the odds of FASD: 
prenatal smoking (adjusted odds ratio; aOR 1.19 95% confidence interval; CI 
1.03 - 1.36), prenatal anxiety (aOR 1.30 95% CI 1.13 - 1.50) and prenatal 
depression (aOR 1.32 95% CI 1.12 - 1.55). The odds of FASD were also 
higher among children born to mothers who experienced major financial 
problems in the prenatal period (aOR 1.24 95% CI 1.05 - 1.46), and 
increased further among those born to mothers who reported that they had 
been very affected by prenatal financial problems (aOR 1.39 95% CI 1.11 - 
1.75). 
• Factors that decreased the odds of FASD among children with PAE included: 
prenatal folic acid supplementation (aOR 0.82 95% CI 0.69 - 0.97) and 
increased prenatal social support (aOR per 5-point increase in prenatal 
social support score 0.84 95% CI 0.79 - 0.89). 
• Population attributable fractions indicated that social support interventions 
may have the largest impact on reducing FASD prevalence. Based on the 
exposure distributions in this sample, and assuming that relationships are 
causal, an increase in social support score of 5 points was associated with 
an estimated 28% reduction in the prevalence of FASD. Folic acid 
supplementation had the next largest expected impact (estimated 22% 
reduction), followed by smoking cessation (estimated 17% reduction), 
mental health interventions (estimated 11% reduction), and interventions 
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aimed at reducing the stress caused by prenatal financial problems 
(estimated 4% to 9% reduction). 
3 Strengths and limitations of key results 
3.1 Data considerations 
A key strength of this research was the use of existing data from a large-population 
based birth cohort in England (ALSPAC). This rich dataset enabled me to derive and 
validate a comprehensive FASD case ascertainment algorithm, using data from 
multiple informants, standardised tests, and multiple time points to create a 
detailed profile of each child’s prenatal exposures, and physical and 
neuropsychological profile. Furthermore, to the best of my knowledge, the sample 
sizes in the prevalence and risk factor studies are the largest in the FASD 
epidemiological literature to date. 
However, as described in detail in previous chapters (Chapters 3, 4 and 6), one 
important caveat of the data is the likelihood of measurement error due to the use 
of self-report methods. Most notably, potential misclassification of PAE will have 
implications for the validity of the PAE and FASD prevalence and effect estimates. 
Since PAE is likely to be underreported, FASD may be underestimated. 
Nevertheless, in the absence of a valid objective measure of PAE, the ALSPAC 
dataset represents a valuable source of PAE data. Compared to other UK-based 
cohorts (such as the Millennium Cohort Study,307 which collected information 
about PAE postnatally), the ALSPAC dataset benefits from prospective and 
anonymous collection of PAE data at several time points during pregnancy. This 
reduces the risk of recall bias and counters some of the potential reasons for 
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underreporting, such as social desirability bias and the fear of repercussions from 
disclosing PAE.125 Furthermore, the PAE items included in the ALSPAC 
questionnaires had a range of formats, included examples of drink sizes, and 
incorporated dose/frequency and drink type options, which have been shown to 
improve the accuracy of reporting.62  
It is also important to re-emphasise that the FASD status outcome that I have used 
in this thesis is not equivalent to a formal diagnosis. Confidence in this outcome 
measure is strengthened by the use of a multidisciplinary case conference panel to 
validate the algorithm (Chapter 3). Nevertheless, the possibility of misclassification 
of FASD remains.  
On reflection, it may have been preferable to use multiple imputation methods to 
address missing data prior to the case conference panel. However, this was not 
feasible, given the availability of the expert-panel and the need to progress with 
the algorithm development within the project timescale.  
Finally, participants in the ALSPAC sample tended to be of higher socioeconomic 
status, and children tended to have better educational outcomes, than those in the 
general population of the UK. These differences should be considered when 
attempting to generalise prevalence estimates to the rest of the UK.228,229 
3.2 Statistical methods 
As in many cohort studies, missing data were common in the ALSPAC sample. The 
epidemiological studies that I present in this thesis were strengthened by the use 
of multiple imputation methods to reduce selection bias and maximise sample size. 
However, the actual values of the missing data remain unknown and therefore it is 
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not possible to determine whether this method resulted in an accurate imputed 
dataset, or whether data were truly missing at random. Nevertheless, investigation 
of the observed and imputed values offered support for the validity of the 
imputation model. 
The use of causal inference methods (DAGs) to guide the statistical modelling 
strategy and the interpretation of FASD risk factors is a further strength of this 
work. This approach enabled me to identify plausible causal risk factors for FASD, 
and to use a transparent method for covariate selection to minimise bias in effect 
estimates. The DAG that I created was informed by subject-matter knowledge 
based on a synthesis of the current available evidence. Using this evidence, I linked 
all nodes in the DAG for which there was plausible evidence of a connection. This 
approach is consistent with the view that DAGs should represent a researcher’s 
understanding and beliefs about how the world works for a particular causal 
question.305 Another approach to DAG construction is to link all of the variables 
based on temporal precedence, regardless of whether there is convincing evidence 
of a causal link.293,532 This method asserts that in a DAG, all exposures that precede 
another exposure in time should be linked, unless there is convincing evidence that 
a causal path does not exist. This approach can lead to large ‘forward saturated’ 
models. Due to the complexity of the multiple imputation models, and their failure 
to converge under specifications that included larger numbers of variables, I 
favoured the DAG approach that was based on subject matter knowledge, rather 
than simply temporal precedence. I assumed, therefore, that any extra covariates 
that might have been suggested by the temporal precedence approach would have 
had a negligible impact on estimates, after accounting for the key variables 
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suggested by the DAG that was derived from subject matter knowledge. Further 
research will help elucidate the optimal method for DAG development.  
Although I grounded my analyses in causal inference, it is important to again note 
the limitations of observational data. The risk factor effect estimates (odds ratios 
and population attributable fractions) that I have presented are based on measures 
of association, and will only resemble the true causal effect to the extent to which 
there is no unmeasured confounding. The assumption of no unmeasured 
confounding is unlikely to hold for most epidemiological investigations. Therefore, 
the results I have presented represent my attempt to obtain the most rigorous 
estimates, given the limitations of the data.  
4 Implications and future research 
4.1 Research gaps and extensions 
There has been a paucity of evidence on FASD in the UK. Contributors to the All 
Party Parliamentary Group on FASD argue that this lack of evidence has 
contributed to uncertainty and mixed messaging around the ‘safety’ of PAE among 
health professionals and pregnant women, and inadequate service provision.108 
The British Medical Association further note that accurate data on FASD in the UK 
are crucial to inform decisions on prevention, health, education, and justice 
policy.10 The results that I have presented in this thesis indicate the potential 
burden of FASD in the UK and suggest that further investigation is warranted. In 
particular, results point to a need for an active case ascertainment study to further 
elucidate the true prevalence of FASD in the UK. 
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Second, clinic-based studies suggest that individuals with FASD have an increased 
risk of a range of adverse secondary conditions including mental health problems, 
substance misuse and antisocial behaviour.90,91,93 However, there are no large 
population-based studies of the long-term outcomes of people with FASD. 
Therefore, the needs of these individuals and the impact of this condition on health 
services are not well understood. My development of a case ascertainment 
algorithm for FASD in ALSPAC allows for longitudinal analyses of outcomes, 
including mental and physical health, antisocial behaviour, independent living and 
substance use. Such research would be useful for estimating the wider impact of 
FASD and highlighting opportunities for intervention to reduce the adverse 
outcomes associated with FASD. 
Third, results from this thesis indicate potential targets for FASD prevention, among 
children exposed to alcohol prenatally. Future research is required to test the 
feasibility and effectiveness of these proposed interventions, which include 
smoking cessation, nutritional supplementation and social support. For example, 
randomised studies in Ukraine are investigating the impact of multivitamin and 
choline supplementation on the outcomes of children with PAE.394,533 Results from 
this thesis indicate that evaluation of iron and folic acid supplementation may also 
be warranted.  
Finally, the ALSPAC study has recently enhanced data linkage to NHS records.248 
This provides an opportunity to increase detection of FASD in the cohort and to 
further validate the FASD algorithm that I have developed. Using this resource, it 
may be possible to estimate the prevalence of FASD using GP-linked data, to 
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further evaluate the performance of the FASD algorithm, and to create a pooled 
dataset of participants’ FASD status by combining information from GP codes and 
the FASD algorithm.  
4.2 Methodological and statistical recommendations 
Results from this thesis indicate that the complete case and single imputation 
methods that are commonly used to manage missing data in epidemiological 
studies of FASD are likely to underestimate true prevalence. Therefore, I would 
suggest that future research should consider multiple imputation methods to 
address missing data. In particular, it would be interesting to determine how the 
prevalence estimates from existing active case ascertainment studies, such as 
those from the Collaboration on FASD Prevalence (CoFASP) research consortium in 
the USA,534 compare to estimates with multiply imputed data. 
Like the UK, many countries lack population-based estimates of FASD prevalence.86 
The application of a FASD case ascertainment algorithm to existing data mitigated 
the ethical and resource concerns that have precluded active-case ascertainment 
studies of FASD to date in the UK.108 This methodology presents a potential model 
for similar studies in other countries that have comprehensive datasets on prenatal 
exposures and children’s physical and neurobehavioural outcomes.  
5 Main conclusions 
This thesis identified and addressed gaps in the evidence on PAE and the 
epidemiology of FASD in the UK. The research in this thesis has highlighted 
limitations in current objective measures of PAE; presented a case ascertainment 
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algorithm for FASD that can be applied to existing data; described the aetiological 
context of FASD using causal diagram methodology; and has presented the first 
population-based estimates of FASD prevalence and risk factors in the UK.  
Taken together, the results from this thesis suggest that PAE and FASD are a 
significant public health concern in the UK. Children at particular risk include those 
whose mothers report that pregnancy was unplanned, those of lower 
socioeconomic status, and those who experience adverse prenatal environments 
including concurrent exposure to smoking, mental health issues and lower social 
support. Given the paucity of evidence in this population, further research is 
required to corroborate prevalence estimates and to investigate risk factors for 
FASD as potential targets for intervention. 
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Appendix 1: Medline search string for systematic review 
Search: Objective measurement of alcohol use during pregnancy 
Interface: OVID SP Databases: Medline 
Limits: Humans, English Language Date Range: 1990 to August 2015 
1. (Objectiv* adj (measure* or test* or assess* or screen*)).ti,ab. 
2. (Aminotransferase or AST or ALT or Biomarker* or Carbohydrate-deficient 
transferrin or CDT or Ethyl or (Fatty adj Acid) or FAEE or (Gamma adj 
glutamyltransferase) or GGT or (Guthrie adj card*) or Mean Corpuscular Volume 
or MCV or Phosphatidylethanol or PEth).tw. 
3. "area under curve"/ or "predictive value of tests"/ or roc curve/ or "sensitivity 
and specificity"/ or validation studies/ 
4. exp Biological Markers/ or Fetal Monitoring/ or exp Prenatal Diagnosis/ 
5. 1 or 2 or 3 or 4 
6. exp Alcoholism/ or exp Alcohol drinking/ or exp Alcohol induced disorders/ or 
exp Alcoholic intoxication/ or exp Binge drinking/ or exp Drunkenness/ or exp 
Ethanol/ 
7. (Alcohol* or Binge drinking or ARBD or ARND or Drunk* or Ethanol or FAS or 
FASD or Intoxicat* or PAE or pFAS).tw. 
8. 6 or 7 
9. maternal-fetal exchange/ or pregnancy, high-risk/ or exp Infant, Newborn/ 
10. (Baby or F?etus or F?etal or Gestation* or Infant or In?utero or Matern* or 
Mother or Newborn or Neonat* or Postnat* or Pregnan* or Antenat* or 
Prenatal*).tw. 
11. 9 or 10 
12. 5 and 8 and 11 
13. limit 12 to (english language and humans and yr="1990 -Current") 
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Appendix 2: Coding criteria for methodological quality assessment  
Quality domain Question Coding criteria 
Participant selection Were participants selected in a 
way that avoided bias? 
Yes: If the characteristics of the spectrum of patients fulfilled the pre-stated 
requirements of the study, if inappropriate exclusions, were avoided, if the 
study avoided a case-control design and the method of recruitment was 
consecutive or random samples were taken from consecutive series. 
No: If the sample does not fit with what was pre-specified within the primary 
study as acceptable or if groups with and without the target disorder were 
recruited separately, particularly with healthy controls. If there were 
systematic differences between those with and without the target condition. 
Unclear: If there is insufficient information available to make a judgement 
either about the spectrum or the method of sampling. 
Reference standard Is the reference standard likely to 
correctly classify the target 
condition? 
Yes: The reference standard is likely to correctly classify the target condition. 
No: The reference standard is not likely to correctly classify the target 
condition. 
Unclear: It is unclear exactly what reference standard was used/it is unclear 
whether the reference standard will correctly classify the target condition. 
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Quality domain Question Coding criteria 
Detection window Does the window of detection for 
the index test [i.e. the period in 
which the biomarker can be 
detected following alcohol 
consumption] overlap with the 
period assessed by the reference 
standard? 
Yes: If the time between tests was within the window of detection (see 
guidance below for detection periods), at least for an acceptably high 
proportion of patients. 
No: If the time between tests was outside of the window of detection for an 
unacceptably high proportion of patients. 
Unclear: If information on timing of tests is not provided. 
Biomarker (abbreviation; matrix) Window of detection 
Carbohydrate deficient transferrin 
(CDT; blood) 
2 - 4 weeks 
Ethyl sulphate (EtS; urine) ≤ 30 hours  
Ethyl glucuronide (EtG; urine) ≤ 5 days 
Ethyl glucuronide (EtG; hair) Months to years depending on the 
length of hair collected. Human hair 
grows at approximately 1cm per 
month.   
Fatty acid ethyl esters (FAEE; 
meconium) 
2nd and 3rd trimester 
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Quality domain Question Coding criteria 
Fatty acid ethyl esters (FAEE; 
placenta) 
Unknown 
Gamma glutamyltransferase (GGT; 
blood)  
≤ 3 - 4 weeks 
Haemoglobin-acetaldehyde adducts 
(Hb-Ach; maternal blood) 
≤ 4 weeks 
Mean corpuscular volume (MCV; 
maternal blood) 
≤ 17 weeks 
Phosphatidylethanol (PEth; 
maternal and infant blood) 
≤ 3 weeks 
 
 
Partial verification Did the whole sample or a 
random selection of the sample, 
receive verification using the 
intended reference standard? 
Yes: If all patients, or a random selection of patients, who received the index 
test received verification of their disease status using a reference standard, 
even if the reference standard was not the same for all patients. 
No: If some of the patients who received the index test did not receive 
verification of their true disease state, and the selection of patients to receive 
the reference standard was not random. 
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Quality domain Question Coding criteria 
Unclear: If this information is not reported by the study. 
Differential verification Did patients receive the same 
reference standard? 
Yes: If the same reference standard was used in all patients. 
No: If the choice of reference standard varied between individuals. 
Unclear: If it is unclear whether different reference standards were used. 
Incorporation bias Was the reference standard 
independent of the index test [i.e. 
the index test did not form part of 
the reference standard]? 
Yes: If the index test did not form part of the reference standard. 
No: If the reference standard included components of the index test. 
Unclear: If it is unclear whether the results of the index test were used in the 
final diagnosis. 
Uninterpretable results Were uninterpretable/ 
intermediate test results 
reported? 
Yes: If the number of uninterpretable test results is stated, or if the number of 
results reported agrees with the number of patients recruited (indicating no 
uninterpretable test results). 
No: If it states that uninterpretable test results occurred or were excluded and 
does not report how many. 
Unclear: If it is not possible to work out whether uninterpretable results 
occurred. 
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Quality domain Question Coding criteria 
Withdrawals Were withdrawals from the study 
explained? 
Yes: If it is clear what happened to all patients who entered the study, for 
example if a flow diagram of study participants is reported explaining any 
withdrawals or exclusions, or the numbers recruited match those in the 
analysis. 
No: If it appears that some of the patients who entered the study did not 
complete the study, i.e. did not receive both the index test and reference 
standard, and these patients were not accounted for. 
Unclear: If it is unclear how many patients entered and hence whether there 
were any withdrawals. 
  232 
Quality domain Question Coding criteria 
Selective outcome 
reporting 
Did the study avoid selective 
outcome reporting? 
Yes: If there is no evidence to suggest that the study has omitted key data or 
outcomes. For example: 
i. If summary statistics including sensitivity, specificity and predictive 
values and the number of true positive, false positive, true negative and false 
negative results are reported directly and the study reports the accuracy of all 
of the index tests that were investigated. 
ii. If summary statistics are reported directly in combination with the 
number of participants included in analysis and prevalence of the target 
condition in order to allow calculation of the number of true positive, false 
positive, true negative and false negative results. The study reports the 
accuracy of all of the index tests that were investigated.  
iii. If the number of true positive, false positive, true negative and false 
negative results are reported in a way that enables calculation of diagnostic 
summary statistics and the study reports the accuracy of all of the index tests 
that were investigated.  
No: If the study does not report summary statistics or raw data, or does not 
provide sufficient information for each to be calculated. If it appears that the 
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Quality domain Question Coding criteria 
study has investigated an index test but not reported the findings. If it is not 
possible to replicate the summary statistics presented in the paper.  
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No’; for 
example if a study protocol is not available.  
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Appendix 3: Comparison of FASD criteria across diagnostic frameworks.  
Note: A description of how these criteria correspond to FASD subcategories is presented within the diagnostic categories row. Bold 
emphasis denotes key differences in criteria between guidelines. 
 Canadian 200572 Canadian 2016227 4-Digit Code 2004535 IOM revised 200573 IOM revised 201674 DSM-5 ND-PAE212 
Growtha 
(A) 
Pre- and/or postnatal 
height or weight ≤ 
10th percentile or low 
weight-to-height 
ratio ≤ 10th percentile 
Not included Pre- and/or postnatal 
height or weight ≤ 
10th percentile 
Pre- and/or postnatal 
height or weight ≤ 
10th percentile 
Pre- and/or postnatal 
height or weight ≤ 
10th percentile 
Not included 
Faceb 
(B) 
All 3 facial features: 
short palpebral 
fissures ≤ 3rd 
percentile; smooth 
philtrum, thin upper 
lip 
All 3 facial features: 
short palpebral 
fissures ≤ 3rd 
percentile; smooth 
philtrum, thin upper 
lip 
All 3 facial features: 
short palpebral 
fissures ≤ 3rd 
percentile; smooth 
philtrum, thin upper 
lip 
≥ 2 facial features: 
short palpebral 
fissures ≤ 10th 
percentile; smooth 
philtrum, thin upper 
lip 
≥ 2 facial features: 
short palpebral 
fissures ≤ 10th 
percentile; smooth 
philtrum, thin upper 
lip 
Not included 
Central 
nervous 
system 
(C) 
Impairment in ≥ 3 
subdomains 
including: 
neurological signs; 
brain structure; CNS 
functioning 
Impairment in ≥ 3 
subdomains 
including: 
neurological signs; 
brain structure; CNS 
functioning 
Impairment in ≥ 1 
structural or 
neurological 
subdomain(s) 
including: brain 
structure; 
seizures/other 
neurological signs; or 
impairment in ≥ 3 
domains of CNS 
functioning 
Impairment in ≥ 1 
structural 
subdomain and/or 
evidence of a 
behavioural or 
cognitive 
abnormalities 
inconsistent with 
developmental level 
Impairment in ≥ 1 
structural or 
neurological 
subdomain(s) 
including: brain 
structure; seizures; 
and/or global 
cognitive impairment 
and/or cognitive or 
behavioural deficit 
not including 
adaptive functioning 
in ≥ 1 subdomain(s) 
Impairment in ≥ 3 
subdomains which 
must include: 
neurocognitive 
functioning; self-
regulation; and 
adaptive functioning 
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 Canadian 200572 Canadian 2016227 4-Digit Code 2004535 IOM revised 200573 IOM revised 201674 DSM-5 ND-PAE212 
Alcohol 
exposure 
(D)c 
Any 
 
 
 
 
More than specified 
threshold:  
≥ 7 drinks per week, 
or > 4 drinks per 
occasion 
 
Any More than specified 
threshold: 
Pattern of excessive 
intake characterized 
by substantial regular 
intake or heavy 
episodic drinking 
More than specified 
threshold:  
≥ 6 drinks/week for ≥ 
2 weeks during 
pregnancy 
 ≥ 3 drinks per 
occasion on ≥ 2 
occasions during 
pregnancy 
Documentation of 
alcohol-related social 
or legal problems in 
proximity to (before 
or during) the index 
pregnancy 
Documentation of 
intoxication during 
pregnancy by blood, 
breath, or urine 
alcohol content 
testing 
Positive testing with 
established alcohol-
exposure 
biomarker(s) during 
pregnancy or at birth 
(eg, analysis of 
FAEEs, PEth and/or 
EtG in maternal hair, 
nails, urine, blood, 
More than specified 
threshold:  
> 13 drinks per 
month or more than 
2 drinks per occasion 
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 Canadian 200572 Canadian 2016227 4-Digit Code 2004535 IOM revised 200573 IOM revised 201674 DSM-5 ND-PAE212 
placenta, or 
meconium) 
− Increased prenatal 
risk associated with 
drinking during 
pregnancy as 
assessed by a 
validated screening 
tool of, for example, 
T-ACE or AUDIT  
Diagnostic 
categories 
(criteria) 
FAS (A, B, C and D 
[but external 
confirmation of PAE 
not required when 
facial phenotype is 
present]) 
Partial FAS (2 
features from B plus C 
and D - confirmed 
exposure only) 
ARND (C and D - 
confirmed exposure 
only) 
FASD with sentinel 
facial features (B, C 
and D [but external 
confirmation of PAE 
not required when 
facial phenotype is 
present]) 
 
FASD without 
sentinel facial 
features (C and D - 
confirmed exposure 
only) 
FAS (A, B, C and D 
[but external 
confirmation of PAE 
not required when 
facial phenotype is 
present]) 
Partial FAS (B with 
relaxed criteria: ≤ 1 
SD below mean for 
palpebral fissures, or 
rank 3 for 
lip/philtrum, C and D 
- confirmed exposure 
only) 
Static 
encephalopathy 
/alcohol-exposed 
(SE/AE) C with 1 
structural or hard 
neurological sign of 
impairment e.g. 
seizures or 3 
FAS (A, B, C [which 
must include 
structural 
impairment] and D 
[but external 
confirmation of PAE 
not required when 
facial phenotype is 
present]) 
Partial FAS (B and A 
or C extended to 
include evidence of 
behavioural/cognitiv
e abnormalities, and 
D [but external 
confirmation of PAE 
not required when 
facial phenotype is 
present]) 
ARBD (B and 
evidence of 
congenital 
FAS (A, B, C [which 
must include 
structural or 
neurophysiological 
impairment with 
global impairment or 
cognitive or 
behavioural 
impairment in ≥ 1 
domain] and D [but 
external 
confirmation of PAE 
not required when 
facial phenotype is 
present]) 
Partial FAS (A, 
[required if D is 
unconfirmed only] B, 
C [which must 
include cognitive or 
behavioural 
impairment in ≥ 1 
Neurobehavioral 
Disorder Due to 
Prenatal Alcohol 
Exposure (ND-PAE; C 
and D, plus onset 
must be in childhood 
and disturbance must 
cause clinically 
significant distress or 
impairment in 
functioning) 
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 Canadian 200572 Canadian 2016227 4-Digit Code 2004535 IOM revised 200573 IOM revised 201674 DSM-5 ND-PAE212 
functional domains 
with performance ≥ 2 
SDs below the mean, 
D - confirmed 
exposure only) 
Neurobehavioral 
disorder / alcohol-
exposed (ND/AE) C 
but with no 
structural/hard 
neurological 
abnormalities and 
with 1-2 functional 
domains with 
performance ≥1.5 
SDs below the mean, 
D - confirmed 
exposure only) 
abnormalities and D - 
confirmed exposure 
only) 
ARND (C [structural 
and or 
behavioural/cognitiv
e abnormalities] and 
D - confirmed 
exposure only) 
domain] and D [but 
external 
confirmation of PAE 
not required when 
facial phenotype is 
present]) 
ARBD (evidence of 
congenital 
abnormalities and D - 
confirmed exposure 
only) 
ARND (C [global 
impairment or 
cognitive or 
behavioural 
impairment in ≥ 2 
domains] and D - 
confirmed exposure 
only) 
a In the UK, the 9th percentile is used as the threshold for growth deficiency, rather than the 10th percentile.106 
b With the exception of the revised IOM 2016 guideline, which is not explicit about which lip-philtrum guide to use (except that it should be ‘racially normed’ if 
available), and the ND-PAE criteria, which do not consider the facial phenotype, all other diagnostic frameworks recommend the use of the University of 
Washington Lip-Philtrum Guide247 to assess the FAS facial phenotype. Ranks 4/5 correspond to the FAS facial phenotype based on the University of 
Washington Guide. 
c Confirmation of PAE by external sources is not required for a diagnosis of FAS (or FASD with sentinel facial features) because the facial phenotype is highly 
specific to PAE. Relative to other guidelines, the IOM guidelines relax their criteria so that pFAS may also be diagnosed without confirmed PAE. 
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Appendix 4: Overview of the ALSPAC assessment measures used to derive FASD classifications 
Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
Growth 
(A) 
Weight Weight Birth -  9 £ 9th percentile at birth  
 
 
 
Standard 
norms 
Excel LMS Growth Add-in based on UK growth 
norms.239,240 
 
Centiles for pre-term babies < 35 weeks gestation 
were generated using the Fenton Growth 
Calculator.241 
Height Height Birth -  9 £ 9th percentile at birth and 
postnatally (up to puberty) 
 
Standard 
norms 
Body mass index 
(BMI) 
BMI Birth -  9 £ 9th percentile at birth and 
postnatally (up to puberty) 
 
Standard 
norms 
Face 
(B) 
Palpebral fissure 
length 
3D facial 
scan data 
 
15.5 ≤ 2.5th percentile Standard 
norms 
FAS Diagnostic and Prevention Network Z-Score 
Calculator for palpebral fissure length.237,238 
 
Thin upper lip Equivalent to 4/5 on the lip-
philtrum guide 
Standard 
norms 
Wilson Scale for Lips.236 
Smooth 
philtrum  
Standard 
norms 
CNS 
(C) 
a) Hard and 
soft 
neurologic 
signs 
(including 
sensory-
motor) 
Movemen
t score 
7 Top 5% (95th percentile) 
Score: ≥ 6 for girls 
            ≥ 7 for boys 
 
Research 
literature 
ALSPAC coordination test (modified version of 
Movement Assessment Battery) 
 
The Movement Assessment Battery for Children 
was used to test the children’s motor ability.246 
It comprises three sections, assessing static and 
dynamic balance, manual dexterity and ball skills.  
Because of time constraints, it was not possible to 
conduct the whole assessment, so specific 
subtests from each of the three sections were 
carried out: 
Manual dexterity: Placing Pegs and Threading lace 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
Ball skills: Bean bags 
Balance: Heel to toe walking 
 
Odd et al. derived a summary score based on the 
three tasks. 'The top (i.e. indicating worse 
performance) 5th centile of this summed score was 
used to define severe motor coordination 
difficulties as has been used previously in the 
literature.235 
 
Seizures 1 - 13 > 1 seizure not due to fever, 
breath-holding or response 
to immunisation (i.e. due to 
epilepsy) 
Expert opinion 
and FASD 
Canadian 2005 
guidelines 
ALSPAC asks the child’s caregiver:  
Has the child ever had a seizure, fit or convulsion?  
And whether the seizure was due to factors 
including immunisation, fever or breath-holding, 
epilepsy. 
 
Cerebral 
palsy 
NR Cerebral palsy Expert opinion Cerebral palsy reported by mother/carer 
b) Brain 
structure 
Head 
circumfer
ence 
Birth and 
7 
≤ 2nd percentile 
 
 
Standard 
norms 
Excel LMS Growth Add-in based on UK growth 
norms.239,240 
 
c) Cognition  WISC-III  
(short-
form) 
8  Score ≤ 70 on total, verbal or 
performance IQ 
 
Discrepancy of at least 1 SD 
(i.e. 15 points) between the 
subdomains (i.e. verbal and 
performance IQ).  
 
Standard 
norms and 
FASD 
Canadian 2005 
guidelines 
WISC-III (short form) 
 
Alternate WISC items were used for all subtests, 
except for the coding subtest which was 
administered in its full form.536-539 
Administered by members of the psychology 
team.  
Raw scores were calculated according to the items 
used in the alternate item form of the WISC, 
  240 
Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
making the raw scores comparable to those that 
would have been obtained had the full test been 
administered.245,281 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
d) Communica
tion: 
receptive 
and 
expressive 
WOLD 
(Wechsler 
Objective 
Language 
Dimensio
ns) 
8 Score ≤3 for wold_list  
Score ≤3 for  wold_express 
Based on the 
distribution of 
ALSPAC 
participant 
data. 
Wechsler Objective Language Dimensions (WOLD; 
modified):245 
 
Listening comprehension: The listening 
comprehension subtest of the WOLD is divided 
into two parts. The first is a single word receptive 
vocabulary test, similar to the vocabulary subtest 
of the WISC. This was not therefore used.  
In the second part of the assessment, the child 
listens to the tester read aloud a paragraph about 
a picture, which the child is shown. The child then 
answers questions on what they have heard. 
The child has to make inferences about what was 
read to them and answer the questions verbally. 
The task was discontinued if the child got three 
consecutive questions incorrect. Alternate items 
from the standard test were sampled except 
where the item had American cultural loading. In 
those cases, the next item was selected. 
 
Expressive language: The WOLD has two 
expressive language subtests. In the second 
subtest three tasks were performed. Firstly, a 
picture was shown to the child who was asked to 
describe the scene, as if to someone who was not 
present and so could not see the picture. 
Secondly, the child was shown a map and asked to 
give directions from one location to another, using 
the shortest route possible and finally they were 
asked to explain the steps involved in a sequential 
task of putting batteries into a torch using pictures 
to help. 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
These tasks assess the child’s descriptive, narrative 
and sequencing skills. All responses in this task 
were recorded on audio tape for later coding on 
five features, relating to the relevance, accuracy 
and logicality of the child’s responses. In the full 
WOLD assessment, each task has two examples. 
Only one of each was used in the ALPSAC tests. 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
Communi
cation 
(general) 
7 and 10 ‘Yes’ indicates reported 
impairment at any time point  
 
 
 
Expert opinion Teacher-reported speech and language difficulties 
in school (needing special assistance) 
e) Academic 
achievemen
t 
Special 
needs 
9 to 10 
10 to 11 
11 to 12  
2 (School Action) 3 (School 
Action plus) and 4 (SEN 
statement) indicate 
impairment  
 
Standard 
norms 
Pupil Level Annual School Census (PLASC) 
recorded SEN: School action, school action plus 
and statement.540 
Academic 
attainme
nt 
6-7 “Failing to meet expected 
level” 
Key stage 1: Level 1 or W  
Standard 
norms 
 
Key 
Stag
e 
Range 
of 
levels 
withi
n 
which 
most 
childr
en 
will 
work 
 
Target 
that 
most 
children 
reach by 
the end 
of the 
key 
stage 
Further 
information about 
Key Stage levels  
(Source: ALSPAC 
SATS Doc and 
ALSPAC Key Stage 
2 File) 
 
1 1 - 3 2 W = Code W 
(“working towards 
level 1”) means 
that the child was 
assessed but didn’t 
achieve level 1.  
2 2 - 5 4 The basic scale 
consists of levels 1, 
2, 3 and 4+, with 
10-11 “Failing to meet expected 
level” 
Key Stage 2: < Level 4 
Standard 
norms 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
grades A, B and C 
within level 2. 
Point Score - All 
Subjects 
4+ = 27 
3 = 21 
2A = 17 
2B = 15 
2C = 13 
1 = 9 
 
f) Memory Short 
term 
memory 
8 Score ≤ 3 
 
 
Based on the 
distribution of 
ALSPAC 
participant 
data. 
WISC-III forward digit span245,281,541,542 
 
Children repeated lists of digits in order. 
8 Score ≤ 2 Based on the 
distribution of 
ALSPAC 
participant 
data. 
Modified Non-word Repetition Test245,543 
 
Twelve nonsense words, four each of 3, 4 and 5 
syllables and conforming to English rules for sound 
combinations.  
The child was asked to listen to each word via an 
audio cassette recorder and then repeat each 
item. 
g) Executive 
functioning 
and 
abstract 
reasoning  
Working 
memory 
10 Score ≤ 2 Based on the 
distribution of 
ALSPAC 
participant 
data. 
Counting Span Task544-546 
 
The child was presented with red and blue dots on 
a white screen. The child was asked to point to 
and count the number of red dots out loud (the 
processing component).  
The children were shown: 
• Two practice sets of two screens 
• Three sets of two screens 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
• Three sets of three screens 
• Three sets of four screens 
• Three sets of five screens 
After each set, the child was asked to recall the 
number of red dots seen on each screen 
in the order they were presented within that set 
(the storage component).  
 
Working 
memory 
8 ≤ 2 correct responses Based on the 
distribution of 
ALSPAC 
participant 
data. 
WISC-III (short form) Backwards Digit 
Span.245,281,541,542 
 
Children repeated lists of digits in reverse order. 
Inhibition 10 ≤ 12 correct responses Based on the 
distribution of 
ALSPAC 
participant 
data. 
Stop-signal paradigm545-547 
 
This task observes the child’s ability to inhibit a 
body movement that has already been requested 
using a computerized measure of impulsivity.  
When a ‘stop signal cue’ (bleep) was not heard the 
child was asked to press the corresponding button 
according to what was presented on screen. When 
the bleep was sounded the child was told to 
refrain from pressing the response button, 
therefore 
inhibiting the stimulus response. 
 
Opposite 
Worlds 
Task 
8 Time (secs) 
≥ 28 for males aged 7 - <9  
≥ 24.5 for males aged 9 - 11  
 
≥ 26 for females aged 7 - <9  
≥ 24 for females aged 9 - 11  
Based on the 
distribution of 
ALSPAC 
participant 
data. 
TEACh- Opposite Worlds Task245,548 
 
 A Stroop task, where the child is required to give a 
verbal response that contradicts the visual 
information he or she is given. The child is shown a 
trail made up of the numbers 1 and 2. In the 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
 ‘opposite world’ condition, the child must call out 
‘two’ when he or she reaches a 1 and ‘one’ when 
he or she reaches a 2.  
 
h) Attention 
deficit/hype
ractivity 
Selective 
attention 
8 ≥ 11 for males aged 7 - <9  
≥ 9 for males aged 9 - 11  
 
≥ 8 for females aged 7 - 11  
Based on the 
distribution of 
ALSPAC 
participant 
data. 
TEA-Ch Sky Search Task245,548 
 
The child was asked to circle identical pairs of 
spaceships as quickly as possible but not missing 
any out. The child was asked to tick a box on the 
sheet to indicate that he/she had circled all the 
identical pairs he/she could find.  
 
DAWBA 
ADHD  
7.5  
 
DAWBA ADHD  
 
Clinical 
diagnosis by 
ALSPAC team 
Development and Well-Being Assessment 
(DAWBA)549 
 
DAWBA diagnoses were classified by psychiatrists.  
For ADHD and oppositional/conduct disorders, the 
diagnostic procedure considers the teacher report 
in addition to the parent report. Full DSM-IV 
diagnoses were only made for children for whom 
the parent report had been completed. 
 
SDQ 
Hyperacti
vity Score  
7 to 11 
years 
High SDQ  
Score ≥ 8 
Standard 
norms 
Strengths and difficulties questionnaire (SDQ)550 
i) Adaptive 
behaviour, 
social skills, 
social 
communica
tion 
SDQ Peer 
Problems 
Score  
High SDQ   
Score ≥ 5 for teacher-rated 
Score ≥ 4 for parent-rated 
Standard 
norms 
SDQ 
Conduct 
Problems 
Score  
High SDQ 
Score ≥ 4 
Standard 
norms 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
DAWBA 
Oppositio
nal-
conduct 
disorder 
7.5  DAWBA Oppositional-
conduct disorder  
Clinical 
diagnosis by 
ALSPAC team 
Development and Well-Being Assessment 
(DAWBA)549 
 
DAWBA diagnoses were classified by psychiatrists.  
For ADHD and oppositional/conduct disorders, the 
diagnostic procedure considers the teacher report 
in addition to the parent report.  
Full DSM-IV diagnoses were only made for 
children for whom the parent report had been 
completed. 
 
Diagnosti
c Analysis 
of Non-
Verbal 
Accuracy 
(DANVA)  
8 ≥ 7 errors  
 
 
Research 
literature 
Diagnostic Analysis of Non-Verbal Accuracy 
(DANVA)551 
 
The DANVA faces subtest comprises 24 photos of 
child faces, with each face showing one of four 
emotions: happiness, sadness, anger or fear. The 
photos are presented to the child for two seconds 
each and he or she must respond as to whether 
the person in the photo is happy, sad, angry or 
afraid. 
 Social 
cognition 
7.5 and 11 Score ≥ 9 Standard 
norms 
Social Communication Disorders Checklist 
(SCDC)552-554 
 
Measure of social-cognitive dysfunction. 
Autism 
spectrum 
disorder  
Up to age 
11 
Any autism spectrum 
disorder 
Clinical 
diagnosis 
recorded in 
NHS or PLASC 
Autism identified by NHS or PLASC records.204 
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Criterion Domain ALSPAC 
variable 
Age 
assessed 
(years) 
Suggested threshold for 
impairment 
Method for 
deriving 
threshold for 
impairment 
Test details 
Teacher 
reported 
emotional 
or 
behaviour
al 
difficultie
s  
 
7 and 10 ‘Yes’ indicates reported 
impairment at any time point  
 
Expert opinion Teacher-reported emotional or behavioural 
difficulties at school  
Prenatal 
alcohol 
exposure 
(D) 
Prenatal alcohol 
exposure (PAE) 
 
Prenatal 
alcohol 
exposure  
 
Prenatal 
(reported 
for each 
trimester): 
Data 
collected 
at 
approxima
tely 8, 18 
and 32 
weeks 
gestation 
and 8 
weeks 
postpartu
m. 
N/A Self-reported alcohol consumption during pregnancy including 
information about dose, frequency and timing. 
 
Timing: First, second or third trimester 
Duration: None, one trimester, two trimesters, all trimesters 
Dose/frequency: <1 glass per week 
                                At least one glass per week 
1-2 glasses daily  
3-9 glasses daily  
>9 glasses daily  
The ALSPAC questionnaire defined a glass of alcohol as equivalent to 
a pub measure of spirits, ½ pint lager/beer, wine glass of wine etc. 
 
‘Binge’ drinking in the last month:              1-2 days 
3-4 days  
5-10 days  
>10 days  
everyday  
‘Binge drinking’ defined as the consumption of 2 pints of beer, 4 
glasses of wine, 4 pub measures of spirits or equivalent on a single 
occasion. Information on first trimester binge drinking was not 
available. 
Dose (units): UK standard units  
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Appendix 5: Factors for differential diagnosis in the ALSPAC sample 
Domain ALSPAC variable Details Age assessed Details Actiona 
Genetic Genetic anomalies 
dataset 
Down Syndrome 
Genetic 
anomalies 
NA Exclude Ps with any recorded genetic disorders. 
Microarray not available. 
Exclude 
 
Perinatal 
trauma/complications 
Eclamptic 
convulsions  
Umbilical cord 
around neck or 
prolapse during 
labour 
Blood transfusion in 
labour 
Resuscitation of 
baby 
Premature delivery 
≤ 34 weeks 
Apnoeic attacks in 
first 14 days 
postnatally 
Admitted to SCBU 
Perinatal trauma NA Any of the complications listed may account for 
neurological abnormalities, particularly if related to 
hypoxia. 
Consider 
Prematurity  Gestational age at 
delivery 
Prematurity NA Consider prematurity but note that prematurity may 
be caused by PAE as well as influencing later 
outcomes.  
Consider 
Abuse/neglect Postnatal 
abuse/neglect 
Physical or 
sexual abuse 
6 months to  
8  years 
Any reported physical or sexual abuse. Some 
variables list ‘how affected’ the child was, however I 
have coded to indicate any abuse, regardless of 
perceived impact, as is it reasonable to assume that 
the child is likely to have been adversely affected, 
even if the caregiver reports otherwise.  
Consider 
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Domain ALSPAC variable Details Age assessed Details Actiona 
Taken into care Taken into care 
after 6 months old 
Child taken into 
care 
6 months to 6 
years 
Children taken into care aged < 6 months generally 
have better outcomes than those aged > 6 months 
(shorter duration of exposure to neglectful 
environment) 
Consider 
Illicit substances 
during pregnancy 
Cannabis 
Amphetamine  
Barbiturate  
Crack  
Cocaine  
Heroin  
Methadone  
Ecstasy  
Other  
Illicit substance 
use in pregnancy 
Prenatal Consider associated adverse effects Consider 
Smoking in pregnancy Tobacco 
 
Smoking in 
pregnancy 
Prenatal Consider associated adverse effects Consider  
Postnatal injury Head injury causing 
loss of 
consciousness 
Head injury 0 to 12 years Consider timing of injury with time of CNS 
assessment. I.e. if head injury occurs after CNS 
impairment then not a plausible alternative diagnosis. 
Consider 
Postnatal illness Readmitted to 
hospital 
 
Health of child  
 
Postnatal illness 4 weeks to 18 
months 
 
Coded to indicate severe postnatal illness as only 
severe illness may be a plausible alternative cause for 
the extensive range of impairments associated with 
FASD.  
e.g. child ‘mostly unwell’ at any time point, or child 
readmitted to hospital. 
Consider 
Postnatal nutrition Weak Sucking 
Feeding difficulty 
Number of solid 
meals a day 
Postnatal 
nutrition 
4 weeks to 6 
months 
Not informative in terms of providing adequate 
information about alternative explanations for 
growth deficiency. Also birth weight will not be 
affected by postnatal nutrition and since evidence of 
consistent growth impairment is needed this should 
Not relevant - 
accounted for 
in criteria that 
requires 
evidence of 
  251 
Domain ALSPAC variable Details Age assessed Details Actiona 
exclude postnatal nutrition as an alternative 
explanation. 
consistent 
growth 
deficiency as 
per 4 Digit 
Code 
Parental mental 
health 
Parental learning 
disabilities/ADHD 
N/A N/A N/A Not available  
Child’s main language Language child 
speaks 
 
English is main 
language spoken by 
study child 
Child’s main 
language 
Age ~3 and ~5 
years 
Variables describe whether English is the child’s main 
(or equal) language or not. This is a consideration 
when considering whether CNS test performance 
reflects genuine ability or language capability.  
Exclude 
children for 
whom English 
is not the 
main language 
Physical and sensory 
disability 
Child has physical 
disabilities 
 
Childs needs special 
arrangements at 
school for a physical 
problem 
 
PLASC SEN areas  
Physical 
disability 
Age 7 to 11 
years 
Consider whether physical or sensory disabilities may 
have affected testing outcomes 
 
In general, physical and sensory disabilities should 
not be a plausible explanation for impairment across 
the diverse range of domains included in the FASD 
case definition. In addition, the ALSPAC team 
considered children’s special needs to minimise 
problems with test procedures as described in the 
following excerpt: 
“It is envisaged that some children with special needs 
will find some of the tests difficult at any Focus visit. 
All parents are asked if they think their child will have 
difficulties with any of the activities. If so, they are 
telephoned by a member of staff with responsibility 
for families with special needs to discuss whether a 
visit to the clinic is feasible; if not, then other 
possibilities for assessment are discussed. If they 
would like to come, modifications to the visit or to 
particular measures are discussed. If necessary extra 
staff or specialists such as signers for the deaf are 
brought in for the visit.” (F10 file). 
Consider  
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Domain ALSPAC variable Details Age assessed Details Actiona 
 
PLASC SEN codes group sensory and physical needs so 
it is not clear which of these is present for child. 
Also, consider timing of disability and whether this 
coincides with time of testing. Teacher reports 
indicate whether disability is past or current.  
Sensory impairment  Hearing 
 
Hearing 
Sensorineural 
hearing loss 
 
Hearing Impairment 
 
High frequency 
hearing loss 
 
Child has hearing 
problems requiring 
special 
arrangements at 
school 
 
PLASC SEN areas  
 
Vision 
 
Observable 
abnormality 
 
Child has eyesight 
problems requiring 
special 
arrangements at 
school 
Sensory 
impairment 
(vision and/or 
hearing) 
7 to 11 Note: PLASC SEN codes group sensory and physical so 
not clear which of these is present for child. 
Also, consider timing of disability and whether this 
coincides with time of testing. Teacher reports 
identify disability as past or current. 
 
Relevance of impairment for differential diagnosis 
depends on CNS test type (i.e. could sensory disability 
be a plausible explanation for poor performance?). 
Also check test arrangements on built files to see if 
adaptations made for Ps with sensory problems.  
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Domain ALSPAC variable Details Age assessed Details Actiona 
 
Child has sensory 
impairment (visual) 
 
Parental height  Height of mother 
and father 
Parental height N/A Consider genetic potential for growth. If mother 
and/or father have significantly short stature then 
child may not truly be growth deficient 
Not adjusted 
for. 
Substantial 
amount of 
missing 
information 
on father’s 
height (71% 
missing data) 
a ‘Consider’ means that this factor should be considered as an alternative explanation for a child’s presentation but this does not rule out the possibility that 
alcohol has been an important causal factor in influencing this child’s outcome. 
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Appendix 6: Example participant profile for case conference panel 
Case conference file 
 
 
 
 
 
Participant ID: 297 
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General information 
Sex: Female 
Ethnicity: White 
Gestational age at delivery: 36 weeks 
Maternal age at delivery: 29 years 
DOMAIN D 
Prenatal alcohol exposure history (maternal self-report) 
Duration 
This mother reported drinking in the first trimester only 
 
Dose/frequency 
First trimester: Less than one glass of alcohol per week 
 
Units of alcohol per week 
First trimester: 0 
 
Binge drinking 
No  
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DOMAIN B 
FAS Facial Phenotype 
 
Normal palpebral fissure length, smooth philtrum and normal upper lip 
DOMAIN A 
Growth centiles 
Normal 
 
Age Weight Height BMI 
Birth 85 59 95 
7 98 98 96 
8 98 98 94 
9 Missing Missing Missing 
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DOMAIN C 
Central Nervous System 
 
a) Hard and soft neurologic signs (including sensory-motor) 
EVIDENCE OF IMPAIRMENT 
Seizures: No evidence of multiple seizures 
ALSPAC Coordination Test: Poor motor coordination 
b) Brain structure 
NORMAL 
Head circumference 
Birth centile: 53 
Age 7 centile: 30 
c) Cognition (IQ) 
EVIDENCE OF IMPAIRMENT 
WISC-III (short form) 
Full Scale IQ = 68 (exceptionally low) 
Performance IQ = 67 (exceptionally low) 
Verbal IQ = 75 (low) 
Significant difference between IQ subdomains (≥ 1 SD): No 
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d) Communication: receptive and expressive 
 
EVIDENCE OF IMPAIRMENT 
 
Wechsler Objective Language Dimension (WOLD) 
Normal listening comprehension (score = 6) 
Missing expressive language  
Teacher-reported speech and language problems requiring special assistance at school 
Yes  
e) Academic achievement 
EVIDENCE OF IMPAIRMENT 
Special Educational Needs (SEN) 
SEN age 9-10: Missing 
SEN age 10-11: SEN Statement 
SEN age 11-12: SEN Statement 
Primary reason for SEN: Other needs 
Secondary reason for SEN: Missing 
Key Stage attainment  
 Key Stage 1 Key Stage 2 
Subject Reading  Writing  Spelling  Maths  English  Maths  Science  
Level Low Low Low Low Normal 
2C w Missing w N N 4 
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f) Memory 
EVIDENCE OF IMPAIRMENT 
WISC-III - Forward Digit Span 
Normal (score = 6) 
Non-Word Repetition Task 
Low non-word repetition (score = 1) 
g) Executive functioning and abstract reasoning 
EVIDENCE OF IMPAIRMENT 
Working Memory tasks: 
Counting Span Task: Missing  
Backwards Digit Span: Low backwards digit span (score = 2) 
Inhibition tasks: 
Stop Signal Task: Missing 
Opposite Worlds Task: Slow Opposite Worlds (score = 34) 
h) Attention deficit/hyperactivity 
EVIDENCE OF IMPAIRMENT 
Selective Attention: Normal (score = 6) 
Development and Well-Being Assessment - ADHD: Missing 
Strengths and Difficulties Questionnaire Hyperactivity: Yes (parent-rated) 
SDQ parent-rated hyperactivity score: 
Very high at age 7 
Missing at age 9, 11 and 13 
SDQ teacher-rated hyperactivity score: 
Close to average at age 7 and 10 
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i) Adaptive behaviour, social skills, social communication 
EVIDENCE OF IMPAIRMENT 
Strengths and Difficulties Questionnaire Peer Problems: Yes (parent and teacher-rated) 
SDQ parent-rated peer-problems score:  
High at age 7 
Missing at age 9, 11 and 13 
SDQ teacher-rated peer-problems score:  
Very high at age 7 and 10 
Strengths and Difficulties Questionnaire Conduct Problems: Yes (parent-rated) 
SDQ parent-rated conduct problems score:  
High at age 7 
Missing at age 9, 11 and 13 
SDQ teacher-rated conduct problems score:  
Close to average at age 7 and 10 
DAWBA Conduct/Oppositional Defiant Disorder (CD/ODD): Missing 
Autism: No 
Diagnostic Analysis of Non-Verbal Accuracy (DANVA): Significantly low 
Social Communication Disorder Checklist (SCDC): Missing 
Teacher-reported emotional or behavioural difficulties:  
Emotional/behavioural problems in Year 3: Yes 
Emotional/behavioural problems in Year 6: No 
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Other pre- and postnatal exposures (factors for differential diagnosis) 
Any considerations for differential diagnosis: Yes 
Perinatal trauma/complications: Umbilical cord wrapped around neck and baby 
resuscitated at delivery. 
Physical disability: Teacher-completed questionnaires suggest that this child had physical 
problems requiring special support at school, but that these problems had resolved by age 
7. Parent reports are missing.  
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Participant number:  297 
Tick box if evidence of significant impairment for each domain 
FASD Domain Definition of significant impairment 
Growth (A) 
  
Pre- and/or postnatal height or weight ≤ 9th percentile or 
disproportionately low weight-to-height ratio ≤ 9th percentile 
Face (B) 
  
3 facial features: short palpebral fissures ≤ 3rd percentile; 
smooth/flattened philtrum, thin upper lip 
Central nervous 
system (C) 
  
Impairment in ≥ 3 of the below subdomains: 
q Hard and soft neurologic signs  
q Brain structure  
q Cognition (IQ). 
q Communication: receptive and expressive. 
q Academic achievement. 
q Memory. 
q Executive functioning and abstract reasoning. 
q Attention deficit/hyperactivity. 
q Adaptive behaviour, social skills, social communication. 
A domain is considered “impaired” when on a standardized 
measure:  
Scores are 2 standard deviations or more below the mean (or ≤ 3rd 
percentile), or there is a discrepancy of at least 1 standard deviation 
between subdomains.  
In areas where standardized measurements are not available, a 
clinical judgment of “significant dysfunction” is made, taking into 
consideration that important variables, including the child’s age, 
mental health factors, socioeconomic factors and disrupted family 
or home environment (e.g., multiple foster placements, history of 
abuse and neglect), may affect development but do not indicate 
brain damage. 
Alcohol exposure 
(D) 
  
Prenatal alcohol exposure requires confirmation of alcohol 
consumption by the mother during the index pregnancy based on 
reliable clinical observation, self-report, reports by a reliable source 
or medical records documenting positive blood alcohol, alcohol 
treatment or other social, legal or medical problems related to 
drinking during the pregnancy. 
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FASD definitions: 
 
Fetal alcohol syndrome (FAS) (A, B, C and D [confirmed or unconfirmed PAE]) 
Partial FAS (2 features from B plus C and D - confirmed exposure only) 
Alcohol-related neurodevelopmental disorder (ARND) (C and D - confirmed exposure 
only) 
Final decision 
  FASD          Not FASD 
Comments 
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Appendix 7: Qualitative summary of the discussions relevant to FASD classification decisions from the case conference 
panel 
Participant Discussion notes Panel decision Most stringent FASD 
algorithm 
classification 
  FASD NOT 
FASD 
1.  Insufficient information to determine FASD although general agreement of a 
disorder/difficulty. Low level of alcohol exposure and unlikely to cause 
significant problems. Parents education ‘CSE’ level and social class 4 (manual 
unskilled). A clinical setting would diagnose a ‘possible’ case and further 
information would be requested. 
  Strict CNS/Any PAE 
2.  Low level of alcohol exposure. High level key stage 2 attainment.  Huge 
difference in verbal cognition IQ. Does not meet criteria. 
  Liberal CNS/Any PAE 
3.  Very difficult case to determine.  Some alcohol/some smoking/small baby. 
Mother’s height 157m - which may account for short stature.  Some difficulties 
which improved with age when the opposite is expected.  Hyperactivity 
reported by teacher and parents. 
  Mid CNS/Strict PAE 
4.  Possible case but based on the information provided there is insufficient 
evidence to confirm FASD.  In a clinical setting this case would be asked to 
return to the clinic and complete the missing data.  Agreement that there is 
some problem/disorder present. 
  Mid CNS/Strict PAE 
5.  Low level of alcohol exposure, short in stature.  Some risk as the mother drank 
alcohol in 2nd and 3rd trimester.  Cognition appears to be fine although a 
question mark over cognitive dysfunction. 
  Liberal CNS/Mid PAE 
6.  Parents degree educated and social class 2 (managerial). 
Mother’s height normal 170m. IQ is high.  ADHD result interesting. SEN result - 
average but underachieved based on IQ - possible functional issue. Definitely 
something to investigate in more detail.  Cognitive domain is limited.  More 
detailed sensitive testing required. 
  Strict CNS/Mid PAE 
7.  Insufficient information. Good progress at key stage 2 level.   Mid CNS/Mid PAE 
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Participant Discussion notes Panel decision Most stringent FASD 
algorithm 
classification 
  FASD NOT 
FASD 
8.  Some risk due to alcohol intake during all trimesters.  Nothing else to note.  No 
functional issues. 
  No FASD 
9.  Cognition details missing.  Low risk due to alcohol intake.  A possible case but 
more information required. 
  Mid CNS/Any PAE 
10.  Low level of alcohol exposure.  No functional deficit so no disorder.   Liberal CNS/Strict 
PAE 
11.  Evidence of alcohol exposure.  Academic functioning is fine.  Meets adaptive 
and educational criteria.  ODD at 7½ years.  Clearly a problem and highest risk 
so far.  Confirmed as FASD but information is missing to be confident with this 
diagnosis. 
  Strict CNS/Strict PAE 
12.  No discussion required.   No FASD 
13.  Parents educational level missing. Educational attainment is low but not at a 
level to indicate a problem and may be comparable to parents if this was 
available.  Science level satisfactory.  Not FASD based on information provided. 
  Liberal CNS/Mid PAE 
14.  Parents - vocational qualifications and social class 3. Smooth philtrum - 2 
features which suggest partial FASD. Low key stage 1 and low English key stage 
2 attainment.  Out of kilter with expectation. 
Evidence of hyperactivity in teenage years.  Discrepancy on WISC.  No adaptive 
deficits.  A low possible case. 
  Mid CNS/Mid PAE 
15.  Resuscitated immediately after birth but no re-admittance to hospital.  
Question over neurological difficulties.  Probable case based on low growth, 
low IQ, co-ordination problems - which are more classic symptoms, difficulties 
with education and impairment with memory. 
  Strict CNS/Any PAE 
16.  Unconfirmed hearing difficulties which could be the cause for sensory 
problems.  Symptoms worsen with age.  Data to prove alcohol intake is missing.  
Possible case but not enough information to make a reliable decision 
  Liberal CNS/Strict 
PAE 
17.  High risk of exposure.  Short and small.  Issues at school.  School action plus 
then downgraded to school action.  Meets 4 domains but not adaptive. 
  Strict CNS/Strict PAE 
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Participant Discussion notes Panel decision Most stringent FASD 
algorithm 
classification 
  FASD NOT 
FASD 
18.  Question over whether measurement was correct at birth.  Use of cannabis 
throughout pregnancy but there is no evidence that cannabis causes long 
standing disability. Parents ‘O’ level education, social class 3 (skilled non-
manual). Abnormal at age 7, small head circumference, growth issues, alcohol 
exposure is low, executive function is low, memory low. 
  Mid CNS/Any PAE 
19.  Parents ‘O’ and ‘A’ level educated; social class 3 and 5. 
Below predicted genetic potential, significantly low for DANVA, social cognitive 
dysfunction and ODD.  Attention deficit high. Fairly low for alcohol intake but 
older maternal age increases risk. 
  Strict CNS/Mid PAE 
20.  Parents ‘A’ level and degree educated.  Social class 2.  Discrepancy on reported 
alcohol dose frequency.  Data inconsistent, non-verbal difficulties, peer 
problems, ADHD traits.  Possible/probable case. 
  Mid CNS/Strict PAE 
21.  Missing information.  Parents reported hyperactivity.  Low attainment at one 
time point. 
  Liberal CNS/Any PAE 
22.  Parents ‘O’ level and ‘CSE’ educated.  Social class 3 (skilled non-manual). 
Low IQ, significantly low non-verbal accuracy.  Low key stage impairment but 
consistent with genetic level.  Social communication deficit, low risk of alcohol, 
adaptive functioning.  Not enough evidence and only meets 2 domains. 
  Liberal CNS/Strict 
PAE 
23.  SEN action plus but achieved normal attainment.  Suspect SEN for functional 
and ADHD behavioural issues.  Early problems addressed.  Three domains 
reduced to 2 if SEN due to behavioural problems. 
  Mid CNS/Strict PAE 
24.  Parents ‘A’ level and degree educated.  Social class 1 and 2.  Not enough 
information to make a positive diagnosis. 
  No FASD 
25.  Head injury and loss of consciousness but evidence of improvement following 
head injury.  ADHD reported by parents. 
Parents ‘A’ level, social class 2 and 3. Education impairment, adaptive 
behaviour, social skills and motor impairment poor.  SEN after head injury 
therefore cannot be associated with alcohol intake. 
  Strict CNS/Strict PAE 
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Participant Discussion notes Panel decision Most stringent FASD 
algorithm 
classification 
  FASD NOT 
FASD 
26.  Parents ‘CSE’ educated, social class 3 and 5. Genetically linked to IQ from 
parents.  Low level of exposure, low educational attainment can be linked to 
parents.  Although this case is hitting the indicators it was agreed that it is an 
unlikely case due to differential diagnosis. 
  Strict CNS/Any PAE 
27.  Parents ‘O’ and ‘A’ level educated.  Social class 3. Meets 5 domains.  Alcohol 
exposure in 1st and 3rd trimester.  Some facial evidence.  Dysfunction not what 
would be expected. 
  Strict CNS/Mid PAE 
28.  Parents ‘O’ level and ‘CSE’ educated, social class 3. Not enough information to 
make a diagnosis.  Speech reported problems by teacher, contradictory 
information on school action plus, SDQ problems and some social issues.  
Unsafe diagnosis. 
  Liberal CNS/Any PAE 
29.  Parents degree and ‘O’ level education, social class 1 and 3. 
Inconsistencies in units of alcohol reported. Average IQ - should have achieved 
higher at key stage 1.  Key stage 2 missing which would have helped with 
diagnosis. Meets 3 domains - attention, adaptive and executive function, but 
these could also suggest ADHD.  Certain risk of alcohol but no physical features.  
Meets criteria and enough information to support further investigation. 
  Liberal CNS/Mid PAE 
30.  Parents ‘A’ level education.  Social class 3 and 5. Head circumference small but 
smoking could be responsible.  Missing information but agreed on FASD due to 
academic achievement, query hyperactivity, adaptive problems, peer conduct 
problems. 
  Mid CNS/Mid PAE 
31.  Parents vocational and ‘A’ level educated.  Some facial evidence. No evidence 
of ADHD from teachers and true hyperactivity would be evident in all 
environments.  DANVA significantly low and social cognitive dysfunction.  Using 
criteria this would be FASD. 
  Mid CNS/Any PAE 
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Appendix 8: Qualitative summary of case conference panel recommendations for refinements to the FASD case 
ascertainment algorithm 
Discussion point Relevant domain Action point Method Decision 
A child’s level of 
functioning must be 
compared to their 
expected capability to 
determine whether 
there is likely to be a 
true impairment 
 
A discrepancy between 
WISC subdomains is 
likely to indicate 
impairment, expect in 
cases where child has 
very high IQ in one 
domain and high in 
another. 
CNS: c) Cognition 
 
Compare child cognitive 
ability to educational 
attainment to see if both are 
consistent. If both are low 
then only count as evidence 
of impairment in one distinct 
area to avoid ‘double 
counting’ of this impairment.  
 
Given evidence of impaired 
educational attainment, recode 
educational attainment as not 
impaired if IQ low/borderline. 
Education remains as impaired if ≥ 
average IQ. 
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
If WISC is missing use parental 
attainment to estimate child’s 
genetic potential. 
 
Lisa Hurt [LH] subsequently 
queried this - parental attainment 
may not be good indicator of child 
potential. 
 
Not actioned: Parental 
attainment reflects both 
genetic potential and 
social factors and is an 
imperfect proxy for child 
potential. 
CNS: e) 
Educational 
attainment 
Compare cognition and 
educational attainment to 
genetic potential - using 
parental social class and 
educational attainment as 
proxies. 
Recode parental attainment as 
low if highest educational level is 
equivalent to CSE or below for one 
or both parents or if highest 
parental social class is unskilled.  
 
In further discussion with LH we 
considered the limitations of this 
approach, which implies that 
children may not be able to 
succeed if their parents have low 
attainment/social class. Parental 
attainment may not be a good 
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Discussion point Relevant domain Action point Method Decision 
substitute for genetic potential, as 
it will reflect a mixture of cognitive 
ability and social opportunities. 
Also, parents with alcohol 
problems may be less likely to 
have high achievement so low 
attainment among participants 
whose parents were low 
attainment/social class does not 
rule out the possible influence of 
prenatal alcohol exposure. 
CNS: c) Cognition 
 
Explore level of WISC 
functioning among discrepant 
cases (≥ 1 SD between 
subdomains) 
Recode c) Cognition as not 
impaired if discrepancy between 
subdomains but high IQ. 
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
There must be 
convergent evidence of 
hyperactivity from more 
than one source and/or 
across time points. In 
this dataset 
hyperactivity would be 
expected to be stable, 
as medication for ADHD 
was much less common 
in the 1990s.  
CNS: h) Attention 
deficit 
hyperactivity 
Look for convergent evidence 
in CNS domain h) 
Recode hyperactivity so that it is 
only classed as impaired if 
convergent evidence across raters 
and/or time points. 
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
There should be 
convergent evidence 
between measures 
within the adaptive 
functioning domain. For 
example, a child with 
CNS: i) Adaptive 
functioning 
Look for convergent evidence 
in domain i) 
Recode i) Adaptive functioning so 
only impaired if convergent 
evidence across measures. 
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
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Discussion point Relevant domain Action point Method Decision 
low DANVA or SCDC 
would be expected to 
have peer problems.  
Functional deficits 
should be considered a 
core feature of FASD 
diagnosis.  
CNS: i) Adaptive 
functioning 
Look for evidence of 
functional impairment to 
classify a participant as FASD. 
Recode final FASD categorisation 
so that a FASD classification is 
given only if there is evidence of 
impairment in ≥ CNS domains and  
CNS domains i) and/or e) are 
classed as impaired.  
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm CNS: e) 
Educational 
attainment 
Special educational 
needs may indicate a 
range of different 
impairments. Need to 
reclassify so that SEN 
categories are placed in 
the correct domain.  
CNS: e) 
Educational 
attainment 
Look for SEN reason and 
reclassify under relevant CNS 
domains where necessary 
If SEN code: 
1. Cognition and Learning - keep in 
domain e) 
2. Behavioural/emotional - move 
to domain i) 
3. Communication and interaction 
- move to domain d) 
If SEN reason missing then keep 
SEN in domain e)  
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
CNS: i) Adaptive 
functioning 
CNS: d) 
Communication 
School attainment 
should remain low 
across Key Stages 1 and 
2 if indicative of a true, 
stable impairment 
CNS: e) 
Educational 
attainment 
Look for stable impairment Recode education so that only low 
if evidence of impairment across 
time points i.e. low grades across 
time points  
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
Head circumference ≤2nd 
percentile at any point 
should be classed as 
deficient 
CNS: a) Head 
circumference 
Consider small OFC at all time 
points 
Recode a) as impaired if small OFC 
at birth or age 7 
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
Consider parental height 
when assessing whether 
child’s height is deficient 
Growth Add parental height to 
prevalence considerations 
Recode growth as not deficient for 
children with short mother or 
Not actioned: 
Substantial amount of 
missing information on 
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Discussion point Relevant domain Action point Method Decision 
 biological father <=9th centile, if 
BMI not also deficient 
father’s height (71% 
missing). Lack of 
adjustment for parental 
height will not affect 
prevalence estimates for 
total FASD. It could 
affect prevalence 
estimates for FAS and 
descriptive 
characteristics of clinical 
features. 
WISC score seems 
pivotal for establishing a 
child’s baseline cognitive 
ability. Drop participants 
from the dataset if they 
have a missing WISC and 
no indicator of genetic 
potential based on 
parental ability 
CNS: c) Cognition 
and participant 
selection 
Check for missingness of WISC 
and parental attainment 
Drop participants with missing 
WISC and missing parental 
educational attainment as it 
makes it difficult to determine 
their potential  
Not actioned: This 
would lead to a 
significant reduction in 
sample size and the 
absence of a WISC score 
does not preclude the 
assignment of FASD 
status, as it is still 
possible to obtain 
evidence of impairment 
in ≥ 3 distinct domains 
even if WISC score is 
missing.  
Partial FAS facial 
features and low 
reported PAE make the 
reported levels of PAE 
questionable, as facial 
features are highly 
specific to heavy PAE 
Prenatal alcohol 
exposure 
Be aware that participants 
with the partial FAS facial 
phenotype are likely to have 
had heavy PAE 
If we decide to apply a threshold 
for FASD classification based on 
reported PAE then consider 
lowering the threshold for 
participants with the partial FAS 
facial phenotype 
Not actioned: PAE 
threshold already 
systematically varied 
across case 
ascertainment 
algorithms and 
subcategories include 
assignment of FAS 
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Discussion point Relevant domain Action point Method Decision 
category if the full FAS 
facial phenotype is 
present, even in the 
absence of confirmed 
PAE. Only the full facial 
phenotype is highly 
specific to PAE. 
The inclusion of seizures 
as a criterion was not 
discussed explicitly at 
case conference, as 
none of the participant 
profile examples had 
seizures. The main 
diagnostic frameworks 
(Canadian, 4-Digit) 
suggest seizures as a 
marker of neurological 
impairment for domain 
a) so I think it is 
reasonable to include 
this for reasons of 
consistency with the 
chosen Canadian 
diagnostic framework. 
CNS: a) Sensory-
motor 
Add seizures to domain a)  Add multiple seizures not due to 
postnatal insult as criterion for 
CNS domain a) for mid and strict 
CNS classifications (already 
included in liberal CNS) 
Actioned: Incorporated 
in Revised CNS case 
ascertainment algorithm 
Abbreviations: CNS; central nervous system; CSE, Certificate of Secondary Education; DANVA; Diagnostic Analysis of Non-Verbal Accuracy; IQ, intelligence 
quotient; OFC, occipital frontal head circumference; SD, standard deviation; SCDC, Social Communication Disorders Checklist; SEN, special educational needs; 
SES, socioeconomic status; WISC, Weschler Intelligence Scale for Children. 
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Appendix 9: Multiple imputation model specification and missing data frequencies 
   Prevalence 
analyses 
(Chapter 4) 
N eligible = 13,495 
Risk factor 
analyses 
(Chapter 6) 
N eligible = 9,135 
 
Variable name Variable description Categories N 
availabl
e 
Missing 
(%) 
N 
availabl
e 
Missin
g (%) 
Imputation 
command 
Variables included in multiple imputation model and featured in prevalence and/or risk factor analyses   
(exposures, confounding variables and clinical characteristics that contribute to FASD status) 
dosefreq Alcohol dose/frequency during pregnancy 
None/<1 glass per week/1-6 glasses per 
week/7+ glasses per week 12,947 4 9,045 1 ologit 
bingeb Binge drinking during 
pregnancy (Questionnaire 
B) 
No/Yes 
12,519 7 8,847 3 logit 
bingec Binge drinking during 
pregnancy (Questionnaire 
C) 
No/Yes 
8,411 38 5,957 35 logit 
b720 Alcohol consumption pre-
pregnancy 
Never/<1 glass per wk/1+ glasses per week/1-2 
glasses daily/3-9 glasses daily/10+ glasses daily 12,602 7 8,899 3 ologit 
pregdrinkchange Alcohol drinking change 
during pregnancy 
No evidence of continued drinking/Had more or 
No change 11,621 14 8,100 11 logit 
a261 Measures of alcohol per 
week (Questionnaire A) 
Continuous 11,375 16 7,790 15 regress 
c373 Measures of alcohol per 
week (Questionnaire C) 
Continuous 6,619 51 4,586 50 regress 
shortpfl Short palpebral fissure 
length 
No/Yes 4,370 68 3,214 65 logit 
Philtrum4Digit Philtrum shape Smooth/Indentation near nose/Indentation in 
middle/Indentation near vermillion 
border/Deep groove from nose to vermillion 
border/Deep groove to Cupid's bow 
4,370 68 3,213 65 ologit 
UpperLipFullness Upper lip fullness Thin/Medium/Thick 4,370 68 3,213 65 ologit 
coordination Low coordination No/Yes 6,520 52 4,774 48 logit 
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   Prevalence 
analyses 
(Chapter 4) 
N eligible = 13,495 
Risk factor 
analyses 
(Chapter 6) 
N eligible = 9,135 
 
Variable name Variable description Categories N 
availabl
e 
Missing 
(%) 
N 
availabl
e 
Missin
g (%) 
Imputation 
command 
seizmulti More than one seizure not 
due to postnatal insult 
No/Yes 11,646 14 8,208 10 logit 
ofcbirthLMS Small head circumference 
(OFC) at birth 
No/Yes 8,340 38 5,749 37 logit 
ofc7LMS Small head circumference 
(OFC) at age 7 
No/Yes 7,449 45 5,453 40 logit 
f8ws110 Verbal IQ Continuous 6,830 49 5,005 45 regress 
f8ws111 Performance IQ Continuous 6,821 49 4,994 45 regress 
f8ws112 Full-scale IQ Continuous 6,800 50 4,979 45 regress 
wold_list Low listening 
comprehension 
No/Yes 6,821 49 5,003 45 logit 
wold_express Low expressive language No/Yes 4,493 67 3,315 64 logit 
comm_schoolany2 Communication problems 
at school 
No/Yes 4,100 70 2,795 69 logit 
sen Special educational needs No/Yes 11,312 16 7,633 16 logit 
lowedu_all3 Low academic attainment 
at KS1 and KS2 
No/Yes 11,824 12 8,032 12 logit 
nonwordrep Low non-word repetition No/Yes 6,809 50 4,995 45 logit 
digitspanf Low forward digit span No/Yes 6,702 50 4,909 46 logit 
oppworldfinal Low opposite world task No/Yes 6,657 51 4,890 46 logit 
countspan Low counting span No/Yes 6,455 52 4,706 48 logit 
stopsigfinal Low stop signal No/Yes 6,426 52 4,668 49 logit 
digitspanb Low backwards digit span No/Yes 6,683 50 4,900 46 logit 
adhd ADHD No/Yes 7,952 41 5,772 37 logit 
sdq_hypparent SDQ hyperactivity (parent-
rated) 
No/Yes 9,402 30 6,759 26 logit 
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   Prevalence 
analyses 
(Chapter 4) 
N eligible = 13,495 
Risk factor 
analyses 
(Chapter 6) 
N eligible = 9,135 
 
Variable name Variable description Categories N 
availabl
e 
Missing 
(%) 
N 
availabl
e 
Missin
g (%) 
Imputation 
command 
sdq_hypteacher SDQ hyperactivity (teacher-
rated) 
No/Yes 9,145 32 6,251 32 logit 
selectattfinal Low selective attention No/Yes 6,638 51 4,875 47 logit 
ODD_CD Oppositional-conduct 
disorder 
No/Yes 7,952 41 5,772 37 logit 
sdq_peerparent SDQ peer problems 
(parent-rated) 
No/Yes 9,414 30 6,771 26 logit 
sdq_peerteacher SDQ peer problems 
(teacher-rated) 
No/Yes 9,145 32 6,251 32 logit 
sdq_condparent SDQ conduct problems 
(parent-rated) 
No/Yes 9,412 30 6,769 26 logit 
sdq_condteacher SDQ conduct problems 
(teacher-rated) 
No/Yes 9,137 32 6,245 32 logit 
sigsoccog Significant social cognitive 
dysfunction 
No/Yes 8,678 36 6,270 31 logit 
emobeh_schoolan
y 
Emotional/behavioural 
problems at school 
No/Yes 9,088 33 6,204 32 logit 
autism Autism No/Yes 13,495 0 4,614 49 - 
danva DANVA ≥ 7 errors No/Yes 6,304 53 9,086 1 logit 
lowgrowth Growth impairment No/Yes 13,419 1 9,013 1 logit 
drugpreg Illicit drug use during 
pregnancy 
No/Yes 12,886 5 9,133 0 logit 
smokepreg Smoking during pregnancy No/Yes 13,304 1 9,005 1 logit 
multivitaminsupp Multivitamin supplements 
during pregnancy 
No/Yes 12,898 4 9,014 1 logit 
ironsupp Iron supplements during 
pregnancy 
No/Yes 12,907 4 9,014 1 logit 
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   Prevalence 
analyses 
(Chapter 4) 
N eligible = 13,495 
Risk factor 
analyses 
(Chapter 6) 
N eligible = 9,135 
 
Variable name Variable description Categories N 
availabl
e 
Missing 
(%) 
N 
availabl
e 
Missin
g (%) 
Imputation 
command 
zincsupp Zinc supplements during 
pregnancy 
No/Yes 12,906 4 9,013 1 logit 
calciumsupp Calcium supplements 
during pregnancy 
No/Yes 12,905 4 9,014 1 logit 
folicacidsupp Folic acid supplements 
during pregnancy 
No/Yes 12,903 4 9,015 1 logit 
vitaminsupp Any vitamin supplements 
during pregnancy 
No/Yes 12,908 4 6,270 31 logit 
calories Daily calorie intake during 
pregnancy 
Continuous 11,660 14 8,242 10 regress 
retinol Retinol (RNI met) No/Yes 11,660 14 8,242 10 logit 
calcium Calcium(RNI met) No/Yes 11,660 14 8,242 10 logit 
omega3 Omega-3 (RNI met) No/Yes 11,660 14 8,242 10 logit 
folate Folate (RNI met) No/Yes 11,660 14 8,242 10 logit 
riboflavin Riboflavin (RNI met) No/Yes 11,660 14 8,242 10 logit 
selenium Selenium (RNI met) No/Yes 11,660 14 8,242 10 logit 
vitb12 Vitamin B12 (RNI met) No/Yes 11,660 14 8,242 10 logit 
vitc Vitamin C (RNI met) No/Yes 11,660 14 8,242 10 logit 
vite Vitamin E (RNI met) No/Yes 11,660 14 8,242 10 logit 
zinc Zinc (RNI met) No/Yes 11,660 14 8,242 10 logit 
iodine Iodine (RNI met) No/Yes 11,660 14 8,242 10 logit 
iron Iron (RNI met) No/Yes 11,660 14 8,242 10 logit 
magnesium Magnesium (RNI met) No/Yes 11,660 14 8,242 10 logit 
niacin Niacin (RNI met) No/Yes 11,660 14 8,242 10 logit 
phosphorus Phosphorous (RNI met) No/Yes 11,660 14 8,242 10 logit 
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   Prevalence 
analyses 
(Chapter 4) 
N eligible = 13,495 
Risk factor 
analyses 
(Chapter 6) 
N eligible = 9,135 
 
Variable name Variable description Categories N 
availabl
e 
Missing 
(%) 
N 
availabl
e 
Missin
g (%) 
Imputation 
command 
potassium Potassium (RNI met) No/Yes 11,660 14 8,242 10 logit 
sodium Sodium RNI met) No/Yes 11,660 14 8,242 10 logit 
thiamin Thiamin (RNI met) No/Yes 11,660 14 8,242 10 logit 
vitb6 Vitamin B6 (RNI met) No/Yes 11,660 14 8,242 10 logit 
married Marital status Married/Not married 12,646 6 8,800 4 logit 
home Home ownership Mortgaged or owned/Council or housing 
assoc./Rented (private)/Other 12,595 7 8,763 4 mlogit 
socialclassm Maternal social class Professional/Mangerial or technical/Skilled 
non-manual/Skilled manual/Partly 
skilled/unskilled 
9,718 28 7,004 23 ologit 
socialclassp Paternal social class Professional/Mangerial or technical/Skilled 
non-manual/Skilled manual/Partly 
skilled/unskilled 
10,590 22 7,570 17 ologit 
mumedu Highest educational 
qualification (maternal) 
CSE/Vocational/O Level/A Level/Degree 11,988 11 8,449 8 ologit 
partneredu Highest educational 
qualification (paternal) 
CSE/Vocational/O Level/A Level/Degree 11,516 15 8,125 11 ologit 
agecat2 Maternal age (years) < 20/20-29/30+ 13,495 0 8,294 9 - 
relig Religion (maternal) None/Christian/Other 11,783 13 8,887 3 mlogit 
unplanned Unplanned pregnancy No/Yes 12,620 6 7,335 20 logit 
totallifeevents Total life events during 
pregnancy 
Continuous 10,204 24 7,335 20 regress 
weightedlifeevent
s 
Weighted total life events 
during pregnancy 
Continuous 10,204 24 8,949 2 regress 
relationdiff Relationship problems 
during pregnancy 
No/Yes 12,801 5 8,949 2 logit 
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   Prevalence 
analyses 
(Chapter 4) 
N eligible = 13,495 
Risk factor 
analyses 
(Chapter 6) 
N eligible = 9,135 
 
Variable name Variable description Categories N 
availabl
e 
Missing 
(%) 
N 
availabl
e 
Missin
g (%) 
Imputation 
command 
relationdiffimpact Very affected by 
relationship problems 
during pregnancy 
No/Yes 
12,801 5 8,940 2 logit 
bereavement Bereavement during 
pregnancy (any) 
No/Yes 12,781 5 8,940 2 logit 
bereavementimpa
ct 
Very affected by 
bereavement during 
pregnancy 
No/Yes 
12,781 5 8,933 2 logit 
financeprob Major financial problem 
during pregnancy 
No/Yes 12,763 5 8,933 2 logit 
financeprobimpac
t 
Very affected by major 
financial problems during 
pregnancy 
No/Yes 
12,763 5 9,033 1 logit 
housemove Moved house during 
pregnancy 
No/Yes 12,984 4 8,800 4 logit 
housemoveimpact Very affected by house 
move during pregnancy 
No/Yes 12,769 5 8,936 2 logit 
ill Very affected by illness or 
accident during pregnancy 
No/Yes 12,783 5 8,943 2 logit 
illimpact Illness or accident during 
pregnancy 
No/Yes 12,783 5 8,943 2 logit 
partnerill Partner ill during pregnancy No/Yes 12,765 5 8,932 2 logit 
partnerillimpact Very affected by partner 
illness during pregnancy 
No/Yes 12,765 5 8,932 2 logit 
childill Child ill during pregnancy No/Yes 12,762 5 8,931 2 logit 
childillimpact Very affected by child 
illness during pregnancy 
No/Yes 12,762 5 8,931 2 logit 
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   Prevalence 
analyses 
(Chapter 4) 
N eligible = 13,495 
Risk factor 
analyses 
(Chapter 6) 
N eligible = 9,135 
 
Variable name Variable description Categories N 
availabl
e 
Missing 
(%) 
N 
availabl
e 
Missin
g (%) 
Imputation 
command 
depressany Depression during 
pregnancy 
No/Yes 12,551 7 8,774 4 logit 
anxany Anxiety during pregnancy No/Yes 12,469 8 8,714 5 logit 
d800 Social support during 
pregnancy 
Continuous 11,050 18 7,831 14 regress 
maternalabuse Any abuse (mother) No/Yes 12,902 4 8,979 2 logit 
grandmotheralc Maternal grandmother had 
alcoholism 
No or Don't Know/Yes 11,716 13 8,257 10 logit 
rs1229984m Maternal rs1229984 
genotype (>= 1 rare allele) 
No/Yes 7,712 43 5,438 40 logit 
riskybeh Maternal impulsivity No/Yes 7,149 47 5,219 43 logit 
Auxiliary variables 
pregcomp Perinatal 
trauma/complications 
No/Yes 12,665 6 8,727 4 logit 
binge8w Postnatal binge drinking (8 
weeks) 
No/Yes 8,214 39 5,843 36 logit 
alcprobpostall Postnatal alcohol problems No/Yes 9,680 28 6,956 24 logit 
parity Parity 0/1/2/>2 12,487 7 8,777 4 ologit 
bestgest Gestational age at delivery Continuous 13,495 0 9,135 0 - 
miscarriage Previous miscarriage 0/1/≥2 12,539 7 8,807 4 ologit 
ultrasound Ultrasound at any point in 
pregnancy 
No/Yes 10,858 20 7,747 15 logit 
bmi Maternal BMI (pre-
pregnancy) 
Underweight/Normal/Overweight/Obese 11,140 17 7,861 14 ologit 
sex Child gender Male/Female 13,495 0 9,135 0 - 
ethnic Maternal ethnicity White/Non-White 11,904 12 8,413 8 logit 
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Appendix 10: Missing data patterns 
Table 19: Comparison of the distribution of sociodemographic factors, prenatal exposures and FASD outcome 
variables among participants with complete data, compared to those who had missing data for one or more of 
the measures required to ascertain FASD status 
 Eligible sample 
N = 13,495 
N (%)a 
 
Participants with 
complete data 
N = 223 
(N [%]) 
Participants with 
missing data for 
one or more of the 
measures required 
to ascertain FASD  
status 
N = 13,272 
 (N [%]) 
SOCIODEMOGRAPHIC FACTORS     
Maternal age (years)  
<20 641 (4.8) 0 (0) 641 (4.8) 
20-29 7,839 (58.1) 105 (47.1) 7,734 (58.3) 
30+ 5,015 (37.2) 118 (52.9) 4,897 (36.9) 
Maternal ethnicity  
White 11,600 (97.5) 219 (98.2) 11,381 (97.4) 
Non-White 304 (2.6) 4 (1.8) 300 (2.6) 
Marital status  
Not married 3,163 (25.0) 28 (12.6) 3,135 (25.3) 
Married 9,483 (75.0) 194 (87.4) 9,289 (74.7) 
Maternal social class  
Professional 573 (5.9) 12 (5.7) 561 (5.9) 
Managerial/technical 3,060 (31.5) 74 (35.4) 2,986 (31.4) 
Skilled non-manual 4,153 (42.7) 96 (45.9) 4,057 (42.7) 
Skilled manual 763 (7.9) 13 (6.2) 750 (7.9) 
Partly skilled/unskilled 1,169 (12.0) 14 (6.7) 1,155 (12.2) 
Paternal social class  
Professional 1,160 (11.0) 40 (18.5) 1,120 (10.8) 
Managerial/technical 3,596 (34.0) 74 (34.3) 3,522 (34.0) 
Skilled non-manual 1,156 (10.9) 33 (15.3) 1,123 (10.8) 
Skilled manual 3,333 (31.5) 53 (24.5) 3,280 (31.6) 
Partly skilled/unskilled 1,345 (12.7) 16 (7.4) 1,329 (12.8) 
Maternal education  
CSE 2,416 (20.2) 19 (8.5) 2,397 (20.4) 
Vocational 1,182 (9.9) 13 (5.8) 1,169 (9.9) 
O Level 4,149 (34.6) 77 (34.5) 4,072 (34.6) 
A Level 2,706 (22.6) 76 (34.1) 2,630 (22.4) 
Degree 1,535 (12.8) 38 (17.0) 1,497 (12.7) 
Paternal education 
CSE 3,013 (26.2) 25 (11.3) 2,988 (26.5) 
Vocational 975 (8.5) 21 (9.5) 954 (8.5) 
O Level 2,436 (21.2) 49 (22.2) 2,387 (21.1) 
A Level 3,004 (26.1) 68 (30.8) 2,936 (26.0) 
Degree 2,088 (18.1) 58 (26.2) 2,030 (18.0) 
Home ownership status     
Mortgaged/owned 9,240 (73.4) 205 (92.3) 9,035 (73.0) 
Council/housing association 2,016 (16.0) 5 (2.3) 2,011 (16.3) 
Rented (private) 902 (7.2) 5 (2.3) 897 (7.3) 
Other 437 (3.5) 7 (3.2) 430 (3.5) 
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 Eligible sample 
N = 13,495 
N (%)a 
 
Participants with 
complete data 
N = 223 
(N [%]) 
Participants with 
missing data for 
one or more of the 
measures required 
to ascertain FASD  
status 
N = 13,272 
 (N [%]) 
PRENATAL EXPOSURES 
Prenatal alcohol use (any)    
No 4,132 (31.1) 61 (27.4) 4,071 (31.2) 
Yes 9,135 (68.9) 162 (72.7) 8,973 (68.8) 
Prenatal alcohol exposure (max dose/frequency during pregnancy) 
None 4,171 (32.2) 63 (28.3) 4,108 (32.3) 
<1 glass per week 5,480 (42.3) 103 (46.2) 5,377 (42.3) 
1-6 glasses per week 2,872 (22.2) 49 (22.0) 2,823 (22.2) 
7+ glasses per week 424 (3.3) 8 (3.6) 416 (3.3) 
Prenatal binge drinking 
No 9,927 (77.8) 180 (80.7) 9,747 (77.7) 
Yes 2,839 (22.2) 43 (19.3) 2,796 (22.3) 
Alcohol use before pregnancy 
None 1,048 (8.3) 5 (2.2) 1,043 (8.4) 
≤ 1 - 6 glasses per week 10,144 (80.5) 191 (85.7) 9,953 (80.4) 
7 - 14 glasses per week 1,200 (9.5) 23 (10.3) 1,177 (9.5) 
> 14 glasses per week 210 (1.7) 4 (1.8) 206 (1.7) 
Prenatal smoking 
No 9,601 (72.2) 192 (86.1) 9,409 (71.9) 
Yes 3,703 (27.8) 31 (13.9) 3,672 (28.1) 
Prenatal illicit drug use 
No 12,464 (96.7) 220 (98.7) 12,244 (96.7) 
Yes 422 (3.3) 3 (1.4) 419 (3.3) 
Prenatal vitamin supplement use (any) 
No 5,938 (46.0) 95 (42.6) 5,843 (46.1) 
Yes 6,970 (54.0) 128 (57.4) 6,842 (53.9) 
Prenatal stressful life events 
Mean (SD) 7 (4) 6 (4) 7 (4) 
Social support score 
Mean (SD) 20 (5) 21 (4) 20 (5) 
Prenatal anxiety 
No 9,545 (76.6) 184 (82.5) 9,361 (76.4) 
Yes 2,924 (23.4) 39 (17.5) 2,885 (23.6) 
Prenatal depression 
No 9,940 (79.2) 194 (87.0) 9,746 (79.1)  
Yes 2,611 (20.8) 29 (13.0) 2,582 (20.9) 
Unplanned pregnancy     
No 8,722 (69.1) 187 (83.9) 8,535 (68.9) 
Yes 3,898 (30.9) 36 (16.1) 3,862 (31.2) 
CLINICAL CHARACTERISTICS     
Facial phenotype     
Short palpebral fissure length 
No 3,390 (77.6) 174 (78.0) 3,216 (77.6) 
Yes 980 (22.4)   49 (22.0)           931 (22.5) 
Smooth philtrum 
No 3,461 (79.2) 166 (74.4) 3,295 (79.5) 
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 Eligible sample 
N = 13,495 
N (%)a 
 
Participants with 
complete data 
N = 223 
(N [%]) 
Participants with 
missing data for 
one or more of the 
measures required 
to ascertain FASD  
status 
N = 13,272 
 (N [%]) 
Yes 909 (20.8) 57 (25.6) 852 (20.5) 
Thin upper lip 
No 3,951 (90.4) 193 (86.6) 3,758 (90.6) 
Yes 419 (9.6) 30 (13.5) 389 (9.4) 
CENTRAL NERVOUS SYSTEM     
Coordination test 
Normal  6,204 (95.1) 218 (97.8) 5,986 (95.1) 
Poor motor coordination 316 (4.9) 5 (2.2) 311 (4.9) 
Head circumference at birth 
Normal  8,229 (98.7) 222 (99.6) 8,007 (98.6) 
Small (<2nd percentile) 111 (1.3) 1 (0.5) 110 (1.4) 
Head circumference at age 7 
Normal  6,841 (91.8) 200 (89.7) 6,641 (91.9)  
Small (<2nd percentile) 608 (8.2) 23 (10.3) 585 (8.1) 
Full scale IQ 
Mean (SD) 104 (17) 109 (15) 104 (17) 
Verbal IQ 
Mean (SD) 107 (17) 111 (15) 107 (17) 
Performance IQ 
Mean (SD) 100 (17) 102 (17) 100 (17) 
Significant difference between IQ subdomains 
No 3,772 (55.5) 119 (53.4) 3,653 (55.5) 
Yes 3,028 (44.5) 104 (46.6) 2,924 (44.5) 
WOLD listening comprehension task 
Normal 6,627 (97.2) 216 (96.9) 6,411 (97.2) 
Low performance 194 (2.8) 7 (3.1) 187 (2.8) 
WOLD expressive language     
Normal 4,324 (96.2) 223 (100.0) 4,101 (96.0) 
Low performance 169 (3.8) 0 (0.0) 169 (4.0) 
Speech and language problems at school 
No 3,552 (86.6) 217 (97.3) 3,335 (86.0) 
Yes 548 (13.4) 6 (2.7) 542 (14.0) 
Special educational needs     
No 8,867 (78.4) 195 (87.4) 8,672 (78.2) 
Yes 2,445 (21.6) 28 (12.6) 2,417 (21.8) 
Low academic attainment at Key Stage 1 and 2 
No 10,174 (86.1) 209 (93.7) 9,965 (85.9) 
Yes 1,650 (14.0) 14 (6.3) 1,636 (14.1) 
Non-word repetition task 
Normal  6,565 (96.4) 212 (95.1) 6,353 (96.5) 
Low performance 244 (3.6) 11 (4.9) 233 (3.5) 
Forward digit span task 
Normal  6,557 (97.8) 214 (96.0) 6,343 (97.9) 
Low performance 145 (2.2) 9 (4.0) 136 (2.1) 
Opposite worlds task 
Normal  6,460 (97.0) 221 (99.1) 6,239 (97.0) 
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 Eligible sample 
N = 13,495 
N (%)a 
 
Participants with 
complete data 
N = 223 
(N [%]) 
Participants with 
missing data for 
one or more of the 
measures required 
to ascertain FASD  
status 
N = 13,272 
 (N [%]) 
Low performance 197 (3.0) 2 (0.9) 195 (3.0) 
Counting span task 
Normal  6,166 (95.5) 218 (97.8) 5,948 (95.4) 
Low performance 290 (4.5) 5 (2.2) 284 (4.6) 
Stop signal task 
Normal  6,214 (96.7) 215 (96.4) 5,999 (96.7) 
Low performance 212 (3.3) 8 (3.6) 204 (3.3) 
Backwards digit span task 
Normal  6,182 (92.5)  204 (91.5)     5,978 (92.5) 
Low performance 501 (7.5) 19 (8.5) 482 (7.5) 
ADHD 
No 7,786 (97.9)  215 (96.4)      7,571 (98.0) 
Yes 166 (2.1) 8 (3.6)      158 (2.0) 
SDQ hyperactivity 
No 10,174 (86.4) 195 (87.4) 9,979 (86.4) 
Yes 1,604 (13.7) 28 (12.6) 1,576 (13.6) 
Oppositional-conduct disorder 
No 7,703 (96.9)  215 (96.4)    7,488 (96.9) 
Yes 249 (3.1) 8 (3.6) 241 (3.1) 
SDQ peer problems 
No 9,594 (81.4) 186 (83.4) 9,408 (81.4) 
Yes 2,189 (18.6) 37 (16.6) 2,152 (18.6) 
SDQ conduct problems 
No 9,530 (80.9) 189 (84.8) 9,341 (80.8) 
Yes 2,249 (19.1) 34 (15.3) 2,215 (19.2) 
SCDC social communication problems 
No 7,820 (90.1) 206 (92.4) 7,614 (90.1) 
Yes 858 (9.9) 17 (7.6) 841 (10.0) 
Emotional or behavioural problems at school 
No 8,245 (90.7) 210 (94.2) 8,035 (90.6) 
Yes 843 (9.3) 13 (5.8) 830 (9.4) 
Autism 
No 13,414 (99.4) 221 (99.1) 13,193 (99.4) 
Yes 81 (0.6) 2 (0.9) 79 (0.6) 
DANVA task 
Normal 4,891 (77.6) 177 (79.4) 4,714 (77.5) 
Low performance 1,413 (22.4) 46 (20.6) 1,367 (22.5) 
GROWTH     
Growth deficiency 
No 12,310 (91.7) 214 (96.0) 12,096 (91.7) 
Yes 1,109 (8.3) 9 (4.0) 1,100 (8.3) 
Auxiliary variables      
Pregnancy/perinatal complications 
No 8,881 (70.1) 157 (70.7) 8,724 (70.1) 
Yes 3,784 (29.9) 65 (29.3) 3,719 (29.9) 
Binge drinking (8 weeks postpartum) 
No 4,973 (60.5)  152 (69.1)    4,821 (60.3) 
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 Eligible sample 
N = 13,495 
N (%)a 
 
Participants with 
complete data 
N = 223 
(N [%]) 
Participants with 
missing data for 
one or more of the 
measures required 
to ascertain FASD  
status 
N = 13,272 
 (N [%]) 
Yes 3,241 (39.5) 68 (30.9) 3,173 (39.7) 
Postnatal alcohol problems (maternal self-report and AUDIT 5 to 18 years postpartum) 
No 7,900 (81.6) 162 (72.7) 7,738 (81.8) 
Yes 1,780 (18.4) 61 (27.4) 1,719 (18.2) 
Parity     
0 5,597 (44.8) 109 (49.8) 5,488 (44.7) 
1 4,369 (35.0) 72 (32.9) 4,297 (35.0) 
2 1,781 (14.3) 26 (11.9) 1,755 (14.3) 
>2 740 (5.9) 12 (5.5) 728 (5.9) 
Gestational age at delivery (weeks) 
Mean (SD) 39.5 (1.8) 39.5 (1.5) 39.5 (1.9) 
Previous miscarriage     
0 9,861 (78.6) 169 (76.5) 9,692 (78.7) 
1 2,017 (16.1) 45 (20.4) 1,972 (16.0) 
≥2 661 (5.3) 7 (3.2) 654 (5.3) 
Ultrasound scan during pregnancy 
No 533 (4.9) 9 (4.0) 524 (4.9) 
Yes 10,035 (95.1) 214 (96.0) 10,111 (95.1) 
Maternal BMI (pre-pregnancy)     
Underweight 558 (5.0) 9 (4.2) 549 (5.0) 
Normal 8,280 (74.3) 162 (75.4) 8,118 (74.3) 
Overweight  1,684 (15.1) 33 (15.4) 1,651 (15.1) 
Obese 618 (5.6) 11 (5.1) 607 (5.6) 
Child sex     
Female 6,541 (48.5) 101 (45.3) 6,853 (51.6) 
Male 6,954 (51.5)  122 (54.7)  6,419 (48.4) 
a Sample size for each variable differs from eligible sample due to missing data. Percentages do 
not always sum to 100 due to rounding. 
Abbreviations: BMI, body mass index; CSE, Certificate of secondary education; DANVA, Diagnostic 
Analysis of Nonverbal Accuracy; SCDC, Social Communication Disorder Checklist; SD, standard 
deviation; SDQ, Strengths and Difficulties Questionnaire; WOLD, Weschler Objective Language 
Dimensions. 
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Appendix 11: Sociodemographic and pregnancy characteristics of 
participants by FASD status based on multiply imputed data 
 Total sample 
N = 13,495 
% (95% CI) 
Not FASDa 
 
% (95% CI) 
FASDa 
 
% (95% CI) 
Sociodemographic factors    
Child sex    
Female 48.5 (47.6 - 49.3) 51.5 (50.5 - 52.4) 33.9 (31.5- 36.2) 
Male 51.5 (50.7 - 52.4) 48.5 (47.6 - 49.5) 66.1 (63.8 - 68.5) 
Maternal ethnicity    
White 97.1 (96.8 - 97.5) 97.3 (96.9 - 97.6) 96.5 (95.5 - 97.6) 
Non-White 2.9 (2.5 - 3.2) 2.7 (2.4 - 3.1) 3.5 (2.4 - 4.6) 
Maternal age at pregnancy (years) 
<20 4.7 (4.4 - 5.1) 4.2 (3.8 - 4.7) 7.2 (5.9 - 8.6) 
20-29 58.1 (57.3 - 58.9) 57.4 (56.4 - 58.3) 61.5 (59.3 - 63.8) 
30+ 37.2 (36.3 - 38.0) 38.4 (37.5 - 39.3) 31.2 (29.2 - 33.3) 
Home ownership    
Mortgaged/owned 72.4 (71.6 - 73.2) 75.6 (74.6 - 76.5) 57.0 (54.3 - 59.6) 
Council/housing association 16.6 (15.9 - 17.3) 14.1 (13.3 - 14.8) 29.0 (26.7 - 31.3) 
Rented (private) 7.4 (6.9 - 7.8) 6.9 (6.4 - 7.4) 9.6 (8.0 - 11.3) 
Other 3.7 (3.3 - 4.0) 3.5 (3.1 - 3.9) 4.4 (3.3 - 5.5) 
Maternal highest educational qualification 
CSE 21.5 (20.8 - 22.3) 19.0 (18.2 - 19.8) 33.8 (31.3 - 36.3) 
Vocational 10.1 (9.5 - 10.7) 9.8 (9.2 - 10.3) 11.7 (10.0 - 13.3) 
O level 34.3 (33.5 - 35.2) 35.1 (34.1 - 36.0) 30.9 (28.3 - 33.4) 
A level 21.9 (21.2 - 22.6) 22.9 (22.1 - 23.8) 17.0 (15.0 - 18.9) 
Degree 12.1 (11.6 - 12.7) 13.2 (12.6 - 13.9) 6.7 (5.4 - 8.0) 
Paternal highest educational qualification 
CSE 28.6 (27.8 - 29.4) 25.7 (24.8 - 26.5) 42.9 (40.4 - 45.5) 
Vocational 8.7 (8.2 - 9.2) 8.6 (8.0 - 9.2) 9.3 (7.7 - 10.9) 
O level 20.9 (20.2 - 21.6) 21.3 (20.5 - 22.2) 18.9 (16.8 - 20.9) 
A level 25.0 (24.3 - 25.8) 26.1 (25.2 - 26.9) 19.9 (18.0 - 21.9) 
Degree 16.7 (16.1 - 17.4) 18.3 (17.5 - 19.1) 9.0 (7.3 - 10.6) 
Maternal social class    
Professional 5.0 (4.6 - 5.4) 5.6 (5.1 - 6.1) 2.1 (1.4 - 2.8) 
Managerial/technical 28.4 (27.5 - 29.3) 29.6 (28.7 - 30.6) 22.3 (20.3 - 24.3) 
Skilled non-manual 42.9 (41.9 - 43.8) 43.0 (42.0 - 44.0) 42.2 (39.8 - 44.6) 
Skilled manual 8.8 (8.2 - 9.4) 8.3 (7.7 - 9.0) 11.1 (9.5 - 12.6) 
Partly skilled/unskilled 15.0 (14.2 - 15.7) 13.5 (12.6 - 14.3) 22.3 (20.0 - 24.6) 
Paternal social class    
Professional 9.8 (9.3 - 10.4) 10.8 (10.1 - 11.4) 5.3 (4.1 - 6.5) 
Managerial/technical 31.6 (30.8 - 32.5) 32.9 (31.8 - 33.9) 25.6 (23.4 - 27.9) 
Skilled non-manual 10.7 (10.1 - 11.3) 11.0 (10.4 - 11.6) 9.2 (7.6 - 10.7) 
Skilled manual 32.8 (31.9 - 33.7) 31.8 (30.8 - 32.8) 37.4 (35.2 - 39.6) 
Partly skilled/unskilled 15.1 (14.3 - 15.8) 13.5 (12.8 - 14.3) 22.5 (20.2 - 24.8) 
Marital status    
Not married 26.0 (25.2 - 26.7) 23.8 (23.0 - 24.7) 36.6 (34.3 - 38.8) 
Married 74.0 (73.3 - 74.8) 76.2 (75.3 - 77.0) 63.4 (61.2 - 65.7) 
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 Total sample 
N = 13,495 
% (95% CI) 
Not FASDa 
 
% (95% CI) 
FASDa 
 
% (95% CI) 
Pregnancy factors    
Parity    
0 44.9 (44.0 - 45.7) 45.7 (44.7 - 46.7) 40.9 (38.5 - 43.3) 
1 34.9 (34.0 - 35.7) 35.0 (34.1 - 35.9) 34.3 (31.8 - 36.7) 
2 14.3 (13.7 - 14.9) 13.9 (13.2 - 14.5) 16.2 (14.6 - 17.9) 
> 2 6.0 (5.6 - 6.4) 5.5 (5.0 - 5.9) 8.6 (7.1 - 10.1) 
Preterm delivery (< 37 weeks) 
Yes 5.0 (4.6 - 5.3) 4.6 (4.2 - 5.0) 6.8 (5.7 - 8.0) 
No 95.0 (94.7 - 95.4) 95.4 (95.0 - 95.8) 93.2 (92.0 - 94.3) 
Unplanned pregnancy    
Yes 31.4 (30.6 - 32.3) 29.8 (28.9 - 30.7) 39.3 (36.8 - 41.8) 
No 68.6 (67.8 - 69.4) 70.2 (69.3 - 71.1) 60.7 (58.2 - 63.3) 
a Total sample size for multiply imputed data = 13,495. The number of participants with and 
without FASD varies for each imputation set. 
Abbreviations: CI, confidence interval; CSE, Certificate of Secondary Education; FASD, fetal 
alcohol spectrum disorder; N, sample size. 
  
  287 
Appendix 12: Prenatal alcohol exposure and clinical characteristics by 
FASD status based on multiply imputed data 
 
Total sample 
N = 13,495 
% (95% CI) 
Not FASDa 
 
 
% (95% CI) 
FASDa 
 
 
% (95% CI) 
PRENATAL ALCOHOL EXPOSURE 
Prenatal alcohol exposure (any) 
No 21.3 (20.5 - 22.0) 25.6 (24.8 - 26.4) 0.03 (0.00 - 0.09) 
Yes 78.7 (78.0 - 79.5) 74.4 (73.6 - 75.2) 99.97 (99.90 - 100.00) 
Prenatal binge drinking 
No 74.7 (73.7 - 75.6) 77.2 (76.2 - 78.3) 62.2 (59.4 - 64.9) 
Yes 25.3 (24.4 - 26.3) 22.8 (21.7 - 23.8) 37.8 (35.1 - 40.6) 
Prenatal alcohol exposure (max dose/frequency during pregnancy)b 
None 32.4 (31.6 - 33.2) 35.2 (34.3 - 36.1) 19.0 (16.8 - 21.1) 
<1 glass per week 42.2 (41.3 - 43.0) 40.4 (39.4 - 41.3) 51.1 (48.7 - 53.5) 
1-6 glasses per week 22.1 (21.4 - 22.8) 21.5 (20.7 - 22.3) 25.1 (22.9 - 27.3) 
7+ glasses per week 3.3 (3.0 - 3.6) 3.0 (2.6 - 3.3) 4.8 (3.9 - 5.8) 
FACIAL PHENOTYPE    
FAS facial phenotype    
No 99.5 (99.3 - 99.7) 99.5 (99.4 - 99.7) 99.3 (98.7 - 99.9) 
Yes 0.5 (0.3 - 0.7) 0.5 (0.3 - 0.6) 0.7 (0.1 - 1.3) 
Partial FAS facial phenotype 
No 91.5 (90.4 - 92.7) 91.7 (90.7 - 92.7) 90.5 (87.6 - 93.5) 
Yes 8.5 (7.3 - 9.6) 8.3 (7.3 - 9.3) 9.5 (6.5 - 12.4) 
GROWTH    
Growth impairment (< 9th percentile) 
No 91.7 (91.3 - 92.2) 92.5 (91.9 - 93.0) 88.3 (86.6 - 90.0) 
Yes 8.3 (7.8 - 8.7) 7.6 (7.0 - 8.1) 11.7 (10.0 - 13.4) 
CENTRAL NERVOUS SYSTEM 
CNS impairment in ≥ 3 domains 
No 78.3 (77.3 - 79.2) 94.3 (93.7 - 94.8) 0.0 (0.0 - 0.0)c 
Yes 21.7 (20.8 - 22.7) 5.7 (5.2 - 6.3) 100.0 (100.0 - 100.0)c 
Impaired CNS domain a) Hard and soft neurologic signs 
No 93.0 (92.2 - 93.8) 95.8 (95.2 - 96.4) 79.2 (76.4 - 82.0) 
Yes 7.0 (6.2 - 7.8) 4.2 (3.6 - 4.8) 20.8 (18.0 - 23.6) 
Impaired CNS domain b) Brain structure 
No 99.4 (99.1 - 99.6) 99.6 (99.4 - 99.7) 98.4 (97.5 - 99.2) 
Yes 0.6 (0.4 - 0.9) 0.4 (0.3 - 0.6) 1.6 (0.8 - 2.5) 
Impaired CNS domain c) Cognition 
No 44.1 (43.0 - 45.2) 48.4 (47.2 - 49.5) 23.2 (20.8 - 25.5) 
Yes 55.9 (54.8 - 57.0) 51.6 (50.5 - 52.8) 76.8 (74.5 - 79.2) 
Impaired CNS domain d) Communication 
No 97.0 (96.4 - 97.6) 98.7 (98.3 - 99.0) 89.0 (86.4 - 91.5) 
Yes 3.0 (2.4 - 3.6) 1.3 (1.0 - 1.7) 11.0 (8.5 - 13.6) 
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Total sample 
N = 13,495 
% (95% CI) 
Not FASDa 
 
 
% (95% CI) 
FASDa 
 
 
% (95% CI) 
Impaired CNS domain e) Education 
No 75.0 (74.3 - 75.8) 85.1 (84.2 - 85.9) 26.1 (23.8 - 28.3) 
Yes 25.0 (24.2 - 25.8) 14.9 (14.1 - 15.8) 73.9 (71.7 - 76.2) 
Impaired CNS domain f) Memory 
No 91.1 (90.0 - 92.2) 94.7 (94.0 - 95.4) 73.7 (69.7 - 77.7) 
Yes 8.9 (7.8 - 10.0) 5.3 (4.6 - 6.0) 26.3 (22.3 - 30.3) 
Impaired CNS domain g) Executive functioning 
No 96.1 (95.5 - 96.7) 98.1 (97.7 - 98.5) 86.1 (83.6 - 88.7) 
Yes 3.9 (3.3 - 4.5) 1.9 (1.5 - 2.3) 13.9 (11.3 - 16.4) 
Impaired CNS domain h) Attention deficit/hyperactivity 
No 81.7 (81.0 - 82.5) 90.3 (89.7 - 91.0) 39.7 (37.1 - 42.3) 
Yes 18.3 (17.5 - 19.0) 9.7 (9.0 - 10.3) 60.3 (57.7 - 62.9) 
Impaired CNS domain i) Adaptive behaviour 
No 61.3 (60.3 - 62.3) 70.8 (69.8 - 71.7) 15.2 (13.1 - 17.3) 
Yes 38.7 (37.7 - 39.7) 29.2 (28.3 - 30.2) 84.8 (82.7 - 86.9) 
a Total sample size for multiply imputed data = 13,495. The number of participants with and 
without FASD varies for each imputation set. 
b Participants who reported ‘none’ for alcohol consumption using the dose/frequency measure 
may still have reported PAE on other measures of alcohol consumption (such as binge drinking, 
unit-based measures or continuation of pre-pregnancy drinking patterns). 
c By definition all participants who meet criteria for FASD must have CNS impairment in ≥ 3 
domains. Therefore, confidence intervals were constrained to reflect this (i.e. for participants 
with FASD, the value in the true population can only be 0% for ‘no impairment’ and 100% for 
‘impairment in ≥ 3 domains’). 
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Appendix 13: Causal diagram theory (directed acyclic graphs; DAGs) 
Causal diagram language 
Causal diagram theory presents its own language, which uses ancestry (family tree) 
terminology. This terminology is presented below, with an example based on 
Figure 21, derived from the work of Greenland and colleagues.522 
Figure 21: Causal diagram example 
 
In Figure 21, the variables depicted by letters (A, B, C, D, E) are called nodes. Arrows 
represent cause-effect relationships and are called arcs or edges. A path is any 
unbroken route that follows the arcs (regardless of direction) between adjacent 
nodes. Causal or directed paths are those which follow a sequence of arcs in a tail-
to-head route, such as A → E → D. Any path which is not directed, is undirected. In 
particular, a path which starts with a head-to-tail arc is known as a backdoor path. 
In Figure 21, all paths from E to D except E → D (e.g. E ← C → D) are backdoor 
paths.  
A path is blocked at the point at which two arrowheads meet. The variable at which 
the arrowheads meet is called a collider. For example, the path A → C ← B → D is 
blocked by collider C. The arc from C to D represents a direct causal effect of C on 
D, as it is not intercepted by any of the other variables included in the diagram. In 
contrast, the causal path from A → C → D from A to D is indirect, as the effect is 
mediated by C. The absence of an arc, or any other open path, between A and B 
implies independence.  
Descendants of a variable X are those that are affected directly or indirectly by X. 
For example, E and D are descendants of A in the path A → E → D. More 
specifically, children of a variable X are those that follow a single directed arc. D is a 
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child of E in the path E → D. Ancestors or causes are variables that affect other 
variables directly or indirectly and, more specifically, parents are ancestor variables 
that are adjacent to the affected variable. In the path A → E → D, A and E are both 
ancestors of D, and E is also a parent of D.  
DAGs are directed, as the arcs connecting variables suggest a direction of effect, 
they are acyclic as they do not contain feedback loopsr and they are causal as they 
include all common causes of a pair of variables.522,523  
Graphical properties and rules 
Causal diagrams have several properties that are important to their interpretation. 
First, causal diagrams are qualitative and do not provide information about the 
strength or nature of association between two variables. For example, causal 
diagrams do not convey whether variables are categorical or continuous, whether 
dose-response relationships are linear or non-linear, whether causes are necessary 
or sufficient, whether there is effect modification, or whether effects are harmful 
or protective.305,522,523 These properties must be determined by statistical 
investigation.  
Second, the parent-child and direct/indirect relationships implied by causal graphs 
are not inherent properties of the biologic relationship between two variables. This 
terminology simply reflects the level of detail that is captured in the diagram.522 If 
we consider the relationship PAE → FASD, PAE is represented as a direct cause of 
FASD only because the specific intermediate causal mechanisms between PAE and 
FASD remain unknown and/or unmeasured.10  
The presence of an arc between two nodes indicates the possibility of a direct 
causal effect. If there is inconclusive evidence about whether there is a causal link 
between two variables, it is appropriate to include an arc between them (and in the 
direction deemed most plausible), since the presence of an arc indicates the 
                                                        
r The absence of feedback loops means that a variable cannot be an ancestor or descendant of itself 
such that X causes Y and Y simultaneously causes X. If the value of X affects Y and then Y affects a 
later value of X this temporal sequence must be represented in separate variables (e.g. X0 → Y0 → 
X1). 305. Glymour MM, Greenland S. Causal Diagrams. In: Rothman KJ, Greenland, S., & Lash, T. L., 
ed. Modern epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008:183-209. 
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possibility of an effect in the depicted direction whereas the absence of an arc or 
node indicates the stronger assumption of no effect in either direction, or at least 
the belief that the effect has a negligible impact given all other factors in the 
graph.290 
Finally, it is not necessary to include all causes of a variable within a causal diagram. 
However, if two variables share a common cause then this must be represented.305 
If this common cause is unmeasured then it must be included and can be 
represented graphically as shown by node U in Figure 22. Although not necessary, 
it is possible to include other variables that are not a common cause of two other 
variables,290 as in the case of node F in Figure 22. For the purposes of the DAG 
developed in this chapter I will include some variables that are not common causes 
of two other variables to ensure complete coverage of the risk factors that have 
been described to date in the FASD literature. Sometimes, such variables are 
important in the analysis (e.g. to improve precision, to investigate effect 
modification/ mediation), even if they are not important for reducing bias in the 
total causal effect estimate. 
Figure 22: Causal diagram with unmeasured confounder (U) and additional variable (F) 
 
Two key concepts are integral to the interpretation and manipulation of DAGs. 
They are the d-Separation criteria and Causal Markovian Condition described by 
Pearl304 and presented in an epidemiological context by Glymour and colleagues.305  
The d-Separation criteria are graphical rules that can be used to infer 
independencies between variables. D-separation can be either unconditional or 
conditional. Unconditional d-separation occurs when there is no open path 
between two nodes. For example, in Figure 23a, variables A and B are 
unconditionally d-separated, as the only paths between them are blocked by 
colliders C, D and E. Since variables A and B are d-separated, the graph predicts 
E
F U
D
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that, statistically, they will be marginally independent. In other words, causal 
diagram theory states that only open paths will create associations.305  
Conditioning has different implications for d-separation according to whether the 
node that is conditioned on is a collider or not. Non-colliders may be mediating 
variables, as in Figure 23b, where C is the mediator; or non-colliders may be a 
common cause of two variables as in Figure 23c, where C is a confounder. 
Conditioning a non-collider blocks the flow of statistical dependence along that 
path and (providing that there are no other open paths) creates d-separation and, 
therefore, statistical independence between E and D. Conversely, conditioning on a 
collider can create associations between two marginally independent variables. For 
example, in Figure 23d the path between A and B is unconditionally blocked by 
collider C and so (in the absence of other paths from A to B) there is no marginal 
association between A and B; however, adjusting for C opens that path and creates 
a conditional association between A and B.304,305 Figure 23d provides a graphical 
representation of how an open path is created by conditioning on a collider. The 
dashed line in this figure is a non-directional arc that indicates that A and B are 
associated for reasons other than influencing each other or sharing a common 
cause.522 This dashed line is not formally a part of the DAG, but is often added 
informally to highlight the conditional associations that may be induced. Collider 
bias is explained more fully, with an intuitive example, in the next section. 
A set of variables (S) is said to block the path between E and D if the path is closed 
after conditioning on this set. The set (S) unblocks the path if the path is open after 
conditioning. If there was no open path between E and D to begin with then the 
empty set is said to separate them.305  
  
  293 
Figure 23: Causal diagrams for illustration of the d-separation criteria.  Figure a) presents the full diagram, 
where colliders C, E and D create unconditional separation between A and B. Figure b) presents a causal 
pathway, where the causal effect between A and D is mediated by C, Figure c) presents a biasing pathway 
between E and D due to not adjusting for confounder C and Figure d) shows the introduction of a non-causal 
relationship between variables A and B (depicted by dashed line), due to inappropriate adjustment (depicted by 
square) on collider C. 
 
Bias 
As well as facilitating expression of complex causal networks,304 DAGs have been 
advocated as useful tools for informing strategies for bias reduction.305 Bias is 
present when the chosen measure of association differs from the true causal 
effect.298 Under these circumstances, different exposure groups differ in their 
probability of the outcome for reasons other than the effect of the exposure. This 
section will compare traditional and graphical approaches to confounding, 
selection, and information bias.  
Confounding has been defined as a bias of the estimated effect of an exposure on 
an outcome due to the presence of a common cause of the exposure and the 
outcome.555 In epidemiology, confounding variables have commonly been defined 
by the following criteria:301 
i. The variable must be associated with both the exposure and the 
outcome. 
ii. The variable must predict the outcome, independent of its association 
with the exposure. 
iii. The variable must not lie on the causal pathway between the exposure 
and the outcome (i.e. it should not be a mediator). 
A
C
E D
B
b)	a)	
A
C
D
C
E D
c)	
A
C
B
d)	
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Selection bias may also lead to misleading effect estimates within epidemiological 
studies. Selection bias occurs when the study population does not represent the 
target population556 or, more formally, when: 
“the association between exposure and disease includes a non-causal 
component attributable to restricting the analysis to certain level(s) of a 
common effect of exposure and disease or, more generally, to conditioning 
on a common effect of variables correlated with exposure and disease.”557(p. 
182) 
In contrast to epidemiological approaches, graphical methods offer a more precise 
definition by expressing bias as any unblocked backdoor path between the 
exposure and outcome. Although in many instances, the traditional epidemiological 
and DAG definitions coincide, examples can be found in which the traditional 
definition would dictate that confounding is present, but the graphical definition 
would not, and vice versa.  For example, in Figure 23a, all paths, except for the 
direct path from E → D are backdoor paths. Therefore, the estimate for the total 
effect of E on D will be partly due to the direct causal effect and partly due to the 
remaining biasing paths.522 Some argue that because graphical rules are sufficient 
to identify structural sources of bias there is no need to distinguish between 
confounding and selection bias.305 Nevertheless, for the purposes of unifying 
graphical and epidemiological definitions of bias it is useful to indicate how these 
concepts overlap.305 Also, knowing whether the source of bias is due to 
confounding or selection issues may suggest approaches for minimising bias by 
study design. 
Graphical methods depict confounding as an open backdoor path formed by a 
common cause of two variables. In many instances, application of the traditional 
and graphical criteria for confounding identify the same variables as confounders 
and would recommend similar strategies for control of this bias.  
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Figure 24: Partial a) and full version b) of a causal diagram to illustrate complexities when adjusting for 
confounders, including over-adjustment when C is both a confounder and collider c). 
 
For example, Figure 24a is a sub-section of Figure 24b and demonstrates that the 
effect estimate for the relationship between E and D is partly confounded by C. If 
we take Figure 24a to be a complete DAG (i.e. assume that there are no further 
common causes that are not represented in the graph), then the traditional and 
graphical approaches would both identify C as a confounder and would both 
suggest C as a covariate that should be controlled for to gain an unbiased estimate 
of the effect of E on D. However, the traditional and graphical approaches to 
confounding sometimes diverge. Greenland and colleagues522 presented the full 
DAG (Figure 24b) to colleagues and asked them identify which variables would be 
sufficient to adjust for in order to create an unbiased estimate of the effect of E on 
D. Most suggested that adjusting for A or B only would not be sufficient, but that 
adjusting for C alone would be sufficient. This choice was based on the reasoning 
that adjustment for only A and B would not resolve the confounding by C. 
Adjustment for C, however, would block the pathway between A and D, given E, 
and would leave B unassociated with E. Therefore, A and B would no longer meet 
the traditional criteria for confounding, as they would not be associated with both 
the exposure and the outcome. However, the graphical criteria for confounding 
indicate that controlling for C alone would not be sufficient to eliminate bias. This is 
because C is a collider (a common effect of A and B, on the pathway A → C ← B). As 
previously described, conditioning on a collider creates an association between its 
parents. This, in turn, creates a new backdoor pathway, which, if uncontrolled, will 
lead to a biased effect estimate between E and D (see Figure 24c). Therefore, to 
C
E D
a)	
A
C
E D
B
b)	
A
C
E D
B
c)	
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create an unbiased estimate of E on D, it is also necessary to control for A or B, in 
addition to C.522 
Collider bias arises because observing information about one of the common 
causes of an effect, makes the other cause more or less likely given the occurrence 
of that effect, even if these causes were previously independent.304 Hernan 
provides the following example.557 Suppose that dieting (E) and a particular form of 
cancer (D) are statistically independent and, therefore, knowing that someone was 
on a diet does not change their risk of cancer. A common effect of dieting and 
cancer is weight loss (C). Given that we know that someone had lost weight (i.e. we 
condition on C), cancer and diet no longer remain independent. This is because 
knowing that someone had lost weight and was not on a diet increases the 
probability that this person has cancer (intuitively: if they lost weight but weren’t 
on a diet then it must have been something else [e.g. cancer] that caused them to 
lose weight). Therefore, within categories of weight loss, dieting and cancer 
become inversely associated. In these circumstances the crude effect estimate of 
the relationship between E and D is unbiased and conditioning on collider C creates 
a spurious association between E and D, thus leading to a biased adjusted estimate. 
Collider bias is a form of selection bias. Of particular relevance to this thesis, which 
explores the epidemiology of FASD within the ALSPAC cohort, is consideration of 
loss to follow up/missing data. Selection bias due to loss to follow-up and missing 
data can also be represented graphically.558 These forms of bias occur when study 
drop-out or completeness of data are associated with both the exposure and the 
outcome.301 Restriction of analysis to participants with complete data represents a 
form of conditioning on the common effect of exposure and outcome - data 
availability.  
In summary, DAGs can assist with the identification and representation of bias as 
well as assisting with the choice of adjustment variables that will help to remove or 
reduce that bias. Graphical methods can be applied to complex causal networks in 
situations where traditional criteria for confounder identification may fail.522 Bias 
due to confounding can typically be reduced via multivariable regression modelling, 
using the method outlined above to identify suitable covariates. Selection bias can 
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be minimised by avoiding harmful adjustment on common effects of the exposure 
and outcome, or by using appropriate methods to account for missing data.  In this 
thesis, I used multiple imputation, as described in Chapter 4, to reduce the impact 
of selection bias due to missing data.  
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Appendix 14: DAGitty code (compatible with html version) 
dag { 
"Antenatal care" [pos="0.945,1.014"] 
"Current alcohol use" [pos="0.367,0.996"] 
"Differential diagnosis" [latent,pos="0.880,0.596"] 
"Drug use" [pos="0.823,0.446"] 
"FASD classification" [outcome,pos="0.880,0.688"] 
"FASD diagnostic framework/detection" [pos="0.885,0.480"] 
"Genotype (maternal)" [pos="0.417,0.791"] 
"Genotype_(infant)" [pos="0.543,0.742"] 
"Having another child with FASD" [pos="0.562,0.982"] 
"Marital status" [pos="0.092,0.417"] 
"Maternal FASD" [pos="0.018,0.327"] 
"Maternal knowledge/attitudes towards PAE" [latent,pos="0.086,0.800"] 
"Maternal prenatal alcohol consumption" [latent,pos="0.193,0.883"] 
"Mental health" [pos="0.559,0.430"] 
"Other unmeasured exposures" [latent,pos="0.956,0.326"] 
"PAE guidance" [latent,pos="0.019,0.466"] 
"Pre-pregnancy alcohol use" [pos="0.143,0.299"] 
"Professional knowledge/guidance on PAE" [latent,pos="0.074,0.680"] 
"Reasons for PAE measurement error" [latent,pos="0.266,1.102"] 
"Risky behaviour" [pos="0.816,0.210"] 
"Substance use of friends/family" [pos="0.079,0.190"] 
"True FASD" [latent,pos="0.882,0.884"] 
"Unplanned pregnancy" [pos="0.774,0.283"] 
Abuse [pos="0.356,0.295"] 
Age [pos="0.200,0.533"] 
BMI [pos="0.686,0.651"] 
Nutrition [pos="0.561,0.590"] 
Parity [pos="0.065,0.548"] 
Preg_comp [pos="0.027,1.056"] 
Religion [pos="0.224,0.256"] 
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Reported_PAE [pos="0.196,0.987"] 
SES [pos="0.303,0.376"] 
Smoking [pos="0.669,0.526"] 
Stress [pos="0.243,0.650"] 
Support [pos="0.427,0.450"] 
"Antenatal care" -> Nutrition [pos="0.785,0.551"] 
"Antenatal care" -> Preg_comp [pos="0.905,1.106"] 
"Differential diagnosis" -> "FASD classification" 
"Differential diagnosis" -> BMI 
"Drug use" -> "Antenatal care" [pos="0.966,0.558"] 
"Drug use" -> "Differential diagnosis" 
"Drug use" -> "True FASD" [pos="0.803,0.689"] 
"Drug use" -> Nutrition [pos="0.788,0.580"] 
"Drug use" -> Preg_comp [pos="-0.028,0.208"] 
"FASD diagnostic framework/detection" -> "Differential diagnosis" 
"Genotype (maternal)" -> "Current alcohol use" 
"Genotype (maternal)" -> "Genotype_(infant)" 
"Genotype (maternal)" -> "Maternal prenatal alcohol consumption" 
"Genotype (maternal)" -> "Pre-pregnancy alcohol use" [pos="0.004,0.425"] 
"Genotype (maternal)" -> "True FASD" 
"Genotype_(infant)" -> "True FASD" 
"Marital status" -> "Unplanned pregnancy" 
"Marital status" -> SES 
"Marital status" -> Support 
"Maternal FASD" -> "Maternal prenatal alcohol consumption" [pos="-0.030,0.659"] 
"Maternal FASD" -> "Mental health" 
"Maternal FASD" -> "Pre-pregnancy alcohol use" 
"Maternal knowledge/attitudes towards PAE" -> "Maternal prenatal alcohol consumption" 
"Maternal prenatal alcohol consumption" -> "Antenatal care" [pos="0.597,0.921"] 
"Maternal prenatal alcohol consumption" -> "Current alcohol use" 
"Maternal prenatal alcohol consumption" -> "FASD classification" 
"Maternal prenatal alcohol consumption" -> "Having another child with FASD" 
[pos="0.450,0.927"] 
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"Maternal prenatal alcohol consumption" -> "True FASD" 
"Maternal prenatal alcohol consumption" -> Nutrition [pos="0.035,0.530"] 
"Maternal prenatal alcohol consumption" -> Preg_comp 
"Maternal prenatal alcohol consumption" -> Reported_PAE 
"Mental health" -> "Differential diagnosis" 
"Mental health" -> "Drug use" 
"Mental health" -> "Maternal prenatal alcohol consumption" [pos="-0.011,0.114"] 
"Mental health" -> "True FASD" [pos="0.585,0.686"] 
"Mental health" -> Nutrition 
"Mental health" -> Smoking 
"Mental health" -> Stress 
"Other unmeasured exposures" -> "Differential diagnosis" 
"PAE guidance" -> "Maternal knowledge/attitudes towards PAE" 
"PAE guidance" -> "Professional knowledge/guidance on PAE" 
"Pre-pregnancy alcohol use" -> "Current alcohol use" [pos="0.400,0.812"] 
"Pre-pregnancy alcohol use" -> "Maternal prenatal alcohol consumption" [pos="-
0.023,0.339"] 
"Pre-pregnancy alcohol use" -> "Unplanned pregnancy" [pos="0.519,0.362"] 
"Pre-pregnancy alcohol use" -> Nutrition [pos="0.569,0.369"] 
"Professional knowledge/guidance on PAE" -> "Maternal knowledge/attitudes towards 
PAE" 
"Reasons for PAE measurement error" -> Reported_PAE 
"Risky behaviour" -> "Differential diagnosis" 
"Risky behaviour" -> "Drug use" 
"Risky behaviour" -> "Maternal prenatal alcohol consumption" [pos="-0.016,0.266"] 
"Risky behaviour" -> "Other unmeasured exposures" 
"Risky behaviour" -> "Pre-pregnancy alcohol use" [pos="0.333,0.249"] 
"Risky behaviour" -> "Substance use of friends/family" 
"Risky behaviour" -> "Unplanned pregnancy" 
"Risky behaviour" -> Nutrition [pos="0.613,0.221"] 
"Risky behaviour" -> Smoking [pos="0.640,0.289"] 
"Risky behaviour" -> Stress [pos="0.423,0.260"] 
"Substance use of friends/family" -> "Maternal FASD" 
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"Substance use of friends/family" -> "Maternal knowledge/attitudes towards PAE" 
"Substance use of friends/family" -> "Maternal prenatal alcohol consumption" [pos="-
0.011,0.474"] 
"Substance use of friends/family" -> "Pre-pregnancy alcohol use" 
"True FASD" -> "FASD classification" 
"Unplanned pregnancy" -> "Antenatal care" [pos="0.987,0.439"] 
"Unplanned pregnancy" -> "Drug use" 
"Unplanned pregnancy" -> "Maternal prenatal alcohol consumption" [pos="0.442,0.381"] 
"Unplanned pregnancy" -> Nutrition [pos="0.785,0.560"] 
"Unplanned pregnancy" -> Smoking 
Abuse -> "Antenatal care" [pos="0.975,0.247"] 
Abuse -> "Mental health" 
Abuse -> "Unplanned pregnancy" [pos="0.562,0.254"] 
Abuse -> Stress [pos="0.010,0.344"] 
Age -> "Drug use" [pos="0.211,0.344"] 
Age -> "Maternal prenatal alcohol consumption" [pos="-0.007,0.629"] 
Age -> "Pre-pregnancy alcohol use" 
Age -> "True FASD" 
Age -> Parity [pos="0.104,0.543"] 
Age -> Smoking [pos="0.359,0.474"] 
BMI -> "True FASD" 
Nutrition -> "Differential diagnosis" [pos="0.662,0.618"] 
Nutrition -> "True FASD" [pos="0.626,0.703"] 
Nutrition -> BMI 
Nutrition -> Preg_comp [pos="0.038,0.380"] 
Religion -> "Current alcohol use" 
Religion -> "Marital status" [pos="0.249,0.354"] 
Religion -> "Maternal prenatal alcohol consumption" [pos="-0.031,0.231"] 
Religion -> "Pre-pregnancy alcohol use" 
Religion -> "Unplanned pregnancy" [pos="0.551,0.230"] 
Religion -> Support 
Reported_PAE -> "FASD classification" 
SES -> "Antenatal care" [pos="0.626,1.067"] 
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SES -> "Current alcohol use" 
SES -> "Drug use" [pos="0.337,0.267"] 
SES -> "Maternal prenatal alcohol consumption" [pos="-0.021,0.498"] 
SES -> "Mental health" 
SES -> "Pre-pregnancy alcohol use" [pos="-0.008,0.260"] 
SES -> "Unplanned pregnancy" [pos="0.376,0.309"] 
SES -> Nutrition [pos="0.467,0.366"] 
SES -> Parity [pos="0.084,0.458"] 
SES -> Smoking [pos="0.432,0.349"] 
SES -> Stress 
SES -> Support 
Smoking -> "Differential diagnosis" 
Smoking -> "True FASD" 
Smoking -> Nutrition 
Smoking -> Preg_comp [pos="0.036,0.523"] 
Stress -> "Differential diagnosis" [pos="0.548,0.761"] 
Stress -> "Drug use" [pos="0.292,0.114"] 
Stress -> "Maternal prenatal alcohol consumption" [pos="0.165,0.799"] 
Stress -> "True FASD" 
Stress -> Nutrition [pos="0.429,0.691"] 
Stress -> Preg_comp [pos="0.085,0.802"] 
Stress -> Smoking 
Support -> "Mental health" 
Support -> Stress 
} 
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Appendix 15: Causal diagrams for multivariable FASD risk factor analyses (DAGitty output) 
Prenatal alcohol exposure (PAE) dose/pattern 
Note: In this DAG, I assumed that true PAE was observed (assumed that it was equivalent to reported PAE) to enable identification of the covariate set. 
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Prenatal smoking 
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Prenatal illicit drug use 
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Prenatal nutrition 
Note: In this this DAG, I assumed that true PAE was observed (assumed that it was equivalent to reported PAE) to enable identification of the covariate set. 
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Prenatal mental health 
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Prenatal stress 
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Prenatal social support 
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Appendix 16: Sample flow diagram showing the number of participants at each stage of the FASD risk factor analyses
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Appendix 17: Comparison of the characteristics of participants who 
had complete versus incomplete data for one or more of the risk factor 
models prior to multiple imputation 
 Total  
N = 9,135 
N (%)a 
 
Included in all 
risk factor 
analyses 
N = 109 
(N [%]) 
Missing from 
one or more 
risk factor 
analysesb 
N = 9,026 
(N [%]) 
Sociodemographic factors    
Maternal age at delivery (years)  
<20 338 (3.7) 0 (0.0) 338 (3.7) 
20-29 5,055 (55.3) 53 (48.6) 5,002 (55.4) 
30+ 3,742 (41.0) 56 (51.4) 3,686 (40.8) 
Maternal ethnicity 
White 8,261 (98.2) 109 (100.0) 8,152 (98.1) 
Non-White 152 (1.8) 0 (0.0) 152 (1.8) 
Marital status 
Not married 2,158 (24.5) 13 (11.9) 2,145 (24.7) 
Married 6,642 (75.5) 96 (88.1) 6,546 (75.3) 
Maternal social class 
Professional 453 (6.5) 4 (3.7) 449 (6.5) 
Managerial/technical 2,354 (33.6) 46 (42.2) 2,308 (33.5) 
Skilled non-manual 2,924 (41.8) 49 (45.0) 2,875 (41.7) 
Skilled manual 502 (7.2) 5 (4.6) 497 (7.2) 
Partly skilled/unskilled 771 (11.0) 5 (4.6) 766 (11.1) 
Paternal social class 
Professional 892 (11.8)  23 (21.1) 869 (11.7) 
Managerial/technical 2,680 (35.4) 40 (36.7)  2,640 (35.4) 
Skilled non-manual 851 (11.2)  9 (8.3) 842 (11.3) 
Skilled manual 2,250 (29.7) 32 (29.4) 2,218 (29.7) 
Partly skilled/unskilled 897 (11.9)  5 (4.6) 892 (12.0) 
Maternal education 
CSE 1,484 (17.6)  9 (8.3) 1,475 (17.7) 
Vocational 783 (9.3)  5 (4.6)  778 (9.3) 
O Level 2,894 (34.3)  38 (34.9) 2,856 (34.2) 
A Level 2,051 (24.3) 38 (34.9) 2,013 (24.1) 
Degree 1,237 (14.6) 19 (17.4) 1,218 (14.6) 
Paternal education 
CSE 1,931 (23.8) 14 (12.8) 1,917 (23.9) 
Vocational 663 (8.2) 8 (7.3) 655 (8.2) 
O Level 1,703 (21.0) 27 (24.8) 1,676 (20.9) 
A Level 2,180 (26.8) 33 (30.3) 2,147 (26.8) 
Degree 1,648 (20.3) 27 (24.7) 1,621 (20.2) 
Home ownership status    
Mortgaged/owned 6,644 (75.8)  102 (93.6) 6,542 (75.6) 
Council/housing association 1,199 (13.7)  3 (2.8)  1,196 (13.8) 
Rented (private) 629 (7.2)  2 (1.8)  627 (7.3) 
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 Total  
N = 9,135 
N (%)a 
 
Included in all 
risk factor 
analyses 
N = 109 
(N [%]) 
Missing from 
one or more 
risk factor 
analysesb 
N = 9,026 
(N [%]) 
Other 291 (3.3) 2 (1.8) 289 (3.3) 
Exposures 
Prenatal alcohol exposure (max dose/frequency during pregnancy)  
None 269 (3.0) 1 (0.9) 268 (3.0) 
<1 glass per week 5,480 (60.6) 69 (63.3) 5,411 (60.6) 
1-6 glasses per week 2,872 (31.8) 36 (33.0) 2,836 (31.7) 
7+ glasses per week 424 (4.7) 3 (2.8) 421 (4.7) 
Prenatal binge drinking 
No 6,121 (68.3) 85 (78.0) 6,036 (68.2) 
Yes 2,839 (31.7) 24 (22.2) 2,815 (31.8) 
Prenatal smoking 
No 6,560 (71.8) 95 (87.2) 6,465 (71.6) 
Yes 2,573 (28.2) 14 (12.8) 2,559 (28.4) 
Prenatal illicit drug use 
No 8,674 (96.2) 107 (98.2) 8,567 (96.2) 
Yes 339 (3.8) 2 (1.8) 337 (3.8) 
Prenatal calcium supplement use 
No 8,496 (94.3) 102 (93.6) 8,394 (94.3) 
Yes 517 (5.7) 7 (6.4) 510 (5.7) 
Prenatal folic acid supplement use 
No 7,256 (80.5) 85 (78.0) 7,171 (80.5) 
Yes  1,758 (19.5)  24 (22.0) 1,734 (19.5) 
Prenatal iron supplement use    
No 4,991 (55.4) 56 (51.4) 4,935 (55.4) 
Yes 4,023 (44.6) 53 (48.6) 3,970 (44.6) 
Calories (RNI met)    
No 7,450 (90.4)  101 (92.7) 7,349 (90.4) 
Yes 792 (9.6)  8 (7.3) 784 (9.6) 
Prenatal stressful life events 
Mean (SD) 7.3 (4.4) 6.6 (3.8) 7.3 (4.4) 
Weighted prenatal stressful life events 
Median (IQR) 14.0 (15.0) 13.0 (12.0) 14.0 (15.0) 
Social support score  
Mean (SD) 3.9 (1.0) 4.2 (0.8) 3.9 (1.0) 
Prenatal anxiety 
No 6,633 (76.1) 89 (81.7) 6,544 (76.1) 
Yes 2,081 (23.9) 20 (18.4) 2,061 (24.0) 
Prenatal depression 
No 6,974 (79.5) 94 (86.2) 6,880 (79.4) 
Yes 1,800 (20.5)  15 (13.8)  1,785 (20.6) 
Outcome    
FASD status 
Not FASD 146 (90.1) 100 (91.7) 46 (86.8) 
FASD 16 (9.9)  9 (8.3) 7 (13.2) 
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 Total  
N = 9,135 
N (%)a 
 
Included in all 
risk factor 
analyses 
N = 109 
(N [%]) 
Missing from 
one or more 
risk factor 
analysesb 
N = 9,026 
(N [%]) 
Auxiliary variables    
Pregnancy/perinatal complications 
No 6,207 (71.1) 73 (67.6) 6,134 (71.2) 
Yes 2,520 (28.9) 35 (32.4) 2,485 (28.8) 
Binge drinking (8 weeks postpartum) 
No 3,102 (53.1) 71 (65.7) 3,031 (52.8) 
Yes 2,741 (46.9) 37 (34.3) 2,704 (47.2) 
Postnatal alcohol problems (maternal self-report and AUDIT 5 - 18 years postpartum) 
No 5,405 (77.7) 74 (67.9) 5,331 (77.9) 
Yes 1,551 (22.3) 35 (32.1) 1,516 (22.1) 
Parity    
0 3,837 (43.7) 57 (53.3) 3,780 (43.6) 
1 3,141 (35.8) 33 (30.8) 3,108 (35.8) 
2 1,305 (14.9) 11 (10.3) 1,294 (14.9) 
>2 494 (5.6) 6 (5.6) 488 (5.6) 
Gestational age at delivery (weeks) 
Mean (SD) 39.5 (1.8) 39.6 (1.5) 39.5 (1.8) 
Previous miscarriage    
0 6,978 (79.2) 89 (82.4) 6,889 (79.2) 
1 1,411 (16.0) 18 (16.7) 1,393 (16.0) 
≥2 418 (4.8)  1 (0.9) 417 (4.8) 
Ultrasound scan during 
pregnancy 
   
No 355 (4.6) 4 (3.6) 351 (4.6) 
Yes 7,392 (95.4) 105 (96.3) 7,287 (95.4) 
Maternal BMI (pre-pregnancy)    
Underweight 361 (4.6)  3 (2.8) 358 (4.6) 
Normal 5,924 (75.4) 89 (83.2)  5,835 (75.3) 
Overweight  1,180 (15.0)  14 (13.1)  1,166 (15.0) 
Obese 396 (5.0) 1 (0.9) 395 (5.1) 
Child sex    
Female 4,433 (48.5) 65 (40.4) 4,658 (51.6) 
Male 4,702 (51.5) 44 (59.6) 4,368 (48.4) 
a N varies for each variable due to missing data. Percentages do not always sum to 100 
due to rounding. 
b Missing from one or more of the following risk factor models: prenatal alcohol use 
pattern, prenatal smoking, prenatal illicit drug use, prenatal nutrition, prenatal stress, 
prenatal mental health, prenatal social support. Preliminary analyses indicated that 
missing data patterns were similar for each of the risk factor models. 
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Appendix 18: Graphs of the association between continuous measures of PAE and the odds of FASD 
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